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Drug development and use have evolved dramatically over the centuries, with an 
increasingly important role in extending life expectancy and improving quality of life. 
The fundamental role of drugs in healthcare is evident, among else, by the recorded 
consumption: 64% of all patient visits to physicians result in prescriptions; in the year 
2000 alone, 2.8 billion prescriptions were filled, equalling 10 prescriptions for every 
person in the United States. 
Despite their contribution, many limitations are still encountered in existing drug 
usage and new drug development. Among the top ones is the high incidence and 
severity of adverse drug reactions (ADRs). ADRs manifest in a range of forms from 
common, pharmacologically anticipated side effects or toxicities to therapeutic failures 
to rare, severe idiosyncratic drug reactions. Strikingly, over 2 million people are 
hospitalized and another 100,000 die every year, in the United States alone, due to 
ADRs, rendering them the 5th leading cause of death, ahead of pulmonary disease, 
diabetes, AIDS, pneumonia, accidents, and automobile deaths. Unpredictable patient 
fatalities have also resulted in the overall withdrawal of nineteen drugs from the US 
market since 1998, although these drugs could have been safe and beneficial for 
specific, yet uncharacterized, patient subgroups.  
Significant challenges are also noted in drug response, with approximately 30%-70% of 
patients failing to respond to a drug treatment, although this percentage varies 
considerably between different drug categories. The limited drug response is 
encountered either as variability of response to the recommended dose or as complete 
lack of response to the specific drug. In both cases however, reduced drug response 
compromises quality of life by prolonging disease duration and treatment, increasing 
psychological stress and exposure to multiple drugs, while in cases requiring urgent 
treatment it can prove lethal. 
The high frequency of ADRs and the low drug response rates have a broad range of 
implications at the level of the individual patients and their family/social circle, as well 
as the society and global economy as a whole. Of note, the cost of drug-related 
morbidity and mortality is estimated to be $136 billion annually in the United States 
alone. Taken together, this evidence demonstrates that drug development processes 
and clinical drug administration criteria need to be carefully reconsidered and 
significantly improved in order to better serve the patients and our society as a whole. 
X Preface 
 
The rapidly evolving field of Pharmacogenetics aims at identifying the genetic factors 
implicated in the inter-individual variation of drug response. These factors could 
enable patient sub-classification based on their treatment needs thus expediting drug 
development and promoting personalized, safer and more effective treatments. 
Although still at an early stage, Pharmacogenetic findings on a few drugs have already 
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evaluation or application. It has been designed so as to serve both the unfamiliar 
reader through explanations of basic Pharmacogenetic concepts, the clinician with 
presentation of the latest developments and international guidelines, and the research 
scientist with examples of Pharmacogenetic applications, discussions on the 
limitations and an outlook on the new scientific trends in this field.   
 
Despina Sanoudou, PhD FACMG Cibiol 
Assistant Professor 
Department of Pharmacology 
Medical School 





The rapidly evolving field of Pharmacogenetics aims at identifying the genetic factors 
implicated in the inter-individual variation of drug response. These factors could 
enable patient sub-classification based on their treatment needs thus expediting drug 
development and promoting personalized, safer and more effective treatments. 
Although still at an early stage, Pharmacogenetic findings on a few drugs have already 
transitioned to clinical practice, while many more drugs are being investigated. This 
book aims at presenting Pharmacogenetic examples from a broad spectrum of 
different drugs, for different diseases, which are representative of different stages of 
evaluation or application. It has been designed so as to serve both the unfamiliar 
reader through explanations of basic Pharmacogenetic concepts, the clinician with 
presentation of the latest developments and international guidelines, and the research 
scientist with examples of Pharmacogenetic applications, discussions on the 
limitations and an outlook on the new scientific trends in this field.   
 
Despina Sanoudou, PhD FACMG Cibiol 
Assistant Professor 
Department of Pharmacology 
Medical School 





 Part 1 
Pharmacogenetics – Theory and Practice 
 
 
 Part 1 
Pharmacogenetics – Theory and Practice 
 1 
Pharmacogenetics:  
Matching the Right Foundation at  
Personalized Medicine in the Right Genomic Era 
Roxana-Georgiana Tauser 
University of Medicine and Pharmacy “Gr. T. Popa” Iasi,  
 Romania 
 
There are more things in heaven and in earth, Horatio, 
Than are dreamt of in your philosophy... 
      W. Shakespeare, Hamlet act I scene 5 
1. Introduction 
The aim of this chapter is to overview the promises of the pioneering field of 
pharmacogenetics towards personalized medicine, completely changing the present 
therapeutic paradigm of “one dose fits all patients” and “trial-and-error” prescriptions to 
“matching the right dose to the right, specific genetic signature of the patient and at the 
right time”. The review points out the evolution from pharmacogenetics to 
pharmacogenomics, as well as the impact of genome-wide-associated studies (GWAS) and 
next generation sequencing technologies on deciphering “missing heritability” and on 
validation and approval of pharmacogenetic biomarkers as it is reflected both in regulatory 
authorities recommendations and from consortia perspectives. Pharmacogenetics’ 
translation from bench towards clinical practice in personalized medicine and drug 
discovery and development underlies the increasing benefits of pipeline pharmacogenetics, 
especially in the high-priority domains, as well as the emergence of the electronic health 
records-, biobanking- and bioinformatics-driven pharmacogenetics within extended 
international networks. More effective and successful integration of pharmacogenetics in 
clinical practice should address challenges regarding bioethics, insurance and privacy, 
consensus scientific guidelines, education, pharmacoeconomics and regulatory policy 
issues. Finally, there are illustrated the promising perspectives opened by: the interrogation 
of extensive electronic databases comprising clinical phenotype and genotype information; 
discovery of novel biomarkers by mining epigenoms, “junk DNA”, mitochondrial and RNA 
polymorphisms; and integration of nanotechnologies, in order to achieve the major objective 
of selecting the right therapeutic strategy endowed with the highest level of efficacy and 
safety among a predictable segment of the genotyped patients’ population. 
2. Pharmacogenetics: Conceptual evolution to pharmacogenomics 
2.1 Pharmacogenetics: Brief history and definition 
The first clinical observations of interpatient variability in clinical response to standard 
therapeutic doses and the pioneering contributions of Sir Archibald Garrod, Arno Motulsky, 
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Friedrich Vogel and Werner Kalow led to the concept of pharmacogenetics. In “Inborn Factors 
of Disease” (1909), Sir Archibald Garrod noticed the implication of the “biochemical 
individuality” in the interpatient variability of the metabolism and efficacy of the standard 
regimens. In 1950s there were described sensitivity to primaquin and the risk of hemolytic 
anemia of the patients with glucose-6-phosphate deficiency (G6PD), slow metabolizers/ 
acetylators of standard doses of isoniasid among tuberculosis patients with increased risk of 
peripheral neuropathy, prolonged apnea after succynilcholine administration, in relation to 
hereditary factors. The involvement of genetic factors in the adverse drug reactions was 
mentioned for the first time by Arno Motulsky – considered the father of the 
pharmacogenetics – in his paper “Drug Reactions, Enzymes and Biochemical Genetics” (1957). 
The concept of pharmacogenetics was introduced by Friedrich Vogel in “Moderne problem 
der humangenetik” (1959) as the study of genetic determinism of the interindividual 
variability to drugs action. The first monography on pharmacogenetics „Pharmacogenetics: 
Heredity and the Response to Drugs“ (1962) belongs to Werner Kalow, based on his 
pioneering work on the relation between genetic polymorphisms of butyrilcholinesterase and 
the risk of prolonged apnea to the standard therapeutic doses of succynilcholine. (Liewei et al., 
2011; Grossman & Goldstein, 2009; Tepper & Roubenoff, 2009) 
Pharmacogenetics correlates genetic factors to the interindividual variability in drug-
response phenotypes and has mainly focused on the association between monogenic 
polymorphisms and the variation of the drugs’ metabolism. (Liewei et al., 2011) 
Pharmacogenetics has the potential to increase the clinical benefit and reduce the risk of 
adverse drug reactions (ADR) in outliers, i.e. people whose drug responses are not 
“average”. (Woodcock & Lesko, 2009) 
Pharmacogenetic studies involve the identification of genetic classifiers or markers used to 
predict interpatient variability concerning drugs’ efficacy and/or safety. These genetic 
markers could be generated through one of the following approaches: candidate gene 
approach, pathway-based approach or whole genome scan (also cited as Genome Wide 
Association Studies GWAS) approach.  
2.2 Candidate gene, pathway-based and genome-wide studies  
In the candidate gene approach,  a panel of genes (candidate gene list) is generated based on 
the hypothesis in question to include drug target and mechanism pathway genes, as well as 
genes encoding the drug-metabolizing enzymes and membrane transporters involved in 
absorption, distribution, metabolism and elimination (i.e., drug pharmacokinetics). (Spraggs 
et al., 2009) The candidate gene approach has been applied by the majority of 
pharmacogenetics studies to detect associations between known single nucleotide 
polymorphisms (SNPs) and clinical or pharmacological end points, especially in the cases 
where there is a major drug metabolism or target gene that has a polymorphism that 
significantly changes its function. It is a hypothesis-driven approach that enables a study-
design adjustment so as to acquire sufficient statistical power. The major drawback resides 
in its inconsistency in validating genetic markers, especially in cases where allelic variants 
are not highly penetrant, making the results of these studies difficult to interpret. (Wu et al., 
2008 as cited in Sissung et al., 2010; Sissung et al., 2010) 
The pathway-based approach uses foreknowledge of both genetic variants and the 
pathways in which they are involved, therefore this approach has proven particularly useful 
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in identifying and characterizing pharmacogenetics end points within studies aimed to test 
the interaction between genes. The major obstacles reside in: the necessity of machine 
learning techniques; complexity of studies requiring larger sample sizes than candidate gene 
approaches; difficulty to validate gene–gene interactions due to incomplete understanding 
of the fundamental biology of the pathways’ interactions. (Sissung et al., 2010) 
The genome-wide approach is useful in determining the most significant SNPs associated 
with a phenotype amongst a high-density set of polymorphisms. GWAS are most useful to 
discover SNP associations where prior knowledge (i.e., mechanism, inheritance pattern, 
protein interactions and so on) is not available. Genome-wide association studies require a 
careful design of key issues like: a) type of study (case/control or continuous phenotype) 
according to the key-question and with a well-defined phenotype across all samples; b) 
sample sizes, dependent on specific effect size and type of study; c) population stratification 
between cases and controls; d) genotyping technology; e) raw data quality control and 
processing. (Wu et al., 2008 as cited in Sissung et al., 2010; Shianna, 2009)  
GWAS are discovery-driven rather than hypothesis-driven, they evaluate multiple 
hypotheses and require large sample size, cost and computing power, often resulting in 
weak statistical signals and false positives (i.e., Type I error). Frequently, GWAS require a 
two-stage design where discoveries are made using a high-density SNP array and are then 
validated using additional patient sets and a more hypothesis-driven approach. (Wu et al., 
2008 as cited in Sissung et al., 2010) Although recently GWAS application has dramatically 
increased, few studies have been published partially due to its primarily exploratory nature 
that requires further replication in large size and independent samples of the initial findings 
above the genome-wide significance and after correcting for multiple testing. For instance, 
in the case of antipsychotics drugs (ziprasidone, olanzapine, risperidone, iloperidone) 
GWAS revealed SNPs located in intergenic regions, but the functions of the variants on the 
drugs’ response are still unknown. (Jian-Ping Zhang, 2011) 
The application of GWAS in a population-based cohort allows the study of all possible 
genetic determinants of a drug response’s phenotype in a hypothesis-free (i.e., unbiased) 
approach and is performed on commercially available, efficient and cost-effective high-
throughput, genome-wide genotyping platforms (such as: Illumina’s Infinium BeadChips, 
Affymetrix GeneChips) targeting 100,000 SNPs, or 500,000 SNPs or even 1,000,000 SNPs of 
the genome. (Spraggs et al., 2009)   
Functional SNPs for each selected gene are added based on a literature survey and 
especially by using a minimum set of “tagging SNPs” (tSNPs) sufficient to capture the 
common genetic variations (whose minor allele frequency is higher than 2-5%) which allow 
almost complete genome coverage for the most of genetic diversity in human populations. 
(Grossman & Goldstein, 2009) Tagging SNPs greatly increase the genomic coverage of 
genetic variability and they reflect the well-established patterns of linkage disequilibrium, 
making possible to genotype only the tagging SNPs in order to capture the content of other 
associated SNPs in the region. The HapMap database with its incorporated software was 
created by The International HapMap Project (2005) and is an appropriate publicly available 
resource for selecting globally useful “tagging SNPs” that has been implemented by both 
commercial companies and academic laboratories. Tagging SNPs are chosen mainly based 
on r2 threshold, besides a variety of other criteria (ethnicity, SNP’s functional effects etc.). 
The r2 threshold is the correlation coefficient between any observed marker and a putative 
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causal allele and is a study-independent measure of SNP utility, being considered a leading 
standard for evaluating performance of marker sets; the minimum customary pair-wise 
value for r2 is 0.7-0.8. (Bakker, 2005 and Pe’er, 2006 as cited in Grossman & Goldstein, 2009) 
There are currently commercially available arrays (SNP chips) that contain close to 1 million 
tagging SNPs with excellent genomic coverage for most populations as defined in HapMap 
Project. For example, Illumina HumanMap 300 has essentially the same statistical genomic 
coverage as the Affymetrix Mapping 500 K Set, while the Illumina HumanMap 550 array is 
statistically superior for GWAS. (Hirschhorn & Daly, 2005; Barrett & Cardon, 2006; Pe’er et 
al., 2006, as cited in Shianna, 2009) 
2.3 Pharmacogenomics’ scope and goals 
The elucidation of the sequence of the human genome in 2001 and the identification and 
analysis of functional elements in the human genome by the ENCODE (ENCyclopedia Of 
DNA Elements) Project represented major steps towards a more comprehensive 
characterization of all functional elements in the human genome. Moreover, the HapMap 
Project aims to generate a haplotype map of the human genome, describing the common 
patterns of the human genetic variation which would affect complex, multigenic diseases and 
responses to drugs and environmental factors. The emergence of the term pharmacogenomics 
was possible after the availability of the human haplotype map (HapMap) and of high-
throughput genotyping platforms that have been facilitating more systematic genetic screens 
for new and clinically important drug targets. (Passetti et al., 2009) Therefore the concept of 
pharmacogenomics has progressively evolved from pharmacogenetics and expands beyond 
monogenic pharmacokinetics traits, making also the transition from associative genetic studies 
based on candidate gene hypothesis towards genome-wide association/screening studies 
(GWAS) in order to identify genetic biomarkers with prognostic role for disease progression 
and predictive capacity for drug responsiveness.  
The evolution from pharmacogenetics to pharmacogenomics was due to: a) the integration 
of –omics technologies and bioinformatics into the genomic medicine and systems 
pharmacology; b) the acquisition of catalogued genomic and clinical data bases (such as 
“Pharmacogenetics and Pharmacogenomics Knowledge Base”, „Connectivity Map”, 
International HapMap Project); c) identification of SNPs that ‘tag’ much of the common 
haplotype variation across any genomic region of a given population; d) positive genetic 
associations studies between specific genetic signature of patients and variations to standard 
therapeutic regimens; e) analytical and clinical validation of genetic biomarkers predictive 
for drug response. (Ayslin et al., 2009) 
According to the US Food and Drug Administration (FDA)-approved definitions, 
pharmacogenetics is ‘the study of variations in DNA sequence as related to drug response’ 
(Liewei et al., 2011), and currently is regarded as a subdomain of the much more 
comprehensive pharmacogenomics that is FDA-defined as ‘the study of variations of DNA 
and RNA characteristics as related to drug response’. (Trent, 2010) 
Pharmacogenomics studies the differential expression profiles at the level of the entire human 
genome in complex interaction to drugs, in a systemic and integrative manner. The 
identification of all the genetic and epigenetic differences that are the cause of phenotypic 
variations in patients’ responsivity to therapy is a major objective in pharmacogenomics. 
(Passetti et al., 2009) Each person’s phenotype is best determined by the paired combination of 
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the genome and the epigenome. Epigenetics and epigenomics refer to the study of factors that 
affect gene (or, more globally, genome) function, but without an accompanying change in 
genes. Typical epigenetic factors might be illustrated by changes in DNA methylation or in 
chromatin that modify genome structure and hence influence gene expression even in the 
absence of variations of DNA sequence. (Willard, 2009) Therefore, to achieve the main goal of 
therapy individualization, pharmacogenomics should also evaluate genetic variation in the 
context of the individual: gene–gene, gene–drug and gene–environment interactions which 
might influence the course of a disease and the response to treatment. (Passetti et al., 2009)  
Pharmacogenomics is the interface between genomic medicine and systems pharmacology, 
the two essential pillars supporting the gateway to personalized medicine. (Aislyn et al., 
2009) The transdisciplinary field of genomic medicine refers to the use of large-scale 
genomic information and to the consideration of the full extent of an individual’s genome, 
proteome, transcriptome, metabolome and/or epigenome in the practice of medicine and 
medical decision-making. Genomic medicine’s approaches include gene expression 
profiling to characterize diseases and define diseases’ prognosis, genotyping variants in 
genes involved in drug metabolism or action in order to select the correct therapeutic 
dosage for an individual, scanning the entire genome for millions of variants that influence 
an individual’s susceptibility to disease, or analyzing multiple biomarkers to monitor 
therapy and to provide predictive information in presymptomatic individuals. (Willard, 
2009) Genomic medicine brings together knowledge on the relationships between genetics, 
pathophysiology and pharmacology, thus forming the base for systems pharmacology. 
Experimental and computational approaches enable systems pharmacology to provide 
holistic, mechanistic information on disease networks and drug responses, and to identify 
new drug targets and specific drug combinations. Network analyses of interactions involved 
in pathophysiology and drug response across multiple scales of organization, from 
molecular to whole organism, will allow the integration of the systems-level understanding 
of drug action with genomic medicine, thus generating the personalized medicine. (Aislyn 
et al., 2009) Personalized medicine refers to a rapidly advancing field of health care that 
takes into account each person’s unique clinical, genomic and environmental information. 
The goals of personalized medicine are to optimize preventive health care strategies and 
outcomes of drug therapies for each individual, while people are still healthy or at the 
earliest stages of disease, by an unprecedented customization or tailoring of medication 
types and dosages and/or prophylactic measures. (Willard, 2009) 
The great promise of pharmacogenomics towards personalized medicine resides mainly in 
generating an individualized therapeutic guide, highly predictive for much safer and more 
efficient drug and doses choice for an accurately predicted, homogenously genotype-
segment of patients who are responders to the treatment, rather being focused around each 
individual specifically. (Grossman & Goldstein, 2009) 
Pharmacogenomics aims to individualize therapy on the patient’s specific genetic profile, by 
matching the right drug to the right patient at the right time. Pharmacogenomics’ translation 
from bench into clinical practice is broadening the perspective of personalized medicine so 
as in the near future we might rely on a “DNA chip”/“pharmacogenomic card” specific to 
each patient and on each genotype preemptively recorded in electronic medical records in 
order to individualize both the diagnostic procedures and the safest and most efficient 
medications prior to treatment initiation. 
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3. Pharmacokinetic pharmacogenetics 
Relevant allelic variants to drug treatment’s outcome have been discovered in the genes 
encoding enzymes and transporters involved in drug pharmacokinetics: absorption, 
distribution, metabolism and excretion (ADME). Enzymes involved in the 
biotransformation of xenobiotics are classified as phase I or phase II. Phase I enzymes 
catalyze hydrolysis, reduction and oxidation reactions, while phase II enzymes catalyze 
conjugation reactions such as sulfation, acetylation and glucuronidation. (Sissung et al. 
2010). The majority of phase I reactions are catalyzed by the cytochrome P450 (CYP) 
enzymes. There are 57 cytochrome P450 (CYP) genes and about the same number of 
pseudogenes, which are grouped according to their sequence similarity into 18 families 
and 44 subfamilies. However, only three of those families, CYP1, CYP2 and CYP3, 
catalyze most phase I reactions of drugs; over 75% of prescribed drugs are metabolized at 
least in part by three subfamilies: CYP3A, CYP2D6 and CYP2C. (Zanger et al., 2008; van 
Schaik, 2008, as cited in Sissung et al., 2010) Phase II reactions significantly enable the 
excretion of drugs by considerably increasing the hydrophilicity of the substrate or 
deactivate highly reactive species. Key phase II enzymes include N-acetyltransferases 1 
and 2 (NAT1 and NAT2), thiopurine S-methyltransferase (TPMT), and the uridine 
diphosphate glucuronosyltransferase (UGT) family; polymorphisms in these genes have 
been shown to have clinical implications for a variety of diseases. (Zhou et al., 2008, as 
cited in Sissung et al., 2010) 
3.1 Pharmacogenetics of drug-metabolizing enzymes 
Biotransformation of the 200 most often prescribed drugs is catalyzed by members of the 
CYP3A family (37% of the drugs), followed by CYP2C9 (17%), CYP2D6 (15%), CYP2C19 
(10%), CYP1A2 (9%), and CYP2C8 (6%), while CYP2B6 and other CYP isoforms (CYP2A6 
and CYP2E1) participate in the metabolism of 4% and 2% of the drugs, respectively. The 
clinically well-established polymorphisms of CYP2C9, CYP2C19, and CYP2D6 genes are 
involved in approximately half of these top 200 drugs, since many of the drugs used in high-
prevalence diseases in the Western countries are known to be metabolized by these CYPs. 
(Zanger et al., 2008) 
CYP2C9, highly expressed in liver, metabolizes many weakly acidic substances like the 
anticoagulant warfarin, the anticonvulsants phenytoin and valproic acid, cardiovascular 
drugs like rosuvastatin and losartan, and several nonsteroidal anti-inflammatory drugs 
(NSAIDs). Many of these drugs have a narrow therapeutic index, and variations in CYP2C9 
activity are among the recognized factors for adverse drug reactions. In vitro and clinical 
studies have consistently demonstrated that the CYP2C9*2 and *3 alleles are associated with 
significant, but highly variable, reductions in intrinsic clearance depending on the particular 
substrate; for instance, CYP2C9*3 allele might be associated to up to 90% reduction in the 
enzymatic activity of the CYP2C9 protein. The prevalence of CYP2C9*2 and *3 alleles is 35% 
in Caucasians and much lower in black and Asian populations. Carriers of CYP2C9*2 and 
CYP2C9*3 alleles are poor metabolizers and have high plasma levels due to low clearance of 
the substrate-drugs, therefore they experience higher incidences of adverse drug reactions 
like hypoglycemia from antidiabetic drugs, gastrointestinal bleeding from NSAIDs, and 
serious bleeding from warfarin treatment. (Pilotto et al., 2007, and Flockhart et al., 2008, as 
cited in Zanger et al., 2008) 
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The CYP2C19 isozyme metabolizes preferentially proton-pump inhibitors (PPI) like 
omeprazole and pantoprazole indicated in gastroesophageal reflux disease, gastric and 
duodenal ulcer. The poor metabolizer (PM) phenotype results from two null alleles, leading 
to the absence of functional CYP2C19 protein, whereas extensive metabolizers carry at least 
one functional allele. The prevalence of null alleles is about 3–5% to white and black 
populations, whereas up to 20% of Asians are carriers of two null alleles. The two most 
common null alleles are CYP2C19*2 occurring exclusively in Caucasians, and CYP2C19*3 
occurring primarily in Asians. The PPI-efficacy depends on the plasma concentrations 
achieved over time, which are strongly influenced by CYP2C19 gene polymorphisms. PM 
subjects who are carriers of null alleles benefit from their lower metabolism rate because 
their drug levels are maintained higher for longer periods. On the contrary, subjects with the 
CYP2C9 *1/*1 wild-type genotype should receive higher doses of these PPIs in order to 
achieve stronger acid suppression compared to *1/*2 and *2/*2 subjects. (Kawamura et al., 
2007, as cited in Zanger et al., 2008; Zanger et al., 2008; Tomalik-Scharte et al., 2008) 
The clinical consequences of pharmacokinetic variability associated to genetic 
polymorphisms of CYP2D6 gene for tricyclic and selective serotonin re-uptake inhibitors 
antidepressants, beta-blockers, anticancer agent tamoxifen, as well as to the CYP2C9 genetic 
variants for AT1 (angiotensin II type 1) receptor antagonists (sartans), and anticoagulants 
(warfarin, acenocoumarol, phenprocoumon), are covered in other chapters of the book. 
The CYP3A4 subfamily contributes to the metabolism of the most diverse group of 
substrates of all human P450s, as their active sites are flexible enough to bind and 
metabolize many preferentially lipophilic, structurally large compounds, such as: the 
immunosuppressants cyclosporin A and tacrolimus, macrolide antibiotics like 
erythromycin, anticancer drugs like taxol, benzodiazepines, hydroxymethylglutaryl-
coenzyme A (HMG-CoA) reductase inhibitors like simvastatin and atorvastatin, and 
anesthetics. In addition, CYP3A4 is the only human drug-metabolizing P450 that shows a 
significant sex difference, in that women express approximately 1.5- to 2-fold more CYP3A4 
and have higher in vivo clearance of several typical CYP3A4 drug substrates than men. 
Although a number of large-scale sequencing and phenotype–genotype correlation studies 
have been carried out, the functional effects of CYP3A4 gene polymorphisms on drugs 
pharmacokinetic variability remain controversial. (Zanger et al., 2008) However, CYP3A4 
basal and inducible expression phenotype might be influenced by other genes, such as: a) 
multiple drug resistance gene MDR1 whose 2677T (Ser893) allele induced higher basal 
CYP3A4 expression and activity, whereas the 2677G allele showed a higher rifampicin 
induction ratio in primary hepatocytes; b) pregnan X receptor PXR gene polymorphisms 
mostly located in promoter or intron 1 regions associated with CYP3A4 basal and inducible 
expression levels. (Liu, 2007 and Lamba, 2008, as cited in Zanger et al., 2008) 
N-acetyltransferase type 2 (NAT2) is a phase II drug metabolizing enzyme responsible for 
hepatic bioconversion of major antituberculosis agent isoniazid to acetylisoniazid. Isoniazid 
is a pivotal agent in the treatment of tuberculosis, that remains a global emergency due to 
the growing prevalence of drug-resistant Mycobacterium tuberculosis and of HIV infection. 
NAT2 gene is affected by a bimodal distribution polymorphism (acetylation polymorphism) 
described after clinical observation of more frequently and more severely peripheral 
neuropathy and hepatotoxicity as adverse drug reactions to the slow-acetylators patients. 
These patients have mean elimination half-lives of 180 min. in comparison with 80 min. for 
rapid-acetylators. Carriers of at least one wild-type allele (NAT2*4) or a high-activity variant 
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allele (NAT2*12) have proven high NAT2 enzymatic activity (rapid acetylators), whereas 
those with two low-activity variants are slow acetylators. Rapid acetylators are more 
prevalent in East Asia (58-90%) than in Europe (32-43%). Tailoring isoniazid therapy means 
to increase isoniazid dose to rapid acetylators so as to achieve therapeutic efficacy and to 
reduce the dose administered to slow-acetylators so as to avoid adverse drug reactions 
while maintaining the desired antituberculosis effect. (Tomalik-Scharte et al., 2008) 
Pharmacogenetics of other phase II drug-metabolizing enzymes is discussed in detail in 
other chapters for: thiopurine-S-methyl-transferase (TPMT) polymorphisms and the 
necessity to individualize the therapeutic doses of mercaptopurine and azathioprine; 
dihydropyrimidine dehydrogenase deficiency syndrome noticed during the treatment with 
standard doses of fluoropyrimidines (5-fluorouracil) to a segment of cancer patients carriers 
of certain genetic mutations; the pharmacokinetic variability and increased risk of 
myelotoxicity noticed for the anticancer drug irinotecan as a consequence of genetic 
polymorphism of UDP-glucuronosyltransferase (UGT1A1). 
3.2 Pharmacogenetics of transporters 
Transporters play a critical role in ADME because they are involved in the efflux and/or 
influx of drugs via active transport or facilitated diffusion, thus transporters affect drug 
uptake, bioavailability, targeting, efficacy, toxicity and clearance and they should be 
considered in combination with metabolic enzymes when discussing drugs’ outcomes. Two 
types of transport superfamilies, ATP-binding cassette (ABC) proteins generally acting as 
efflux pumps and solute-linked carrier (SLC) proteins as typically influx transporters, are 
responsible for the majority of drug and endogenous substrates transport. Many 
transporters have a broad range of substrates; for instance, ABCB1, also known as P-
glycoprotein and MRD1, transports several classes of drugs, including anticancer agents, 
antibiotics, immunosuppressants and statins. (Sissung et al., 2010) 
Largely as a result of the Human Genome Project, great advances in molecular biology, 
sequencing methods and availability of genome-wide technologies, genetic variants across the 
entire genome, including coding and noncoding regions of multiple transporter genes were 
identified, functionally characterized and associated with various drug-response phenotypes. 
Thus, functionally relevant polymorphisms were discovered for the members of ABC and SLC 
superfamilies of transporters and have been widely studied with positive associations to 
individual susceptibility to drug-induced adverse events, to variations in drug plasma levels, 
or renal clearance. (Yee SW et al., 2010) For instance, the organic anion transporting 
polypeptide polymorphism SLCO1B1*5 (Val174Ala, c.521T>C) is associated with variability in 
response to statins (atorvastatin, pravastatin, pitavastatin, rosuvastatin, simvastatin), 
repaglinide, fexofenadine and methotrexate. The SLCO1B1 genotype affects the transport 
function and may predict, in a substrate-dependent manner, the attenuated lipid-lowering 
response to statin therapy. Moreover, stronger evidence has been provided for the role of the 
SLCO1B1 genotype in predicting the development of myopathy among patients receiving 
simvastatin in 40 mg doses. (Yee SW et al., 2010; Romaine et al., 2010) Prescribing relatively 
low dose of simvastatin to those who are heterozygous for the high risk allele SLCO1B1 could 
reduce the incidence of myopathy by nearly 60%, while avoiding simvastatin only to those 
who are homozygous for the risk allele (nearly 2% of the population analyzed by the SEARCH 
group) could reduce the incidence of myopathy by 25%. Further investigation is required to 
identify the optimal therapeutic approach. (Nakamura, 2008)  
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Furthermore, organic cationic transporter OCT1 (R61C, P160L, G401S, 420del and G465R) 
and OCT2 (A270S) polymorphisms are associated with response’s variability to metformin, 
cisplatin and imatinib. The ABCG2 genotype (rs2231142, Gln141Lys, c.421C>A) is associated 
with variable pharmacokinetics parameters of atorvastatin, rosuvastatin, gefitinib, 
sulfasalazine and diflomotecan. ABCB1 gene polymorphisms (c.3435C>T, 2677G/T/A) 
and/or ABCC2 (-24C>T, c.1249G>T, c.3972C>T, c.4544C>T) are related to therapeutic and 
adverse effects to anticancer, antiviral and/or antiepileptic drugs. (Yee SW et al., 2010)  
SNPs of ABCB1 were found to be associated with moderate-to-severe neutropenia, hand–
foot syndrome and diarrhoea in colorectal patients treated with capecitabine or 5-
fluorouracil. (Gonzales-Haba et al., 2010) 
Nonsynonymous (coding) SNPs generally appear to affect the expression level of the 
transporter on the plasma membrane and the transporter function in a substrate-dependent 
manner. In comparison to nonsynonymous variants, noncoding region variants (such as in 
the proximal promoter region) are more abundant, minor allele frequencies being often 
higher and the functional consequences are more modest and highly dependent upon the 
haplotype. The frequency of noncoding polymorphisms are greater in ABC transporters 
highly expressed in the liver than in SLC predominantly expressed in the kidney. The 
projected functional map of the ‘transporter genome’ will characterize gene regions 
(enhancer regions upstream, downstream and intronic regions of transporter genes) having 
relevant functional variants and it will be superimposed on the genetic variants resulted 
from the 1000 Genomes Project in multiple ethnic populations. (Yee SW et al., 2010) 
3.3 AmpliChip™ CYP450 test 
In 2005, the FDA approved the first pharmacogenetic test AmpliChip™ CYP450 Test (Roche 
Molecular Systems, Inc., NJ, USA) based on Affymetrix (CA, USA) microarray technology 
for genotyping 27 alleles in CYP2D6 and three alleles in CYP2C19 genes associated with 
different metabolizing phenotypes. The test is recommended for the assessment of the 
patient’s metabolizing status for each drug that is a substrate for CYP450 isoenzymes 2D6 
and 2C19 and for the dose adjustements in outlier patients who are either ultrarapid- (UM) 
or poor-metabolizers (PM), in order to achieve the therapeutic efficacy and to avoid the risk 
of severe adverse reactions. (Squassina et al., 2010) Key genetic mutations associated with 
clinical relevance on drug plasma concentrations and risk of either lack of efficacy for UM or 
adverse drug reactions for PM, are used to predict the metabolizer phenotype (ultrarapid, 
extensive, intermediate and poor metabolizers). FDA has included these biomarkers only as 
informational pharmacogenetic tests on labels of drugs mainly metabolized by these 
pathways, such as: CYP2C19 genotyping for prasugrel, voriconazol, (es)omeprazole, and 
genotyping CYP2D6 for tamoxifen, atomoxetine, fluoxetine, paroxetine, amitriptyline, 
aripiprazole, risperidone, codeine, tramadol, timolol, propranolol, carvedilol. The purpose 
of these informational pharmacogenetic tests is to improve drug safety by dose optimization 
based on genotypes predictive for poor- or ultrarapid-metabolizer status, as well as to avoid 
high plasma concentration when co-administered with other drugs which are CYP2D6 
strong inhibitors. (Squassina et al., 2010) 
For instance, patients with poor metabolizer phenotype associated to null alleles CYP2D6*4, 
*3, *5, or CYP2D6*6, will have higher risk of the adverse reaction tardive diskinesia at 
standard doses of antipsychotics. The individualized doses for these PM patients will be 
reduced than standard regimens designed for wild-type normally functional allele. On the 
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reduce the dose administered to slow-acetylators so as to avoid adverse drug reactions 
while maintaining the desired antituberculosis effect. (Tomalik-Scharte et al., 2008) 
Pharmacogenetics of other phase II drug-metabolizing enzymes is discussed in detail in 
other chapters for: thiopurine-S-methyl-transferase (TPMT) polymorphisms and the 
necessity to individualize the therapeutic doses of mercaptopurine and azathioprine; 
dihydropyrimidine dehydrogenase deficiency syndrome noticed during the treatment with 
standard doses of fluoropyrimidines (5-fluorouracil) to a segment of cancer patients carriers 
of certain genetic mutations; the pharmacokinetic variability and increased risk of 
myelotoxicity noticed for the anticancer drug irinotecan as a consequence of genetic 
polymorphism of UDP-glucuronosyltransferase (UGT1A1). 
3.2 Pharmacogenetics of transporters 
Transporters play a critical role in ADME because they are involved in the efflux and/or 
influx of drugs via active transport or facilitated diffusion, thus transporters affect drug 
uptake, bioavailability, targeting, efficacy, toxicity and clearance and they should be 
considered in combination with metabolic enzymes when discussing drugs’ outcomes. Two 
types of transport superfamilies, ATP-binding cassette (ABC) proteins generally acting as 
efflux pumps and solute-linked carrier (SLC) proteins as typically influx transporters, are 
responsible for the majority of drug and endogenous substrates transport. Many 
transporters have a broad range of substrates; for instance, ABCB1, also known as P-
glycoprotein and MRD1, transports several classes of drugs, including anticancer agents, 
antibiotics, immunosuppressants and statins. (Sissung et al., 2010) 
Largely as a result of the Human Genome Project, great advances in molecular biology, 
sequencing methods and availability of genome-wide technologies, genetic variants across the 
entire genome, including coding and noncoding regions of multiple transporter genes were 
identified, functionally characterized and associated with various drug-response phenotypes. 
Thus, functionally relevant polymorphisms were discovered for the members of ABC and SLC 
superfamilies of transporters and have been widely studied with positive associations to 
individual susceptibility to drug-induced adverse events, to variations in drug plasma levels, 
or renal clearance. (Yee SW et al., 2010) For instance, the organic anion transporting 
polypeptide polymorphism SLCO1B1*5 (Val174Ala, c.521T>C) is associated with variability in 
response to statins (atorvastatin, pravastatin, pitavastatin, rosuvastatin, simvastatin), 
repaglinide, fexofenadine and methotrexate. The SLCO1B1 genotype affects the transport 
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contrary, to achieve the required level of therapeutic efficacy, ultrarapid metabolizers who 
are carriers of CYP2D6*Nxn multiple functional alleles will be treated with higher doses 
than those standard recommended for the “average” patients population able to normally 
metabolize the drugs. However, mothers with phenotype of ultrarapid metabolizers will 
rapidly convert standard doses of codeine into morphine thus increasing the risk of CNS 
depression of their breast-fed babies; in such cases of prodrug bioconversion, dose 
optimization requires to be lower than the standard dose. (Loo et al., 2010) 
Although it is widely available in commercial labs, the AmpliChip™ CYP450 Test has still a 
limited clinical value because it is expensive (over $600/test), time-consuming (i.e. about 
two weeks), and yet there are no prospective study to demonstrate the cost-effective benefit 
of genotyping patients and selecting and dosing antipsychotic drugs accordingly. (Jian-Ping 
Zhang, 2011)  
3.4 DMET Plus Panel genotyping platform 
While the field of pharmacogenetics is moving towards exploratory, large-scale analyses of 
the interaction between genetic variation and drug treatment, the Drug Metabolizing 
Enzymes and Transporters DMET Plus Panel (Affymetrix) genotyping platform has proven 
a significant research tool. The DMET Plus Panel platform is a low- to mid-scale pathway-
based, hypothesis-driven and exploratory pharmacogenetic approach, which interrogates 
1936 genetic variations (copy-number variations, insertions/deletions, biallelic and triallelic 
single nucleotide polymorphisms SNPs) in 225 genes involved in the absorption, 
distribution, metabolism and elimination (ADME) of a very wide range of therapeutics, as 
well as a number of genes which regulate intracellular processes that facilitate ADME 
through indirect relationships, thus comprising biomarkers for all FDA-validated genes and 
included in the drugs’ label. (Sissung et al., 2010; Squassina et al., 2010) 
The DMET Plus Panel platform is particularly useful for standardization of exploratory 
pharmacogenetics and for improvement of the clinical trials’ design conducted on smaller 
patient populations, having more variable end points and polygenetic traits, enabling 
increased statistical power and reduction of type I error (i.e., false positive) of GWAS. In 
addition, the application of DMET Plus Panel platform in phase I early clinical trials could 
identify the polymorphisms consistently associated with drugs’ pharmacokinetic 
variations, determine the recommended dose for later phase II and phase III trials based 
on genetic profile, thus reducing the attrition rate for new investigational agents. 
Moreover, besides detection of more common genetic variants, DMET is able to 
interrogate core biomarkers with an average minor allele frequency below 9%, in 
comparison with other SNP detection methods for minor alleles with an average 
frequency of 20%. However, the DMET Plus Panel platform’s utility resides mainly in the 
research setting, since it is not yet FDA approved, not customizable, does not include 
polymorphisms in many drug targets or in genes that are related to environmental 
exposures that could influence drug metabolism, and requires prospective clinical 
validation in order to translate the results in pertinent personalized medicine. (Sissung et 
al., 2010; Squassina et al., 2010) 
Although genetic variation in ADME genes is essential in personalizing therapy, 
polymorphisms in genes not directly responsible for drug metabolism or transport, but 
regulating expression of many genes that encode transporters and phase I and phase II 
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enzymes, play critical roles in patients’ response to treatment. For example, many SNPs in 
the nuclear receptors pregnane X receptor (PXR) and constitutive/active androstane 
receptor genes alter the expression levels of ABCB1, ABCC2, CYP2C8, CYP3A4, UGTs and 
sulfotransferases (SULTs) genes and contribute to variability in drug efficacy and safety. 
(Sissung et al., 2010) 
4. Pharmacodynamic pharmacogenetics 
Pharmacodynamics can be defined as the study of the biochemical and physiological 
effects of drugs and their mechanism of action. The effects of drugs result from their 
interaction with macromolecular components of the organism – receptors, which are 
grouped in a wide range of structural and functional families. The receptor occupancy by 
a particular drug class triggers biochemical cascades in target cells and modulates diverse 
intrinsic signaling pathways and functions, explaining the pharmacodynamic effect. (Ross 
& Kenakin, 2006) 
In addition to  genetic polymorphisms of ADME genes, the clinical outcome of standard 
therapeutic drug regimens is influenced by genetic variations in genes encoding drug 
targets (receptors, enzymes, ion channels, neurotransmitter’s transporter) and pathways 
affected by drugs. 
Since pharmacogenetics of heart diseases therapy, anticoagulants, asthma medication, 
anticancer agents including thiopurines, antidepressants, osteoporosis and antimalaria 
drugs, represent other distinct chapters of the book, in order to avoid overlapping 
information, this chapter will illustrate some functionally relevant polymorphisms of the 
drug target genes and their role in the interindividual variability of drugs’ 
pharmacodynamics, in a complementary manner to the aforementioned issues. 
4.1 Pharmacogenetics of drug hypersensitivity: Human Leukocytes Antigens (HLA) 
system 
In the field of highly active antiretroviral therapy (HAART), abacavir has created a 
translational roadmap for a pharmacogenetic biomarker from discovery to a test used in real 
clinical practice. The strong association between abacavir hypersensitivity reaction and 
HLA-B*5701 genotype has been demonstrated in both observational and blinded 
randomized clinical trials in racially diverse populations and represents the best example of 
the clinical utility of pharmacogenetic screening in HIV medicine. (Mallal et al., 2008) 
Hypersensitivity reaction to abacavir was observed during the clinical development 
program in approximately 5–8% of patients. Hypersensitivity reaction (HSR) symptoms 
appear early and resolve upon discontinuation of the drug, but worsen (and can be life-
threatening) with continued drug administration. Development of an abacavir skin patch 
assay enabled refinement of the hypersensitivity reaction phenotype. The biomarker HLA-
B*5701, validated in retrospective and prospective studies, was recommended in the drug 
label in the EU and USA. The prospective screening for this biomarker in Caucasians as high 
risk population allows a reduction in HSR frequency from 7.8% to 3.4%. (Trent, 2010)  
The increased benefit–to–risk ratio and the economic consequences of HLA-B*5701  
pre-screening of HIV-infected patients before abacavir treatment’s initiation were 
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are carriers of CYP2D6*Nxn multiple functional alleles will be treated with higher doses 
than those standard recommended for the “average” patients population able to normally 
metabolize the drugs. However, mothers with phenotype of ultrarapid metabolizers will 
rapidly convert standard doses of codeine into morphine thus increasing the risk of CNS 
depression of their breast-fed babies; in such cases of prodrug bioconversion, dose 
optimization requires to be lower than the standard dose. (Loo et al., 2010) 
Although it is widely available in commercial labs, the AmpliChip™ CYP450 Test has still a 
limited clinical value because it is expensive (over $600/test), time-consuming (i.e. about 
two weeks), and yet there are no prospective study to demonstrate the cost-effective benefit 
of genotyping patients and selecting and dosing antipsychotic drugs accordingly. (Jian-Ping 
Zhang, 2011)  
3.4 DMET Plus Panel genotyping platform 
While the field of pharmacogenetics is moving towards exploratory, large-scale analyses of 
the interaction between genetic variation and drug treatment, the Drug Metabolizing 
Enzymes and Transporters DMET Plus Panel (Affymetrix) genotyping platform has proven 
a significant research tool. The DMET Plus Panel platform is a low- to mid-scale pathway-
based, hypothesis-driven and exploratory pharmacogenetic approach, which interrogates 
1936 genetic variations (copy-number variations, insertions/deletions, biallelic and triallelic 
single nucleotide polymorphisms SNPs) in 225 genes involved in the absorption, 
distribution, metabolism and elimination (ADME) of a very wide range of therapeutics, as 
well as a number of genes which regulate intracellular processes that facilitate ADME 
through indirect relationships, thus comprising biomarkers for all FDA-validated genes and 
included in the drugs’ label. (Sissung et al., 2010; Squassina et al., 2010) 
The DMET Plus Panel platform is particularly useful for standardization of exploratory 
pharmacogenetics and for improvement of the clinical trials’ design conducted on smaller 
patient populations, having more variable end points and polygenetic traits, enabling 
increased statistical power and reduction of type I error (i.e., false positive) of GWAS. In 
addition, the application of DMET Plus Panel platform in phase I early clinical trials could 
identify the polymorphisms consistently associated with drugs’ pharmacokinetic 
variations, determine the recommended dose for later phase II and phase III trials based 
on genetic profile, thus reducing the attrition rate for new investigational agents. 
Moreover, besides detection of more common genetic variants, DMET is able to 
interrogate core biomarkers with an average minor allele frequency below 9%, in 
comparison with other SNP detection methods for minor alleles with an average 
frequency of 20%. However, the DMET Plus Panel platform’s utility resides mainly in the 
research setting, since it is not yet FDA approved, not customizable, does not include 
polymorphisms in many drug targets or in genes that are related to environmental 
exposures that could influence drug metabolism, and requires prospective clinical 
validation in order to translate the results in pertinent personalized medicine. (Sissung et 
al., 2010; Squassina et al., 2010) 
Although genetic variation in ADME genes is essential in personalizing therapy, 
polymorphisms in genes not directly responsible for drug metabolism or transport, but 
regulating expression of many genes that encode transporters and phase I and phase II 
Pharmacogenetics:  
Matching the Right Foundation at Personalized Medicine in the Right Genomic Era 
 
13 
enzymes, play critical roles in patients’ response to treatment. For example, many SNPs in 
the nuclear receptors pregnane X receptor (PXR) and constitutive/active androstane 
receptor genes alter the expression levels of ABCB1, ABCC2, CYP2C8, CYP3A4, UGTs and 
sulfotransferases (SULTs) genes and contribute to variability in drug efficacy and safety. 
(Sissung et al., 2010) 
4. Pharmacodynamic pharmacogenetics 
Pharmacodynamics can be defined as the study of the biochemical and physiological 
effects of drugs and their mechanism of action. The effects of drugs result from their 
interaction with macromolecular components of the organism – receptors, which are 
grouped in a wide range of structural and functional families. The receptor occupancy by 
a particular drug class triggers biochemical cascades in target cells and modulates diverse 
intrinsic signaling pathways and functions, explaining the pharmacodynamic effect. (Ross 
& Kenakin, 2006) 
In addition to  genetic polymorphisms of ADME genes, the clinical outcome of standard 
therapeutic drug regimens is influenced by genetic variations in genes encoding drug 
targets (receptors, enzymes, ion channels, neurotransmitter’s transporter) and pathways 
affected by drugs. 
Since pharmacogenetics of heart diseases therapy, anticoagulants, asthma medication, 
anticancer agents including thiopurines, antidepressants, osteoporosis and antimalaria 
drugs, represent other distinct chapters of the book, in order to avoid overlapping 
information, this chapter will illustrate some functionally relevant polymorphisms of the 
drug target genes and their role in the interindividual variability of drugs’ 
pharmacodynamics, in a complementary manner to the aforementioned issues. 
4.1 Pharmacogenetics of drug hypersensitivity: Human Leukocytes Antigens (HLA) 
system 
In the field of highly active antiretroviral therapy (HAART), abacavir has created a 
translational roadmap for a pharmacogenetic biomarker from discovery to a test used in real 
clinical practice. The strong association between abacavir hypersensitivity reaction and 
HLA-B*5701 genotype has been demonstrated in both observational and blinded 
randomized clinical trials in racially diverse populations and represents the best example of 
the clinical utility of pharmacogenetic screening in HIV medicine. (Mallal et al., 2008) 
Hypersensitivity reaction to abacavir was observed during the clinical development 
program in approximately 5–8% of patients. Hypersensitivity reaction (HSR) symptoms 
appear early and resolve upon discontinuation of the drug, but worsen (and can be life-
threatening) with continued drug administration. Development of an abacavir skin patch 
assay enabled refinement of the hypersensitivity reaction phenotype. The biomarker HLA-
B*5701, validated in retrospective and prospective studies, was recommended in the drug 
label in the EU and USA. The prospective screening for this biomarker in Caucasians as high 
risk population allows a reduction in HSR frequency from 7.8% to 3.4%. (Trent, 2010)  
The increased benefit–to–risk ratio and the economic consequences of HLA-B*5701  
pre-screening of HIV-infected patients before abacavir treatment’s initiation were 
 
Clinical Applications of Pharmacogenetics 
 
14
demonstrated in a prospective double-blinded clinical trial sponsored by GSK. (Mallal et al., 
2008; Roses, 2009; Phillips et al., 2011) 
Moreover, consistent data support the association of the HLA class II allele HLA-DRB*0101 
with an increased risk of nevirapine-induced hepatotoxicity, as well as genotype-related 
peripheral neuropathy, hyperlipidaemia, lipodystrophy to HAART, nucleoside reverse 
transcriptase inhibitors-related pancreatitis and tenofovir-associated renal proximal 
tubulopathy. (Tozzi, 2010) 
Other recent examples of important HLA associations with drug hypersensitivity include 
HLA-B*1502 and Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) 
that are associated with carbamazepine in Han Chinese; HLA-B*5801 and SJS/TEN and 
drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic 
symptoms associated with allopurinol; HLA-B*5701 and flucloxacillin-induced liver 
injury. These pharmacogenetic associations hold the promise to convert the severe and 
adverse drug reactions into predictable and preventable ones in the future. (Phillips et al., 
2011) 
4.2 Pharmacodynamic pharmacogenetics of antipsychotics  
Pharmacogenetic investigations of schizophrenia susceptibility loci and genes controlling 
drug target receptors, the blood–brain barrier systems, and epigenetic mechanisms could 
lead to a molecular classification of treatment response and adverse events of psychotropic 
drugs. It is estimated that more than 70% of patients with chronic schizophrenia 
discontinued their antipsychotic drugs, owing to poor effectiveness or tolerability. Most of 
the pharmacodynamic pharmacogenetic studies in schizophrenia have evaluated treatment 
response using the candidate gene approach.  
The most relevant associations of genetics variants and antipsychotic clinical response 
were found for 141C Ins/Del in dopamine receptor gene DRD2, A-1438G in 5-
hydroxytriptamine/ serotonin receptor gene HTR2A, His452Tyr in HTR2A gene, Taq1A in 
DRD2, Ser9Gly in DRD3, T102C SNP in HTR2A, C759T SNP in HTR2C gene. For instance, 
patients who carry one or two Del alleles tend to have less favorable antipsychotic drug 
responses than patients with the Ins/Ins genotype in DRD2 141C Ins/Del SNPs. Patients 
with G/G genotype for the HTR2A A-1438G polymorphism were less likely to respond to 
clozapine, olanzapine and aripiprazole, especially in negative symptoms, than other 
polymorphisms at this HTR2A locus. For the His452Tyr HTR2A genetic variants, the 
Tyr/Tyr genotype predicted poor response to clozapine. Higher risk of the adverse 
reaction tardive diskinesia was found for carriers of either: A2/A2 genotype at DRD2 
Taq1A locus, Gly allele at DRD3  Ser9Gly, or C allele for 5HT2A T102C. (Jian-Ping Zhang, 
2011) 
Furthermore, single-nucleotide substitutions in the promoter region of serotonin receptor 
type 2C (5-HT2C) could be associated with antipsychotics-induced weight gain and 
metabolic abnormalities in Han Chinese patients treated over a 10-week period. The C/C 
genotype from 5HT2C SNP C759T was associated with higher weight gain to clozapine and 
olanzapine. Comparable results were found in Caucasians treated 9 months with these anti-
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psychotics: carriers of the -795T variation gained less weight than study participants without 
this allele. (Broich & Moeller, 2008) 
A repeat length polymorphism of the gene encoding the serotonin transporter, 5-HTTLPR, 
involves insertion/deletion of a 44-bp segment located upstream of the transcription start 
site in the promoter region; patients carrying the long allele are about twice as likely to 
respond to treatment at 4 weeks and reach remission, and less likely to suffer from side 
effects, than patients with the short/short genotype; short allele is associated with poor 
response to clozapine and risperidone treatment. (Jian-Ping Zhang, 2011) Moreover, 
insertion/deletion polymorphism in the promoter region of the serotonin transporter gene 
is also associated to clinical phenotype response to the antidepressants citalopram, 
paroxetine and fluoxetine. (Yee SW et al., 2010) 
4.3 Pharmacodynamic pharmacogenetics of antidiabetics 
Thiazolidinedione drugs (pioglitazone, rosiglitazone) promote the binding of the 
transcription factor peroxisome proliferator-activated receptor- (PPAR- ) to its DNA 
response element. Thiazolidinediones promote adipocyte differentiation, increase insulin-
stimulated glucose uptake into muscle, insulin suppression of hepatic glucose output, and 
insulin-stimulated lipolysis. The genetic variation Pro12Ala at the PPARG gene (encoding 
PPAR- ) influences the clinical outcome: those carrying the Ala allele have a greater 
response to rosiglitazone, as well as a lower risk of edema after farglitazar or ragaglitazar 
therapy, than Pro/Pro homozygotes. (Kang ES et al., 2005 and Hansen et al., 2006, both cited 
in Pearson, 2009) The hypoglycemic effect of rosiglitazone might also be influenced by 
adiponectin gene ADIPOQ polymorphisms SNP +45T/G and SNP +276G/T: homozygotes 
G/G at +45 or +276 have a smaller clinical benefit. (Kang ES et al., 2005 as cited in Pearson, 
2009) Sulfonylureas (tolbutamide, glimepiride, glibenclamide) bind to the SUR1 moiety of 
the pancreatic -cell KATP channel causing the channel to close and triggering insulin 
secretion. The clinical efficacy of sulfonylureas seems to be associated to genetic variations 
in the KCNJ11 gene (encoding the Kir6.2 subunit of the KATP channel) and the ABCC8 gene. 
(Pearson, 2009) The polymorphisms ABCC8 Ser1369Ala and KCNJ11 rs5210 and E23K are in 
strong linkage disequilibrium and significantly associated with variations in fasting plasma 
glucose levels induced by sulfonylureas. (Feng Y et al., 2008, Glyon AL et al., 2003 and Sesti 
G et al., 2006, all cited in Pearson, 2009)  
4.4 Pharmacogenetics of hepatitis C virus therapy 
Response to pegylated interferon-alfa (PEG-IFN) and ribavirin (RBV) therapy in chronic 
infection with hepatitis C virus (HCV) is variable and a sustained virological response (SVR) 
is dependent on genetic factors, hepatitis C viral load, patient age, sex, weight, liver fibrosis 
stage, and adherence to therapy. Strong predictive, clinically relevant effect of IL28B 
genotype on SVR shows that C/C genotype at rs12979860 has a greater HCV-genotype 1 
RNA decline from days 0-28 than patients with the C/T or T/T genotype. The IL28B genotype 
may also be considered in conjunction with virological response after 4 weeks: thus, patients 
with poor viral kinetics and T/T genotype at rs12979860 may decide to stop therapy. In 
North America, a commercial test for IL28B genotyping is now available and costs 
approximately $300. (Afdhal et al., 2011) 
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2008; Roses, 2009; Phillips et al., 2011) 
Moreover, consistent data support the association of the HLA class II allele HLA-DRB*0101 
with an increased risk of nevirapine-induced hepatotoxicity, as well as genotype-related 
peripheral neuropathy, hyperlipidaemia, lipodystrophy to HAART, nucleoside reverse 
transcriptase inhibitors-related pancreatitis and tenofovir-associated renal proximal 
tubulopathy. (Tozzi, 2010) 
Other recent examples of important HLA associations with drug hypersensitivity include 
HLA-B*1502 and Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) 
that are associated with carbamazepine in Han Chinese; HLA-B*5801 and SJS/TEN and 
drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic 
symptoms associated with allopurinol; HLA-B*5701 and flucloxacillin-induced liver 
injury. These pharmacogenetic associations hold the promise to convert the severe and 
adverse drug reactions into predictable and preventable ones in the future. (Phillips et al., 
2011) 
4.2 Pharmacodynamic pharmacogenetics of antipsychotics  
Pharmacogenetic investigations of schizophrenia susceptibility loci and genes controlling 
drug target receptors, the blood–brain barrier systems, and epigenetic mechanisms could 
lead to a molecular classification of treatment response and adverse events of psychotropic 
drugs. It is estimated that more than 70% of patients with chronic schizophrenia 
discontinued their antipsychotic drugs, owing to poor effectiveness or tolerability. Most of 
the pharmacodynamic pharmacogenetic studies in schizophrenia have evaluated treatment 
response using the candidate gene approach.  
The most relevant associations of genetics variants and antipsychotic clinical response 
were found for 141C Ins/Del in dopamine receptor gene DRD2, A-1438G in 5-
hydroxytriptamine/ serotonin receptor gene HTR2A, His452Tyr in HTR2A gene, Taq1A in 
DRD2, Ser9Gly in DRD3, T102C SNP in HTR2A, C759T SNP in HTR2C gene. For instance, 
patients who carry one or two Del alleles tend to have less favorable antipsychotic drug 
responses than patients with the Ins/Ins genotype in DRD2 141C Ins/Del SNPs. Patients 
with G/G genotype for the HTR2A A-1438G polymorphism were less likely to respond to 
clozapine, olanzapine and aripiprazole, especially in negative symptoms, than other 
polymorphisms at this HTR2A locus. For the His452Tyr HTR2A genetic variants, the 
Tyr/Tyr genotype predicted poor response to clozapine. Higher risk of the adverse 
reaction tardive diskinesia was found for carriers of either: A2/A2 genotype at DRD2 
Taq1A locus, Gly allele at DRD3  Ser9Gly, or C allele for 5HT2A T102C. (Jian-Ping Zhang, 
2011) 
Furthermore, single-nucleotide substitutions in the promoter region of serotonin receptor 
type 2C (5-HT2C) could be associated with antipsychotics-induced weight gain and 
metabolic abnormalities in Han Chinese patients treated over a 10-week period. The C/C 
genotype from 5HT2C SNP C759T was associated with higher weight gain to clozapine and 
olanzapine. Comparable results were found in Caucasians treated 9 months with these anti-
Pharmacogenetics:  
Matching the Right Foundation at Personalized Medicine in the Right Genomic Era 
 
15 
psychotics: carriers of the -795T variation gained less weight than study participants without 
this allele. (Broich & Moeller, 2008) 
A repeat length polymorphism of the gene encoding the serotonin transporter, 5-HTTLPR, 
involves insertion/deletion of a 44-bp segment located upstream of the transcription start 
site in the promoter region; patients carrying the long allele are about twice as likely to 
respond to treatment at 4 weeks and reach remission, and less likely to suffer from side 
effects, than patients with the short/short genotype; short allele is associated with poor 
response to clozapine and risperidone treatment. (Jian-Ping Zhang, 2011) Moreover, 
insertion/deletion polymorphism in the promoter region of the serotonin transporter gene 
is also associated to clinical phenotype response to the antidepressants citalopram, 
paroxetine and fluoxetine. (Yee SW et al., 2010) 
4.3 Pharmacodynamic pharmacogenetics of antidiabetics 
Thiazolidinedione drugs (pioglitazone, rosiglitazone) promote the binding of the 
transcription factor peroxisome proliferator-activated receptor- (PPAR- ) to its DNA 
response element. Thiazolidinediones promote adipocyte differentiation, increase insulin-
stimulated glucose uptake into muscle, insulin suppression of hepatic glucose output, and 
insulin-stimulated lipolysis. The genetic variation Pro12Ala at the PPARG gene (encoding 
PPAR- ) influences the clinical outcome: those carrying the Ala allele have a greater 
response to rosiglitazone, as well as a lower risk of edema after farglitazar or ragaglitazar 
therapy, than Pro/Pro homozygotes. (Kang ES et al., 2005 and Hansen et al., 2006, both cited 
in Pearson, 2009) The hypoglycemic effect of rosiglitazone might also be influenced by 
adiponectin gene ADIPOQ polymorphisms SNP +45T/G and SNP +276G/T: homozygotes 
G/G at +45 or +276 have a smaller clinical benefit. (Kang ES et al., 2005 as cited in Pearson, 
2009) Sulfonylureas (tolbutamide, glimepiride, glibenclamide) bind to the SUR1 moiety of 
the pancreatic -cell KATP channel causing the channel to close and triggering insulin 
secretion. The clinical efficacy of sulfonylureas seems to be associated to genetic variations 
in the KCNJ11 gene (encoding the Kir6.2 subunit of the KATP channel) and the ABCC8 gene. 
(Pearson, 2009) The polymorphisms ABCC8 Ser1369Ala and KCNJ11 rs5210 and E23K are in 
strong linkage disequilibrium and significantly associated with variations in fasting plasma 
glucose levels induced by sulfonylureas. (Feng Y et al., 2008, Glyon AL et al., 2003 and Sesti 
G et al., 2006, all cited in Pearson, 2009)  
4.4 Pharmacogenetics of hepatitis C virus therapy 
Response to pegylated interferon-alfa (PEG-IFN) and ribavirin (RBV) therapy in chronic 
infection with hepatitis C virus (HCV) is variable and a sustained virological response (SVR) 
is dependent on genetic factors, hepatitis C viral load, patient age, sex, weight, liver fibrosis 
stage, and adherence to therapy. Strong predictive, clinically relevant effect of IL28B 
genotype on SVR shows that C/C genotype at rs12979860 has a greater HCV-genotype 1 
RNA decline from days 0-28 than patients with the C/T or T/T genotype. The IL28B genotype 
may also be considered in conjunction with virological response after 4 weeks: thus, patients 
with poor viral kinetics and T/T genotype at rs12979860 may decide to stop therapy. In 
North America, a commercial test for IL28B genotyping is now available and costs 
approximately $300. (Afdhal et al., 2011) 
 
Clinical Applications of Pharmacogenetics 
 
16
5. Pharmacogenetics’ translation from bench towards clinical practice in 
personalized medicine and drug design 
The great majority of drugs prescribed upon the classical paradigm of “one-drug-fits-all” and 
“trial-and-error” are effective only in 25-60% of the treated patients. Moreover, 50% from new 
chemical entities fail in the highly expensive phase III of clinical development. (Spraggs, 2009) 
Regulatory authorities FDA, European Medicines Agency (EMA) and the Japanese 
Pharmaceuticals and Medical Devices Agency (PMDA) recognize pharmacogenetics as an 
essential opportunity to predict drug responsiveness and to personalize therapy, and are 
increasingly integrating pharmacogenetic information to label updates of approved drugs, as 
well as incorporating pharmacogenetics into their regulatory review of new medicines. In 
addition, the regulatory framework that facilitates pharmacogenetics integration into drug 
development such as the Voluntary Exploratory Data Submissions in the USA and the 
Pharmacogenomics Briefing Meetings in Europe and Japan, as well as the more recent, formal 
biomarker qualification by the regulators are developed. (Surh et al., 2010) 
5.1 Pharmacogenetic markers validation 
Defining clinical guidelines for pharmacogenetic testing has to tackle the following issues: a) 
establishment of clinical end points; b) validation of pharmacogenetic testing in terms of its 
sensitivity, specificity, predictive power, cost-efficiency and time to perform; c) interpretation 
guidelines of the results and their impact on dosing algorithms, population’s stratification, 
clinical trials design, dissemination to clinicians and patients, incorporation into clinical practice 
without major interference to efficiency and cost of health care system. (Loo et al., 2010)  
Pharmacogenetic algorithms should include clinical and genetic factors to guide therapy 
individualization, should be cost-effective and offer supplementary information over 
traditional approaches. However, broader dialogue and additional regulatory guidance are 
needed to reach a consensus regarding: the quantity of pharmacogenetic information in 
drug labels, indications for physicians (informative vs. recommended vs. required 
pharmacogenetic test) and measures to keep this information up to date, relevant sections 
on the labels (which currently ranges from Warnings to Indications to Clinical 
Pharmacology), levels of compelling evidence leading to decision-making translation (i.e., 
type of trial design, sample size, replication, reproducibility, consistency, effect size and 
other predictor variables). (Surh et al., 2010) 
Regulatory recommendations for pharmacogenetic markers concern to: identification of 
responders and nonresponders; reduction of drug toxicity by minimizing or eliminating 
ADR; and optimization of the safety and effectiveness of drugs through personalized dosing 
strategies. This will enhance drug response predictability and safety in preclinical, clinical 
and postmarket trials. The biomarkers could be classified by their purpose in: improving 
drug safety, improving drug efficacy and confirming disease status. The FDA has three 
types of amendments for pharmacogenetic biomarkers, depending on the available evidence 
and the ability to implement the identified biomarker in clinical practice. These are as 
follows: information on the biomarker, which is strictly for informational purposes and does 
not require any action; recommended testing for the biomarker on the label; and mandated 
testing for the biomarker before drug use. (Squassina et al., 2010; Surh et al., 2010; Burns et 
al., 2010) Pharmacogenetic tests validated in clinical studies and recommended in the drug 
labels are detailed in table 1. 
Pharmacogenetics:  













Improve drug efficacy: clinical benefit is limited to the 
responsive patients, whose tumors overexpress the drug-target 






Improve drug efficacy: clinical benefit limited to tumors 













Disease confirmation and patients’ selection: BCR-ABL 






Disease confirmation: infection with CCR-5-tropic HIV-1 and 
resistance to other antiretrovirals 
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Improve drug safety: avoid hypersensitivity reactions to 
homozygous or heterozygous HLA-B*5701 genotypes. 
Screening is also recommended in reinitiation of drug in 
populations with previous tolerance of abacavir and unknown 









Improve drug safety: avoid myelotoxicity in patients with 
phenotype or genotype of TPMT deficiency or lower activity. 
Subjects homozygous for TPMT 3A are at high risk for life-
threatening myelosuppression when treated with standard 
doses of thiopurines: individualized doses are one tenth to one 
fifteenth the standard dose, in parallel with careful monitoring 
to avoid myelotoxicity. Patients with intermediate TPMT levels 
can safely receive thiopurines at lower doses (30–50% of the 






First FDA approved pharmacogenetic test “Third Wave 
Technologies, Invader assay” (2005), with dose optimization 
guidelines dependent on UGT1A1 genotype: avoid severe 
(grade III/IV) neutropenia and diarrhoea for those who are at 
high risk, i.e.  homozygous (and possibly heterozygous) for 







Improve drug efficacy and safety: avoid increased risk of 
bleeding to patients homozygous or heterozygous for 
CYP2C9*2 or CYP2C9*3 alleles by prescribing differentiated 
doses (as compared with those for CYP2C9*1 homozygous). 
Pharmacogenetic test: “Nanosphere Verigene Warfarin 
Metabolism Nucleic Acid Test; therapeutic algorithm based on 







Improve efficacy and safety: doses adjustment for  ultrarapid 
metabolizers who are carriers of CYP2C19*17/*17 genotype and 






Improve drug safety: avoid serious dermatologic reactions 
(Stevens–Johnson syndrome and/or toxic epidermal 
necrolysis). 
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Improved safety: pharmacogenetic testing, in parallel with 
WBC monitoring, avoid prescription to patients with high 
agranulocytosis risk.  
Test „PGxPredict: Clozapine”  
Tretinoin VESANOID® 
APL PML/RAR
Improve drug efficacy and safety. 




UCD deficiency Confirm disease: consider evaluation of UCD before therapy with valproate  
















Improve drug efficacy: responders are positives for 





Improve drug safety: decreased DPD and increased level of 5-
fluorouracil is associated with severe toxicity (e.g., stomatitis, 











Improve drug safety: dose adjustements based on NAT-
metabolic status, for slow acetylators and fast acetylators to 
avoid severe adverse reaction of peripheral neuropathy, or lack 






Confirm disease (at least 10% of the cells are EGFR-positive) 








Confirm disease: indicated to treat those with transfusion 
dependent anemia caused by low- or intermediate-risk of 
myelodysplasic syndromes associated with 5q(del[5q]) 
IHC: immunohistochemistry; FISH: Flourescence In Situ Hybridization; BC: breast cancer; CRC: 
colorectal cancer; EGFR: epidermal growth factor receptor; G6PD: glucose-6-phosphate dehydrogenase; 
ALL: acute lymphoblastic leukemia; 6-MP: 6-mercaptopurine; TPMT: thiopurin-S-methyltransferase; 
UGT: UDP glucuronyltransferase; CYP: cytochrome P450; VKORC1: vitamin K epoxide-reductase 
receptor complex 1; HLA: human leukocytes antigens; APL: acute promyelocytic leukemia; PML: 
progressive multifocal leukoencephalopathy; GIST: gastrointestinal stromal tumor; CML: chronic 
myelogenous leukemia; DPD: dihydropyrimidine dehydrogenase; NAT: N-acetyltransferase; UCD: 
urea cycle disorder; WBC: white blood cells; NSCLC: non-small-cell lung cancer.  
Data taken from: Burns et al., 2010; Squassina et al., 2010; Loo et al., 2010; Spraggs et al., 2009; Sagreiya 
et al., 2010; Seip et al., 2010; Pare et al., 2010; Holmes et al., 2010; McDonald et al., 2009; Shuldiner et al., 
2009; Mega et al., 2009. 
Table 1. Predictive pharmacogenetic tests integrated into drug labels  
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5.2 Clinical trials with genotype-guided design 
Pharmacogenetic cohort studies within randomized controlled clinical trials (RCT) may 
provide final evidence concerning the impact of specific genetic polymorphisms on the 
outcome of drug therapy. Patients are randomly assigned to groups receiving either the 
substance under investigation or the comparison (control) therapy. If pharmacogenetic 
genotypes are analyzed in all the participants in such studies, genotypes that differentially 
predict the response to the administered treatments may be identified. (Stingl & 
Brockmöller, 2011) 
Adequate design and well-controlled clinical investigations with randomization elements 
are defined in the Code of Federal Regulations (CFR) (21CFR 314.126) and they provide the 
FDA with a legal framework for establishing evidentiary standards for approval of a new 
molecular entity, that is, they attest to a drug’s efficacy and safety when used under label 
conditions. In a pharmacogenetic context, RCTs can determine whether a genetic test, on 
average, is beneficial, harmful, or of no clinical value at the population level. When 
comparing the results of RCTs, there is a potential to find conflicting results due to 
differences in the null hypothesis, estimated effect size and study power, patient inclusion 
and exclusion criteria, clinical end points, and methods of data analysis. RCTs also have the 
potential to underestimate clinical events, for example, adverse reactions, when compared 
to ‘‘real-life’’ clinical events. (Lesko, 2007) 
Although randomized controlled trials (RCT) are considered the gold standard for 
demonstrating the efficacy of therapeutic interventions, their application for the validation 
of many biomarkers, especially for multiple SNPs markers derived from GWAS, is limited 
by large sample sizes, time and financial restraints. Although pharmacogenetic studies as 
part of RCT allow to distinguish between prognostic markers and “true” predictive 
pharmacogenetic markers, there might be situations when RCT are unethical to conduct 
such as: the prescription of azathioprine or 6-mercaptopurine to homozygous carriers of 
thiopurine methyltransferase deficiency and the prescription of warfarin to combined 
carriers of low CYP2C9 activity and low vitamin K epoxide reductase complex subunit 1 
VKORC1 activity. (Lesko, 2007) 
Alternatively, carefully designed retrospective and prospective case-control and cohort 
studies based on large, robust databases and conducted with appropriate power and 
corrections, will facilitate the discovery and replication of genotype-phenotype associations. 
Thus, prospective collection and banking of samples with appropriate consent, combined 
with retrospective DNA testing, is a necessity for exploration and potential validation of 
pharmacogenetic biomarkers. (Burns et al., 2010; Frueh, 2009; Stingl & Brockmöller, 2011) 
The case–control study design is the most frequently applied type of observational 
retrospective study in pharmacogenetics and genotype-related disease susceptibility 
research. The frequencies of genotypes in persons identified as having specific adverse drug 
events or poor therapy outcomes (“cases”) are compared with those of concurrently 
sampled controls who have had comparable drug exposure but who do not present the 
particular outcome. The advantages of case–control studies are: moderate resources, 
sufficiently high statistical power, performance in the natural settings of populations, 
focused on one type of well documented drug exposure. However, case–control studies are 
particularly prone to systematic error, also called “bias” and usually they have a supportive 
role requiring data replication in differently designed studies. (Stingl & Brockmöller, 2011) 
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The case–control Study of Hypersensitivity to Abacavir and Pharmacogenetic Evaluation 
(SHAPE) showed that 100% of both white and black patch test-positive patients carried 
HLA-B*5701, suggesting a 100% negative predictive value of HLA-B*5701 for abacavir HSR, 
generalizable across race. (Saag, 2010 as cited in Phillips et al., 2011) 
A pharmacogenetic cohort study involves no controls and the group of patients receiving 
one type of therapeutic intervention is defined at the initiation of therapy and followed over 
the course of the study. This study design reflects true medical reality, is relatively easy to 
perform, and produced less biased results. In the time-series modified design, each patient 
serves as his or her own control because the drug treatment period is interrupted by a 
placebo period, thus a more precise differentiation between the drug effect and the effects of 
other factors may be obtained. The major drawbacks of cohort studies are: low statistical 
power requiring larger samples; a significant risk of confounding if there is heterogeneity in 
drug treatments, disease stages, and disease severity within the study sample; impossibility 
to differentiate between predictive and prognostic genotypes; insufficiency to serve as the 
only basis of therapy recommendations incorporating pharmacogenetics. (Lin & Chen, 2008 
as cited in Stingl & Brockmöller, 2011) 
Prospective interventional pharmacogenetic trials are based on the sequential pre-post or 
before-after design and patients receive drug therapies first before genotyping and then 
again after genotyping; sometimes it is also included a concurrently studied comparison 
group (parallel-controlled pharmacogenetic study) that implies randomized allocation to 
either the “therapy-guided by pharmacogenetic” arm or the “therapy as usual” arm. 
Prospective interventional pharmacogenetic trials allow a comparison between the efficacy 
of a new mode of treatment and that of the usual therapy and the extent to which the 
outcome of drug therapy would improve if it is guided by predictive pharmacogenetic 
testing. Randomized parallel diagnostic trials are more expensive, difficult to blind 
pharmacogenetic testing and might require larger sample sizes than phase III drug trials. 
(Haga et al., 2009 as cited in Stingl & Brockmöller, 2011) 
Prospective on-going clinical trials with genotype-guided design may be illustrated by: a) 
IDANAT2 (“Isoniazid Dose Adjustment According to NAT2 Genotype”), initiated in Europe 
since 2008, aims to comparatively evaluate efficacy and liver toxicity of  isoniazid 
administered in adjusted doses upon slow or fast acetylator status; b) phase II trial in North 
America on therapeutic strategy choice based on the presence of genotype tymidilate 
synthase TYMS TSER*3 “increased-risk” allele to the non-responders to fluoropyrimidines; 
c) phase III trial on rosiglitazone efficacy in Alzheimer’s patients stratified by APOE4 allele 
presence or absence; d) prospective study on Lapatinib (TYKERB) efficacy in metastatic 
breast cancer overexpressing Her2/ErbB2 to identify biomarkers of acquired 
chemoresistance to initial anthracyclins, taxans and trastuzumab therapy. (Spraggs et al., 
2009) 
PREDICT-1 is the first powered, randomized, blinded, prospective trial to evaluate the 
clinical utility of prospective pharmacogenetic screening for HLA-B*5701 to reduce the 
incidence of abacavir hypersensitivity in an abacavir-naïve population of HIV-infected 
subjects. (Hughes et al., 2008)  
GENDEP is the largest prospective study to examine the interaction of a moderate effect size 
between genetic (SLC6A4 variants) and clinical predictors (stressful life event - SLE) on 
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response to antidepressants escitalopram and nortriptyline. The occurrence of antecedent 
SLEs predicted response to escitalopram and these effects were moderated by two 
functional polymorphisms 5-HTTLPR and STin4 in gene SLC6A4 encoding the serotonin 
transporter. (Keers et al., 2011) 
The large, randomized controlled clinical trials COAG and EU-PACT (European 
Pharmacogenetics of Anticoagulant Therapy) will establish the safety and clinical utility of 
genotype-guided dosing in daily practice for the three main coumarin derivatives (warfarin, 
acenocoumarol, phenprocoumone) used in Europe, measuring as primary outcome the 
percentage time in the therapeutic range for international normalized ratio. (van Schie et al., 
2009; Squasina et al., 2010) In the meantime, a new rapid and inexpensive Allele-Specific 
Amplification (ASA)-PCR genotyping assay for vitamin K antagonist pharmacogenetics was 
validated that may reduce the frequency of over- and undertreatment patients, especially 
during drug initiation, and thus will improve patient safety. (Spohn et al., 2011) 
5.3 Pharmacogenetics in drug design and development 
Pharmacogenetics is integrated in all phases of drug discovery and development. A) 
Preclinically, in high-throughput screening of whole genome expression profile in 
interaction with drugs and validation of new “druggable” targets; identification the ADME 
polymorphisms relevant to the investigational substance and evaluate ADME genotyping in 
all subsequent clinical studies; prediction of the risk of allergy and organ toxicities in 
carriers of specific genotypes before first application in humans. B) In phase I, identification 
and validation of pharmacogenetic biomarkers obtained from preclinical data in order to 
stratify patients into genotypic segments of responders vs. non-responders; guide phase II 
trials design; explain the lack of efficacy or adverse drug reactions, in more cost-effective 
manner than later, in separate human pharmacogenetic studies. C) In phase II, guide 
evidenced-based decisions about further development of the investigational substance; 
potential for further drug/genotype test co-development in phase III. D) Phase III, extensive 
biomarker research for clear evidence-based data concerning pharmacogenetics for drug 
labeling (genotype-defined subgroups having particularly high efficacy or high risk for 
ADR); improving risk–benefit ratio in the case of label extension; identification of innovative 
treatment principles and drug targets; enrollment in the phase III-IV clinical trials only of 
the group of patients highly predictable to respond to therapy and excluding those with 
high risk of adverse drug reactions according to genotype. E) Pharmacovigilance in the post-
marketing phase of drugs allows optimization and label changes of approved drugs to 
include pharmacogenetic genotyping in order to exclude patients who carry genotypes 
predicting high risk ADR or no response. F) Reconsideration of potentially valuable drugs 
withdrawn because of adverse drug effects by excluding carriers of risk genotypes and by 
indicating only to genotypes predictive for high efficacy. (Stingl & Brockmöller, 2011) 
Pipeline pharmacogenetics marks the change from the current lag phase towards the log 
phase, thus accelerating the rate of marketed new chemical entities, reducing the attrition 
rate during the expensive late phase clinical development, increasing the benefit to risk ratio 
through early identification of nonresponders or those individuals with high risk of ADRs, 
especially if the critical proof of concept for efficacy is prospectively predicted in the 
protocol for a clinical trial so as to be regarded by regulators as hypothesis testing. 
Pharmacogenetics has determined a paradigm shift within pharmaceutical industry towards 
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The case–control Study of Hypersensitivity to Abacavir and Pharmacogenetic Evaluation 
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a ‘‘mini-blockbuster business model’’, thus recognizing its significant commercial and 
success rate contribution. (Lesko, 2007) Among other pipeline pharmacogenetics’ benefits 
for pharmaceutical companies are: the opportunity to reconsider drugs which were initially 
stopped during development or withdrawn from the market; the ability to avoid investing 
in unfavorable products at earlier stages of development; the higher quality and more 
effective clinical trials design; reduction of research and development costs and periods; 
favorable impact on profit by increasing peak sales correspondent to a higher market share 
much earlier during the commercial life of the drug. For example, Eli Lilly has applied the 
tailored therapy strategy for drugs Xigris and Strattera. (Lechleiter, 2009, as cited in Fackler 
& McGuire, 2009; Roses, 2009) 
Stingl and Brockmöller realize a comparative analysis of a variety of pharmacogenetics-
related study designs integrated in all phases of drug development and clinical practice, 
evaluating  the following issues: type and quality of evidence gained by each category of 
study design, their appropriated timeliness, as well as their pros and cons. The authors 
underline the necessity for new study designs for the clinical application of 
pharmacogenetics knowledge, as well as for mandatory requirements for the comprehensive 
characterization of relevant genetic variation in drug development. Future prospective 
interventional pharmacogenetic-trials in a genotype-preselected or outcomes-preselected 
population might represent one possible strategy to increase power in pharmacogenetic 
research at acceptable cost levels, especially to discover and validate the impact of genetic 
polymorphisms on drug response variability on the difficult-to-treat patients (poor-
responders or severe adverse reactions) and in the elderly, on drug–drug interactions, or 
gene-gene interactions. (Stingl & Brockmöller, 2011) 
Successful application of pipeline pharmacogenetics should meet some basic requirements, 
such as: obtaining the appropriately-documented informed consent;  collection and storage 
of DNA samples for regulatory submission; implementing predictive exploratory 
pharmacogenetics studies on candidate gene and pathway-associated SNPs (rather than 
GWAS) during phase I clinical trials to generate hypothesis for early phase IIA, followed by 
hypothesis testing during phase IIB, in order to increase the statistical significance within a 
relatively smaller, well-defined group of patients. However, standardized methodologies 
should be established regarding: specification of sample source, standardization of 
diagnostic systems and treatments, adequate monitoring, sufficient length of observation, 
inclusion of possible confounding factors. (Roses, 2009; Spraggs et al., 2009) 
The cost of pipeline pharmacogenetics is much lower in comparison with the cost of clinical 
trials and drug attrition. The advantages of large public-private partnerships at all stages of 
drug development in order to accelerate new medicines approval and biomarkers 
qualification and validation for selection of patients for clinical trials, monitoring drug 
effects and safety risk, regulatory guidelines harmonization and implementation, are 
illustrated by Eck and Paul. (Eck & Paul, 2010) 
6. Pharmacogenetics’ perspectives and challenges 
High priority directions in the pharmacogenetic research for maximizing its potential 
benefit for personalized medicine are: 1) Chronic diseases (hypertension, diabetes, asthma, 
epilepsy, multiple sclerosis etc) which imply: high costs for healthcare system and patients, 
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considerable management care costs; polymedication; low clinical outcomes due to 
compromised patients’ quality of life, continuous suffering and low compliance to 
medication. 2) Medications with long adjustment periods of therapeutic doses and currently 
prescribed on “trial-and-error” basis, resulting in reduced compliance rates and increased 
management care costs. 3) Drugs with narrow therapeutic index (mercaptopurine, warfarin) 
that require close monitoring and constant dosage adjustment procedures to maintain 
therapeutic efficacy and minimize adverse reactions. 4) Drugs with severe, life-threatening 
adverse reactions which require high hospitalization costs (abacavir). 5) Very expensive 
medications with high clinical efficacy in some segments of population and for which a 
predictive diagnostic test might be developed (herceptin). (Grossman & Goldstein, 2009) 
Pharmacogenetic testing is already implemented in some clinical areas, such as in 
cardiovascular diseases or in cancer, for selecting and/or dosing a specific medication, while 
in other fields, such as in psychiatry, the pharmacogenetic approach has been mostly used 
for the identification, validation and development of new meaningful biomarkers. 
(Squassina et al., 2010) 
Of particular interest is pediatric pharmacogenetics that should consider both variation  
in gene expression and developmental context in which the genes of interest are functionally 
active (ontogeny). Apart from the application of pharmacogenetic testing to children  
for thiopurine-induced myelotoxicity, no other genotype-drug response associations 
validated in adults have been conclusively validated and no diagnostic or pharmacogenetic 
dosing algorithms have been so far translated in pediatric patients. (Ross CJ et al., 2011; 
Becker & Leeder, 2010) In order to achieve this gap, the Canadian Pharmacogenomics 
Network for Drug Safety (CPNDS) has implemented an active and targeted adverse drug 
reaction surveillance in pediatric patients with the aim of functional validation of identified 
gene markers, such as: warfarin-induced bleeding and thrombosis, vincristine-induced 
peripheral neuropathy, glucocorticoid-induced osteotoxicity, methotrexate-induced 
mucositis or leukoencephalopathy or nausea and vomiting, anthracycline cardiotoxicity, 
cisplatine-induced ototoxicity, neurotoxicity and nephrotoxicity. The final objective is to 
ensure generalizability of clinically significant findings and translation into a 
pharmacogenetic test of each predictive biomarker evaluated in prospective clinical trials 
(such as those dedicated to cisplatin ototoxicity and codeine-induced mortality in breastfed 
infants by mothers who are CYP2D6 ultrarapid metabolizers and UGT2B7*2 homozygous 
carriers), as well as to provide a cost–benefit analysis for validated predictive biomarker. 
(Loo et al., 2010) 
6.1 Translational challenges  
Successful integration of pharmacogenetics into future clinical practice and personalized 
medicine should overcome further translation barriers related to: a) global problems of 
scarcity of data demonstrating pharmacogenetic testing’s clinical validity and utility; b) 
standardized and powerful statistical correlations between genotype and drug-response 
phenotype across different populations; c) education of health professionals and public; d) 
pharmacoeconomics issues; e) bioethical and social aspects; f) more favorable regulatory 
policy for clinical uptake of pharmacogenetics via sustaining large-scale industry-academia 
collaborations; g) the adoption of harmonized and standardized guidelines for biorepository 
and data sharing across multi-national networks; h) lack of incentives for the private sector 
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to invest in the development and licensing of pharmacogenetics diagnostic tests for 
improving the safety and efficacy of out-of-patent drugs. (Spraggs et al., 2009; Gurwitz et al., 
2009) 
Scientific community and International Society of Pharmacogenomics Education Forum 
have called for the enhanced implementation of pharmacogenomics and personalized 
medicine into core medical teaching curricula and practice, in order to fill in the gap 
between intensive research on validated pharmacogenetic testing and its appropriate, 
effective clinical integration and interpretation in routine individualized therapy. (Squassina 
et al., 2010) For instance, Pharmacogenomics Education Program (PharmGenEd™) is an 
educational platform for dissemination of evidence-based clinically relevant 
pharmacogenomics, fostering educational and scientific collaboration among educators, 
researchers and clinicians (http://pharmacogenomics.ucsd.edu). PharmGenEd also 
participates along with Pharmacogenomics Knowledge Base (PharmGKB) and National 
Institute of Health Pharmacogenomic Research Network (NIH PGRN), in the Clinical 
Pharmacogenetics Implementation Consortium (CPIC) to create a curated resource for 
storing, annotating and updating specific data relevant for clinical implementation of 
pharmacogenetic testing. (Kuo et al., 2011) 
The adoption of the pharmacogenetics tests for personalized medicine depends on clinical- 
and cost-effectiveness analyses on which the reimbursement for their routine use will be 
based. (Liewei et al., 2011) In the context of pharmacoeconomic models, pharmacogenetic 
testing might be regarded more cost-effective than cost-saving, or at least cost-effective for 
particular combinations of treatment, genetic polymorphisms and disease, depending 
greatly on the differences among healthcare systems and reimbursement policies.  
(Squassina et al., 2010; Trent, 2010) 
Appropriate protection for privacy and confidentiality of databases with large amount of 
genotypic, phenotypic and demographic data regarding individuals is crucial in order to 
avoid the possible risk of psychosocial harm, genetic and social discrimination, privacy and 
possible implications for employment and access to life and health insurance. (Squassina et 
al., 2010) Moreover, pharmaceutical companies could voluntarily ignore, for economic 
reasons, patients with rare or complex genetic conditions or those who are not responding 
to any known treatment, leading to consequent deprivation of effective treatments. These 
concerns are attenuated by USA specific regulations, such as the Genetic Information 
Nondiscrimination Act (GINA), the Health Insurance Portability and Accountability Act 
Privacy Rule, and the Genomics and Personalized Medicine Act (GPMA), as well as by 
founded nonprofit organizations of major key stakeholders (pharmaceutical companies, 
healthcare providers and payers, patient advocacy groups, industry policy organizations, 
academic institutions and government agencies), like the Personalized Medicine Coalition 
and Pharmacogenetics for Every Nation Initiative (PGENI). (Squassina et al., 2010)  
Taking into account the ethical, legal and social issues of pharmacogenetics research, as well 
as the multi-disciplinary opinions of the key stakeholders, Howard and colleagues have 
identified six outstanding ethical issues raised by the informed consent process in 
pharmacogenetics research and proposed valuable recommendations  for the development 
of future practical pharmacogenetics consent guidelines, such as: 1) scope of consent; 2) 
consent to pharmacogenetics ‘add-on’ studies; (3) confidentiality, privacy protection and 
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coding of personal information in long-term databases, especially in those controlled by 
private pharmaceutical companies; (4) intellectual property and commercialization policy of 
pharmacogenetics research projects with financial benefit-sharing plan; (5) disclosure of the 
possibility of deposition and sharing in public repository of the samples and data, at the 
onset of the pharmacogenetics study; (6) potential risks stemming from population-based 
research so as to avoid overgeneralizations and  undermining the moral, cultural and 
religious standards. (Howard et al., 2011) 
6.2 Pharmacogenetics’ perspectives by next generation sequencing 
GWAS are particularly useful to determine the most significant SNPs associated with a 
phenotype amongst a high-density set of polymorphisms, in cases where there are large 
cohorts to evaluate, clinical end points are simple to define without variability, and the 
genetic factors associated with the end points are highly penetrant. However, GWAS are 
discovery- rather than hypothesis-driven, result in weak statistical power and false 
positives, need large sample size, cost and computing power requirements. Therefore, 
GWAS imply a two-stage design where discoveries made using a high-density SNP array 
are then validated using a hypothesis design on replicative populations. (Sissung et al., 
2010) Nonetheless, for ADR with a significant genetic component that confers a large effect 
(carbamazepine-induced Stevens–Johnson syndrome, abacavir-induced hypersensitivity, 
statin-induced myopathy and gefitinib-induced diarrhoea), associations can be identified 
with a relatively small number of samples (10–100 cases). (Loo et al., 2010; Davis & Johnson, 
2011) 
Rare variants in complex mixtures of DNA might be quantitatively measured by mass 
spectrometry-based genotyping. Fluidigm‘s microfluidic device (“lab-on-chip”), able to mix 
96 samples and 96 primer sets in nano-scale assay chambers that support over 9000 parallel 
qRT-PCR reactions, could be also used for genotyping and targeted sequence capture; thus 
filling the gap between biomarker evaluation of a few candidate genes and the hundreds of 
markers GWAS-discovered. (Gibson, 2011) 
The development of next-generation sequencing (NGS) or massively parallel sequencing, as 
well as nanopore sequencing technologies, through whole-genome, whole-exome and 
whole-transcriptome analysis, allows fast, inexpensive, reliable production of large volumes 
of DNA or RNA sequence data. (Metzker, 2011; Tucker et al., 2009) NGS comprises a 
number of methods that are grouped broadly as template preparation, sequencing and 
imaging, genome alignment and assembly, and data analysis. The unique combination of 
specific protocols distinguishes one technology from another and determines the type of 
data produced from commercial platforms such as: Roche/454, Illumina/Solexa, Life/APG 
and Helicos BioSciences, the Polonator instrument and the Pacific Biosciences. The NGS 
technologies, their broad applications and guidelines for platform selection to address 
biological questions of interest are reviewed by Metzker (Metzker, 2011). Having aligned the 
digested fragments of individuals’ targeted regions of genome to a reference genome, ‘SNP 
calling’ identifies variable sites, whereas ‘genotype calling’ determines the genotype for each 
individual at each site, thus revealing principal types of genome alterations (like nucleotide 
substitutions, small insertions and deletions, copy number alterations, chromosomal 
rearrangements). (Rasmus et al., 2011) Computational, biological and clinical analyses of the 
resulting genome data will assess reproducibility and statistical significance; links to 
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to invest in the development and licensing of pharmacogenetics diagnostic tests for 
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coding of personal information in long-term databases, especially in those controlled by 
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pathways and the functional relevance of mutated genes to disease; and the relationships of 
genome alterations with cancer prognosis and response to therapy, respectively. (Meyerson 
et al., 2010)  
Over a relatively short time frame, DNA sequencing has become cheaper and faster  
(US$ 1,000 price tag for a whole human genome sequence now seems feasible) and even 
more with the foreseeable third-generation DNA sequencers utilizing single molecules and 
avoiding initial cloning or amplification steps. (Trent, 2010; Pushkarev et al., 2009)  
In addition to NGS rapid technological developments, the promotion of alternative 
strategies for delivery of healthcare through nontraditional pathology laboratories, such as 
direct-to-consumer (DTC) DNA tests and point-of-care DNA testing, will expand the 
integration of pharmacogenetics into clinical practice by assisting health practitioner to 
make on-the-spot decisions about the individualisation of drug and dose directly at the 
bedside in the intensive care unit or consulting room. (Trent, 2010) 
6.3 New players in pharmacogenetics: Alternative splicing, miRNAs and structural 
RNA polymorphisms 
In addition to polymorphisms in protein-coding genes (nonsynonymous SNPs) associated to 
complex diseases, alternative splicing in protein-coding genes and variations in microRNAs 
and other noncoding RNAs have emerged as new players in pharmacogenetics and they 
should be considered in an integrative approach in deciphering the genotype-induced inter-
individual variability of drugs’ tolerance, efficacy and metabolism.  
Alternative splicing of pre-mRNAs was proposed 30 years ago by the Nobel Prize winner 
Walter Gilbert as a way of generating different mRNAs from a single gene and it is regarded 
as one of the most elegant and important mechanisms for proteome diversity generation. 
Alternative splicing in protein-coding genes can affect the biological activity of proteins, 
having major consequences on drug metabolism and drug response phenotype. Generation 
of wrong alternative splicing variants is a common feature of complex diseases and also an 
important player in drug resistance and ADME. For example, alternative splicing variants in 
the BCR–ABL fused gene were correlated with Imatinib mesylate resistance in chronic 
myelogenous leukemia patients (Gruber et al., 2006, as cited in Passetti et al., 2009); whereas 
splicing isoforms of nuclear pregnane and constitutive androstane receptors can affect the 
pharmacokinetics and pharmacodynamics of docetaxel and doxorubicin in Asian patients. 
(Horr et al., 2008, as cited in Passetti et al., 2009) The functional relevance of alternative 
splicing of pre-mRNAs and generated splice variants in the context of whole genome 
studies instead of a single gene would reveal how they will affect cellular networks and 
pathways. (Passetti et al., 2009) 
The noncoding RNAs (ncRNAs) are a large group of transcripts lacking protein-coding 
potential, having variable size range from approx. 18 to 25 nucleotides for the families of 
microRNAs (miRNAs) and small interfering RNAs (siRNAs), approx. 20 to 300 nucleotides 
for small RNAs commonly found as transcriptional and translational regulators, or up to 
and beyond 10 000 nucleotides in length for RNAs involved in various other processes. 
(Costa FF, 2008, as cited in Passetti et al., 2009) miRNAs are noncoding RNAs that can 
regulate gene expression by Watson–Crick base pairing to target several mRNAs in a gene 
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regulatory network. The binding of miRNAs to their target mRNAs is critical for regulating 
mRNA levels and therefore protein expression. miRNAs are master regulators of important 
gene and transcriptome networks in eukaryotic cells, they can block mRNA translation and 
affect both the expression of at least 30% of all protein-coding genes by targeting their 3'-
UTR sequences and long ncRNAs. A growing number of reports have been showing the 
associations of deregulated expression of miRNAs in complex diseases (cancer, obesity, 
diabetes, schizophrenia) by altering the regulation of expression of many important genes. 
One miRNA can downregulate multiple target proteins by interacting with different target 
mRNAs ('one hit multiple targets' concept), thus pointing out the particular therapeutic 
relevance of miRNAs as an attractive drug target. (Wurdinger & Costa, 2007, as cited in 
Passetti et al., 2009) Moreover, polymorphisms in miRNAs represent a newly identified type 
of genetic variability that can influence the risk of diseases and also variability in 
pharmacokinetics and pharmacodynamics of drugs. For instance, polymorphisms in 
miRNA target sites of protein-coding genes are associated to cancer, hypertension, asthma, 
cardiovascular disease, and polymorphisms in microRNAs are associated with 
schizophrenia, Parkinson. (Passetti et al., 2009) In addition, long ncRNAs, increasingly seen 
as functional genes, have been involved in disease progression, such as: ZNFX1-NA1 in 
breast cancer, SPRY4-IN in melanoma; NEAT1 long ncRNA in Alzheimer. (Gibson, 2011) 
Alternative splicing might affect microRNA regulation and subsequently microRNAs are 
able to regulate hundreds of effector genes in a multilevel regulatory mechanism that allow 
individual miRNAs to profoundly affect the gene expression program in the cells. Both 
microRNA regulation and alternative splicing will induce changes in proteome diversity 
that can affect the way drugs are metabolized by patients, and this will have major 
implications for both drug design and personalized medicine in the future. Furthermore, 
genetic variations in the sequence of miRNAs, target sites of miRNAs and alternative 
splicing will affect gene regulatory networks and pathways responsible for drug metabolism 
and resistance, thus emerging as a new paradigm clearly redefining the pharmacogenomics 
field and personalized medicine. (Passetti et al., 2009) 
Structural RNA SNPs (srSNPs) designate genetic polymorphisms in the transcribed regions 
of genes that affect RNA functions and represent ~49% (synonymous SNPs, 2%; those in 5 - 
and 3 -untranslated regions, 2%; intronic, 45%) from disease-associated SNPs derived from 
GWAS, whereas nonsynonymous (coding  cSNPs) account for only ~9% and regulatory 
SNPs (rSNPs; SNPs in intergenic regions that alter transcription of protein-coding genes) for 
~43%. (Hindorff et al., 2009, as cited in Sadee et al., 2011) Structural RNA SNPs affect RNA 
functions such as splicing, turnover and translation, having tissue-specific effects, while 
regulatory single-nucleotide polymorphisms (rSNPs) affect transcription. (Sadee et al., 2011) 
Recent GWAS and next-generation sequencing of the transcriptome have opened path for 
large-scale exploration of mRNA expression quantitative trait loci (eQTLs) which are 
commonly categorized as rSNPs affecting transcription and altering mRNA expression 
levels in target tissues. (Sadee, 2009, as cited in Sadee et al., 2011) Furthermore, the 
evaluation of allelic ratios of transcripts would enable the detection of rSNPs and srSNPs, by 
revealing any deviation from unity expected in an autosomal gene - termed “allelic 
expression imbalance” (AEI) – that indicates the presence of cis-regulatory factors and 
represents a more precise relative measure of transcript activity as compared with total 
mRNA levels. (Johnson, 2008, as cited in Sadee et al., 2011) Structural RNA polymorphisms 
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(Costa FF, 2008, as cited in Passetti et al., 2009) miRNAs are noncoding RNAs that can 
regulate gene expression by Watson–Crick base pairing to target several mRNAs in a gene 
Pharmacogenetics:  
Matching the Right Foundation at Personalized Medicine in the Right Genomic Era 
 
27 
regulatory network. The binding of miRNAs to their target mRNAs is critical for regulating 
mRNA levels and therefore protein expression. miRNAs are master regulators of important 
gene and transcriptome networks in eukaryotic cells, they can block mRNA translation and 
affect both the expression of at least 30% of all protein-coding genes by targeting their 3'-
UTR sequences and long ncRNAs. A growing number of reports have been showing the 
associations of deregulated expression of miRNAs in complex diseases (cancer, obesity, 
diabetes, schizophrenia) by altering the regulation of expression of many important genes. 
One miRNA can downregulate multiple target proteins by interacting with different target 
mRNAs ('one hit multiple targets' concept), thus pointing out the particular therapeutic 
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miRNA target sites of protein-coding genes are associated to cancer, hypertension, asthma, 
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schizophrenia, Parkinson. (Passetti et al., 2009) In addition, long ncRNAs, increasingly seen 
as functional genes, have been involved in disease progression, such as: ZNFX1-NA1 in 
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regulatory single-nucleotide polymorphisms (rSNPs) affect transcription. (Sadee et al., 2011) 
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will likely prove essential to fill gaps in the “missing heritability”, substantially contributing 
to discover pharmacogenetic biomarkers of increased predictive power. The clinical 
relevance of rSNPs and srSNPs has greatly contributed the available validated predictive 
genetic variants. For example, there are validated srSNPs and rSNPs in DME (CYP2C19, 
CYP2D6, CYP3A5, UGT1A1, NAT1, ABCB1, ABCC2) associated with variability in the 
bioactivation, pharmacokinetics and clinical outcome of clopidogrel, tamoxifen, statins, 
efavirenz, tacrolimus, paclitaxel, antiretrovirals. Moreover, validated srSNPs and rSNPs in 
genes that encode drug targets (D2 dopamine receptor gene  DRD2) are associated with 
poor response to antipsychotics or with risk for metabolic syndrome (rSNPs in gene TPH2 
encoding tryptophan hydroxylase). (Sadee et al., 2011) 
6.4 Pharmacogenetics’ perspectives by biobanking and electronic health records 
Global surveys conducted by the Industry Pharmacogenomics Working Group (I-PWG) in 
order to determine current industry and institutional review boards/ ethical committee 
(IRB/EC) practices, policies and standards, for prospective biospecimens’ collection and 
storage for pharmacogenomics research, emphasize the significant value of pharmacogenetics 
research and biobanking for personalized medicine, as well as the necessity for harmonization 
and standardization across the industry and the key stakeholders in regulations concerning: 
sample acquisition and data privacy protection, pharmacogenetics-related language in 
informed consent, outsourcing of DNA sample storage, “clinical relevance” of the genetic 
information to be returned to the patients, benefits and foreseeable risks. (Franc et al., 2011a, 
2011b; Warner et al., 2011; Ricci et al., 2011) 
The creation of a biorepository that are closely link with electronic medical records (EMR) 
may be an economically efficient approach to genomic medicine and especially to GWAS 
that require DNA sample from large populations with robust phenotypic data. The 
Geisinger MyCode Biorepository is perhaps the first large-scale biobanking project around 
EMR. In addition, a data warehouse project – the Clinical Decision Information System – 
initiated in 2006 aims to assembly in a single point of reference 40 different data sources 
regarding patients’ clinical phenotype, biobanks, clinical trials databases, as well as 
financial, administrative, operational and patient survey databases. Such data warehouses 
allow optimizing performance, maintaining control and privacy aspects, reliability, 
robustness and fast-response. (Gerhard et al., 2009) 
Large multi-national consortia have been already established, such as NIH-funded PGRN, 
and NIH-funded Electronic Medical Records and Genomics Network (eMERGE), which are 
catalogued in Pharmacogenomics Knowledge Base. (McCarty & Wilke, 2010) 
The convergence of the rapidly expanding biomedical informatics, high-throughput 
genotyping, DNA biobanks and EMR across large health-care networks, plays a pivotal role 
in pharmacogenomics’ translation to the bedside. Through real-time monitoring of multiple 
de-identified EMR databases integrated in sophisticated cross-institutional networks (e.g., 
the PGRN, the eMERGE network, and the HMO Research Network, Harvard 
University/Partners Healthcare system i2b2, the Vanderbilt BioVu), highly accurate 
quantifying disease phenotypes  and treatment outcomes could be efficiently extracted by 
the application of natural language processing (NLP), semantic interoperability, data 
normalization strategies and novel bioinformatics platforms. The following translational 
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mechanisms are envisaged: (i) retrospective assessment of previously known findings in a 
clinical practice-setting; (ii) discovery of new associations in huge observational cohorts; (iii) 
prospective application in a setting capable of providing real-time decision support; iv) 
enhance pharmacovigilance, especially during the postmarketing phase; vi) validation of 
previous conventional cohort-driven GWAS, in a cost-effective, earlier and more accurately 
manner. (Wilke et al., 2011; Kohane, 2011) In addition, electronic health records-driven 
genomic research (EDGR) will provide a rich set of comprehensive clinical phenotypes, in 
close to real time, at a low cost and a high degree of timeliness, matched to the 
corresponding DNA samples from biorepositories. The cost-efficiency advantage of EDGR 
comes from maximizing the research utility of that clinical-care investment such that it is 
only a fraction of a de novo research cohort pipeline. Other advantages of EDGR include: 
ability to assess in-depth the clinical significance of genomic associations; great 
representation of a clinical population; data on environmental exposures; broad and 
accurate reflection of clinical phenotypes and controls; identification of confounders. 
(Kohane, 2011) In the future, as standardization across national biobanks-linked EMR, 
consent procedures and ownership of the derived intellectual property will be adopted, 
genetic data will be recorded preemptively into each patient’s EMR, and robust biomedical 
informatics platforms will interrogate this information during the process of clinical 
decision making, providing efficient real-time decision support at the point of care. (Wilke et 
al., 2011; Kohane, 2011)  
Development of simple, up-to-date, easily accessible, reliable clinical algorithms and 
guidelines must guide physicians in the interpretation of genetic data, decision making 
about diagnostic testing and follow-up clinical care. These point-of-care tools will be 
embedded in electronic health records system and it will be crucial to accelerate the 
individualized medicine. (Fackler & McGuire, 2009; Liewei et al., 2011) 
In addition, the implementation of robust health information technology able to 
electronically manage all different types of -omics biomarker data and phenotypic 
characterization of research study participants, might be illustrated by software platforms 
like: Hewlett-Packard’s Gateway for Integrated Genomics - Proteomics Applications and 
Data (GIGPAD) or Microsoft’s Amalga. (Fackler & McGuire, 2009) 
The National Institute of Health’s Pharmacogenomics Research Network (PGRN) is a 
collaborative partnership of research groups funded “to lead discovery and advance 
translation in genomics in order to enable safer and more effective drug therapies”, with the 
ultimate goal to predict and personalize medicine in routine clinical practice. (Long & Berg, 
2011) PGRN’s accomplishments and future projects to provide peer-reviewed, updated, 
evidence-based, freely accessible guidelines for gene/drug pairs, so as to facilitate the 
translation and interpretation of preemptive pharmacogenomic tests for the most relevant 
pharmacogenes from laboratory, through electronic medical records system, into decision-
making prescription recommendations, have been extensively discussed. (Long & Berg, 
2011; Roden & Tyndale, 2011; Relling & Klein, 2011) 
6.5 Further perspectives in pharmacogenomics 
Further perspectives for pharmacogenomics to emerge as an important piece in the puzzle 
of personalized medicine will concern: a) the integration of pharmacogenomics with 
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guidelines must guide physicians in the interpretation of genetic data, decision making 
about diagnostic testing and follow-up clinical care. These point-of-care tools will be 
embedded in electronic health records system and it will be crucial to accelerate the 
individualized medicine. (Fackler & McGuire, 2009; Liewei et al., 2011) 
In addition, the implementation of robust health information technology able to 
electronically manage all different types of -omics biomarker data and phenotypic 
characterization of research study participants, might be illustrated by software platforms 
like: Hewlett-Packard’s Gateway for Integrated Genomics - Proteomics Applications and 
Data (GIGPAD) or Microsoft’s Amalga. (Fackler & McGuire, 2009) 
The National Institute of Health’s Pharmacogenomics Research Network (PGRN) is a 
collaborative partnership of research groups funded “to lead discovery and advance 
translation in genomics in order to enable safer and more effective drug therapies”, with the 
ultimate goal to predict and personalize medicine in routine clinical practice. (Long & Berg, 
2011) PGRN’s accomplishments and future projects to provide peer-reviewed, updated, 
evidence-based, freely accessible guidelines for gene/drug pairs, so as to facilitate the 
translation and interpretation of preemptive pharmacogenomic tests for the most relevant 
pharmacogenes from laboratory, through electronic medical records system, into decision-
making prescription recommendations, have been extensively discussed. (Long & Berg, 
2011; Roden & Tyndale, 2011; Relling & Klein, 2011) 
6.5 Further perspectives in pharmacogenomics 
Further perspectives for pharmacogenomics to emerge as an important piece in the puzzle 
of personalized medicine will concern: a) the integration of pharmacogenomics with 
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additional, non-drug-related patient characteristics, individual disease factors, and 
environmental aspects (Kroemer, 2010); b) tissue-specific epigenetic changes, microRNAs or 
“junk DNA” (Trent, 2010); c) discovery of useful pharmacogenetic markers in the 
mitochondrial DNA (mtDNA) within transmitochondrial cell lines or cybrids in order to 
optimize antibiotherapy (Squassina et al., 2010); d) biomarkers validation for drug therapy 
in organ transplantation and for complex diseases characterized by a great phenotypic and 
genetic variability; e) coordinated implementation into certified laboratories of the 
pharmacogenes’ next-generation-sequencing, according to GCP guidelines; f) the adaptation 
of the regulatory and reimbursement environment. (Fackler & McGuire, 2009) 
Moreover, nanotechnology is projected to play a critical role in personalized medicine, 
greatly dependent on the evolutionary development of a systems biology approach to 
clinical medicine based upon “-omic” technology analysis and integration. In a 
comprehensive review, Sakamoto and colleagues analyse: the current state of nano-based 
products over a vast array of clinical indications and patient specificity;  rational design of 
nanotechnologies for individualized therapy; nano-based injectable therapeutics, 
implantable drug-delivery devices; nanotechnology and tissue engineering; nanowires and 
cantilevers arrays that are used to detect minute amount of protein biomarkers. (Sakamoto 
et al., 2010) 
7. Conclusions 
Pharmacogenomics is the interface between genomic medicine and systems pharmacology 
and its translation from bench into clinical practice is broadening the perspective of 
personalized medicine so as in the near future we might rely on a “DNA 
chip”/“pharmacogenomic card” specific to each patient and on each genotype preemptively 
recorded in EMR, in order to individualize both the diagnostic procedures and the safest 
and most efficient medications prior to treatment initiation. Although it is still regarded as 
an elusive dream due to limited marketed drug–test companion products and actually 
implemented clinical practices, pharmacogenomics translation into personalized medicine 
has become a more imminent reality. Advances in next-generation sequencing technology to 
uncover the contribution of “missing heritability” to biomarker-guided therapeutic 
individualization, the convergence of biorepositories- and electronic health records-
pharmacogenomics research, the encouraging initiatives for policy and guidelines 
harmonization, as well as extensive collaborations across large pharmacogenomic  
networks, will hopefully overcome the current challenges ahead on the road to personalized 
medicine and will play a pivotal role in pharmacogenomics’ translation  to the bedside. 
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1. Introduction  
In this article, we provide an overview of the cytochrome P450 drug metabolism system, a 
major target for pharmacogenetics assays. We discuss briefly the major enzyme subfamilies 
and highlight some of the important members of each. We then delve into the currently 
available methodologies that are used for genotyping including single base (primer) 
extension, hybridization, ligation, and sequencing. The various methods have distinct 
requirements but all can be used for the interrogation of single nucleotide polymorphisms. 
These genetic differences may confer altered properties in the encoded enzymes including 
differences in the ability to metabolize drugs. Methods to identify such differences can help 
select subsets of patients who may or may not be able to effectively utilize particular 
medications. In such a manner, these techniques allow for the appropriate triage of patients 
to therapies that are targeted for their genotype, allowing for a tailored, individualized 
treatment regimen. Pharmacogenetic testing of this nature can help to usher in the era of 
personalized medicine. 
2. Genotypic variation in cytochrome P450s and effects on drug metabolism  
Adverse drug reactions are important causes of morbidity and mortality, and have been 
reported to result in significantly increased healthcare costs and longer hospital lengths of 
stay. Adverse drug reactions can result from comorbid diseases that affect drug 
metabolism such as renal or hepatic insufficiency, from drug-drug interactions, and from 
genetic factors affecting drug pharmacokinetics. Reduction of adverse drug reactions 
associated with comorbid conditions and drug-drug interactions is potentially achievable 
through increased awareness and reporting; however prevention of adverse drug 
reactions due to individual genetic differences requires a different approach – efficient 
and cost-effective determination of individual genotypic profiles of the enzymes involved 
in drug metabolism.  
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Drugs are metabolized through a series of reactions, the majority of which are carried out by 
cytochrome P450 (CYP), a monooxygenase superfamily of enzymes with over 60 members. 
The CYP genes are highly polymorphic in humans, with hundreds of single nucleotide 
polymorphisms (SNPs), insertions and deletions, and copy number variations described to 
date. These genetic polymorphisms give rise to different metabolic phenotypes: ultrarapid 
metabolizers (UM), extensive metabolizers (EM), intermediate metabolizers (IM) and poor 
metabolizers (PM). Individuals with the EM phenotype have two normal alleles and have 
normal metabolism; those with the IM phenotype have one defective allele and may have 
reduced drug metabolism; and those with the UM phenotype have gene duplications and 
have increased drug metabolism. The PM phenotype is characterized by two defective 
alleles, resulting in markedly decreased drug metabolism and in particular situations, 
higher levels of drugs and increased risk for adverse drug reactions.  
Of the many isoforms of CYP, CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and 
CYP3A4, are responsible for the metabolism of the majority of clinically important drugs. 
(Table 1)  
 
 #SNPs Clinically significant alleles or %poor metabolizers Examples of substrates 
CYP1A2 >30 N.D. Caffeine, estradiol, clozapine, olanzapine, theophylline 









Caucasians, 3.3% Asians 
NSAIDs, angiotensin receptor 
blockers, sulfonylureas, 
warfarin 
CYP2C19 >30 PM: 3-5% Caucasians, 15-20% Asians 
Proton pump inhibitors, anti-
epileptics, clopidogrel 
CYP2D6 >100 
PM: <1% Asians, 2-5% 
African-Americans, 6-10% 
Caucasians 
Tricyclic antidepressants, SSRIs, 
opiods, anti-psychotics, 
tamoxifen, beta blockers, anti-
arrhythmics 
CYP2E1 10 N.D. Anesthetics 




calcium channel blockers, HMG 
CoA reductase inhibitors 
Table 1. Common CYP polymorphisms affect the metabolism of clinically important drugs. 
N.D.= not determined. 
CYP1A2 metabolizes several drugs including clozapine (used in the treatment of 
schizophrenia), theophylline (used to treat respiratory disorders such as COPD and asthma), 
and caffeine. Greater than 30 SNPs have been identified to date , but a genotype-phenotype 
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relationship has not yet been established. Similarly, a genotype-phenotype relationship has 
not yet been established for CYP2E1, a CYP protein responsible for the metabolism of most 
anesthetics.  
CYP2B6 is highly polymorphic (>70 SNPs) and metabolizes approximately 8% of clinically 
important drugs including the anti-retroviral drugs efavirenz and nevirapine, which are 
used in the treatment of HIV infection. The CYP2B6*6 allele, which is found commonly in 
Asians and African-Americans, results in decreased metabolism and response to efavirenz.  
Greater than 50 SNPs have been identified for CYP2C9, which metabolizes approximately 10% 
of all clinically prescribed medications. One of the most important drugs metabolized by 
CYP2C9 is warfarin, a widely used anticoagulant. CYP2C9*2 and CYP2C9*3 alleles which are 
relatively common in Caucasians (approximately 8%) have been implicated as playing a large 
role in the interindividual variation in the metabolism of this drug. These alleles have been 
demonstrated to reduce enzymatic activity in vitro, *2 by 70% and *3 by 30%, respectively.  
CYP2C19 plays a role in the metabolism of several drugs, but perhaps has been best studied 
for its role in the metabolism of proton pump inhibitors which are used to treat 
gastroesophageal reflux disorders. 3-5% of Caucasians and 15-20% of Asians are CYP2C19 
poor metabolizers. PMs have reduced metabolism of proton pump inhibitors, leading to 
increased plasma levels of drug and increased response to treatment. Recently, 2C19 has 
become popular because of its involvement in the metabolism of Plavix, an antiplatelet drug 
used to prevent strokes and heart attacks. Important alleles include *2 and *3 which reduce 
enzymatic activity, and *17 which produces an ultrarapid metabolizer phenotype. Of great 
interest, 2C19 shares homology with 2C9. In fact, >90% of the amino acid sequence is identical 
between these two isoforms. Despite their near identity at the amino acid level, the active site 
of the two enzymes differs, and thus accounts for the differences in substrate specificity. 
CYP2D6 is highly polymorphic with greater than 100 SNPs thus far characterized. These 
genetic polymorphisms play a significant role in affecting the metabolism of ~20% of 
clinically important drugs including anti-depressants, anti-psychotics, anti-arrhythmics, and 
beta blockers. These features make CYP2D6 an attractive target for pharmacogenetic assays. 
The PM phenotype is found in < 1% of Asians, 2-5% of African-Americans, and 6-10% of 
Caucasians. Interestingly, only six alleles of CYP2D6 account for >99% of the poor 
metabolizers in the Caucasian population (Roberts et al. 2006). Hence, a targeted approach 
to interrogate these six SNPs could provide a useful assay to identify such individuals in 
this limited cohort. 
The CYP3A family of isoforms are crucial drivers of drug metabolism in the liver. In fact, CYPs 
3A4 and 3A5 are responsible for 40-50% of all such activity. CYP3A4 metabolizes a large range 
of clinically important drugs, and over 30 SNPs have been described. However, no significant 
interindividual variability has yet been reported , suggesting that genetic variation may not 
play a large role in regulating CYP3A4 activity. Interestingly however, the *3 allele which 
results in a variant with a reduced metabolism phenotype is found in ~30% of Caucasians. The 
3A5 isoform is less well characterized but shares overlapping substrate specificity with 3A4. 
In summary, hundreds of SNPs have been identified within the multiple members of the 
SNP superfamily and other genes involved in drug metabolism, making these genes an 
important target for SNP genotyping in pharmacogenetics and personalized medicine. 
Various techniques for SNP genotyping are described in the following section.  
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3. SNP genotyping methods 
Many SNP genotyping strategies have been developed, ranging from small scale, low-
throughput approaches to interrogate one of few SNPs, to large scale, high-throughput 
approaches that can genotype hundreds of SNPs. Both small and large scale approaches 
have been applied for pharmacogenetics studies. These approaches generally detect SNP 
alleles using one of the following strategies: primer extension, hybridization, ligation, or 
sequencing.  
3.1 Single base (primer) extension 
Single base (primer) extension is a process that involves the use of a SNP probe with the 3’ 
end a single base upstream of the SNP of interest. The SNP probe is then extended by a 
single base, and the incorporated base is detected. Detection can be either through 
fluorescence, if a fluorophore is incorporated into the dideoxynucleotides and an 
appropriate detector is used, or can be done based on sizing of fragments if a size separation 
technique, such as mass spectrometry, is used. 
As an example, we have developed an assay using this technology to determine the 
genotype profile of genes affecting the metabolism of warfarin. Warfarin is a widely used 
anticoagulant. However, the combination of variable, genetically-based, individual 
responses to warfarin and a narrow therapeutic window with potentially serious 
complications, make this an ideal situation in which pharmacogenetics testing could be 
beneficial. As described above, the CYP2C9*2 and CYP2C9*3 alleles have been shown to 
be important in the metabolism of warfarin. In addition, warfarin inhibits Vitamin K 
epoxide reductase complex subunit 1 (VKORC1), an enzyme complex that reduces 
vitamin K 2,3 epoxide to its active form. Multiple SNPs have been identified in VKORC1, 
leading to either low-dose or high-dose phenotypes. VKORC1 polymorphisms, which are 
found commonly in many populations, have been estimated to account for approximately 
25% of the variability in warfarin dose requirement. Finally, gamma-glutamyl carboxylase 
(GGCX) is an enzyme that catalyzes the post-translational modification of vitamin K-
dependent proteins and has been reported to have a modest effect on warfarin 
metabolism. 
Four SNPs for these genes were examined simultaneously in a multiplexed assay. Genomic 
DNA was isolated from whole blood and the region of interest was amplified by PCR. SNP 
primers (each of different length) were designed with the sequence ending one nucleotide 
upstream of the SNP of interest. The primer was then extended a single base with a 
fluorescently labelled dideoxynucleotide terminator (ddNTP). The reaction product was 
then separated by capillary electrophoresis and analyzed. (Fig 1)  
This method has several advantages. It is an accurate procedure that can be performed 
with minimal hands-on effort. It lends itself to custom design and is flexible in  
that oligonucleotide probes used to detect SNPs of interest can be added or removed 
quickly from an existing panel. In our hands, this method gave results that were 100% 
concordant with traditional sequencing results. This method has the additional benefit of 
a short turnaround time- the entire analysis may be performed in less than 24 hours, the 
majority of which is needed for incubation steps and for the automated electrophoretic 
separation.  
Multiplexed Pharmacogenetic  




Fig. 1. Detection of SNPs by single base primer extension. Blood is collected from a patient 
and genomic DNA is isolated from lymphocytes. A multiplex PCR reaction is performed to 
amplify DNA fragments containing the SNP of interest. This is followed by a multiplex SNP 
reaction whereby oligonucleotides ending one base pair upstream of the SNP of interest are 
added and then extended with nucleotide terminators. In the case of capillary 
electrophoresis, detection is based on fluorescence whereby the ddNTPs are tagged with 
various fluorophores. In contrast, for mass spectrometry detection is based on accurate 
sizing of modified nucleotide terminators. 
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dependent proteins and has been reported to have a modest effect on warfarin 
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primers (each of different length) were designed with the sequence ending one nucleotide 
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fluorescently labelled dideoxynucleotide terminator (ddNTP). The reaction product was 
then separated by capillary electrophoresis and analyzed. (Fig 1)  
This method has several advantages. It is an accurate procedure that can be performed 
with minimal hands-on effort. It lends itself to custom design and is flexible in  
that oligonucleotide probes used to detect SNPs of interest can be added or removed 
quickly from an existing panel. In our hands, this method gave results that were 100% 
concordant with traditional sequencing results. This method has the additional benefit of 
a short turnaround time- the entire analysis may be performed in less than 24 hours, the 
majority of which is needed for incubation steps and for the automated electrophoretic 
separation.  
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Fig. 1. Detection of SNPs by single base primer extension. Blood is collected from a patient 
and genomic DNA is isolated from lymphocytes. A multiplex PCR reaction is performed to 
amplify DNA fragments containing the SNP of interest. This is followed by a multiplex SNP 
reaction whereby oligonucleotides ending one base pair upstream of the SNP of interest are 
added and then extended with nucleotide terminators. In the case of capillary 
electrophoresis, detection is based on fluorescence whereby the ddNTPs are tagged with 
various fluorophores. In contrast, for mass spectrometry detection is based on accurate 
sizing of modified nucleotide terminators. 
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In addition to the assay described above for assessing warfarin metabolism, we have 
successfully used the same approach to interrogate 8 SNPs of CYP2D6. As described in the 
previous section, CYP2D6 is highly polymorphic and plays a role in the metabolism of 
approximately one-fourth of clinically important drugs. We sought to interrogate these SNPs 
to characterize the PM phenotype. One limitation of this approach (and capillary 
electrophoresis in general) is in the resolving capacity of this technique, which under our 
conditions is ~2 nt. In our procedure, we are resolving and visualizing oligonucleotides for 
SNP interrogation in a window from 10-95 nt, the maximum number of fragments that can be 
resolved is ~12. This resolving capacity is inherent to the capillary electrophoresis 
methodology and commercial analyzers of which several are available, all share this limitation. 
A similar approach can be used to multiplex a larger number of SNPs, and can thus 
overcome the limitations described above. Such a genotyping approach needs to exploit 
methods that are of higher resolution (relative to capillary electrophoresis), such as mass 
spectrometry. Using this technique, genomic DNA is isolated, the region of interest is 
amplified by PCR, and SNP primers are hybridized, as described above. These SNP primers 
are extended by a single base with unlabelled dideoxynucleotide terminators.  
The SNP allele is then detected by the mass of the extension product, as a function of the 
time required to traverse the time-of-flight tube. (Fig 1) We have recently used this 
technique to interrogate 11 SNPs simultaneously from a single sample. This technique is 
(theoretically) capable of resolving up to 35-40 SNPs in one well, and thus a greater number 
of SNPs can be interrogated (relative to capillary electrophoresis), whether they reside in 
one gene or many genes. Such a methodology is ideal when the number of SNPs of interest 
is within these parameters.  
Several commercial platforms offer larger scale SNP genotyping using single base extension 
as an approach. The MassARRAY system (Sequenom), an example of a mass spectrometric 
based platform as described above, can interrogate ~35-40 SNPs simultaneously. The 
SNPstream assay (Beckman Coulter) is able to interrogate either 12 or 48 SNPs 
simultaneously in a 384-well plate. A fluorescently labelled nucleotide is added to a tagged 
SNP probe by single base extension. Each well of the 384-well plate contains tagged 
oligonucleotides at specific positions within the well. These tagged oligonucleotides are 
complementary to one of the 12 or 48 tagged SNP probes. The genotype of the SNP is 
identified by determination of the position of fluorescence in the well.  
3.2 Hybridization-based approaches 
Hybridization-based approaches for SNP genotyping depend on stringent hybridization 
conditions (conducive to the ability or inability to form Watson-Crick base pairs) as a means to 
distinguish one or more alleles. As compared to single base primer extension, hybridization 
assays are sensitive to variations on length and sequence of both probe and target 
oligonucleotides. Similar to primer extension, hybridization assays can also interrogate many 
SNPs simultaneously within the same sample. For example, the Affymetrix GeneChip is an 
array of oligonucleotides that allows genome-wide interrogation of SNPs.  
In hybridization-based approaches, genomic DNA is isolated, regions of interest are 
amplified, cleaved, and then tagged, for example with biotin. The tagged products are 
subsequently hybridized under stringent conditions to allele-specific oligonucleotides on a 
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solid matrix, such as a bead or array. These allele-specific oligonucleotides differ by only 
one or few bases, and correspond to the various alleles of the DNA fragment of interest. The 
reaction is performed under conditions whereby mismatched targets, i.e. those that do not 
hybridize perfectly, can be washed away. This leaves only the stably hybridized DNA 
fragments, i.e. those that have a perfect match to their corresponding target, that are 
fluorescently labelled. Subsequent detection of the fluorescent signal allows for the 
determination of the SNP genotype. The specificity of the assay can be increased by using 
multiple probes for each SNP allele (Figure 2). 
 
 
Fig. 2. Detection of SNPs by hybridization. Blood is collected from a patient and genomic 
DNA is isolated from lymphocytes. A PCR reaction is performed to amplify and tag DNA 
fragments containing the SNP of interest. Tagged DNA fragments are hybridized to SNP 
probes bound to a solid matrix, and mismatched fragments are washed away. Hybridized 
fragments are fluorescently labelled and detected to determine the SNP genotype.  
Dynamic allele-specific hybridization (DASH) is another assay that utilizes differential 
hybridization for SNP genotyping. In DASH, genomic DNA is isolated, and the region of 
interest is amplified using a biotinylated primer. The biotin tag allows for the attachment of 
a single stranded DNA fragment to a bead. This is then hybridized with a SNP-specific 
oligonucleotide. Now, a fluorescent molecule that intercalates into the double-stranded 
DNA is added, and the fluorescence signal is measured over an increasing temperature 
 
Clinical Applications of Pharmacogenetics 
 
40
In addition to the assay described above for assessing warfarin metabolism, we have 
successfully used the same approach to interrogate 8 SNPs of CYP2D6. As described in the 
previous section, CYP2D6 is highly polymorphic and plays a role in the metabolism of 
approximately one-fourth of clinically important drugs. We sought to interrogate these SNPs 
to characterize the PM phenotype. One limitation of this approach (and capillary 
electrophoresis in general) is in the resolving capacity of this technique, which under our 
conditions is ~2 nt. In our procedure, we are resolving and visualizing oligonucleotides for 
SNP interrogation in a window from 10-95 nt, the maximum number of fragments that can be 
resolved is ~12. This resolving capacity is inherent to the capillary electrophoresis 
methodology and commercial analyzers of which several are available, all share this limitation. 
A similar approach can be used to multiplex a larger number of SNPs, and can thus 
overcome the limitations described above. Such a genotyping approach needs to exploit 
methods that are of higher resolution (relative to capillary electrophoresis), such as mass 
spectrometry. Using this technique, genomic DNA is isolated, the region of interest is 
amplified by PCR, and SNP primers are hybridized, as described above. These SNP primers 
are extended by a single base with unlabelled dideoxynucleotide terminators.  
The SNP allele is then detected by the mass of the extension product, as a function of the 
time required to traverse the time-of-flight tube. (Fig 1) We have recently used this 
technique to interrogate 11 SNPs simultaneously from a single sample. This technique is 
(theoretically) capable of resolving up to 35-40 SNPs in one well, and thus a greater number 
of SNPs can be interrogated (relative to capillary electrophoresis), whether they reside in 
one gene or many genes. Such a methodology is ideal when the number of SNPs of interest 
is within these parameters.  
Several commercial platforms offer larger scale SNP genotyping using single base extension 
as an approach. The MassARRAY system (Sequenom), an example of a mass spectrometric 
based platform as described above, can interrogate ~35-40 SNPs simultaneously. The 
SNPstream assay (Beckman Coulter) is able to interrogate either 12 or 48 SNPs 
simultaneously in a 384-well plate. A fluorescently labelled nucleotide is added to a tagged 
SNP probe by single base extension. Each well of the 384-well plate contains tagged 
oligonucleotides at specific positions within the well. These tagged oligonucleotides are 
complementary to one of the 12 or 48 tagged SNP probes. The genotype of the SNP is 
identified by determination of the position of fluorescence in the well.  
3.2 Hybridization-based approaches 
Hybridization-based approaches for SNP genotyping depend on stringent hybridization 
conditions (conducive to the ability or inability to form Watson-Crick base pairs) as a means to 
distinguish one or more alleles. As compared to single base primer extension, hybridization 
assays are sensitive to variations on length and sequence of both probe and target 
oligonucleotides. Similar to primer extension, hybridization assays can also interrogate many 
SNPs simultaneously within the same sample. For example, the Affymetrix GeneChip is an 
array of oligonucleotides that allows genome-wide interrogation of SNPs.  
In hybridization-based approaches, genomic DNA is isolated, regions of interest are 
amplified, cleaved, and then tagged, for example with biotin. The tagged products are 
subsequently hybridized under stringent conditions to allele-specific oligonucleotides on a 
Multiplexed Pharmacogenetic  
Assays for SNP Genotyping: Tools and Techniques for Individualizing Patient Therapy 
 
41 
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gradient. A melting curve can thus be established. (Fig 3) A complete match between the 
genomic DNA and the SNP-specific oligonucleotide results in the expected melting 
temperature curve, whereas mismatches result in a curve showing lowered melting 
temperatures. This technique was used in a study of 13 SNPs in the adiponectin gene which 
has been linked to type 2 diabetes.  
 
 
Fig. 3. Dynamic allele-specific hybridization (DASH). Blood is collected from a patient and 
genomic DNA is isolated from lymphocytes. A PCR reaction is performed to amplify and 
tag DNA fragments containing the SNP of interest. The DNA fragment is attached to a 
streptavidin bead, and is hybridized to a SNP probe. A fluorescent intercalating DNA dye is 
added, and a melting curve is determined. A mismatch (dashed line) will result in a lower 
melting temperature. 
A unique take on the use of hybidization for SNP genotyping involves the use of molecular 
beacons. A molecular beacon is an oligonucleotide hairpin with a fluorophore at one end and a 
fluorescence quencher at the other end with a sequence complementary to the SNP allele nested 
in the middle. In the unbound state, no fluorescent signal will be emitted as the fluorophore and 
the fluorescence quencher are in close proximity at the stem of the hairpin structure. When the 
molecular beacon hybridizes with a perfect match to a genomic DNA fragment, the hairpin 
structure of the molecular beacon is linearized, separating the fluorophore and the fluorescence 
quencher, allowing fluorescence signal to be emitted (Figure 4). 
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Fig. 4. Interrogation of SNPs using molecular beacons. Blood is collected from a patient and 
genomic DNA is isolated from lymphocytes. A PCR reaction is performed to amplify DNA 
fragments containing the SNP of interest. The DNA fragment is hybridized to a molecular 
beacon. When the molecular beacon is not bound to the DNA fragment, the fluorophore and 
fluorescence quencher are held in close proximity to each other and no fluorescence signal is 
emitted. When the molecular beacon hybridizes with the DNA fragment, the flurophore and 
fluorescence quencher are separated and fluorescence is emitted.  
The TaqMan (Applied Biosystems) assay is a widely used assay that utilizes hybridization to 
determine SNP genotypes. This assay takes advantage of the 5’ nuclease activity of Taq 
polymerase to detect SNP alleles. In this assay, the region of interest is amplified by PCR. In 
addition to the forward and reverse primers, an allele-specific probe is also hybridized 
under stringent conditions to the template DNA. The allele-specific probe has a fluorophore 
at the 5’ end and a fluorescence quencher at the 3’ end. When the allele-specific probe 
perfectly complements the template DNA, it is stably bound, whereas when there is a 
mismatch, the probe will not hybridize stably with the template DNA and will not be a 
substrate for the 5’ nuclease activity of Taq polymerase. When Taq polymerase reaches the 
allele-specific probe as it extends DNA from the primer, the 5’ fluorophore is released by the 
5’ nuclease activity of Taq polymerase, and the probe is displaced. Release of the 5’ 
fluorophore separates the fluorophore from the 3’ fluorescence quencher, allowing 
fluorescence to be emitted and subsequently measured (Figure 5). The Taqman assay was 
recently used to interrogate 121 SNPs to analyze Y-chromosome variation in 264 samples.  
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Fig. 5. SNP interrogation utilizing the 5’ nuclease activity of Taq polymerase. Blood is 
collected from a patient and genomic DNA is isolated from lymphocytes. A DNA fragment 
containing the SNP of interest is amplified by PCR in the presence of an allele-specific probe 
labelled with a fluorophore at one end, and with a fluorescence quencher at the other end. 
When the allele-specific probe complements the DNA, the 5’ nuclease activity of Taq 
polymerase will release the fluorophore, and fluorescence signal will be detected.  
3.3 Ligation-based approaches 
The ligation-based approach to interrogate SNPs exploits the ability of DNA ligase to ligate two 
adjacent oligonucleotides bound to a template DNA. In this assay, two oligonucleotides are 
required; an allele-specific oligonucleotide which has its 3' end complementary to the SNP 
nucleotide to be interrogated, and a second oligonucleotide with its 5' end designed to anneal 
immediately adjacent to the 3' end of the first oligonucleotide. Both oligonucleotides are 
hybridized to the target DNA. DNA ligase is then added to the reaction. Only if the 3' end of the 
first oligonucleotide is indeed complementary to the SNP allele, will ligation occur, as DNA 
ligase is sensitive to 3’ mismatches. The ligated and unligated products are of different sizes and 
can thus be detected using a separation technique, for example capillary electrophoresis or mass 
spectrometry analysis. This approach can also be scaled up for high throughput analysis. (Fig 6) 
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Fig. 6. SNP allele detection by ligation. Blood is collected from a patient and genomic DNA 
is isolated from lymphocytes. A DNA fragment containing the SNP of interest is amplified 
by PCR. Two oligonucleotides are annealed to the DNA fragment, flanking the SNP site to 
be interrogated. If the allele-specific oligonucleotide is complementary to the SNP allele, 
DNA ligase will be able to ligate the oligonucleotides, and the ligated product can be 
detected by capillary electrophoresis or mass spectrometry.  
The oligonucleotide ligation and capillary electrophoresis method is used in the SNPlex 
assay (Applied Biosystems), a platform which allows multiplexing for the detection of 
multiple SNPs simultaneously. The SNPlex assay has been used in multiple studies; in a 
recent study it was used to detect SNPs in 528 members of families with sarcoidosis. 
3.4 Sequencing based strategies: Pyrosequencing and other next generation 
sequencing methods 
Conventional capillary electrophoresis based Sanger sequencing was developed in the (late) 
1970s and became widely adopted thereafter. It revolutionized life science research in the 
subsequent years by providing a critical tool that was fundamental in the elucidation of 
genetic sequence information. Despite this, the technology suffers from limitations in speed, 
resolution, throughput and scalability 
Next-generation sequencing technologies have recently been developed and have made 
possible cost-efficient, high-throughput sequencing, that can overcome these drawbacks. An 
example of next-generation sequencing is pyrosequencing, a sequencing-by-synthesis 
technique. The pyrosequencing technique sequences approximately 250 bases per read. In 
pyrosequencing, each added base is detected in real-time by fluorescence. Specifically, 
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genomic DNA is isolated, and the region of interest is amplified by PCR. A sequencing 
primer is then annealed to the template DNA, and the reaction components are added: DNA 
polymerase, ATP sulfurylase, luciferase, apyrase, adenosine 5’ phosphosulfate (APS), and 
luciferin. One of four deoxynucleotide triphosphates (dTTP, dCTP, dGTP, or dATP S) is 
then added (dATP S is used in place of dATP as it can be incorporated by DNA 
polymerase, but is not a substrate for luciferase). If the added dNTP is complementary to the 
template DNA, the dNTP is incorporated by DNA polymerase, releasing pyrophosphate 
(PPi). The released PPi is converted to ATP by ATP sulfurylase with adenosine 5’ 
phosphosulfate as a substrate. The ATP serves to drive the conversion of luciferin to 
oxyluciferin by the luciferase enzyme. Oxyluciferin generates visible light proportional to 
the amount of ATP. This visible light is measured and used to determine if a dNTP was 
incorporated, and if so, the number of dNTPs added. The unincorporated dNTPs and ATP 
is degraded by apyrase. This cycle of reactions is repeated with the next dNTP. By this 
process of sequential addition of dNTPs, the sequence can be determined. (Fig 7) 
 
Fig. 7. Pyrosequencing. Blood is collected from a patient and genomic DNA is isolated from 
lymphocytes. A DNA fragment containing the SNP of interest is amplified by PCR. A 
sequencing primer is added, as are the sequencing reaction components: DNA polymerase, 
one of four dNTPs (dTTP, dCTP, dGTP, or dATP S). If the nucleotide is incorporated, PPi is 
released, which is then converted by ATP sulfurylase to ATP. The ATP drives the 
conversion of luciferin to oxyluciferin by luciferase. Oxyluciferin generates visible light 
proportional to the amount of ATP. 
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A high-throughput application of pyrosequencing, termed 454 pyrosequencing, was 
developed in 2005 by 454 Life Sciences. In this technique, the target DNA is attached to a 
bead and placed in a picoliter-sized well of a fiberoptic slide (containing 1.6 million wells). 
The substrates for the pyrosequencing reaction are added to the wells in waves via a flow-
chamber, the light signal is detected, and the sequence is determined. This parallelized 
pyrosequencing technology allows the determination of mega- to gigabase amounts of DNA 
in a fast and cost-efficient manner.  
Illumina (Solexa) sequencing is another next-generation sequencing technology that has 
recently been developed for high-throughput sequencing. DNA is sequenced by repeated 
cycles of single base extension. As in standard single base extension, DNA is extended a 
single base with a fluorescently labelled nucleotide terminator. The nucleotide terminator in 
this case is not a dideoxynucleotide; instead it is a modified, reversible terminator. The 
identity of the incorporated base is determined by detection of fluorescence. Next, the 
flurophore is removed and the terminator is reversed, and the cycle of single base extension 
is repeated. In this manner, approximately 75 bases can be read at a time.  
A third important next-generation sequencing technology is SOLiD sequencing (Sequencing 
by Oligonucleotide Ligation and Detection), a technology developed by Applied 
Biosystems. Rather than utilizing a polymerase, this technology utilizes an elegant system of 
hybridization and ligation steps to determine the sequence of target DNA. In brief, DNA is 
attached to a flow cell and is hybridized and ligated to one of a set of fluorescently labelled 
probes. The fluorescence is detected, then cleaved and the process is repeated to extend the 
sequence. A combination of repeated hybridization and ligation steps and use of primers 
with different offsets allows not only the sequence to be determined, but also provides a 
“two-base” read to improve accuracy. This technology can provide sequence data of 
approximately 50 bases with each individual read. This individual sequencing reaction is 
performed across millions of templates in a massively parallel fashion. Thus, in a rapid 
manner, large stretches of DNA can be sequenced spanning entire genomes. In fact, the 
amount of DNA sequence data that is generated is staggering, exceeding hundreds of 
gigabytes of information from a single run. A single instrument today can generate more 
information in a 24 hour period than was possible using multiple instruments with standard 
technology operating over a decade, in the 1980s, 1990s, and even in the 2000s.  
3.5 Other SNP genotyping methods 
The Invader assay (Third Wave Technologies) utilizes the ability of Flap endonuclease (FEN) 
to cleave specific DNA structures to determine SNP alleles. Flap endonuclease is a 5’ nuclease 
that recognizes DNA structures with a single stranded 5’ overhang, or flap. Flap endonuclease 
will cleave DNA at the junction of the single and double stranded DNA. In this assay, genomic 
DNA is isolated and the region of interest is amplified by PCR. Two probes are hybridized to 
the target DNA: an Invader oligonucleotide and an allele-specific oligonucleotide. The Invader 
oligonucleotide is designed to anneal with its 3’ end immediately upstream to the SNP site. 
The allele-specific oligonucleotide, which has a 5’ fluorophore and a 3’ fluorescence quencher, 
anneals to the SNP site and to the downstream sequence. In addition, the allele-specific 
oligonucleotide has additional 5’ sequence not complementary to upstream sequence that 
extends from the bound DNA, forming a structure recognized by FEN. Cleavage of the allele-
specific oligonucleotide by FEN separates the 5’ fluorophore from the 3’ fluorescence 
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genomic DNA is isolated, and the region of interest is amplified by PCR. A sequencing 
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bead and placed in a picoliter-sized well of a fiberoptic slide (containing 1.6 million wells). 
The substrates for the pyrosequencing reaction are added to the wells in waves via a flow-
chamber, the light signal is detected, and the sequence is determined. This parallelized 
pyrosequencing technology allows the determination of mega- to gigabase amounts of DNA 
in a fast and cost-efficient manner.  
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cycles of single base extension. As in standard single base extension, DNA is extended a 
single base with a fluorescently labelled nucleotide terminator. The nucleotide terminator in 
this case is not a dideoxynucleotide; instead it is a modified, reversible terminator. The 
identity of the incorporated base is determined by detection of fluorescence. Next, the 
flurophore is removed and the terminator is reversed, and the cycle of single base extension 
is repeated. In this manner, approximately 75 bases can be read at a time.  
A third important next-generation sequencing technology is SOLiD sequencing (Sequencing 
by Oligonucleotide Ligation and Detection), a technology developed by Applied 
Biosystems. Rather than utilizing a polymerase, this technology utilizes an elegant system of 
hybridization and ligation steps to determine the sequence of target DNA. In brief, DNA is 
attached to a flow cell and is hybridized and ligated to one of a set of fluorescently labelled 
probes. The fluorescence is detected, then cleaved and the process is repeated to extend the 
sequence. A combination of repeated hybridization and ligation steps and use of primers 
with different offsets allows not only the sequence to be determined, but also provides a 
“two-base” read to improve accuracy. This technology can provide sequence data of 
approximately 50 bases with each individual read. This individual sequencing reaction is 
performed across millions of templates in a massively parallel fashion. Thus, in a rapid 
manner, large stretches of DNA can be sequenced spanning entire genomes. In fact, the 
amount of DNA sequence data that is generated is staggering, exceeding hundreds of 
gigabytes of information from a single run. A single instrument today can generate more 
information in a 24 hour period than was possible using multiple instruments with standard 
technology operating over a decade, in the 1980s, 1990s, and even in the 2000s.  
3.5 Other SNP genotyping methods 
The Invader assay (Third Wave Technologies) utilizes the ability of Flap endonuclease (FEN) 
to cleave specific DNA structures to determine SNP alleles. Flap endonuclease is a 5’ nuclease 
that recognizes DNA structures with a single stranded 5’ overhang, or flap. Flap endonuclease 
will cleave DNA at the junction of the single and double stranded DNA. In this assay, genomic 
DNA is isolated and the region of interest is amplified by PCR. Two probes are hybridized to 
the target DNA: an Invader oligonucleotide and an allele-specific oligonucleotide. The Invader 
oligonucleotide is designed to anneal with its 3’ end immediately upstream to the SNP site. 
The allele-specific oligonucleotide, which has a 5’ fluorophore and a 3’ fluorescence quencher, 
anneals to the SNP site and to the downstream sequence. In addition, the allele-specific 
oligonucleotide has additional 5’ sequence not complementary to upstream sequence that 
extends from the bound DNA, forming a structure recognized by FEN. Cleavage of the allele-
specific oligonucleotide by FEN separates the 5’ fluorophore from the 3’ fluorescence 
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quencher, and allows fluorescence to be emitted. If the allele-specific oligonucleotide does not 
complement the SNP site exactly, the resulting structure is not recognized by Flap 
endonuclease and no fluorescence signal will be detected. (Fig 8) 
 
Fig. 8. Invader assay for SNP interrogation. Blood is collected from a patient and genomic 
DNA is isolated from lymphocytes. A DNA fragment containing the SNP of interest is 
amplified by PCR. An Invader probe (blue) and an allele-specific probe labelled with a 
flurophore and a fluorescence quencher are hybridized to the DNA fragment. FEN 
recognizes the resulting structure and cleaves it, releasing the fluorophore.  
The Invader assay was successfully used (in conjunction with other SNP genotyping 
methods) to genotype 122 SNPs in 9 candidate genes associated with diabetes. In a study by 
Ozaki et al., a multiplexed Invader assay was used to interrogate 92,788 SNPs from 94 
individuals in a genome-wide association study. 
4. Considerations in the selection of the appropriate SNP genotyping tool 
Several factors merit consideration and are important for the judicious selection of an 
appropriate SNP genotyping assay. Accuracy, reliability, and establishment of quality 
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control are intermingled and readily apparent as important factors. These elements are 
critical to the development of a robust assay and the validation of such. The accuracy and 
reliability of results is paramount since these data are used to inform clinical decision 
making by allowing for optimized selection of therapy for the patient. The inclusion and 
establishment of an appropriate quality control paradigm ensures the integrity of reagents, 
test conditions, and experimental and technical workflow. These features form the basis of, 
and are a prerequisite to, generating an accurate and reliable result. 
There are additional factors that will affect more widespread adoption of these assays and 
make individualized patient therapy available and accessible to most patients. Such 
considerations include: speed, automation, customizability, and the requirement for 
specialized equipment and /or technical training. These set of factors deal with the logistics 
in operationalizing the implementation of such assays. 
The speed at which results are obtained and the test’s ease of use can directly affect the 
clinical utility of the assay and further dictate where the assay is performed and who can 
conduct testing (regulatory requirements differ by country, and within the United States 
they may also differ by state, e.g. New York). For example, under certain conditions it may 
be favourable for testing to be conducted by a healthcare provider in an outpatient setting 
where results are immediately used to make treatment decisions. If an assay is fairly 
straightforward & easy to use and the chances of obtaining an accurate result are high, it 
may be advantageous to perform outside the clinical laboratory. On the contrary, it may be 
beneficial for testing to be sent to a centralized laboratory and performed by a trained, 
licensed technologist. This is the ideal situation for a higher complexity test. However, in 
this situation, results may not be immediately available and thus there will be a delay in 
using the information to change clinical management of the patient.  
Assays in which little hands-on effort is required and can be automated will increase speed, 
throughput, and will help to reduce errors. In cases where numerous SNPs are interrogated, 
a single, multiplexed reaction allows for the simultaneous investigation of several SNPs, 
reducing time and cost. The number of SNPs identified and characterized as playing a role 
in drug metabolism to date has been a relatively manageable size; however, as more SNPs 
are identified, both multiplexed and high-throughput assays could further reduce costs 
Customized assays are advantageous in that they are designed to answer focused questions, 
and can be tailored to specific patient populations. In addition, they are flexible and can be 
rapidly changed as new clinically significant SNPs are identified and need to be 
incorporated. A requirement for specialized training and/or equipment may slow 
widespread adoption of a SNP genotyping assay but is necessary for conducting high 
complexity testing of this nature. Finally, cost also can play an important role, particularly in 
an environment of increasing healthcare expenditures. In recent years, pharmacogenetic 
testing (and other molecular diagnostics assays) have come under greater scrutiny and the 
debate over appropriate reimbursement scales by insurance payers continues.  
The methodologies described in the previous section have all been used successfully to 
genotype SNPs, however they have different advantages and limitations that factor into 
their usefulness in individualized SNP genotyping assays. (Table 2) The ideal assay would 
combine the advantages of each methodology, and eliminate the common requirement for 
either large amounts of DNA or for an initial PCR step. New technologies that would 
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a single, multiplexed reaction allows for the simultaneous investigation of several SNPs, 
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increase sensitivity or reduce the need for multiplexed PCR would be necessary to make the 
simultaneous interrogation of hundreds or thousands of SNPs faster and more cost-
effective.  
 









High accuracy of 
incorporation by 
DNA polymerase 
Multiple steps for 
detection/ 
separation 
Hybridization More difficult Yes 
Widely available; 








Ligation Yes Yes High specificity of DNA ligase 
Multiple steps for 
detection/ 
separation 




Table 2. Comparison of SNP genotyping methodologies.  
5. Conclusions 
Multiple genetic differences between individuals have been described in the Cytochrome 
P450 family of drug metabolizing enzymes. These genetic differences may confer altered 
properties including differences in the ability to metabolize drugs. Methods to identify such 
differences can help select subsets of patients who may or may not be able to effectively 
utilize particular medications. Several widely used methods with differing approaches and 
advantages have been highlighted above. Further technological advances will help these 
technologies become more widely adopted. These techniques allow for the appropriate 
triage of patients to therapies that are targeted for their genotype, allowing for a tailored, 
individualized treatment regimen. Pharmacogenetic testing of this nature will help to usher 
in this new era of personalized medicine. 
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1. Introduction 
Worldwide, gastrointestinal (GI) system tumors are the leading group of cancers in terms of 
incidence and cause of cancer deaths (Parkin, 2005). They are usually diagnosed at an 
advanced stage which is rarely curable, and even if detected early the rate of recurrence is 
quite high. Therefore despite improvements in the diagnosis and treatment of GI cancers, 5-
year survival rates remain disappointing. Effective new treatments are urgently needed, and 
existing therapies need to be individualized to determine patients who are likely to respond 
to a given chemotherapy, as well as to identify patients at risk of developing severe toxicity. 
This approach will enable clinicians to optimize and personalize cancer treatment. 
Pharmacogenetics is, perhaps, the most promising method to provide this (Yalcin, 2009). 
Metabolism of chemotherapy agents varies depending on patient age, gender, diet, 
concomitant drug use, comorbidities, and hepatic and renal functions and moreover GI 
functions may be impaired due to surgery, chemotherapy and the disease or existing 
comorbidities in GI cancer patients. 
Pharmacogenetics focuses on the influence of genetic structure on cancer treatment because 
enzymes that metabolize the drug, proteins that transport the drug and its metabolites, and 
drug receptors are determined by a patient’s genetic profile (Vesell, 1989). However, it is not 
only the genetics of the patient, but also the genetic alterations of the tumor that are critical 
(Yong, 2006, Vesell, 1989). Pharmacogenetics may help to decide the most sensitive and least 
toxic therapy in order to increase survival, reduce treatment related cost and improve 
patient’s quality of life. In this chapter, the most common drugs, combinations thereof, and 
biological agents used for the treatment of GI tumors are reviewed for their relevant 
pharmacogenetic aspects. 
2. 5-Fluorouracil (5-FU) 
The uracil analogue 5-FU has been used in the treatment of GI cancers for over 50 years 
(Meta-Analysis Group in Cancer, 1998). 5-FU acts in several ways, but principally as a 
thymidylate synthase (TYMS) inhibitor. Inhibition of this enzyme blocks synthesis of the 
pyrimidine, thymidine which is a nucleotide required for DNA replication. TYMS 
methylates deoxyuridine monophosphate (dUMP) into deoxythymidine monophosphate 
(dTMP). Administration of 5-FU causes a depletion in dTMP, so that rapidly dividing cancer 
cells undergo cell death. 
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5-FU itself is a prodrug, which must be activated by entering the pyrimidine synthesis 
pathway. Although 5-FU can enter the pathway at 3 different points, the key entry point is 
the conversion of UMP to UDP, which is catalyzed by pyrimidine monophosphate kinase. 5-
FU is given intravenously, because oral bioavailability is limited due to high concentrations 
of dihydropyrimidine dehydrogenase (DPYD) in the gut mucosa. DPYD is an enzyme 
present in the liver, intestinal mucosa and various other tissues. DPYD catabolizes 5-FU to 
5,6-dihydro-5-fluorouracil (DHFU). Capecitabine is an oral analogue of 5-FU which can be 
used instead of intravenous 5-FU. Capecitabine is converted to 5-FU via a 3 step activation 
process. The first two steps occur in the liver and the last step is carried out by the enzyme 
thymidine phosphorylase (TYMP), which is over expressed in a large number of tumors 
(approximately 3 times more compared to normal tissue). Only a fraction of the 
administered 5-FU reaches its target cell and is transformed to active metabolites that is 
converted to 5-fluoro-2'-deoxyuridine-5'-monophosphate (5-FdUMP) within the cell to 
inhibit TYMS. Eighty-five percent of 5-FU is catabolized to its inactive metabolites via 
DPYD. Inherited deficiency of DPYD leads to greatly increased drug sensitivity and toxicity 
(Figure 1) (Daher et al, 1990). 
 
Fig. 1. 5-Fluorouracil metabolism 
2.1 Dihydropyrimidine Dehydrogenase (DPYD) 
5-FU is primarily degraded by the enzyme DPYD. When DPYD enzyme deficiency is 
present, blood levels of 5-FU and its active metabolites increase. DPYD enzyme deficiency 
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can result in fatal myelotoxicity, mucositis, neuro and cardiac toxicity such as myocardial 
infarction, sudden death, unstable angina, hypertension and pulmonary edema (Diasio, 
2001, Fleming et al, 1993, Milano et al, 1999). Although technically difficult, determination of 
DPYD enzyme activity in mononuclear cells may be useful (Lu, Zhang, Diasio, 1993). The 
gene encoding the DPYD enzyme is located at 1p22 and consists of 23-exons (Wei et al, 
1998). The reasons for DPYD deficiency are base substitutions, splicing abnormalities, and 
frame-shift mutations. More than 40 different DPYD polymorphisms have been reported so 
far (Ridge et al, 1998). Severe 5-FU toxicity is associated with 17 of these mutations. 
Homozygote and heterozygote DPYD dysfunction is estimated to be 0.1% and 3% to 5%, 
respectively in the general population. DPYD*2A is the most common DPYD polymorphism 
associated with 5-FU toxicity. Partial loss of the enzyme due to heterogeneous G>A 
transition at the 5’ slicing donor consensus sequence in intron 14 leading to exon 14 skipping 
is associated with increased 5-FU toxicity due to inactive enzyme formation. The 
heterozygote form is characterized by severe toxicity while the homozygote form is 
characterized by mental deficiency. DPYD deficiency was demonstrated in 61% of patients 
with severe 5-FU toxicity. DPYD*2A polymorphism was identified in 50% of patients with 
grade 4 neutropenia. P456L (1358C>T) mutation is a novel DPYD variant associated with 5-
FU related cardiotoxicity in pancreatic cancer patients (Shahrokni et al, 2009). However, 
multiple other factors and genes are thought to be involved in 5-FU toxicity because DPYD 
enzyme activity is normal in most patients with severe 5-FU toxicity (Mattison, Soong, 
Diasio, 2002, Ridge et al, 1998). Genetic variations of other enzymes particularly TYMS and 
TYMP involved in 5-FU metabolism are also important. 
2.2 Thymidylate Synthase (TYMS) 
TYMS is a target of 5-FU. It plays a significant role in folate metabolism. TYMS enables 
conversion of deoxyuridylate to deoxythymidylate (Miller and McLeod 2007, Johnston et al, 
1995). Increased TYMS enzyme expression in tumors has been shown to be associated with 
resistance to 5-FU and capecitabine (Kidd et al, 2005). In particular, intratumoral TYMS 
levels in metastatic lesions are indicative of 5-FU resistance. This is a result of differences 
between TYMS expressions of primary and metastatic lesions (Pullarkat et al, 2001, Marsh et 
al, 2001, Salonga et al, 2000). The 5’untranslated region of the TYMS (5'-UTR) gene contains 
a 28-base pair tandem repeat sequence in the promoter region (TSER) which usually hosts 
double (allele *2) and triple (allele *3) repeats. The *3 allele is associated with a two to four 
fold increased expression of TYMS compared to *2. In patients with stage III colon cancer 
treated with adjuvant therapy, the outcome is poor in the presence of a TSER3 
polymorphism. While the response rate is 50% in those with *2/*2, it is 8% in those with 
*3/*3 (Marsh et al, 2001). TYMS polymorphisms also affect survival. Median survival of 
cases with *2/*2 is 16 months vs. 12 months in cases of *3/*3. (Salonga et al, 2000). TYMS 
polymorphisms are also relevant in predicting response to neoadjuvant 5-FU treatment in 
rectal cancer. Cases of *3/*3 are associated with a poor response to the treatment (Salonga et 
al, 2000, Villafranca et al, 2001). 
2.3 Thymidylate Phosphorylase (TYMP) 
TYMP mRNA levels in patients not responding to 5-FU were 2.6-fold higher than in 
responding patients in pretreatment biopsies of patients with colorectal cancer (Metzger et 
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cases with *2/*2 is 16 months vs. 12 months in cases of *3/*3. (Salonga et al, 2000). TYMS 
polymorphisms are also relevant in predicting response to neoadjuvant 5-FU treatment in 
rectal cancer. Cases of *3/*3 are associated with a poor response to the treatment (Salonga et 
al, 2000, Villafranca et al, 2001). 
2.3 Thymidylate Phosphorylase (TYMP) 
TYMP mRNA levels in patients not responding to 5-FU were 2.6-fold higher than in 
responding patients in pretreatment biopsies of patients with colorectal cancer (Metzger et 
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al, 1998). Survival was significantly increased in patients with both TYMS and TYMP under 
nonresponse cutoff values, and low intratumoral expression of TYMS and TYMP was 
associated with a response to 5-FU and improved survival (Metzger et al, 1998, Meropol et 
al, 2006). 
2.4 Methylenetetrahydrofolate reductase (MTHFR) 
MTHFR generates active folate which is necessary for normal hematopoiesis. Reduced 
MTHFR activity has been associated with increased sensitivity to 5-FU. Low activity 
MTHFR variants 677T and 1298C predispose to severe myelotoxicity in patients treated with 
5-FU (Robien et al, 2005). 
3. Gemcitabine 
Chemotherapy has proved of only limited effectiveness in pancreatic cancer. Gemcitabine is 
a deoxycytidine nucleoside analogue used in the treatment of advanced-stage pancreatic 
cancer (Burris et al, 1997). It has also proved to be of benefit in the adjuvant treatment of 
resected pancreatic cancer. Treatment with gemcitabine produces clinical benefit and 
symptom improvement in 20% to 30% of patients and 1-year survival rate of patients raised 
from 2% to 18% by gemcitabine. Gemcitabine undergoes metabolic activation by kinases to 
form a cytotoxic trinucleotide in the cell. Metabolic inactivation of gemcitabine by 
deamination is catalyzed by cytidine deaminase (CDA) or after phosphorylation by 
deoxycytidylate deaminase (DCTD) (Plunkett et al, 1995, Gandhi et al, 1990). Gemcitabine is 
a hydrophilic molecule and therefore does not cross the cell membrane by diffusion. To 
achieve gemcitabine cytotoxicity functional nucleoside transporters, namely human 
equilibrative nucleoside (hENT1) and human concentrative nucleoside transporters are 
needed. Nucleoside-transporter–deficient cells are highly resistant to gemcitabine (Spratlin 
et al, 2004, Mackey et al, 1998). “SLC29A1” is the most abundant of the nucleoside 
transporters. Intratumoral SLC29A1 protein expression, was related to prolonged survival 
in patients with pancreatic carcinoma treated with gemcitabine. Analysis of SLC29A1 
mRNA expression revealed a significant correlation with longer survival in these patients 
following treatment (Sebastiani V et al, 2006, Giovannetti E, 2006). 
Deoxycytidine kinase (DCK) deficiency is one of the most common forms of acquired 
resistance to gemcitabine in vitro (Sebastiani V et al, 2006, Bergman AM, et al, 2002). A 
correlation has been described between higher levels of DCK activity and increased 
gemcitabine sensitivity in patients with advanced pancreatic cancer treated with 
gemcitabine, whereas low tumoral DCK protein expression is associated with a worse 
overall survival (OS) and progression-free survival (PFS) (Sebastiani V et al, 2002, Kocabas 
NA et al, 2009). Ribonucleotide reductase (RR) is a target enzyme for gemcitabine (Goan YG 
et al, 1999). The pharmacology and pharmacogenetics of ribonucleotide reductase subunit 
M1 (RRM1) is of particular interest due to its potential role in gemcitabine chemosensitivity 
and synergy with other chemotherapeutic agents, particularly cisplatin (Sebastiani V, et al, 
Mini E et al, 2006, Ueno H et al, 2007). In genetically modified lung cancer cell lines, RRM1 
expression correlated inversely with gemcitabine sensitivity (Bepler G et al, 2006). 
Deactivating enzymes of gemcitabine include 5', 3'-nucleotidase, cytosolic (NT5C), 
deoxycytidylate deaminase (DCTD), and cytidine deaminase (CDA). Upregulation of CDA 
may play a role in gemcitabine resistance, while impaired activity may result in increased 
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toxicity but not efficacy (Bepler G et al, 2006, Mathijssen RH et al, 2001). In addition to 
impaired tumor-specific mRNAs’/proteins’ expression, a variety of genetic polymorphisms 
can have an impact on gemcitabine efficacy and toxicity. Tumor-specific expression of 
ENT1, RRM1 or ERCC1, and some DNA repair genetic polymorphisms appear to be 
indicators of prognosis in patients receiving gemcitabine chemotherapy. The expression 
level or genetic polymorphism of CDA seems to be a good predictor of adverse side effects 
caused by gemcitabine. SNP, CDA 208A4G, or CDA expression level may be used as 
biomarkers for prediction of gemcitabine-related severe toxicity: germline homozygosity for 
CDA 208A in a Japanese patient with pancreatic cancer treated with gemcitabine and 
cisplatinum resulted in severe hematologic and nonhematologic toxicity (Yonemori K et al, 
2005). This is an important finding since considerable numbers of homozygote carriers of 
CDA 208A exist in Japanese and some African populations (Ueno H et al, 2007, Yonemori K 
et al, 2005). 
4. Irinotecan (CPT-11) 
Irinotecan is a camptothecin analogue which acts as a topoisomerase I inhibitor (Mathijssen 
RH et al, 2001). It is used alone or in combination with 5-FU, and folinic acid, in the 
treatment of colorectal cancer, gastric cancer, and in combination with 5-FU, folinic acid and 
oxaliplatin in advanced pancreatic cancer. Irinotecan may cause unpredictable severe 
toxicity such as diarrhea and neutropenia which may lead to either discontinuation or 
significant dose reduction of the drug. Irinotecan is activated to its cytotoxic metabolite SN-
38 that inhibits the nuclear topoisomerase 1 enzyme, which is critical for DNA replication. 
Activation, transportation, and deactivation of irinotecan are complex and involve several 
enzymes, including carboxylesterase (CE), “CYP3A4”, and uridine diphosphate 
glucuronosyltransferase (UGT1A1). Irinotecan is converted to its active metabolite, SN38, by 
the CE present in the gastrointestinal tract (Figure 2) (Charasson et al, 2004, Khanna et al, 
2000). This enzyme has many allelic variants and genotypes. SN38 is primarily inactivated 
in the liver by UGT1A1 via glucuronidation. Mild hereditary deficiency of UGT1A1 leads to 
Gilberts syndrome which is characterized by intermittent hyperbiliribunemia (Innocenti et 
al, 2004, Iyer et al, 2002). Since patients with Gilbert’s syndrome experienced severe toxicity 
in early phase studies, the association of irinotecan toxicity and the UGT1A1 polymorphism 
has been under thorough investigation (Wasserman et al, 1997). UGT1A1 inactivates SN38 
via a phase II reaction. The wild type UGT1A1 is designated as UGT1A1*1. More than 50 
genetic variations of UGT1A1 have been identified up to now (Tukey et al, 2002). Each of 
these leads to different degrees of functional variations. Among them UGT1A1*6, 
UGT1A1*28, UGT1A1*36 and UGT1A1*37 are functionally important polymorphisms. The 
UGT1A1*28 polymorphism is associated with reduced UGT1A1 expression and, as a result, 
decreased glucuronidation of SN38. This, in turn, increases blood levels of active metabolites 
resulting in increased toxicity (Khanna et al, 2000, Innocenti 2004, Iyer 2002, Hoskins et al, 
2007). The pharmacokinetics of irinotecan is poorly associated with body surface area. Since 
SN38 undergoes glucuronidation to a lesser extent in patients with Gilbert and Crigler 
Najjar syndromes, irinotecan toxicity increases in these patients, because of reduced or 
deficient expression levels of UGT1A1. Gilbert syndrome results from the UGT1A1*28 
homozygote transition of a promoter polymorphism caused by seven TA repetitions. In the 
presence of the UGT1A1*28 polymorphism, transcription is decreased by 70% and toxicity is 
increased. Patients with the 7/7 genotype (homozygous for seven TA repetitions) exhibit a 
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9.3-fold increase in risk of grade 4 neutropenia, and irinotecan is associated with severe side 
effects in this population (Iyer et al, 2002, Hoskins et al, 2007; McLeod et al, 2003). In an early 
study the UGT1A1*28 allele increased the risk of leukopenia and/or diarrhea, however most 
of the later studies found only increased risk of hematological toxicity such as neutropenia 
(Ando et al, 2000). In fact, in a meta-analysis of 10 studies assessing the irinotecan induced 
toxicity in UGT1A1*28 patients, irinotecan dose, and overall toxicity, risk of experiencing 
irinotecan induced hematologic toxicity for homozygous UGT1A1*28 patients was found to 
be a function of the dose of irinotecan administered, and genotyping was recommended at 
only high doses (> 200 mg/m2) of irinotecan (Hoskins et al, 2007). Genotyping has limited 
benefit at intermediate doses, such as 180mg/m2 used in the FOLFIRI (folinic acid/5-
FU/irinotecan) regimen. Unless administered concomitantly with another myelotoxic agent, 
UGT1A1*28 testing is not recommended at doses < 150 mg/m2. 
 
Fig. 2. Irinotecan Metabolism 
Transport proteins that excrete irinotecan and metabolites have also been investigated for 
their potential association with irinotecan response and toxicity. P-glycoprotein represents 
one of these proteins, and it is encoded by the ATP binding B1 (ABCB1 or MDR1) gene. 
However, the pharmacogenetic results regarding ABCB1 and irinotecan are conflicting to 
date. Genetic variation in ABCB1 was associated with early toxicity and lower response to 
treatment. Specifically, carriers of the ABCB1 1236T-2677T-3435T haplotype responded to 
treatment less frequently with shorter survival (Glimelius et al, 2011). 
5. Platinum compounds (Cisplatin and Oxaliplatin) 
Cisplatin and oxaliplatin are commonly used in gastrointestinal cancers (Vermorken et al, 
1984, Raymond et al, 1998, Levi et al, 2000) Platinum analogues block DNA replication by 
forming different DNA adducts, through intra-strand and inter-strand crosslinks. Platin 
resistance occurs due to detoxification or efficient repair of DNA by the nucleotide excision 
repair system. DNA repair enzymes “ERCC1” and “ERCC2”—also known as “XPD” and 
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glutathione S transferase  (GSTP) enzymes—are involved in the activity of these agents 
(Levi et al, 2000). GST  is a phase II metabolic enzyme that inactivates platinum derivatives 
by adding a glutathione to its electrophile group. High expression of the genes that code for 
these enzymes is inversely correlated with therapeutic response in colorectal and gastric 
cancer (Ruzzo et al, 2007). Preclinical models of oxaliplatin resistance have also been studied 
in colorectal cancer cell lines. In these cell lines a total of 6 target genes were identified: 
AKT1, CDK5, RGS11, GARP, TRIP, and UGCGL1. Three of these genes (AKT1, CDK5 and 
TRIP) were shown to be involved in NF-  pathway regulation. It was suggested that low 
levels of TRIP and high levels of AKT1 and CDK5 could contribute to NF-  activation and 
consequently cell antiapoptotic activity and oxaliplatin acquired resistance. These findings 
show that the NF-  pathway plays a pivotal role in mechanisms of acquired oxaliplatin 
resistance (Martinez-Cardus et al, 2009). 
6. Combination chemotherapy 
6.1 Folfox (Oxaliplatin/5-FU/folinic acid) 
Many chemotherapy combinations are used in the treatment of gastrointestinal cancers. 
However, strong evidence of pharmacogenetics is available only in a minority of the 
reference studies (Stoehlmacher et al, 2004; Goldberg et al, 2006). The N9741 trial is a 
randomized phase III trial designed to compare the efficacy of FOLFOX (folinic acid/5-
FU/oxaliplatin), IROX (irinotecan/oxaliplatin), and IFL (irinotecan/bolus 5-FU/folinic acid) 
in patients with metastatic colorectal cancer (Goldberg et al, 2006). The pharmacogenetic 
evaluation of this study revealed that both the objective response rate and incidence of 
grade ¾ side effects, particularly diarrhea, were lower in black patients. The low response 
rate in black patients was especially marked in the FOLFOX arm. Overall, the rate of 
response was 41% and 30% in white and black patients, respectively (P = .015). The rate of 
severe toxicity was 48% in whites and 34% in black patients in the FOLFOX arm (P = .047). 
Despite the lack of significant median survival difference between these two patient groups 
in the FOLFOX arm, median survival was lower in black patients in both the IFL and IROX 
groups. In all arms, black patients experienced less toxicity, particularly less diarrhea, 
compared to white patients. The UGT1A1 7/7 polymorphism was identified at a rate of 21% 
and 9% in black and white patients, respectively, in this study. However, the role of the 
UGT1A1 polymorphism with respect to response and toxicity could not be demonstrated. 
Significant differences were also detected between white and black patients in the 
prevalence of other pharmacogenetic variances such as CYP3A, MDR (multidrug 
resistance), ERCC1, ERCC2, and GSTP. These genes are important in the metabolism and 
detoxification of irinotecan and oxaliplatin (Grothey et al, 2005). Of note, the type of GSTP 
polymorphism was shown to be associated with early development of oxaliplatin 
neuropathy in patients receiving FOLFOX.  
The polymorphism that causes a single nucleotide change of C to T, at codon 118, converts a 
codon of common usage (AAC) to a less used codon (AAT), both coding for asparagine. 
This change results in decreased ERCC1 gene expression, which impairs repair activity. A 
small study showed that the ERCC1 codon 118 polymorphism predicted response to 
oxaliplatin/5-FU chemotherapy in patients with advanced colorectal cancer (Viguier et al, 
2005). In this retrospective study including 91 patients, response rate was 61.9%, 42.3%, and 
21.4% in T/T, C/T, and C/C groups, respectively (P= 0.018). However, the results of the 
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codon of common usage (AAC) to a less used codon (AAT), both coding for asparagine. 
This change results in decreased ERCC1 gene expression, which impairs repair activity. A 
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studies regarding the ERCC1 codon 118 polymorphism are somewhat contradictory, likely 
due to a variety of factors such as ethnicity, environment (smoking or diet), the number of 
patients enrolled and/or linkage to other polymorphisms (Ryu, 2006). A SNP in codon 751 
of the ERCC2 gene which leads to glutamine instead of lysine, was associated with a 
reduced response rate (Park et al, 2001, Stoehlmacher et al, 2004). Additionally, patients with 
the GST  105 Val/Val genotype had a better progression free survival (PFS) and overall 
survival (OS) than patients carrying the GST  105 Ile allele (Stoehlmacher et al, 2004). In a 
more recent study analyzing the pharmacogenetic factors in patients with advanced 
colorectal cancer treated with FOLFOX chemotherapy PFS was related only to genes 
involved in oxaliplatin pharmacodynamics, with a tendency for a better outcome in patients 
bearing the GST  105 Val/Val genotype or the XPD 751Lys allele (Etienne-Grimaldi et al, 
2010). Lymphocytic activity of GST  has been shown to be significantly reduced in GST  
105 Val/Val patients compared with GST  105 Ile/Ile patients (Dusinská et al, 2001). 
However, the functional impact of XPD 751 Lys Gln at the protein level is not clearly 
established.  
6.2 Cisplatin/5-fluorouracil 
Combination of cisplatin and 5-FU (CF) constitutes the backbone of chemotherapy regimens 
commonly used for upper gastrointestinal system tumors including gastric and 
hepatobiliary cancer (Kilickap et al, 2011). In gastric cancer TYMS and ERCC gene 
expression has been studied individually as the predictors of chemoresistance (Lenz et al, 
1996, Metzger et al, 1998). In another study although TYMS and ERCC1 expression 
associated with poor prognosis, it did not reach statistical significance (P = 0.076) (Metzger 
et al, 1998). Kim et al, developed a three gene predictor of clinical outcome for metastatic 
gastric cancer patients treated with cisplatin and 5-FU (Kim et al, 2010). The combined 
expression of MYC, epidermal growth factor receptor (EGFR) and fibroblast growth factor 
receptor 2 (FGFR2) was found to be an independent predictor of decreased OS of CF treated 
metastatic gastric cancer patients (Kim et al, 2010). The findings of the study showed that 
over expression of these 3 genes was associated with chemoresistance and the results were 
consistent with the experimental studies showing that inhibitors of EGFR act synergistically 
with cisplatin and 5-FU, while an FGFR2 inhibitor acts synergistically with 5-FU and MYC 
over expression is associated with cisplatin resistance (Kim et al, 2010). Taken together, 
combined expression of MYC, EGFR and FGFR2 is predictive of poor survival in patients 
with metastatic gastric cancer treated with CF chemotherapy. 
The xCT gene, which codes for part of the plasma membrane cysteine/glutamate 
transporter, contributes to tumor cell protection against immune defense mechanisms 
(Huang et al, 2010). The plasma membrane xc-cysteine/glutamate transporter mediates 
cellular uptake of cysteine in exchange for intracellular glutamate and is highly expressed 
by pancreatic cancer cells. In advanced pancreatic cancer Huang et al, looked at the 
prognostic significance of SNPs in the xCT gene in patients treated with a combination of 
gemcitabine and platinum (Huang et al, 2010). The xCT gene, encodes the cysteine-specific 
xCT protein subunit of xc-, which is important in regulating intracellular glutathione levels, 
critical for cancer cell protection against oxidative stress, tumor growth and resistance to 
chemotherapeutic agents. A statistically significant correlation was noted between the 3' 
UTR xCT SNP rs7674870 and OS: Median survival time (MST) was 10.9 and 13.6 months, 
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respectively, for the TT and TC/CC genotypes (P = 0.027). In another study Pacetti et al, 
investigated polymorphisms in genes involved in activity and resistance to drugs, mainly 
DNA repair gene polymorphisms, in an effort to link them to treatment response. The 
substitution of glutamine for lysine in position 751 of the XPD gene (Figure 2) led to 
increased overall survival from 262 days to 446 days (Pacetti et al, 2010). These studies 
suggest that genetic polymorphisms in xCT gene may serve as a predictor of treatment 
outcome in advanced pancreatic cancer. 
7. Biologic agents 
7.1 Overview 
Biologic agents used in GI cancers alone or in combination with chemotherapy include 
bevacizumab (Avastin, Roche), cetuximab (Erbitux, KGaA), panitumumab (Vectibix, 
Amgen), and erlotinib (Tarceva, Roche), sunitinib (Sutent, Pfizer), imatinib (Glivec, Gleevec, 
Novartis). These drugs do not act only through different mechanisms of action but also 
demonstrate differences in their pharmacokinetics and pharmacodynamics. Meanwhile, 
data on their pharmacogenetics are only now emerging. 
7.2 Bevacizumab 
Bevacizumab is a humanized monoclonal antibody (MoAB) that binds the vascular 
endothelial growth factor (VEGF). Increased VEGF expression is involved in tumoral 
angiogenesis and associated with poor prognosis. Bevacizumab prevents receptor binding 
of VEGF, and inhibits VEGF signaling pathways, thus stops angiogenesis and tumor 
growth. The therapeutic benefit of bevacizumab has been shown in the treatment of patients 
with advanced-stage colorectal cancer. Thus far, however, adequate pharmacogenetic data 
have not been produced to predict toxicity, response, or resistance. 
7.3 EGFR monoclonal antibodies (Cetuximab and Panitumumab)  
Cetuximab and panitumumab are MoAB used as single agents or in combination with 
chemotherapy for the treatment of advanced colorectal cancer. Cetuximab is a MoAB that 
binds to the EGFR and blocks EGF signaling pathway and tumor growth. Panitumumab is 
the anti-EGFR MoAB similar to cetuximab, binds EGFR and inhibits downstream of EGF 
signaling. Panitumumab is a fully human MoAB in contrast to cetuximab which is chimeric. 
The pioneering studies of BOND trials, showed that cetuximab may provide benefit in 
patients with chemotherapy refractory advanced colorectal cancer (Saltz et al, 2007). In the 
BOND 2 trial metastatic colorectal cancer patients progressing after irinotecan-based 
chemotherapy were randomized to receive irinotecan plus bevacizumab plus cetuximab 
(CBI) or bevacizumab and cetuximab (CB) (Lenz et al, 2007). In this trial, germline 
polymorphisms of the genes involved in angiogenesis (VEGF, interleukin-8 [IL-8], 
transforming growth factor [TGF]- ), the EGFR pathway (EGFR, cyclooxygenase-2, E-
cadherin), DNA repair (ERCC1, ERCC2, XRCC1, XPD), and drug metabolism pathway 
(GSTP, UGT1A1) were investigated. Genomic DNA was extracted for genotyping from 65 
patients (31: CBI arm and 34: CB arm). Thirty five patients had tissue samples available for 
the gene expression assay (18: CBI arm and 17: CB arm). High intratumoral gene expression 
levels of EGFR, VEGFR2 and NRP1 were associated with longer OS in patients receiving 
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studies regarding the ERCC1 codon 118 polymorphism are somewhat contradictory, likely 
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combined monoclonal antibodies with or without irinotecan. The FCGR3A V158F, cyclinD1 
A870G and EGFR R497K polymorphisms were associated with clinical outcome in patients 
receiving the cetuximab and bevacizumab combination independent of KRAS mutation 
status (Lenz et al, 2007, Zhang et al, 2007). Patients with high intratumoral EGFR gene 
expression levels had a median survival time of 21.8 (range, 9.6-28.2) months, compared to 
patients with low EGFR gene expression levels, whose median survival was 10.2 (range, 8.3-
13.6) months (P = 0.033). In the RP analysis, the EGFR gene expression level was found to be 
the best single determinant of survival (Zhang et al, 2007) 
Initially anti-EGFR antibodies were tested in patients with metastatic colorectal cancer 
which showed elevated EGFR expression, as determined by immunohistochemistry. 
However, response to EGFR MoAB was not found to be correlated to EGFR expression. 
Retrospective data suggested that the severity of skin rash might be positively correlated 
with tumor response to anti-EGFR MoAB, but only in patients with tumors expressing wild 
type K-RAS. In the NCIC CTG CO17 study a rash of grade 2 or higher was strongly 
associated with improved survival in patients treated with cetuximab (Jonker et al, 2007). A 
correlation between K-RAS mutation and resistance to the EGFR antibodies cetuximab and 
panitumumab has been demonstrated. K-RAS mutations account for approximately 30% to 
40% of patients with mCRC. (Van Cutsem et al, 2008, Amado et al, 2008, Bokemeyer et al, 
2008). Patients with a K-RAS mutation in codons 12, 13 and 61 in their tumor tissue have 
lower rates of response to cetuximab and panitumumab and shorter PFS time. The benefit of 
anti-EGFR MoAB monotherapy is limited to only the patients with K-RAS wild type CRC 
except patients with the codon 13 D13G K-RAS mutation benefit from the therapy similar to 
the wild type tumors (De Roock et al, 2010). Therefore, K-RAS mutation analysis is required 
before prescribing EGFR MoAB therapies. 
The B-type Raf kinase BRAF V600E mutation was detected in 11 of 79 patients who had wild 
type K-RAS (Di Nicolantonio et al, 2008). This BRAF mutation is associated with resistance 
to cetuximab and panitumumab with significantly shorter PFS and OS compared to wild 
type patients (Di Nicolantonio et al, Di Fiore et al, 2008). Mutations of genes other than K-
RAS and BRAF, such as the phosphatase and tensin homologue (PTEN), and 
phosphatidylinositol 3-kinase (PI3K) were also associated with shorter survival of MCRC 
patients receiving EGFR antagonists (Karapedis et al, 2008). Thus, these mutations may 
serve as additional biomarkers to predict resistance of EGFR antagonists. 
7.4 Erlotinib 
Erlotinib belongs to a group of drugs called EGFR tyrosine kinase inhibitors. EGF has 
receptors on cancer cell surfaces. Stimulation of this receptor activates the tyrosine kinase 
enzyme inside the cell. The drugs that inhibit this enzyme, and stop the growth factor 
receptor are known as tyrosine kinase inhibitors (TKIs). Erlotinib is a small-molecule TKI 
targeting EGFR (Hidalgo et al, 2001; Li et al, 2007). Erlotinib, similarly to other EGFR-
directed therapies, is associated with toxicity involving skin rash and diarrhea. The 
molecular basis of these side effects is under investigation. Basal layers of both the 
epidermis and the GI mucosa express EGFR, and EGFR signaling has been implicated in the 
physiological regulation of these tissues. Inhibition of this physiological pathway is 
implicated in toxicity. Erlotinib is metabolized predominantly by CYP3A4, so inhibitors of 
this enzyme would be expected to increase systemic availability and inducers would be 
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expected to decrease it (Moore et al, 2007a). Potent inducers of CYP3A4 may reduce the 
efficacy of erlotinib, whereas potent inhibitors of CYP3A4 may lead to increased toxicity 
(Hidalgo et al, 2001, Li et al, 2007, Rudin et al, 2008). For example, concomitant use of 
ketacanozole, a CYP3A4 and ABCB1 inhibitor, increases the AUC of erlotinib by 66% which 
will result in increased erlotinib toxicity. Meanwhile pre- or co-treatment with rifampicin, a 
CYP3A4 inducer, increases erlotinib clearance by three-fold and reduces AUC by 66%, 
which will result in the loss of clinical activity. Therefore concomitant use of inhibitors and 
inducers of CYP3A4 should be avoided. 
Besides CYP genes the inhibition of glucuronidation may also cause interactions between 
erlotinib and substrates of UGT1A1. Patients with low expression of UGT1A1 or genetic 
glucuronidation disorders may have hyperbilirubinemia (Rudin et al, 2008). In advanced 
pancreatic cancer, erlotinib in combination with gemcitabine showed statistically superior 
overall survival compared with gemcitabine alone (6.4 months vs. 5.9 months, respectively) 
(Moore MJ et al, 2007). In this study, patients responded equally well to treatment with 
erlotinib regardless of whether their tumors expressed abnormal levels of EGFR. In a 
subgroup of analyses in this study the mutation status of the K-RAS and EGFR gene copy 
number (GCN) were evaluated as predictive markers in 26% of patients who had tumor 
samples available for analysis. The K-RAS mutation status was evaluated by direct 
sequencing of exon 2, and EGFR GCN was determined by fluorescence in situ hybridization 
(FISH) analysis. The results were correlated with survival, which was the primary endpoint 
of the trial. K-RAS mutations were identified in 78.6% of the patients and EGFR 
amplification or high polysomy (FISH-positive results) was identified in 46.7% of the 
patients. The hazard ratio of death between gemcitabine/erlotinib and gemcitabine/placebo 
was 0.66 (95% confidence interval [CI], 0.28-1.57) for patients with wild type K-RAS and 1.07 
(95% CI, 0.68-1.66) for patients with mutant K-RAS (P value for interaction = .38), and the 
hazard ratio was 0.6 (95% CI, 0.34-1.07) for FISH-negative patients and 0.90 (95% CI, 0.49-
1.65) for FISH-positive patients (P value for interaction = .32). Although survival was longer 
in patients with wild type K-RAS in comparison to K-RAS mutated patients, in this 
molecular subset analysis of patients from NCIC CTG PA.3, EGFR GCN and K-RAS 
mutation status were not identified as markers predictive of a survival benefit from the 
combination of erlotinib with gemcitabine for the first-line treatment of advanced pancreatic 
carcinoma (da Cunha Santos et al, 2010, Moore MJ et al, 2007b). 
In the AViTA study, patients with advanced stage pancreatic cancer were treated with 
gemcitabine plus erlotinib with or without bevacizumab. In this study, although no 
molecular pharmacogenetic marker has been identified yet, survival was positively 
correlated with severity of erlotinib induced skin rash (Verslype C et al, 2009). Therefore, 
reassessment of erlotinib treatment is recommended in patients who do not develop rash 
within the first 4 to 8 weeks of treatment. 
7.5 Imatinib 
Imatinitib mesylate is approved for the treatment of advanced and also resected high risk 
patients with cKIT or platelet derived growth factor receptor alpha (PDGFRA) activating 
mutation positive gastrointestinal stromal tumors (GIST). Sensitivity of imatinib in GIST 
correlates to exon mutations of cKIT and PDGFRA. The outcome of patients with cKIT exon 
11 mutations are more favorable compared to exon 9 mutations and to wild type tumors. 
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Approximately 80% of GISTs harbor an activating mutation in the cKIT gene and another 
5% to 7% have a PDGFRA gene mutation (Heinrich MC et al, 2008). These mutations are not 
only important in tumorigenesis, but also predict treatment response to imatinib, and 
provide prognostic information. If the tumors have a c-KIT exon 11 mutation the response 
rate is 69% to 86%, but only 17% to 48% in patients with tumors harboring a c-KIT exon 9 
mutation (Heinrich MC et al, 2008). These patients respond better to the dose of 800 mg 
imatinib compared to the standard 400 mg dose. Most of PDGFRA gene mutations are 
associated with imatinib response, with the most notable exception of D842V. In wild type 
GIST without any c-KIT and PDGFRA mutations, the response rate to imatinib is only 0% to 
45% (Heinrich MC et al, 2008). Median time to progression (TTP) is 25, 17, and 13 months for 
patients with tumor mutations in c-KIT exon 11, c-KIT exon 9, and neither c-KIT nor 
PDGFRA genes, respectively (Heinrich et al, 2008). Median OS is 60, 38, and 49 months, 
respectively. Although patients may experience prolonged disease control while on 
imatinib, most patients will develop imatinib resistance within 2-3 years on therapy. 
Lowered plasma levels of imatinib over time is often responsible for disease progression. 
This phenomenon is called as "acquired pharmacokinetic drug resistance". This may be 
because of an altered expression pattern or activity of drug transporters such as efflux 
transporters (ATP-binding cassette transporters, such as ABCB1 and ABCG2) and uptake 
transporters [solute carriers such as organic cation transporter 1 (OCT1) and organic anion 
transporting polypeptide 1A2 (OATP1A2)]. ABCB1 and ABCC1 expression was shown in 
GIST, whereas ABCB1, ABCG2, and OCT1 were found in mononuclear cells in CML 
patients. Despite increasing accumulation of preclinical data, clinical studies on imatinib 
pharmacogenetics are still insufficient and the results are somewhat contradictory. 
7.6 Sunitinib 
Sunitinib is an oral, multitargeted TKI. It inhibits VEGF receptors (VEGFRs) 1, 2, and 3, 
PDGFR  and  KIT, Fms-like tyrosine kinase 3 receptor (FLT3), and the receptor encoded 
by the RET proto-oncogene. Among the GI tumors sunitinib is approved for first-line 
treatment of metastatic pancreatic neuorendocrine tumours (PNET) and in imatinib-
resistant metastatic GIST. In a multicenter study including patients with GIST, metastatic 
renal cell cancer or other cancers, genetic markers in the pharmacokinetic and 
pharmacodynamic pathways of sunitinib that predispose to development of toxicity were 
investigated (van Erp et al, 2009). The study was performed in 219 patients treated with 
single-agent sunitinib. A total of 31 SNPs in 12 candidate genes were analyzed for a possible 
association with toxicity. The risk for leukopenia was increased when the G allele in 
CYP1A1 2455A/G (odds ratio (OR), 6.24; P = .029) or the T allele in FLT3 738T/C (OR, 2.8; P 
= .008) were present or CAG in the NR1I3 (5719C/T, 7738A/C, 7837T/G) haplotype (OR, 
1.74; P = .041) was absent. Any toxicity higher than grade 2 prevalence was increased when 
the T allele of VEGFR2 1191C/T (OR, 2.39; P = .046) or a copy of TT in the ABCG2 (-
15622C/T, 1143C/T) haplotype (OR, 2.63; P = .016) were present. The risk for mucosal 
inflammation was increased in the presence of the G allele in CYP1A1 2455A/G (OR, 4.03; P 
= .021) and the prevalence of hand-foot syndrome was increased when a copy of TTT in the 
ABCB1 (3435C/T, 1236C/T, 2677G/T) haplotype (OR, 2.56; P = .035) was present. This 
study suggested that polymorphisms in specific genes encoding for metabolizing enzymes, 
efflux transporters, and drug targets are associated with sunitinib-related toxicity. The 
response of patients with advanced GIST to sunitinib is related to the type of primary 
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mutation. Patients with original (pre-imatinib) exon 9 mutant or wild type tumor had a 
significantly longer duration of response compared to patients with exon 11 mutations. The 
median time to progression was 14.3 months for patients with original exon 9 mutations, 
13.8 months for patients with wild type cKIT and PDGFRA, and 5.1 months for patients 
whose original mutation was in exon 11 (Heinrich MC et al, 2008). 
8. Conclusion 
Despite progress in the development of new chemotherapy agents and targeted therapies, 
and the improved outcome in patients with GI cancers, there is still need for development of 
more efficacious treatments. Meanwhile, individualization of management of cancer 
patients is also crucial because only a portion of patients respond to a given treatment, 
usually with a low complete response rate. Therefore oncologists are seeking ways to 
predict whether a selected chemotherapy will be effective and tolerable in patients prior to 
treatment. Coupled with the complexity and diversity of each individual patient and the 
disease, each case should be handled uniquely and treatment should be tailor made. At this 
point pharmacogenetic plays a pivotal role. Recent progress in our understanding of 
carcinogenesis and molecular biology led to development of sophisticated pharmacogenetic 
assays to facilitate the delivery of more effective, less toxic chemotherapy regimens by 
individualizing treatments for patients with relatively resistant tumors of the GI tract. Based 
on the results of pharmacogenetic studies of clinical trials new tests are on the horizon and, 
data from these tests will enable cancer physicians to treat their patients better and save 
more lives. In this chapter recent pharmacogenetic studies relevant to the treatment of 
patients with GI cancer are reviewed. Genetic polymorphisms and tumor gene expression 
patterns are discussed. Many of the trials reviewed herein are expected to result in approval 
of new pharmacogenetic tests. 
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Approximately 80% of GISTs harbor an activating mutation in the cKIT gene and another 
5% to 7% have a PDGFRA gene mutation (Heinrich MC et al, 2008). These mutations are not 
only important in tumorigenesis, but also predict treatment response to imatinib, and 
provide prognostic information. If the tumors have a c-KIT exon 11 mutation the response 
rate is 69% to 86%, but only 17% to 48% in patients with tumors harboring a c-KIT exon 9 
mutation (Heinrich MC et al, 2008). These patients respond better to the dose of 800 mg 
imatinib compared to the standard 400 mg dose. Most of PDGFRA gene mutations are 
associated with imatinib response, with the most notable exception of D842V. In wild type 
GIST without any c-KIT and PDGFRA mutations, the response rate to imatinib is only 0% to 
45% (Heinrich MC et al, 2008). Median time to progression (TTP) is 25, 17, and 13 months for 
patients with tumor mutations in c-KIT exon 11, c-KIT exon 9, and neither c-KIT nor 
PDGFRA genes, respectively (Heinrich et al, 2008). Median OS is 60, 38, and 49 months, 
respectively. Although patients may experience prolonged disease control while on 
imatinib, most patients will develop imatinib resistance within 2-3 years on therapy. 
Lowered plasma levels of imatinib over time is often responsible for disease progression. 
This phenomenon is called as "acquired pharmacokinetic drug resistance". This may be 
because of an altered expression pattern or activity of drug transporters such as efflux 
transporters (ATP-binding cassette transporters, such as ABCB1 and ABCG2) and uptake 
transporters [solute carriers such as organic cation transporter 1 (OCT1) and organic anion 
transporting polypeptide 1A2 (OATP1A2)]. ABCB1 and ABCC1 expression was shown in 
GIST, whereas ABCB1, ABCG2, and OCT1 were found in mononuclear cells in CML 
patients. Despite increasing accumulation of preclinical data, clinical studies on imatinib 
pharmacogenetics are still insufficient and the results are somewhat contradictory. 
7.6 Sunitinib 
Sunitinib is an oral, multitargeted TKI. It inhibits VEGF receptors (VEGFRs) 1, 2, and 3, 
PDGFR  and  KIT, Fms-like tyrosine kinase 3 receptor (FLT3), and the receptor encoded 
by the RET proto-oncogene. Among the GI tumors sunitinib is approved for first-line 
treatment of metastatic pancreatic neuorendocrine tumours (PNET) and in imatinib-
resistant metastatic GIST. In a multicenter study including patients with GIST, metastatic 
renal cell cancer or other cancers, genetic markers in the pharmacokinetic and 
pharmacodynamic pathways of sunitinib that predispose to development of toxicity were 
investigated (van Erp et al, 2009). The study was performed in 219 patients treated with 
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= .008) were present or CAG in the NR1I3 (5719C/T, 7738A/C, 7837T/G) haplotype (OR, 
1.74; P = .041) was absent. Any toxicity higher than grade 2 prevalence was increased when 
the T allele of VEGFR2 1191C/T (OR, 2.39; P = .046) or a copy of TT in the ABCG2 (-
15622C/T, 1143C/T) haplotype (OR, 2.63; P = .016) were present. The risk for mucosal 
inflammation was increased in the presence of the G allele in CYP1A1 2455A/G (OR, 4.03; P 
= .021) and the prevalence of hand-foot syndrome was increased when a copy of TTT in the 
ABCB1 (3435C/T, 1236C/T, 2677G/T) haplotype (OR, 2.56; P = .035) was present. This 
study suggested that polymorphisms in specific genes encoding for metabolizing enzymes, 
efflux transporters, and drug targets are associated with sunitinib-related toxicity. The 
response of patients with advanced GIST to sunitinib is related to the type of primary 
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mutation. Patients with original (pre-imatinib) exon 9 mutant or wild type tumor had a 
significantly longer duration of response compared to patients with exon 11 mutations. The 
median time to progression was 14.3 months for patients with original exon 9 mutations, 
13.8 months for patients with wild type cKIT and PDGFRA, and 5.1 months for patients 
whose original mutation was in exon 11 (Heinrich MC et al, 2008). 
8. Conclusion 
Despite progress in the development of new chemotherapy agents and targeted therapies, 
and the improved outcome in patients with GI cancers, there is still need for development of 
more efficacious treatments. Meanwhile, individualization of management of cancer 
patients is also crucial because only a portion of patients respond to a given treatment, 
usually with a low complete response rate. Therefore oncologists are seeking ways to 
predict whether a selected chemotherapy will be effective and tolerable in patients prior to 
treatment. Coupled with the complexity and diversity of each individual patient and the 
disease, each case should be handled uniquely and treatment should be tailor made. At this 
point pharmacogenetic plays a pivotal role. Recent progress in our understanding of 
carcinogenesis and molecular biology led to development of sophisticated pharmacogenetic 
assays to facilitate the delivery of more effective, less toxic chemotherapy regimens by 
individualizing treatments for patients with relatively resistant tumors of the GI tract. Based 
on the results of pharmacogenetic studies of clinical trials new tests are on the horizon and, 
data from these tests will enable cancer physicians to treat their patients better and save 
more lives. In this chapter recent pharmacogenetic studies relevant to the treatment of 
patients with GI cancer are reviewed. Genetic polymorphisms and tumor gene expression 
patterns are discussed. Many of the trials reviewed herein are expected to result in approval 
of new pharmacogenetic tests. 
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1. Introduction 
Sequence variability among individual human genomes has become a key resource for 
modern medicine in the search for genetic markers affecting disease susceptibility, disease 
manifestation and response to treatment. Genetic markers have been used for years as an 
indispensable tool for the diagnosis and follow-up of a number of diseases. They are also 
used as prognostic and predictive markers. Their application as pharmacogenetic markers is 
especially important. 
Pharmacogenetics is referred to as the study of the variations in a DNA sequence as related 
to drug efficacy and toxicity. It began with studying differences among individuals. 
However, as it developed, it became clear that genetic differences between populations 
should also be taken into account. Following great progress in understanding the molecular 
basis of health and disease, pharmacogenetics has evolved into pharmacogenomics, a much 
newer discipline which can be described as the whole-genome application of 
pharmacogenetics. More precisely, pharmacogenomics is the study of variations of DNA 
and RNA characteristics as related to drug response.  
Genetic variability can affect various aspects of drug therapy: disposition of the drug 
(pharmacokinetics), efficacy of the drug (pharmacodynamics) and adverse drug reactions 
(ADRs). Genetic factors are estimated to account for 15-30% of inter-individual differences 
in drug metabolism and response. 
The ultimate goal of pharmacogenetic testing is to aid physicians in the prescription of the 
appropriate medication at the correct dose prior to the initiation of the therapy. This would 
lead to minimizing adverse events and toxicity and maximizing efficacy by excluding those 
who are unlikely to benefit (non-responders) or who may be harmed (adverse responders). 
Here, we provide an overview of the genetic variants of thiopurine S-methyltransferase 
(TPMT) gene that influence inter-individual dosing of thiopurine drugs, to highlight a 
tangible benefit of translating genomic knowledge into clinical practice. Particular single 
nucleotide polymorphisms (SNPs) in TPMT gene have proven to be applicable for 
optimising the dosage in pursuit of maximum efficacy and minimum adverse effects. Thus, 
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they set an important paradigm of the implementation of pharmacogenomics in mainstream 
clinical practice. 
2. Pharmacogenetics 
The role of genetics in response to drugs was first predicted by Sir Archibald Garrod in the 
early 1930s (Garrod 1931). Pharmacogenetics, as it is known today, originated as a new 
scientific discipline in the late 1950s by the merging of two older ones: pharmacology and 
genetics. Pharmacogenetics examines the role of inherited individual differences in response 
to drugs. It is a branch of science that explains variability in response to drugs and genetic 
basis as the cause of this variability. Initially, the focus was on individual human 
differences, but over time the area of interest of this science extended to genetic differences 
between populations. Many professionals from this field deal exclusively with humans, but 
this science has applied its principles to all living organisms that are able to respond to a 
drug or other chemicals. 
Research in the field of pharmacogenetics is being developed into two main directions: first, 
the identification of specific genes and their products that are associated with various 
diseases and that could represent targets for new therapeutics; and second, the identification 
of genes and allelic variants of genes that might influence the response to already existing 
drugs (Wolf et al., 2000).  
3. Human genetic variations 
In 2003, after more than a decade, the Human Genome Project was completed. It was clear 
that the information obtained from the Project had the potential to forever transform 
healthcare and that genome-based medicine, frequently called personalized medicine, is the 
future of healthcare. Ever since, the main goal was achieving faster and cheaper sequencing 
of the whole human genome. The key advantage is the possibility to identify very rare or 
new, “private” genetic variants. Among a patient’s personal genome data, the most 
important data is about inter-individual genetic differences.  
More than ninety-nine percent of the DNA sequence is identical among individuals. The 
remaining DNA is responsible for genetic diversity (Kidd et al., 2004). Polymorphisms are 
common genetic variations in the human genome. They represent sequence variations that 
occur with a frequency >1% in the general population. The most studied polymorphisms are 
SNPs (single nucleotide polymorphisms). They are distributed over the whole genome. The 
number of SNPs is estimated to range from 0.3 to 1 SNP per 100 base pairs (bp). Besides 
SNPs, there are other important classes of polymorphisms, such as VNTRs (variable number 
of tandem repeats, polymorphic sequence containing 20-50 copies of 6-100 bp repeats), STRs 
(short tandem repeats, a subclass of VNTR in which repeat unit consists of only 2-7 
nucleotides) and CNPs (copy number polymorphisms, variation in the number of copies 
(CNV) of a DNA sequence in the > 1 kb size range, which are common and widely 
distributed in the human genome).  
The totality of these genetic variations found in an individual, a variome, should carry an 
answer about inborn diseases, compliance with drug therapies and other processes - all 
specific to that individual. However, in order to be fully understood and finally translated 
into the everyday clinical practice, variome data needs to be adequately interpreted. The 
most important approach of interpretation is to correlate genetic variation with clinical data. 
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4. Thiopurine S-methyltransferase (TPMT) 
One of the best examples of the application of pharmacogenetics in clinical practice is the 
discovery that different individual responses to purine antagonists as therapeutics are 
caused by individual variations in thiopurine S-methyltransferase (TPMT) enzyme activity 
(Weinshilboum et al., 1980). Patients who have reduced TPMT enzyme activity can develop 
toxic effects after the application of standard doses of these drugs (Weinshilboum et al., 
1980). On the other hand, there are patients in whom the activity of this enzyme is extremely 
high and they do not respond to standard doses of drugs (Weinshilboum et al., 1980). The 
characterization of mutations within the TPMT gene enabled the explanation of these inter-
individual differences in enzyme activity. Consequently, the goal of pharmacogenetics, the 
individualization of therapy, becomes a step closer. The characterization of mutations in 
TPMT gene is also a model system that illustrates how knowledge in the field of 
pharmacogenetics is successfully used in clinical practice.  
5. Thiopurine drugs 
Antimetabolites or structural analogs are compounds analogous to natural cell compounds 
such as folic acid, purines and pyrimidines. The mechanism of their action is based on the 
fact that they replace natural metabolites in the biochemical processes of cells. 
Antimetabolites have the greatest impact on the biochemical pathways that are involved in 
the metabolism of nucleotides and nucleic acids. Purine antagonists as thiopurine drugs 
have been widely used in medical practice for over 50 years. The structural analogues of 
purines are 6-mercaptopurine (6-MP), 6-thioguanine (6-TG) and azathioprine (AZA) 
(Coulthrad et al., 2005).  
Thiopurine drugs are indicated for the treatment of various diseases. 6-MP and 6-TG are 
mainly used in the treatment of hematologic malignancies, such as acute leukemia and 
lymphoma in children and adults.  In childhood acute lymphoblastic leukemia (ALL), 6-TG 
is primarily used in the induction phase, and 6-MP in the consolidation phase of ALL 
therapy. The immunosuppressive drug AZA is the drug of choice in the treatment of 
inflammatory bowel diseases, rheumatoid arthritis, autoimmune hemolytic anemia, 
systemic lupus erythematosus, as well as in transplantation medicine.  
Thiopurine drugs were synthesized in 1951 (Elion 1986). It was shown that newly 
synthesized drugs inhibit the use of natural purines and act upon the reduction of some 
tumors in rats (Elion 1967). Soon the activity of these drugs was confirmed in childhood 
ALL. At that time, the prognosis of this disease was extremely poor. The discovery that 6-
MP can lead to the complete remission of childhood ALL, resulted in the approval of the use 
of these drugs in medical practice by the U.S. Food and Drug Administration in 1953 
(Burchenal et al., 1953). AZA was introduced in therapy later, in 1963, after its successful use 
in kidney transplantation (Murray et al., 1963).  
The basic principle of how thiopurine drugs act is the inhibition of many pathways in nucleic 
acid biosynthesis. Consequently they prevent proliferation of cells involved in determination 
and amplification of the immune response, causing suppression of the immune system. 
Thiopurine drugs are also used in cancer treatment (Katzung 2004). An important biochemical 
feature of cancer cells is excessive synthesis of nucleic acids. Thiopurine drugs are able to stop 
this synthesis, and thus prevent the division of neoplastic cells (Katzung 2004). Anticancer and 
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4. Thiopurine S-methyltransferase (TPMT) 
One of the best examples of the application of pharmacogenetics in clinical practice is the 
discovery that different individual responses to purine antagonists as therapeutics are 
caused by individual variations in thiopurine S-methyltransferase (TPMT) enzyme activity 
(Weinshilboum et al., 1980). Patients who have reduced TPMT enzyme activity can develop 
toxic effects after the application of standard doses of these drugs (Weinshilboum et al., 
1980). On the other hand, there are patients in whom the activity of this enzyme is extremely 
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Thiopurine drugs were synthesized in 1951 (Elion 1986). It was shown that newly 
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tumors in rats (Elion 1967). Soon the activity of these drugs was confirmed in childhood 
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MP can lead to the complete remission of childhood ALL, resulted in the approval of the use 
of these drugs in medical practice by the U.S. Food and Drug Administration in 1953 
(Burchenal et al., 1953). AZA was introduced in therapy later, in 1963, after its successful use 
in kidney transplantation (Murray et al., 1963).  
The basic principle of how thiopurine drugs act is the inhibition of many pathways in nucleic 
acid biosynthesis. Consequently they prevent proliferation of cells involved in determination 
and amplification of the immune response, causing suppression of the immune system. 
Thiopurine drugs are also used in cancer treatment (Katzung 2004). An important biochemical 
feature of cancer cells is excessive synthesis of nucleic acids. Thiopurine drugs are able to stop 
this synthesis, and thus prevent the division of neoplastic cells (Katzung 2004). Anticancer and 
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immunosuppressive activity is accomplished through the incorporation of thioguanine 
nucleotides, metabolic products of thiopurine drugs, into DNA.  
Thiopurine drugs are inactive in their original form. They are precursors of the active drug, 
so-called pro-drugs, and they have to be metabolized first in order to exhibit cytotoxic, 
therapeutic effect (Lennard 1992). The first step is the non-enzymatic degradation of AZA to 
6-MP and imidazole group. 6-MP and 6-TG go through metabolic changes prior to the 
expression of their cytotoxic effects. After metabolic conversion, 6-MP and 6-TG are 
incorporated into the DNA and RNA molecules as thioguanine nucleotides (6-TGN) 
(Bertino 1991). 6-MP can also inhibit de novo synthesis of purine nucleotides (Dervieux et al., 
2001; Coulthard et al., 2002). 6-TGN are incorporated into DNA as false  bases, causing 
DNA damage by single strand breaking, inter-strand cross-linking and DNA-protein cross-
linking (Maybaum et al., 1981; Maybaum et al., 1983; Christie et al., 1984; Tay et al., 1969; Pan 
et al., 1990; Bodell 1991). Also, the inhibition of normal DNA replication may occur, through 
the partial inhibition of DNA polymerase and DNA ligase (Ling et al., 1992) as well as 
through the significant inhibition of RNase H (Krynetskaia et al., 1999).  
6. Metabolism of thiopurine drugs  
As already mentioned, 6-MP and 6-TG are metabolically converted to 6-TGN before 
expressing their cytotoxic effect (Fig 1). Metabolic conversion begins with the enzyme 
hypoxanthine-guanine phosphoribosyltransferase (HPRT, EC: 2.4.2.8). After a series of 
metabolic steps, 6-TGN are formed and incorporated into DNA and RNA molecules.  
 
Fig. 1. Thiopurine drug metabolism. The figure shows a simplified representation of 
thiopurine drug biotransformation, with azathioprine being converted in vivo to 6-
mercaptopurine (6-MP), followed by the metabolic activation of 6-MP mediated by 
hypoxanthine-guanine phosphoribosyltransferase (HPRT), to form 6-thioguanine 
nucleotides (6-TGN). 6-MP is inactivated by xanthine oxidase (XO), aldehyde oxidase (AO) 
or thiopurine S-methyltransferase (TPMT). TPMT enzyme uses S-adenosyl-L-methionine as 
a methyl group donor. One of the reaction products is methyl-6-mercaptopurine  (6-MeMP).  
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Thiopurine drugs are inactivated in the organism by oxidation (mediated by aldehyde 
oxidase (AO, EC 1.1.3.13) and xanthine oxidase (XO, EC 1.1. 3.22)) and methylation 
(mediated by thiopurine S-methyltransferase (TPMT, EC 2.1.1.67)), reactions which are 
needed to prevent high drug concentrations and adverse drug-related events. XO and AO 
produce metabolites that have little or no cytotoxic effect. XO activity in hematopoietic 
tissue is very low, almost insignificant. This is the reason why the main pathway of 
thiopurine drug inactivation goes through the TPMT enzyme (Remy 1963).  
The influence of TPMT enzyme activity on cytotoxicity induced by thiopurine drugs was 
first documented in 1987 (Van Loon et al., 1987).  
7. TPMT allozymes 
Thiopurine S-methyltransferase is a cytosolic monomeric enzyme that catalyzes S-
methylation of heterocyclic aromatic sulfhydryl compounds, and consequently, partial 
inactivation of immunosuppressive thiopurine medications. The molecular weight of TPMT 
protein is 28.18 kDa and it consists of 245 amino acids. The natural substrate for TPMT is 
unknown, although this enzyme is expressed in nearly all human tissues (Weinshilboum et 
al., 1978). Structural and biochemical analyses of TPMT protein revealed the existence of 
certain protein variants with altered activity. In some individuals, TPMT enzyme activity is 
significantly decreased or increased compared to the normal TPMT activity level.  
One of the first studies of TPMT activity in red blood cells determined the distribution of 
TPMT activity to be trimodal. Namely, it was found that approximately 90% of individuals 
express high TPMT activity. These individuals are referred to as high methylators. 
Intermediate methylators represent approximately 10% of the population. Low or 
undetectable TPMT activity is reported in 0.3% individuals (Weinshilboum et al., 1980). This 
study initially identified the hereditary nature of the TPMT deficiency in humans. Trimodal 
frequency distribution of TPMT activity corresponds to monogenic co-dominant inheritance. 
Additionally, ultra-high methylators have been observed (Spire-Vayron de la Moureyre et 
al., 1999; Roberts et al., 2008). It has been shown that these different TPMT allozymes are 
defined by certain TPMT gene polymorphisms. 
8. Genetic variants in TPMT gene 
Human TPMT gene (NG_012137, NM_000367, GeneBank: 7172 or MIM: 187680) was 
discovered using a classical  molecular biology strategy. Firstly, TPMT enzyme from kidneys 
was purified and a partial amino acid sequence was obtained (Van Loon et al., 1982). This 
information served for the successful cloning of human TPMT cDNA (Honchel et al., 1993).  
Initially, on chromosome 18q.21.1 the pseudogene for TPMT has been discovered, 
containing a similar sequence to the TPMT gene (Lee et al., 1995). The human gene for TPMT 
was cloned and mapped on the short arm of chromosome 6, at the position 6p22.3 
(Szumlanski et al., 1996). TPMT gene comprises a region of 34 kb and 10 exons, 8 of which 
encode TPMT protein. Krynetski et al. thoroughly characterized the TPMT gene and its 
adjacent sequences (Krynetski et al., 1997). 
TPMT gene exhibits significant genetic heterogeneity. It has been shown that certain 
polymorphisms in TPMT gene define different TPMT allozymes with different enzyme 
activity. At present, the TPMT allele nomenclature comprises at least 27 TPMT alleles (Feng 
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et al., 2010), with wild type allele designated as TPMT*1. There are several TPMT variant 
alleles comprising one or more SNPs (Table 1).  
 
TPMT variant 
allele Genetic variant Molecular alteration 
Position in the 
TPMT gene Reference 
TPMT*1 Wt    
TPMT*1A -178C>T  Exon 1 
Spire-Vayron de 
la Moureyre et 
al., 1998b 
TPMT*1S c.474T>C p.Ile158Ile Exon 7 Alves et al., 1999 
TPMT*2 c.238G>C p.Ala80Pro Exon 5 Krynetski et al., 1995 
TPMT*3A c.460G>A and c.719A>G p.Ala154Thr and p.Tyr240Cys 
Exon 7, Exon 
10 Tai et al., 1997 
TPMT*3B c.460G>A p.Ala154Thr Exon 7 
Szulmanski et al., 
1996; Tai et al., 
1996 
TPMT*3C c.719A>G p.Tyr240Cys Exon 10 
Szulmanski et al., 






p.Ala154Thr, p.Tyr240Cys  
and p.Glu98STOP 
Exon 7, exon 
10 and exon 5 
Otterness et al., 
1997 
TPMT*4 IVS9–1G>A 
exon 10 is shortened as a 
result of use of the cryptic 




Otterness et al., 
1998 
TPMT*5 c.146T>C p.Leu49Ser Exon 4 Otterness et al., 1997 
TPMT*6 c.539A>T p.Tyr180Phe Exon 8 Otterness et al., 1997 
TPMT*7 c.681T>G p.His227Glu Exon 10 
Spire-Vayron de 
la Moureyre et 
al., 1998b 
TPMT*8 c.644G>A p.Arg215His Exon 10 Hon et al., 1999 
TPMT*9 c.356A>C p.Lys119Thr Exon 5 Schaeffeler et al., 2004 
TPMT*10 c.430G>C p.Gly144Arg Exon 7 Colombel et al., 2000 
TPMT*11 c.395G>A p.Cys132Tyr Exon 6 Schaeffeler et al., 2003 
TPMT*12 c.374C>T p.Ser125Leu Exon 6 Hamdan-Khalil et al., 2003 
TPMT*13 c.83A>T p.Glu28Val Exon 3 Hamdan-Khalil et al., 2003 
TPMT*14 c.1A>G p.Met1Val Exon 3 Lindqvist et al., 2004 
TPMT*15 IVS7–1G>A 
p.Arg140_Cys165del  
(deletion of the entire exon 8 in 
the final protein, resulting in a 
frame shift and a premature 
stop codon in exon 9) 
intron 7/ 
exon 8 
Lindqvist et al., 
2004 
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allele Genetic variant Molecular alteration 
Position in the 
TPMT gene Reference 
TPMT*16 c.488G>A p.Arg163His Exon 7 Schaeffeler et al., 2004 
TPMT*17 c.124C>G p.Gln42Glu Exon 3 Schaeffeler et al., 2004 
TPMT*18 c.211C>A p.Gly71Arg Exon 4 Schaeffeler et al., 2004 
TPMT*19 c.365A>C p.Lys122Thr Exon 5 Hamdan-Khalil et al., 2005 
TPMT*20 c.712A>G p.Lys238Glu Exon 10 Schaeffeler et al., 2006 
TPMT*21 c.205C>G p.Leu69Val Exon 4 Schaeffeler et al., 2006 
TPMT*22 c.488G>C p.Arg163Pro Exon 7 Schaeffeler et al., 2006 
TPMT*23 c.500C>G p.Ala167Gly Exon 8 Lindqvist et al., 2007 
TPMT*24 c.537G>T p.Gln179His Exon 8 Garat et al., 2008 
TPMT*25 c.634T>C p.Cys212Arg Exon 10 Garat et al., 2008 
TPMT*26 c.622T>C p.Phe208Leu Exon 9 
Kham et al., 
2009 
TPMT*27 c.319T>G p.Tyr107Asp Exon 5 Feng et al., 2010 
TPMT*28 c.611T>C p.Ile204Thr Exon 9 Appell et al., 2010 
HGVS nomenclature has been applied. IVS-intron 
Table 1. Summary of the currently known SNPs in the TPMT gene. 
The common nonfunctional alleles include TPMT*2 (containing a single c.238 G>C 
polymorphism), TPMT*3A (containing both c.460 G>A and c.719 A>G polymorphisms), 
TPMT*3B (containing a single c.460 G>A polymorphism), TPMT*3C (containing a single c.719 
A>G polymorphism) and TPMT*4 (containing a single nucleotide G>A substitution at the 
3’end of intron 9)  (Krynetski et al., 1995; Tai et al., 1996; Loennechen et al., 1998; Otterness et al., 
1998). Most of these SNPs are located in the coding region of the TPMT gene and lead to non-
synonymous amino acid substitutions (p.Ala80Pro, p.Ala154Thr and p.Tyr240Cys for c.238 
G>C, c.460 G>A and c.719 A>G polymorphisms, respectively), which cause a decrease in 
activity of TPMT enzyme in comparison to the wild type. On the contrary, TPMT*4 allele 
contains a frameshift within exon 10, leading to low-enzyme activity.  
The majority of genetic variants detected in the TPMT gene represent sequence variations 
that alter the encoded amino acid (Weinshilboum et al., 2006). Besides these, there are 
genetic variants that influence transcription and mRNA splicing, resulting in variable TPMT 
gene expression.  
Recently, a great deal of evidence has confirmed the existence of such modifiers of TPMT 
activity within non-coding regions of the TPMT gene. In particular, it has been 
demonstrated that the presence of variable number of tandem repeats, VNTRs, ranging 
from three to nine, in the TPMT gene promoter, directly alters TPMT activity, most likely 
due to the alteration of promoter cis-regulatory elements (Zukic et al., 2010; Pavlovic 2009; 
Pavlovic et al., 2010; Georgitsi et al.,  2011).  
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Table 1. Summary of the currently known SNPs in the TPMT gene. 
The common nonfunctional alleles include TPMT*2 (containing a single c.238 G>C 
polymorphism), TPMT*3A (containing both c.460 G>A and c.719 A>G polymorphisms), 
TPMT*3B (containing a single c.460 G>A polymorphism), TPMT*3C (containing a single c.719 
A>G polymorphism) and TPMT*4 (containing a single nucleotide G>A substitution at the 
3’end of intron 9)  (Krynetski et al., 1995; Tai et al., 1996; Loennechen et al., 1998; Otterness et al., 
1998). Most of these SNPs are located in the coding region of the TPMT gene and lead to non-
synonymous amino acid substitutions (p.Ala80Pro, p.Ala154Thr and p.Tyr240Cys for c.238 
G>C, c.460 G>A and c.719 A>G polymorphisms, respectively), which cause a decrease in 
activity of TPMT enzyme in comparison to the wild type. On the contrary, TPMT*4 allele 
contains a frameshift within exon 10, leading to low-enzyme activity.  
The majority of genetic variants detected in the TPMT gene represent sequence variations 
that alter the encoded amino acid (Weinshilboum et al., 2006). Besides these, there are 
genetic variants that influence transcription and mRNA splicing, resulting in variable TPMT 
gene expression.  
Recently, a great deal of evidence has confirmed the existence of such modifiers of TPMT 
activity within non-coding regions of the TPMT gene. In particular, it has been 
demonstrated that the presence of variable number of tandem repeats, VNTRs, ranging 
from three to nine, in the TPMT gene promoter, directly alters TPMT activity, most likely 
due to the alteration of promoter cis-regulatory elements (Zukic et al., 2010; Pavlovic 2009; 
Pavlovic et al., 2010; Georgitsi et al.,  2011).  
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TPMT promoter VNTRs include GC-rich blocks that are putative binding sites of various 
transcriptional factors (Krynetski et al., 1997, Fessing et al., 1998). The VNTR region architecture 
is defined by three types of repeats (A, B and C) that vary amongst each other by length and 
nucleotide sequence. Repeats are always arranged in the same order: A is followed by B and 
then C, with no intervening sequences. The number of A and B repeats varies, while the C 
repeat is always present in only one copy (Spire-Vayron de la Moureyre et al., 1999). An 
inverse correlation between the total number of repeats and the enzymatic activity was 
observed (Spire-Vayron de la Moureyre et al., 1998a), while findings from Zukic and co-
workers suggest that on top of the total number of VNTRs, the type/architecture of the repeat 
has crucial impact on TPMT gene transcriptional regulation as well (Zukic et al., 2010). 
Recently, trinucleotide repeat variants in the TPMT promoter region have been described 
which may explain the 1-2% of Caucasians who demonstrate ultra-metabolizer phenotype 
(Roberts et al., 2008). 
9. Functional characterization of TPMT allozymes 
The functional characterization and expression analysis in human cells and yeast system 
(Tai et al., 1997; Otterness et al., 1997; Hamdan-Khalil et al., 2003; Lindqvist et al., 2004; 
Schaeffeler et al., 2006; Ujiie et al., 2008), revealed that alleles TPMT*2, TPMT*3A, TPMT*5, 
TPMT*12, TPMT*14, and TPMT*22 encode for TPMT enzymes that have a very reduced 
activity in comparison to wild type allele designated as TPMT*1. In addition, it has been 
shown that TPMT*18 allele encodes for an enzyme that has a slightly reduced activity 
compared to wild-type allele. Alleles TPMT*9, TPMT*19 and TPMT*24 express TPMT 
proteins whose activity is not statistically different from the activity of wild-type enzyme 
(Garat et al., 2008; Hamdan-Khalil et al., 2005). Polymorphisms in the alleles TPMT*4 and 
TPMT*15 cause alternative processing of TPMT mRNA and consequently, the expression 
level of the TPMT enzyme is reduced. They belong to the so-called quantitative 
polymorphisms (Otterness et al., 1998; Lindqvist et al., 2004). The molecular mechanism that 
leads to the reduction of TPMT activity was studied in the most common TPMT genetic 
variants. Expression studies of TPMT*2 and TPMT*3A alleles showed that both alleles are 
about 100 times less expressed than wild type, TPMT*1 allele (Tai et al., 1997). Also, the 
expression of TPMT*2 and TPMT*3A allelic variants was not in correlation with the 
activities of TPMT*2 and TPMT*3A proteins. The mechanism of accelerated degradation of 
TPMT*2 and TPMT*3A proteins is responsible for the reduced level of TPMT proteins and 
thereby for the reduced catalytic ability of enzymes (Tai et al., 1997). More detailed studies 
have confirmed that in the accelerated degradation of TPMT*3A protein, through a 
ubiquitin-mediated system, the molecular chaperones from the family of heat shock proteins 
are involved (Wang et al., 2003). 
10. Population-specific distribution of TPMT variant alleles 
Pharmacogenetics is generally focused on inter-individual differences in drug metabolism 
and on variations in response to drugs. The frequency of pharmacogenetic markers studied 
so far, is different between certain racial and ethnic groups. Historically, the practical 
application of pharmacogenetic achievements, i.e., the individualization of therapy, has 
been based on studies conducted on Caucasians. With time, other ethnic groups have been 
included in clinical trials, and it became clear that responses to drug therapy may depend on 
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ethnic background (Relling et al., 2011a). Thus, if the metabolism of drugs varies among 
different ethnic groups, then the pharmacogenetic data of one population cannot be 
extrapolated to another one without prior assessment. Knowledge of the pharmacogenetic 
differences between populations can be of great importance for the pharmaceutical industry.  
The distribution of clinically relevant TPMT alleles is population specific (Spire-Vayron de 
la Moureyre et al., 1998a; Hon et al., 1999; Collie-Duguid et al., 1999; Schaffeler et al., 2004). 
The TPMT*3A allele is the most common variant allele in Caucasians (frequency 
approximately 3.5%) (Relling et al., 2011a), while TPMT*3C is predominant in subjects with 
Asian or African ancestry (frequencies of 0.3–5.3% and 2.4–10.9 % respectively) (Kubota et 
al., 2001; Hongeng et al., 2000; Hon et al., 1999; McLeod et al., 1999). Additionally, TPMT*8 
has been reported to be common in the African population (Hon et al., 1999; Oliveira et 
al.,2007; Alves et al., 2004). 
The common TPMT variant alleles in Caucasian include TPMT*2, TPMT*3A, TPMT*3B and 
TPMT*3C (Krynetski et al., 1995; Tai et al., 1996; Loennechen et al., 1998). These variant alleles 
are detected in over 80-95% of Caucasians characterized to have low or intermediate TPMT 
activity (Yates et al., 1997). 
11. Methodology for TPMT phenotype and genotype testing 
The TPMT phenotype and genotype can be defined in several ways. Phenotypic analysis of 
TPMT enzyme activity could be performed by radiochemical activity assays (McLeod et al., 
1995; Weinshilboum et al., 1978), or an assay based on high performance liquid 
chromatography (HPLC) method (Kroplin et al., 1998). Genotyping is performed using PCR-
based methods (Yates et al., 1997; Coulthard et al., 1998), denaturing high performance liquid 
chromatography (DHPLC) (Hall et al., 2001; Schaeffeler et al., 2001), Real Time-PCR 
(Lindqvist et al., 2003), a combination of microchip and sequencing (arrayed primer 
extension - APEX) (Yi et al., 2002), molecular haplotype analysis (McDonald et al., 2002) and 
pirosequencing (Haglund et al., 2004).  
Methods based on PCR are used to detect the most common TPMT variant alleles that lead 
to reduced TPMT activity. These analyses are helpful in identifying individuals with a high 
risk of developing potentially fatal hematologic toxicity caused by thiopurine drugs. 
Measurement of TPMT enzyme activity was, until recently, very expensive and relatively 
inaccessible to patients. A concordance of more than 95% exists between actual TPMT 
enzyme activity and the prediction of its activity based on detection of TPMT variant alleles 
(McLeod et al., 2000; Schwab et al., 2001). Therefore, molecular genetic analysis represents a 
quick and efficient method to identify patients at risk for toxicity and adverse effects-free 
guidance of the therapy. 
Commercially available genetic tests change over time. Many of them include only the *2, 
*3A, *3B and *3C alleles. There is no doubt that sequencing of the TPMT gene remains the 
most accurate, although expensive method.   
12. Clinical applicability of TPMT genetic variants: Individualization of 
thiopurine therapy 
All patients with decreased TPMT activity are at risk of hematologic toxicity owing to the 
accumulation of high levels of 6-thioguanine nucleotides (Weinshilboum 2003). Thiopurine-
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12. Clinical applicability of TPMT genetic variants: Individualization of 
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accumulation of high levels of 6-thioguanine nucleotides (Weinshilboum 2003). Thiopurine-
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induced myelosuppression can result in increased morbidity, hospitalization and/or 
treatment discontinuation (Leung et al., 2009; Ugajin et al., 2009). Myelosuppression 
increases an individual’s risk of developing an infection and sepsis (Campbell et al., 2001; 
Posthuma et al., 1995; Connell et al., 1993; Schütz et al., 1993).  The incidence of mild 
leukopenia is approximately 5-25% (Gurwitz et al., 2009). Rare, but severe leukopenia can 
develop suddenly and unpredictably in approximately 3% of patients (Carter et al., 2004). A 
27-year analysis showed that AZA contributed to the incidences of myelosuppression in 5% 
of patients (Connell et al., 1993). Over an 18-year period, 2% of patients with IBD 
experienced 6-MP-induced leukopenia that resulted in hospitalization (Present et al., 1989). 
The incidence of myelosuppression occurred more frequently during the first eight weeks 
after treatment initiation, and was more likely to occur with a higher drug dose (Present et 
al., 1989; Lewis et al., 2009). 
Consequently, thiopurine drug dose reduction is necessary to avoid toxicity (Weinshilboum 
et al., 1980). Therefore, it is of great importance to determine TPMT status before initiating 
thiopurine therapy (Relling et al., 2011a; Gurwitz et al., 2009;  Schmiegelow, K. et al., 2009; 
Relling et al., 2010). TPMT genotyping is commonly used for determination of TPMT status.   
Patients who are homozygotes or compound heterozygotes for nonfunctional genetic 
variants, treated with standard drug doses, develop severe, eventually fatal, 
myelosuppression and require AZA, 6-MP or TG reduced doses by at least 10-fold (Schwab 
et al., 2001; Evans et al., 2001; Schwab et al., 2002; Slanar et al., 2008; Relling et al., 2011a).  
Patients with intermediate TPMT activity, heterozygous carriers of nonfunctional genetic 
variants in the TPMT gene, also require dose reduction (Weinshilboum et al., 1980; 
Dokmanovic et al., 2006). The initial dose of AZA or 6-MP should be reduced by 30-70%.  
The AZA dose can be titrated as tolerated.  The 6-MP dose should be adjusted based on the 
severity of myelosuppression and disease-specific guidelines.  The initial dose of 6-TG 
should be reduced by 30-50%, and adjusted based on the severity of myelosuppression and 
disease-specific guidelines (Weinshilboum 2001; Krynetski et al., 2003; Weinshilboum 2003; 
Dokmanovi  et al., 2008; Relling et al., 2011b).  
In addition, 1 - 2% of patients are ultra-high methylators, who experience thiopurine 
treatment resistance and hepatotoxicity as a result of treatment with elevated 6-MP 
concentrations (Spire-Vayron de la Moureyre et al., 1999; Roberts et al., 2008). These patients 
often do not respond to therapy, although doses of drugs up to 50% higher than the 
standard doses are given. (Schaeffeler et al, 2004; Spire-Vayron de la Moureyre et al., 1998a; 
Dokmanovic et al., 2006). 
13. Guidelines for thiopurine dosing based on TPMT genotype 
The Clinical Pharmacogenetics Implementation Consortium (CPIC), as a part of the National 
Institutes of Health’s Pharmacogenomics Research Network, developed the first guideline 
for the dosing of thiopurines based on TPMT genotype (updates at http://www.pharmgkb.org) 
(Relling et al., 2011b). 
Dose adjustments based on TPMT genotype have reduced thiopurine induced adverse 
effects without compromising the desired antitumor and immunosuppressive therapeutic 
effects in several clinical settings (Relling et al., 2011a). 
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Although the information on TPMT genotype is recommended rather than required as part 
of thiopurine drug treatment, some groups (Relling et al., 2011a; Gurwitz et al., 2009; Relling 
et al., 2010) advocate testing for TPMT status prior to initiating thiopurine therapy, so that 
starting dosages can be adjusted accordingly. This is very important, since, if one starts with 
low doses in all patients in order to avoid severe toxicity, in the minority with a TPMT 
defect, one risks disease progression during the period of upward dosage titration 
(Sandborn 2001). Therefore, the use of this genetic test in routine clinical practice is 
recommended, while clinicians should continue to evaluate markers of disease progression 
and/or myelosuppression to adjust thiopurine doses upward or downward from the 
genotype-directed starting doses (Relling et al., 2011a). 
Besides CPIC guideline, there are recommendations and guidelines offered by other groups 
(Nguyen et al., 2011). Namely, the Royal Dutch Association for the Advancement of 
Pharmacy Pharmacogenomic Working Group recommends for patients who are 
intermediate metabolizers that the dose of AZA or 6-MP should be reduced by 50% and 
titrated based on hematologic monitoring and efficacy. For patients who are poor 
metabolizers, the dose of AZA or 6-MP should be reduced by 90% and titrated based on 
hematologic monitoring and efficacy. Moreover, patients who are intermediate or poor 
metabolizers should not be treated with 6-TG as there are insufficient data to allow 
calculation of dose adjustment  (Swen et al., 2011).  
The US Food and Drug Administration (FDA) and prescribing information for AZA and  
6-MP recommend either TPMT genotyping or phenotyping prior to initiating therapy to 
help identify patients who are at an increased risk of developing toxicity 
(http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378.
htm). The prescribing information for 6-TG indicates that patients with TPMT deficiency 
may be unusually sensitive to the myelosuppressive effects of 6-TG. Substantial dosage 
reductions may be required to avoid the development of life-threatening bone marrow 
suppression . In addition, the American College of Gastroenterology treatment guidelines 
prefer TPMT phenotyping over genotyping in patients who are being treated with 
thiopurines for ulcerative colitis (Korbluth et al., 2010).  
On the other hand, there are research groups that do not advocate for TPMT  
genotyping before treatment with thiopurines (Booth et al., 2011). The Agency for 
Healthcare Research and Quality (AHRQ) concluded that there is currently insufficient 
evidence regarding the effectiveness of determining TPMT status prior to thiopurine 
treatment in terms of improvement in clinical outcomes and incident myelotoxicity in 
comparison with routine monitoring of full blood counts and adverse events  
(http://www.ahrq.gov/clinic/tp/tpmttp.htm#Report).  
Also, the British Society of Gastroenterology does not require either TPMT genotyping or 
phenotyping as a prerequisite to initiating thiopurine therapy because the use of AZA has 
been shown to be safe in patients with Crohn’s disease or ulcerative colitis (Carter et al., 2004).  
14. From TPMT pharmacogenetics to TPMT pharmacogenomics 
It is worth noting that there is no clear boundary between the low and intermediate, or 
intermediate and high methylators. Even individuals within the same methylation  group 
show different enzymatic activity, and these differences are genetically determined 
(Vuchetich et al., 1995). Also, there are many patients with wild type TPMT who develop 
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toxicity. All this leads to the conclusion that the association of a particular genetic variation 
with adverse drug effects could be softened or enhanced by the other genetic variations 
present in the same individual that influence other processes (drug absorption, 
transportation, metabolism, TPMT gene transcription and consequently the abundance of 
TPMT protein). Moreover, the effects and clinical relevance of genetic variants in another 
gene, encoding an enzyme involved in mercaptopurine metabolism (inosine-triphospate-
pyrophosphatase, ITPA), on mercaptopurine pharmacogenetics has been demonstrated 
(Stocco et al., 2010). 
Finally, a myriad of other genetic factors, which influence interactions between thiopurines 
and other drugs, could play an important role in the final TPMT activity phenotype. 
Therefore, more comprehensive study of the modifying role of different genetic factors in 
TPMT pharmacogenetics, will in time lead to our understanding of controversial results 
published in our era. The new era of pharmacogenomics will bring more consistent and 
reliable guidelines for thiopurine dosing based on patient’s genotype.  
In recent years, the term pharmacogenomics is more and more present alongside the term 
pharmacogenetics. Due to rapid technological development and the great success of the 
human genome sequencing project, the variations and interactions of multiple genes, rather 
than variations in individual genes, have been recognized as the cause of diverse responses 
to drugs (O’Brien et al., 1999; Kennedy et al., 2003). Genotyping methods, the application of 
microarrays and GWAS analyses (Genome Wide Association Studies) that are used in 
pharmacogenomics, provide an insight into a number of individual genes at one time, their 
possible interactions and changes in their expression. The final goal of pharmacogenomics is 
the individualization of therapy in accordance with a patient’s genotype and gene 
expression profile. Thus, by using the appropriate therapeutics and adequate doses without 
side effects, the cheapest, fastest and the most efficient treatment for patients would be 
achieved. Under these conditions, patients would not be faced with complications, time and 
money for additional drugs and hospital days would not be wasted for treatment of 
complications, while the primary disease progresses. Unfortunately, widely available 
pharmacogenomic tests for particular diseases still do not exist. The individualization of 
therapy in medical practice, if at all implemented, is conducted based on pharmacogenetic 
achievements, by testing polymorphisms in a single gene.  
15. Conclusions  
Although pharmacogenetics is one of the most promising fields of biomedicine, only a few 
pharmacogenetic markers have been introduced in routine clinical practice. Among them 
are genetic variants in the TPMT gene which can be used for determination of the cause of 
unusual therapeutic response in patients treated with thiopurine drugs. 
TPMT genotyping is recommended prior to initiating thiopurine therapy by several groups 
and consortia, so that starting dosages can be adjusted accordingly. Doses customized on 
the basis of TPMT status reduce the likelihood of acute myelosuppression without 
compromising disease control. 
Nowadays, TPMT genetic testing comprise the analysis of DNA sequence at each of the 
important single-nucleotide polymorphism in the TPMT gene associated with altered level 
of enzyme activity. 
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However, the understanding of a single genetic variation is far more complex when it is put 
in the context of other genetic variations. In that sense, the future of personalized medicine 
is heading towards variomics - the study of the overall genetic variations found in an 
individual. 
Although the knowledge of pharmacogenomics is incomplete and still in expansion, 
evidence presented in this chapter show that up to date knowledge can already be used for 
more successful, personalized patient treatment. There is no doubt that pharmacogenomics 
together with gene therapy will change the future of medicine and will steadily pave the 
path to personalized medicine. 
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and consortia, so that starting dosages can be adjusted accordingly. Doses customized on 
the basis of TPMT status reduce the likelihood of acute myelosuppression without 
compromising disease control. 
Nowadays, TPMT genetic testing comprise the analysis of DNA sequence at each of the 
important single-nucleotide polymorphism in the TPMT gene associated with altered level 
of enzyme activity. 
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and phenotype (Milek et al., 2009; Scheuermann et al., 2004; Tai et al., 1997). In addition, it 
has been shown that polymorphisms in gene for MTHFR, the enzyme involved in SAM 
biosynthesis, correlate with the onset of hematotoxic events during the therapy of acute 
lymphoblastic leukaemia (ALL) (Karas-Kuzelicki et al., 2009).  
As the metabolism of SAM is closely related to the methionine cycle and the folate pathway, 
other endogenous metabolites, such as folates and methionine, as well as enzymes 
participating in their biosynthesis, might also indirectly influence TPMT activity.  
Both the identification and understanding of the factors influencing TPMT activity are 
crucial for improving the efficacy and safety of thiopurine therapy. 
2. Thiopurine drugs 
An ingenious idea, the purpose of which was to stop the growth of rapidly growing cells 
such as bacteria and tumours with modified nucleic acid bases was developed 
concomitantly with the discovery of DNA structure. A synthetic thiol-analogue of 
endogenous nucleic bases, thioguanine (6-TG), followed by 6-mercaptopurine (6-MP), and 
azathioprine (AZA), proved toxic to bacteria and tumours in mice. The initial experiments, 
conducted in 1948, were followed by clinical trials in 1953 and also present the basis for 
contemporary thiopurine therapy.  Gertrude Elion and George Hitchings were rewarded for 
this work with the Nobel Prize in Physiology or Medicine in 1988 (Marx, 1988). 
2.1 Mode of action 
The thiopurines, namely 6-marcaptopurine, azathioprine, and 6-thioguanine are inactive 
prodrugs which require intestinal absorption, cellular uptake and intracellular metabolism 
for their cytotoxic activity. The three main metabolic pathways for thiopurines are  
oxidation by xanthine oxidase (XO), phosphoribosylation by hypoxanthine-guanine 
phosphoribosyltransferase (HGPRT), and S-methylation by TPMT (R. Weinshilboum, 2001). 
Oxidation is a purely inactivating pathway, which is relevant only in non-hematopoietic 
cells, due to the restricted expression of XO in blood cells. Despite the fact that XO activity 
significantly varies among individuals, a molecular basis has not been completely 
delineated yet.   
The conversion of 6-MP by hypoxanthine phosphoribosyltransferase (HGPRT) yields 
thioinosine monophosphate (TIMP), which is further metabolized via inosine 5’-
monophosphate dehydrogenase (IMPD), guanosine monophosphate synthetase (GMPS), 
reductase and kinases to active thioguanine nucleotides (TGNs). Alternatively, TIMP can be 
methylated by thiopurine methyltransferase (TPMT) to 6-methylmercaptopurine 
ribonucleosides (6-MMPR), namely methylthioinosine monophosphate (MeTIMP), -
diphosphate (MeTIDP) and –triphosphate (MeTITP) (Fig.1). 
Incorporation of TGNs into DNA and RNA results in S phase arrest and programmed cell 
death, triggered via the mismatch repair pathway. On the other hand, MeTIMP is a potent 
inhibitor of de novo purine synthesis (DNPS), causing depletion of purine nucleotides, which 
results in cell growth arrest and cytotoxicity. DNPS inhibition is thought to be responsible 
for several adverse effects of thiopurines. Nevertheless, the incorporation of TGNs is 
considered to be the main mode of action of 6-MP (Relling et al., 1999). 
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Phosphorylation of TIMP by kinases yields 6-thioinosine triphosphate (TITP), which can be 
dephosphorylated back to TIMP by inosine triphosphatase (ITPA) (Derijks&Wong, 2010). 
 
 
Fig. 1. Metabolism of thiopurines. Azathioprine is converted to 6-mercaptopurine (6-MP) 
by a non-enzymatic process. Both 6-MP and 6-thioguanine (6-TG) are converted by the 
hypoxanthine–guanine phosphoribosyltransferase (HGPRT) into their respective nucleoside 
monophosphates (TIMP and TGMP). Thiopurine S-methyltransferase (TPMT) inactivates 6-
MP and 6-TG by S-methylation to form 6-methylmercaptopurine (6-MMP) and 6-
methylthioguanine (6-TGN), respectively. Xanthine oxidase (XO) inactivates 6-MP by 
converting it to 6-thiouric acid. TIMP and TGMP are also TPMT substrates, yielding 
methylated TIMP (meTIMP) and methylated TGMP (meTGMP). TIMP may also be 
phosphorylated to TIDP and TITP and dephosphorylated to TIMP by ITPA. TIMP that 
escapes catabolism is further metabolized by inosine monophosphate dehydrogenase 
(IMPD) and guanine monophosphate synthetase (GMPS) to TGMP. Sequential action of 
deoxynucleoside kinases and reductase generates the TGTP and dTGTP that are the 
substrates for incorporation of 6-TG into RNA and DNA, respectively. 
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The third metabolic pathway, catalyzed by TPMT, is S-methylation of thiopurine to 6-
methylmercaptopurine (6-MMP). This pathway is often referred to as being an inactivating 
pathway, since 6-MMP has no cytotoxic activity (Dervieux et al., 2001) (Fig. 1). 
2.2 Efficacy and safety of 6-MP in the treatment of ALL 
Acute lymphoblastic leukaemia is the most common malignancy in children. Treatment is 
stratified on the basis of various combinations of clinical and lymphoblastic characteristics 
in standard, intermediate and intensive therapy groups.  Different therapy protocols  have 
been and continue to be applied, such as USA Pediatric Oncology Group (POG) protocols 
and German Berlin-Frankfurt-Muenster (BFM) protocols (BFM-83, -86, -90, -95 and IC 2002). 
Treatment is generally composed of induction, consolidation and maintenance phases along 
with central nervous system prophylaxis (Moricke et al., 2008).  
The induction phase generally lasts 4-6 weeks and involves combinations of drugs including 
vincristine, prednisone, cyclophosphamide, doxorubicin, and L-asparaginase. This phase is 
followed by the consolidation phase with multiagent therapy including cytarabine and 
methotrexate. Maintenance therapy has been included in all protocols. It lasts from 1 to 3 
years and consists of 6-MP taken daily per os (50 mg/m2) and low weekly doses of oral 
methotrexate (MTX) (20 mg/m2) (Karas Kuzelicki et al., 2009). 
Due to the narrow therapeutic index, a certain level of side effect manifestations is expected 
in most patients treated with 6-MP.  We have investigated the occurrences of side effects in 
Slovenian pediatric ALL patients, identified through the national oncology patient registry. 
These patients had been treated with standard protocols at the University Children`s 
Hospital, University Medical Centre, Ljubljana, Slovenia in the period 1970-2004. The study 
group consisted of 313 ALL patients.  6-MP and other thiopurines were administered in all 
phases of ALL treatment. In order to investigate the occurrences of toxic effects and to 
exclude the influence of other drugs used in ALL treatment, we focused on the maintenance 
phase of the therapy, because it consisted exclusively of 6-MP and low dose MTX. The doses 
of 6-MP were calculated on the basis of a patient`s body surface (50 mg/m2) and adjusted 
during the treatment according to desired WBC counts, these being 2000 – 3000 WBC/ L.  
Therapy data, such as 6-MP dose reduction and the incidence of toxic effects including 
hematotoxicity, stomatitis, infections, and secondary tumours were obtained from patients’ 
charts for the maintenance phase of treatment protocols consisting exclusively of 6-MP and 
low dose MTX. 6-MP dose reduction greater than 10 % for a period longer than 3 months 
was considered significant. The toxic effect was defined as an event causing one of  
the following:  discontinuation of the therapy for longer than one week, a reduction of over 
10 % of 6-MP dose of a duration longer than 3 months, or the hospitalization of the patient. 
Hematotoxicity corresponded to grade 3 and 4 leukopenia, stomatitis to grade 2 and 3, 
infections to grade 3 and 4 and secondary tumours to grade 4 adverse events of National 
Cancer Institute Common Toxicity Criteria (version 2.0) (Karas Kuzelicki et al., 2009). 
The incidences of undesirable toxic effects are presented in Table 1. Despite the relatively 
high safety and efficacy of 6-MP,  a dose reduction was determined in 20 % of patients, 
hematotoxicity in 14 %, stomatitis in 5 %, infections in 21 %, and the incidence of secondary 
tumours in 4 % of patients. Our observations are also in concordance with other published 
data (Sanderson et al., 2004). 
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6-MP DR, 6-MP dose reduction; HET, hematotoxicity; TU, tumours; n indicates number of subjects;  
† More than 10 % 6-MP dose reduction for a period of more than 3 months. 
‡ A 6-MP related toxic effect that caused the discontinuation of the therapy for more than one week, 
more than 10 % 6-MP dose reduction for a period of more than 3 months or hospitalization of the 
patient. 
Table 1. Analysis of 6-MP related toxic effects in Slovenian ALL patients  
2.3 Thiopurines in the immunosuppressive therapy  
Azathioprine (AZA) and 6-MP are the most widely used immunosuppressive agents in 
inflammatory bowel disease (IBD), examples of which being ulcerative colitis and Crohn’s 
disease. AZA is also indicated as an adjunct for the prevention of rejection in renal 
homotransplantations and for the management of active rheumatoid arthritis. Either alone 
or, more usually, in combination with corticosteroids and/or other drugs and procedures, 
AZA has been used in a proportion of patients suffering systemic lupus erythematosus, 
dermatomyositis and polymyositis, autoimmune chronic active hepatitis, pemphigus 
vulgaris, polyarteritis nodosa, autoimmune haemolytic anaemia and chronic refractory 
idiopathic thrombocytopenic purpura (IMURAN® (azathioprine). Product Information). On 
the other hand, 6-MP has been mostly used in either IBD or acute lymphoblastic leukaemia. 
Azathioprine was developed to prolong the half-life of 6-MP; therefore, a 1-methyl-4-nitro-5-
imidazole moiety was added to protect the reactive sulphur group from oxidation and 
hydrolysis. AZA was proven to have better immunomodulatory effects than 6-MP in 
preventing organ rejection in kidney transplants (Murray et al., 1963). It is postulated that 
this is associated with an effect of the methyl-nitro-imidazolyl substitute by a currently 
unknown mechanism. Although both drugs have been extensively used, they have proven 
ineffective in one-third of patients, while up to one-fifth of patients discontinue thiopurine 
therapy due to adverse reactions. The observed interindividual differences in therapeutic 
response and toxicity can, at least partly, be explained by genetic polymorphisms of the 
genes encoding crucial enzymes in thiopurine metabolism (Derijks&Wong, 2010). 
The reported frequencies of dose-dependent and dose-independent adverse effects of AZA 
and 6-MP are in the ranges of 1.4–5.0 % and 1.0–6.5 %, respectively. Myelotoxicity is 
considered a dose-dependent adverse effect that can be caused by elevated concentrations of 
the pharmacologically active 6-TGNs. On the other hand, dose-independent reactions are 
considered to be immune-mediated, and include rashes, arthralgia, hepatitis, myalgia, flu-
like symptoms, gastrointestinal complaints, fever and pancreatitis (de Boer et al., 2007)  
3. Individualization of thiopurine therapy 
Pharmacogenetic testing has been implemented in clinical practice for selected drugs only. 
The implementation of pharmacogenetics in the clinical setting was hampered by the 
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6-MP DR, 6-MP dose reduction; HET, hematotoxicity; TU, tumours; n indicates number of subjects;  
† More than 10 % 6-MP dose reduction for a period of more than 3 months. 
‡ A 6-MP related toxic effect that caused the discontinuation of the therapy for more than one week, 
more than 10 % 6-MP dose reduction for a period of more than 3 months or hospitalization of the 
patient. 
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recognition that the metabolism of a given drug does not depend solely on a single drug-
metabolizing enzyme, but rather on a complex enzymatic network of competing metabolic 
pathways. It has become apparent that the identification of relevant pharmacogenetic 
markers is much more complicated than initially believed. 
Upon entering the cell, thiopurines are also subject to a complex metabolic network; their 
metabolic activation thus depends on genetic predisposition as well as nutritional and other 
environmental factors.  
3.1 Thiopurine S-methyltransferase (TPMT)  
Although TPMT pharmacogenetics is addressed in detail in a separate chapter of this book, 
we need to summarize the most relevant facts, since they are the basis for further 
elaborations. 
TPMT plays a pivotal role in thiopurine drug responses, such that decreased TPMT activity 
correlates with higher cytotoxic thioguanine nucleotide (TGN) levels which may result in 
life-threatening toxicity.  The distribution of TPMT activity in Caucasian populations is 
trimodal: approximately 89 % of population has normal to high, 11 % intermediate and 0.3 
% low or undetectable TPMT activity. Although numerous alleles have been identified, the 
most prevalent and clinically significant are TPMT*3A (460G>A and 719A>G), TPMT*3B 
(460G>A) and TPMT*3C (719A>G). TPMT genotyping prior to the initiation of thiopurine 
therapy represents a quick and reliable pharmacogenetic test. In accordance with advice 
provided by the FDA in 2004, the recommendation to perform the test before starting 
therapy with thiopurines has been included in the Summary of Product Characteristics 
(SmPC) of Purinethol® (6-MP) and Imuran® to highlight the usefulness of TPMT testing in 
predicting risk for thiopurine toxicity.  
TPMT deficient patients tend to be better responders to 6-MP therapy than wild-type 
patients- due to higher TGN accumulation in cancer cells- but are at greater risk of 
developing toxic effects such as hematotoxicity, infections, stomatitis and secondary 
tumours, as a consequence of their accumulation in normal cells. Conversely, ultra-high 
enzyme activity can lead to superior 6-MP tolerability but also to an increased risk of relapse 
and hepatic toxicity, which has been related to methylated metabolites of thiopurines 
(Evans, 2004).  
The clinical relevance of 6-MP dose reduction during maintenance therapy is well defined 
only in patients homozygous for variant TPMT alleles (TPMT*2, *3A, *3C) who exhibit low 
TPMT activity. Dosing adjustments based on TPMT status is recommended in thiopurine 
therapy. In the treatment of malignancies, conventional high doses of thiopurines are 
recommended for homozygous wild-type TPMT patients, while 30-70 % lower-than-normal 
starting doses should be used in heterozygous deficient patients, and at least 10-fold 
reduced doses in homozygous deficient patients (Relling et al., 2011). 
Due to an incomplete genotype-to-phenotype correlation in heterozygous individuals with 
variable intermediate activity, the predictive value of TPMT genotyping for the optimization 
of thiopurine therapy is limited. Therefore, the identification of novel pharmacogenetic 
and/or biochemical markers is necessary for high prediction. One such factor is S-
adenosylmethionine (SAM), which stabilizes the TPMT protein structure by binding to its 
active site (Scheuermann et al., 2004). Thus, SAM may also modulate TPMT activity in the 
 
S-Adenosylmethionine: A Novel Factor in the Individualization of Thiopurine Therapy 
 
101 
intercellular setting, possibly by post-translational stabilization. Consequently, the 
endogenous availability of SAM may influence TPMT activity, the formation of 6-MP 
metabolites, and the toxicity of thiopurine drugs. In addition, endogenous metabolites (e.g. 
folates, methionine, ATP) and enzymes participating in the biosynthesis of SAM, (e.g. 
MTHFR, TYMS), could also influence TPMT activity indirectly.  
3.2 The role of SAM in cellular metabolism and disease 
S-adenosyl-L-methionine (SAM) is one of the most abundant co-factors in eukaryotic cells 
and has been initially described as “active methionine” (Cantoni, 1951). It participates in 
many cellular processes and exerts many biological effects. As a pleiotropic molecule, it is 
the principal methyl donor in processes such as nucleic acid, protein and phospholipid 
methylation, acting as a co-substrate for many SAM-dependent methyltransferases (P. K. 
Chiang et al., 1996). In addition, it is an important regulator of replication, transcription and 
translation, acting on post-transcriptional and post-translational levels and by epigenetic 
mechanisms (Finkelstein, 2007). SAM is also involved in polyamine synthesis as well as 
inhibition of DNA demethylation (Detich et al., 2003), and plays an important role in cell 
growth, cell cycle progression and apoptosis (Loenen, 2006; Nitta et al., 2002).  
Cellular methylation is closely connected to the methionine cycle, methionine recycling 
pathway, folate metabolism, and polyamine synthesis, as well as transsulfuration and 
glutathione synthesis (Fig. 2) (Hitchler&Domann, 2007). Active metabolic conversions of the 
folate pathway and methionine (Met) cycle are ubiquitous, while transsulfuration takes 
place only in the liver, kidney, pancreas, intestinal tract and brain (Finkelstein, 2007). SAM 
and SAH act as efficient regulatory molecules in these processes, such that their molar ratio 
(i.e. methylation potential) determines the activity of many methyltransferases and related 
enzymes. 
SAM is synthesized from Met, the availability of which largely depends on folate pools and 
dietary intake. Tissue SAM levels thus depend on the expression of methionine 
adenosyltransferase (MAT), which catalyzes the conversion from Met, and 5,10-
methylenetetrahydrofolate reductase (MTHFR) that provides the substrate for the 
remethylation of homocysteine into Met. Mechanisms of SAM-induced metabolic regulation 
include the modulation of both tissue expression and kinetic properties of metabolizing 
enzymes as well as the concentrations of their substrates and products. Vice versa, the 
modified expression or enzyme activity of some methyltransferases has been shown to 
impact intracellular SAM and SAH levels, which are most notably determined by the 
expression of glycine N-methyltransferase (GNMT) (Luka et al., 2009). GNMT degrades 
excess SAM to SAH and decreases cell methylation capacity. Importantly, GNMT has been 
described as a key regulator of SAM level and methylation capacity in normal livers, while 
its expression is diminished in tumour tissue and cultured cells such as HepG2 (Martinez-
Chantar et al., 2008). 
Moreover, the modified activity of enzymes (e.g. methionine adenosyltransferase,  
S-adenosylhomocystein hydrolase) that catalyse the afore mentioned metabolic conversions 
significantly influences the dynamics and concentrations of metabolites; most prominently 
those of SAM and SAH, which have pleiotropic biological effects. In addition, aberrations  
in methylation and redox homeostasis have been implicated in several pathologies,  
such as liver carcinogenesis, hepatocellular carcinoma, chronic steatohepatitis and 
hyperhomocysteinemia-associated cardiovascular diseases (Martinez-Chantar et al., 2002a).  
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Fig. 2. SAM metabolism, the methionine cycle and related pathways. SAM is consumed in 
transmethylation reactions catalyzed by SAM-dependent methyltransferases (MT-ases). 
SAM has many diverse biological effects. Its metabolism is closely connected to 
homocysteine (Hcy) remethylation and methionine (Met) cycle, the folate pathway, 
transsulfuration, Met recycling pathway and polyamine synthesis. 5,10-Me-THF, 5,10-
methylenetetrahydrofolate; 5-Me-THF, 5-methyltetrahydrofolate; THF, tetrahydrofolate; 
MS, methionine synthase; MTHFR, 5,10-methylenetetrahydrofolate reductase; CBS, 
cystathionine- -synthase; Cys, cysteine; GSH, glutathione; SAHH, S-adenosylhomocysteine 
hydrolase; MAT, methionine adenosyltransferase; MTA, 5'-methylthioadenosine; MTAP, 5'-
methylthioadenosine phosphorylase;  Cys, cysteine; SAM, S-adenosylmethionine; SAMDC, 
SAM decarboxylase; TPMT, thiopurine S-methyltransferase, GNMT, glycine N-
methyltransferase. 
Unbalanced metabolic conversions in the methionine cycle are most frequently a 
consequence of a low dietary intake of folic acid, high alcohol consumption, poisoning, or 
genetic abnormalities. Most commonly, this is observed as hyperhomocysteinemia (i.e. 
elevated plasma homocysteine, Hcy), as well as SAM depletion, and consequently 
methionine metabolism related pathogenesis. Consequences of inactivated SAM, Met 
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synthesis and methionine adenosyltransferase activity have been well documented in 
patients with liver cyrosis and different forms of hyperhomocysteinemia (Martinez-Chantar 
et al., 2002b).  
3.3 The role of SAM in thiopurine metabolism 
SAM plays an important role in the intracellular conversions of thiopurines. The metabolism 
of 6-mercaptopurine and azathioprine results, apart from the synthesis of cytotoxic TGNs, 
cytosolic, in the production of methylated thiopurine metabolites (methylthioinosine 5’-
monofosphate, MeTIMP). These molecules act as antimetabolites by inhibiting 
phosphoribosyl pyrophosphate amidotransferase, the rate limiting enzyme in de novo purine 
synthesis (DNPS) pathways, which therefore leads to ineffective ATP production. Non-
depleted cellular ATP pools are required for SAM biosynthesis from Met catalyzed by 
methionine adenosyltransferase (MAT).  
The relevance of SAM in thiopurine metabolism has been demonstrated by several in vitro 
studies. Decreased SAM recycling via the methionine cycle was observed upon the addition 
of 6-MP or 6-methylmercaptopurine riboside (6-MMPR) to MOLT cells. Due to DNPS 
inhibition caused by the metabolite MeTIMP (Vogt et al., 1993), endogenous adenine 
nucleotide pools were depleted, limiting the ATP-dependent synthesis of SAM from 
methionine (Stet et al., 1994). The depletion of SAM also resulted in DNA hypomethylation 
(De Abreu et al., 1995). The inhibitory effect of 6-MMPR on the growth of MOLT 
lymphoblasts was reversed by supplementing adenine nucleotide pools with exogenous 
adenosine, adenine and inosine (Stet et al., 1995). Finally, exogenous SAM also prevents 6-
MP induced programmed cell death via the reduction of intracellular TGN and MeTIMP 
levels in MOLT cells (Milek et al., 2009). 
3.4 Effect of SAM-TPMT interaction on thiopurine drug action 
Since TPMT is a SAM-dependent methyltransferase, components of methionine 
metabolism are closely connected to thiopurine drug action. As in other reactions 
catalyzed by SAM-dependent methyltransferases, SAM provides the methyl group in the 
S-methylation of thiopurines, which is catalyzed by TPMT. As a side product in this 
process, SAM is converted to S-adenosylhomocysteine (Sahasranaman et al., 2008), a 
potent methyltransferase inhibitor. Apart from its role as a TPMT cofactor, SAM has been 
shown to exert additional effects on TPMT, in all probability as an efficient post-
translational regulator of its activity. 
Non-synonymous amino-acid substitutions resulting from common genetic polymorphisms 
destabilize TPMT protein structure and increase its susceptibility to proteasomal and 
autophagy-mediated degradation. The tridimensional structure of the yeast TPMT 
orthologue revealed that sinefungin, a SAM analogue, stabilizes the protein backbone 
towards a rigid native conformation, very possibly decreasing its susceptibility to 
proteolytic degradation (Scheuermann et al., 2004; Tai et al., 1999) (Fig. 3).  
A similar effect was observed for catechol-O-methyltransferase (COMT), a SAM-dependent 
methyltransferase, and for cystathionine –sythase (CBS), the rate limiting enzyme in the 
transsulfuration pathway (Prudova et al., 2006). In HepG2 cells SAM was found to modulate 
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its own production by destabilizing MAT2A mRNA, thus regulating the activity of MAT, 
the enzyme catalyzing SAM biosynthesis from Met (Martinez-Chantar et al., 2003). 
 
 
Fig. 3. Role of SAM in TPMT stability and degradation. Decreased tissue TPMT activity is a 
consequence of the rapid degradation of TPMT variant allozymes via the ubiquitin-
proteasome pathway. The binding of SAM to the TPMT protein structure restores 
intramolecular contacts and shifts the equilibrium towards a highly folded conformation 
that is less susceptible to intracellular proteolysis. SAM, S-adenosyl-L-methionine; TPMT, 
thiopurine S-methyltransferase; Ub, ubiquitin. 
Molecular and functional studies of TPMT SNPs have shown that non-synonymous amino-
acid substitutions in variant TPMT allozymes cause the disruption of intra-molecular van 
der Waals contacts (Scheuermann et al., 2003). Consequently, such variant proteins are 
readily degradable via proteasome- and autophagy-mediated proteolysis (Li et al., 2008; Tai 
et al., 1999). The addition of high concentrations of SAM, the principal cellular methyl donor 
and a co-substrate in the S-methylation reaction catalyzed by TPMT, resulted in increased 
TPMT activity in yeast extracts containing recombinant wild-type and TPMT*3C allozymes. 
The binding of SAM has also been shown to stabilize the 3D structure of the enzyme and 
shifts the dynamic balance towards the native structure, which prevents the proteolytic 
degradation of the enzyme. Most recently, exogenous SAM was shown to prevent 6-MP 
induced programmed cell death via the reduction of intracellular TGN and MeTIMP levels 
in MOLT cells, possibly by the post-translational stabilisaton of TPMT (Milek et al., 2009). A 
possible mechanism is indicated in Fig. 4. 
The most important evidence of SAM metabolism on TPMT stabilization was presented by 
two in vivo studies, where the presence of low-activity polymorphisms in 
methylenetetrahydrofolate reductase (MTHFR), the enzyme which catalyzes the formation 
of 5-methyltetrahydrofolate (5-Me-THF), a rate-determining step in the re-methylation of 
methionine from homocysteine (Fig. 2), has been found to correlate with decreased TPMT 
activity in patients with ALL (Arenas et al., 2005). It was postulated that low MTHFR 
activity results in limited SAM synthesis and, consequently, lower TPMT stability, observed 
as a modulation of the TPMT phenotype (Karas-Kuzelicki et al., 2009). 
 




Fig. 4. SAM decreases thiopurine toxicity by stabilizing TPMT protein levels. In TPMT-
catalyzed reactions, SAM acts as a methyl donor, but can also stabilize the TPMT 3D 
structure (indicated by plus, encircled). This results in more extensive deactivation of the 
drug, i.e. the production of 6-methylmercaptopurine (6-MMP) as opposed to cytotoxic 
thioguanine nucleotides (TGN) and methylthioinosine monophosphate. Therefore, SAM 
indirectly decreases the extent of 6-methylmercaptopurine (6-MP) cytotoxicity in MOLT 
cells. TIMP, thioinosine monophosphate; SAM, S-adenosyl-L-methionine; TPMT, thiopurine 
S-methyltransferase. 
3.5 Synergistic effects of low activity TPMT and MTHFR on 6-MP-induced toxicity 
6-MP-induced toxic effects in TPMT heterozygous patients are augmented by a variant 
methylenetetrahydrofolate reductase (MTHFR) genotype. This is the case as SAM levels 
depend on the availability of folates, which themselves depend on the activity of MTHFR, 
the most important folate pathway regulating enzyme. 
MTHFR is an enzyme involved in the metabolism of folic acid, through the conversion of 
5,10- methylenetetrahydrofolate (5, 10-Me-THF) to 5-methyltetrahydrofolate (5-Me-THF). 
MTHFR is the rate-determining enzyme of the folate cycle, which plays a major role in 
methionine and SAM synthesis, and consequently affecting TPMT activity. This is 
demonstrated in homozygous and heterozygous MTHFR knockout mice (Chen et al., 2001), 
where decreased MTHFR activity leads to decreased SAM, increased homocysteine and 
SAH levels, and DNA hypomethylation.  In  humans, the low activity of MTHFR is coded 
by two alleles, 677 C>T and 1298 A>C. Homozygosity for 677 C>T and compound 
heterozygosity for 677 C>T and 1298 A>C is associated with increased blood homocysteine 
levels, while no apparent discrepancies in biochemical profile are detected in 1298 CC 
homozygotes (Botto&Yang, 2000; van der Put et al., 1998). These findings reflect enzymatic 
deficiency due to the presence of polymorphism.  MTHFR activity in homozygotes carrying 
two 677 C>T alleles is 40-50 % of the wild-type enzyme, while in 1298 A>C homozygotes the 
activity is somewhat higher but still below the normal range. The frequency of 677 T allele is 
lower in Africans (6-14 %) than in other races (25-43 %), and the highest frequencies have 
been documented for US Hispanics and Italians. Frequencies of the 1298 C allele are very 
similar, while the frequencies of compound heterozygosity for both variants range from 15 
to 20 % in Caucasian populations (Botto&Yang, 2000).  
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its own production by destabilizing MAT2A mRNA, thus regulating the activity of MAT, 
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Individuals with the MTHFR 677 TT genotype have significantly lower serum folate levels 
(Nishio et al., 2008) and different ratio of methylated to formylated tetrahydrofolates (THF). 
While only the methylated forms of THF are present in wild-type individuals, up to 59 % of 
total RBC folates in 677 TT subjects were formyl-THF, as a consequence of lower MTHFR 
activity and decreased 5,10-Me-THF consumption for the formation of 5-Me-THF 
(Bagley&Selhub, 1998). Besides genetic predisposition, folate intake is crucial, as sufficient 
intake may diminish the effect of low-activity alleles. Similarly, the MTHFR 677 TT 
genotype in transformed human lymphoblasts is most significantly associated with the 
decreased SAM levels arising from decreased folate-dependent homocysteine re-
methylation under conditions of extracellular folate restriction (E. P. Chiang et al., 2007). 
These data suggest that the effect of genotype-dependent MTHFR status on methionine 
regeneration and SAM synthesis is also closely related to intracellular folate concentrations. 
A correlation between MTHFR and TPMT activity was demonstrated in individuals with 
intermediate TPMT activity carrying low activity 677 TT MTHFR and wild-type TPMT 
genotypes (Arenas et al., 2005). The influence of MTHFR activity on TPMT activity is also 
demonstrated in our recent study addressing the thiopurine toxicity in paediatric ALL 
patients. The synergistic effect of TPMT and MTHFR variant alleles was observed in 
patients carrying polymorphisms in both genes, and reflected in severe toxicity. 82 % of 
these patients experienced hematotoxicity, compared to 4 % of patients with wild-type 
MTHFR and TPMT genotypes. Similarly, patients carrying polymorphisms in both TPMT 
and MTHFR genes (59 %) were more likely to have experienced 6-MP dose reductions, as 
well as stomatitis and infections (Karas-Kuzelicki et al., 2008).  
3.6 Other potential pharmacogenetic markers in thiopurine therapy 
Individual responses to thiopurine therapy depend beside genetic predisposition, on 
nutritional and other environmental factors.  The genes and their variants identified so far 
do not suffice to fully justify the variability in drug response. Implementation of novel 
genetic and metabolomic findings is therefore crucial for the improved prediction of drug 
efficacy and safety. 
Xanthine oxidase (XO) is involved in the first-pass metabolism of 6-MP, and is 
predominantly expressed in the intestinal mucosa and liver. XO metabolizes 84 % of 6-MP 
into inactive 6-thiouric acid, resulting in a substantial reduction in 6-MP bioavailability. XO 
is an alternative name for Xanthine dehydrogenase (XDH), also termed Xanthine 
oxidoreductase, (XOR). XDH is a molybdenum-containing hydroxylase, readily converted to 
xanthine oxidase by reversible sulfhydryl oxidation or by irreversible proteolytic 
modification (http://omim.org/entry/607633). Numerous polymorphisms have been 
detected either in promoter or coding region of XDH/XO gene. The functional relevance of 
detected polymorphisms was determined in in vitro assays; in the allelic variants tested, a 
deficiency in enzyme activity was detected in two, low activity in six and high enzymatic 
activity in two (Kudo et al., 2008). In recent studies, a correlation of two polymorphisms in 
XO (1936 A>G and 2107 A>G) with the thiopurine therapy outcomes has been addressed; 
however, due to the small number of patients with myelotoxicity, it was not possible to 
draw any conclusions (Wong et al., 2007). 
Another potential polymorphic enzyme correlating with 6-MP toxicity is inosine triphosphate 
(ITP) pyrophosphatase (ITPA), which catalyses the pyrophosphohydrolysis of ITP into inosine 
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monophosphate, thereby preventing the accumulation of ITP in normal cells. Decreased ITPA 
activity leads to the accumulation of the inosine nucleotide, ITP in the cells. Recent studies 
have shown that the presence of P32T functional polymorphism in ITPA correlates with 
unwanted thiopurine toxicity in ALL patients. However, studies performed on patients with 
inflammatory bowel disease or on liver transplant recipients showed no association. 
Nevertheless, ITPA is emerging as an interesting candidate biomarker, even more so due to 
relatively high allele frequencies in some populations (Marsh&Van Booven, 2009). 
Thymidylate synthase (TYMS) is an enzyme that catalyzes the conversion of dUMP to 
dTMP by utilizing 5,10-Me-THF and, as such, constitutes a competing pathway for MTHFR-
catalyzed 5-Me-THF synthesis. Due to its considerable effect on 5-Me-THF levels and, 
consequently, on methionine and SAM synthesis, TYMS might, potentially, influence TPMT 
activity. There is a common tandem repeat polymorphism in the promoter region of TYMS, 
with the number of tandem repeats affecting TYMS activity levels, mediated through the 
effects of the repeats on translation efficiency (Kawakami et al., (1999, 2001)). The double 
repeat (2R) results in lower gene expression than the triple repeat (3R) (Horie et al., 1995). 
The 3R/3R genotype and high TYMS activity could lead to low 5-Me-THF, methionine and 
SAM levels and, consequently, low TPMT activity, resulting in higher TGN concentrations 
and a better therapy response (Karas-Kuzelicki&Mlinaric-Rascan, 2009).  
In addition, several other polymorphic genes encoding crucial enzymes of thiopurine 
metabolism, such as glutathione S-tranferases, hypoxanthine phosphoribosyltransferase, 
inosine monophosphate dehydrogenase and multidrug resistance proteins, have been 
described and represent novel pharmacogenetic markers influencing thiopurine therapy 
(Derijks&Wong, 2010). 
4. Future directions and clinical application  
The effective stabilization of TPMT by SAM, which prevents thiopurine toxicity, has several 
clinical implications. An in vitro study showed that in patients receiving 6-MP, a decrease in 
TPMT activity may be expected after 6-MP administration, due to DNPS inhibition and 
decreased synthesis of the stabilising factor SAM. In patients with wild-type or heterozygous 
mutant TPMT genotypes, who exhibit high and intermediate TPMT activities respectively, a 
decrease in the enzyme activity may result in an overproduction of TGNs, increasing the risk 
of undesirable toxicity. On the other hand, high levels of endogenous SAM, as well as potential 
compensatory responses to SAM depletion, may contribute to the detoxification of the drug, 
and, consequently, lead to the wild-type patients being non-responders, by decreasing the 
production of cytotoxic TGNs. The availability of folate pools may also significantly influence 
6-MP related cytotoxic effects, since the metabolic fluxes of homocysteine remethylation and 
downstream SAM synthesis are folate dependent. The mechanism described in the present 
study could, therefore, play an important role in patients receiving folates in dietary 
supplements during thiopurine treatment, modulating the amount of SAM, and, consequently, 
TPMT activity. Further in vivo studies of the correlation of TPMT with the activity of enzymes 
involved in SAM metabolism, (e.g. methionine adenosyltransferase, S-adenosylmethionine 
decarboxylase, 5,10-methylenetetrahydrofolate reductase), could reveal additional factors 
influencing treatment with 6-MP. Moreover, the presence of activity-modulating genetic 
polymorphisms in these enzymes could explain the poor TPMT genotype-to-phenotype 
correlations observed in some individuals. 
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Detailed and relevant understanding of TPMT regulation by SAM in the context of Met 
metabolism in several cell lines, primary cells, animal models and human samples is a 
valuable resource for the improved prediction of clinical outcomes. Further studies will 
have direct consequences in the clinic, by improving the genotype-to-phenotype correlation 
in heterozygous and wild-type individuals with unexpectedly low TPMT activity. 
Furthermore, novel factors influencing TPMT activity and thiopurine drug response will 
enable a much more realistic implementation of existing genetic and biochemical test(s) in 
clinical practice. In fact, effective antidotes that rapidly decrease thiopurine toxicity by 
acting as positive regulators of TPMT levels and thiopurine deactivation would be 
substantially favourable in the clinical setting. 
4.1 Methods for measuring SAM 
Given the critical role of SAM in many metabolic pathways and its importance in the 
diagnosis of various pathological manifestations, as well as its potential implication in 
individualization of thiopurine therapy, the development of an accurate, sensitive and 
reproducible method for its quantification is very important. 
Various methods for the analysis of SAM in different tissues have been developed in the last 
two decades. Most of the developed methods are HPLC-based and use UV detection 
(Bottiglieri, 1990; Molloy et al., 1990; Wise et al., 1997) with either ion-pairing or cation 
exchange chromatography. Some of them use fluorescent detection after conversion of the 
analytes to fluorescent analogs (Capdevila&Wagner, 1998; Loehrer et al., 1996), others 
electrochemical detection (Melnyk et al., 2000).  
HPLC methods combined with ultraviolet detection are suitable for measuring the 
concentrations of SAM in tissues, including red blood cells, where SAM can be found in the 
micromolar range, whereas methods with fluorescent detection show greater sensitivity and 
can also be used for the detection of SAM in plasma in nanomolar concentrations. In order 
to enable even better quantification of SAM presented in plasma or cerebrospinal fluid in 
low nanomolar concentration, some more sensitive LC–MS (Stabler&Allen, 2004) and LC–
MS/MS methods (Gellekink et al., 2005; Struys et al., 2000) have also been developed. 
A capillary electrophoresis method has been developed for the determination of SAM and 
SAH in rat liver and kidney as well as in mouse liver, but it can also be used to determine 
SAM in whole blood (Uthus, 2003).  
The stereospecific colorimetric assay for (S,S)-SAM quantification is based on TPMT-
catalyzed thiol methylation. All reagents are commercially available and inexpensive, and 
the necessary enzymes are robust and readily obtainable in large quantities from 
recombinant sources. The assay can be carried out on UV–visible spectrometers available in 
most laboratories and can be adapted for batch assay, for example, in a microplate format. 
The method is linear from 5 M to at least 60 M (S,S)-SAM. The higher limits of the assay 
are restricted by the linear range of individual spectrophotometers at 410 nm, whereas the 
lower limits are determined by the sensitivity and precision of the spectrophotometer. 
Although the method was developed to determine SAM concentration in tablets, it could 
also be applied to measure SAM concentration in physiological fluids (Cannon et al., 2002).  
The commercially available assay for SAM determination is a Mediomics Bridge-It® 
fluorescence assay based on a combination of fluorescence measurement techniques and an 
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assay platform design that utilizes DNA-binding proteins as biosensors for their respective 
ligands. The affinity of the DNA-binding transcriptional repressor MetJ, labelled with 
fluorophore, for its DNA-binding site is greatly increased in the presence of its ligand, SAM. 
This method exhibits a high signal to background ratio, a broad linear dynamic range (0.5 
µM – 20 µM), and a detection sensitivity of 0.5 µM; therefore, it is useful for the purpose of 
quantifying SAM in various samples including biological fluids, cell culture and 
fermentation medium, and extracts of tissues and cells  (www.mediomics.com). 
5. S-adenosylmethionine (SAM) in therapy 
SAM in the form of its stable p-toluensulphonate or butanedisulfonate salt has been used for 
more than 20 years in the treatment of depression, liver disorders, and musculoskeletal and 
joint disorders such as osteoarthritis and fibromyalgia. It has been available as a prescription 
drug marketed under different brand names (Gumbal, Samyr, Adomet, Heptral and 
Admethionine) in Italy, Spain, Germany, the Czech Republic, Russia, Argentina and Mexico, 
whereas in the United States and Canada SAM has been available under the Dietary 
Supplement and Health Education Act as a nutritional supplement under the marketing 
name SAM-e. 
Depression 
Although the mechanism of antidepressant action of SAM is not entirely clear, it is thought 
that its ability to function as a methyl donor increases brain levels of serotonin, dopamine, 
and norepinephrine. It has been previously reported that serum and cerebrospinal fluid 
levels of SAM are low in depressed patients (Bottiglieri 1990; Lakhan 2008) and that 
increases in serum SAM levels correlate with improved treatment response (Bell 1994). 
Besides the stimulatory effect of SAM on central monoaminergic neurotransmitters, there 
may exist alternative mechanisms in which increased or restored membrane phospholipid 
methylation plays a role in the antidepressant effect. SAM may increase the fluidity of cell 
membranes by stimulating phospholipid methylation, which has previously been linked to 
an increase in ß receptor and muscarinic (M1) receptor density (Bottiglieri, 2002).  
SAM has been studied for use in various depressive disorders for many decades, with the 
first clinical trials dating back to as early as 1973 (Fazio et al., 1973). The majority of studies 
performed since then have reported that SAM is effective for treating depression, the 
conclusion also drawn later by a meta-analysis (Bressa, 1994) and some other systematic 
reviews (Williams 2005; Papakostas 2003; Mischoulon 2002). However, due to several 
quality issues and methodological flaws of the individual studies included in these reviews, 
the findings should be interpreted with caution. Most studies are quite dated (1970s or 
1980s), have short treatment duration and are of small sample size (n < 50). Furthermore, the 
most appropriate daily dosage for SAM is also not well established. Due to its low oral 
bioavailability, many of the earlier SAM studies utilized parenteral formulations 
(intramuscular or intravenous), which may also limit the clinical relevance of those studies 
(Carpenter, 2011).  
Osteoarthritis 
SAM has also been studied extensively in the context of the treatment of osteoarthritis. 
Experimental studies indicate that SAM increases the chondrocyte proteoglycan synthesis and 
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Although the mechanism of antidepressant action of SAM is not entirely clear, it is thought 
that its ability to function as a methyl donor increases brain levels of serotonin, dopamine, 
and norepinephrine. It has been previously reported that serum and cerebrospinal fluid 
levels of SAM are low in depressed patients (Bottiglieri 1990; Lakhan 2008) and that 
increases in serum SAM levels correlate with improved treatment response (Bell 1994). 
Besides the stimulatory effect of SAM on central monoaminergic neurotransmitters, there 
may exist alternative mechanisms in which increased or restored membrane phospholipid 
methylation plays a role in the antidepressant effect. SAM may increase the fluidity of cell 
membranes by stimulating phospholipid methylation, which has previously been linked to 
an increase in ß receptor and muscarinic (M1) receptor density (Bottiglieri, 2002).  
SAM has been studied for use in various depressive disorders for many decades, with the 
first clinical trials dating back to as early as 1973 (Fazio et al., 1973). The majority of studies 
performed since then have reported that SAM is effective for treating depression, the 
conclusion also drawn later by a meta-analysis (Bressa, 1994) and some other systematic 
reviews (Williams 2005; Papakostas 2003; Mischoulon 2002). However, due to several 
quality issues and methodological flaws of the individual studies included in these reviews, 
the findings should be interpreted with caution. Most studies are quite dated (1970s or 
1980s), have short treatment duration and are of small sample size (n < 50). Furthermore, the 
most appropriate daily dosage for SAM is also not well established. Due to its low oral 
bioavailability, many of the earlier SAM studies utilized parenteral formulations 
(intramuscular or intravenous), which may also limit the clinical relevance of those studies 
(Carpenter, 2011).  
Osteoarthritis 
SAM has also been studied extensively in the context of the treatment of osteoarthritis. 
Experimental studies indicate that SAM increases the chondrocyte proteoglycan synthesis and 
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proliferation rate. SAM induces the synthesis of polyamines that might stabilize the 
polyanionic macromolecules of proteoglycans and protect them from attack by proteolytic and 
glycotic enzymes. Furthermore, in vitro studies show that SAM can antagonize the tumour 
necrosis factor –induced decreases in synovial cell proliferation and fibronectin mRNA 
expression. These findings indicate that SAM restores basal conditions in cultured synovial 
cells after cytokine-induced cell damage (Bottiglieri, 2002). Many trials have demonstrated that 
SAM reduces the pain associated with osteoarthritis and is well tolerated in this patient 
population. However, a systematic review (Rutjes et al., 2009) found that available studies 
were mainly small and of questionable quality, and that, therefore, the routine use of SAM for 
osteoarthritis of the knee or hip could not be recommended until such time as further 
evaluation through larger randomised controlled studies has taken place.  
Liver Disease 
SAM has been used to treat various types of acute and chronic liver diseases. Although the 
focus of clinical trials in this area has been diffuse, a number of clinical trials have focused 
on the effect of SAM on cholestasis arising from a variety of causes, including pregnancy 
(Almasio et al., 1990; Frezza et al., 1990a; Frezza et al., 1990b). SAM may exert beneficial 
effects on the liver through a variety of mechanisms. Glutathione, the major anti-oxidant in 
the liver, plays a key role in detoxification and the limiting of oxidative damage. Studies 
have shown that abnormal SAM synthesis is associated with chronic liver disease, 
regardless of its etiology. At customary therapeutic doses, SAM has been shown to increase 
hepatic glutathione concentrations in patients with chronic liver disease (Chawla et al., 
1990). Although some studies have demonstrated clinical improvement in patients with 
intrahepatic cholestasis, hepatic steatosis and alcoholic liver cirrhosis, a systematic review of 
9 randomised placebo-controlled studies could not find evidence to support or refute the 
claim that SAM has a beneficial effect in patients with alcoholic liver disease 
(Rambaldi&Gluud, 2006).  
Neurological Disorders 
Several studies indicate that a CNS methyl group deficiency may play a role in the etiology of 
Alzheimer disease (AD). Hyperhomocysteinemia, often related to folate or vitamin B 12 
deficiency, is a common finding in the elderly and is associated with cognitive impairment and 
cognitive decline. The association between hyperhomocysteinemia and AD is well established; 
however, the underlying pathophysiology remains unexplained. Studies in cell culture 
experiments and mouse models have suggested that 2 metabolites of homocysteine, SAM and 
S- adenosylhomocysteine (Sahasranaman et al., 2008), may be important in Alzheimer 
pathogenesis, e.g. by influencing the expression of presenilin 1 and  - secretase, leading to an 
increase in A  production (Linnebank et al., 2010). It is important to note that the use of either 
SAM or alternative methyl group donors (such as betaine or folate and vitamin B-12) might 
improve measures of cognitive function. These treatments may be able to restore methyl group 
metabolism and normalize blood homocysteine concentrations (Bottiglieri, 2002).  
6. Conclusions 
Prediction of TPMT activity and thiopurine drug response based on TPMT genotyping tests 
represents one of the most relevant applications of pharmacogenetics. Prediction of TPMT 
activity and treatment response solely on the basis of presence of mutant TPMT alleles is 
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insufficient, due to the incomplete TPMT phenotype-to-genotype correlation. This problem 
is most pronounced in heterozygous patients (8-10 % in Caucasian populations), which 
exhibit a wide range of intermediate enzyme activity, and in those wild-type individuals 
which do not exhibit high activity. Hence, to improve the prediction of thiopurine therapy 
outcome, identification of new biomarkers is essential.  
One of such candidates is SAM, which, by binding into the active site of TPMT, stabilizes its 
structure. Several studies suggest that measurement of erythrocyte SAM level, in addition to 
TPMT genotyping, could serve as an additional predictor of TPMT activity in some 
thiopurine patient subgroups, and suggest that stabilization of TPMT by SAM has 
substantial clinical relevance. Some analytical methods for the determination of SAM in 
biological samples have already been described which are suitable for the implementation 
into clinical practice.  
In addition, SAM, which has been used for more than 20 years in the treatment of 
depression, liver disorders, and musculoskeletal and joint disorders, may be a promising 
agent to acutely regulate TPMT activity in order to rapidly decrease excess thiopurine 
toxicity in some patient subgroups. 
In addition to measuring SAM levels in red blood cells, analyses of genes directly or 
indirectly involved in the folate metabolism (such as MTHFR and TYMS) can add valuable 
additional information to conventional TPMT genotyping, thus enabling the development of 
complex diagnostic algorithms, and in turn improving the efficacy and safety of the 
thiopurine therapy. 
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1. Introduction 
"Personalized medicine” represents a conceptual change in pharmacotherapeutics, where an 
individual's genetic profile will determine the appropriate drug and/or dose the patient 
should receive. Currently, medicine is addressing this challenge through the lens of genomic 
technologies. In the domain of anthithrombotic therapy, warfarin, clopidogrel and aspirin 
are still the most relevant drugs for treatment of thromboembolic cardiovascular disorders 
and prevention of stroke. Incorporation of pharmacogenetic approaches, particularly in the 
antithrombotic drug therapy, may lead to better understanding of what stands behind the 
individual differences in drug efficacy and adverse drug effects, with the aim of increasing 
benefits and reducing risks on individual level. For now, two antithrombotics, warfarin and 
clopidogrel are emerging as the leading examples for pharmacogenetically-guided 
therapeutic optimization. Several recent randomized and controlled trials have 
demonstrated a number of improved clinical outcomes in warfarin-treated patients 
undertaking pharmacogenetic testing, particularly in patients with exceptionally low or 
high warfarin dose requirements (outliers). In addition, there were significant achievements 
in identification of genetic markers of reduced clopidogrel pharmacokinetics, which can 
partially explain inefficiency of clopidogrel response. The American Food and Drug 
Association (FDA) acted quickly on these developments in approving additional labeling for 
warfarin and clopidogrel package inserts to include relevant genetic testing, and called for 
further large-scale studies on the effectiveness of pharmacogenetic approaches to therapies 
using these drugs. However, there is still a considerable debate on the quality, quantity, and 
type of evidence that are needed to encourage such changes in clinical practice. There are 
also pertinent questions regarding which genetic markers should be used to ensure overall 
population benefits from genetic testing on a population level. It is also important to 
establish the relationship between genetic and non-genetic factors, particularly the effects of 
drug-drug interactions, and also the most appropriate pharmacogenetically-based dosing 
algorithm designed for clinical use. This review provides an update on the most significant 
pharmacogenetic studies on the commonly used oral anticoagulants and antiplatelet drugs, 
summarizing knowledge on the known genetic polymorphisms, their therapeutic effects 
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and utility of pharmacogenetic approaches in various world populations, with special 
emphasis on current gaps of knowledge and challenges for future research. Most recently, a 
new oral warfarin alternative, a direct thrombolytic dabigatran, has been approved by the 
FDA. This new drug is particularly relevant for warfarin dose outliers and un-stabilized 
patients, making warfarin pharmacogenetics especially relevant for selection of safe and 
efficient antithrombotic therapy for each patient.  
2. Antithrombotic therapy 
Cardiovascular disease (CVD) remains the leading cause of death in the modern Western 
societies, despite scientific and technological advancements. According to the American 
Heart Association (AHA) statistical update 2009, an estimated 80 million American adults 
(approximately 1 in 3) have one or more types of CVD (Lloyd-Jones et al., 2009). Arterial and 
venous thrombotic complications closely accompany CVD in contexts of myocardial 
infarction (MI) and stroke (Mackman, 2008). Venous thromboembolitic disorders (VTE), 
including deep venous thrombosis and pulmonary embolism, are considered the third 
leading cause of CVD-related death after MI and stroke (Cushman, 2007), particularly in 
patients with cancer (Heit, 2005). Antithrombotic therapies with anticoagulant and 
antiplatelet agents have been the most important means for prevention and treatment of 
CVD, with validity established in a wide range of clinical conditions, including acute 
coronary syndrome (ACS) (Anderson et al., 2007a), ischemic stroke (Sacco et al., 2006), 
peripheral vascular disease (Hirsch et al., 2006), atrial fibrillation (AF) (Fuster et al., 2006), 
and symptomatic and asymptomatic VTE (Hirsh et al., 2008). Over the past decades, 
increasing resources have been devoted to the improvement of antithrombotic therapy, 
specifically focusing on development and validation of new antithrombotic agents. A series 
of anticoagulants and antiplatelet drugs with already known or totally new mechanisms of 
action have been developed and tested in randomized controlled clinical trials (Table 1). 
However, although providing support for improved clinical outcomes in a population 
defined by explicit clinical criteria, these trials generally did not address the issue why some 
patients do not respond to the antithrombotic treatment, while others have excessive 
pharmacologic responses and distinctive patterns of adverse effects. This broad inter-patient 
variability in drug response in terms of both, pharmacological efficacy and toxicological 
adverse effects, imposes a major concern with the use of antithrombotic drugs. In common 
clinical practice, physicians cope with this variability by "trial and error" approach in ruling 
out inappropriate types of drug or dosage for each patient. The best example over the past 
50 years is warfarin (coumadin) and its derivatives, in which to avoid drug over- or under-
dosing and risks of bleedings or drug insufficiency, individual dose is determined by 
frequent monitoring of the International Normalized Ratio (INR), especially at the initial 
phase of treatment. Furthermore, intermitted medical conditions and subsequent changes in 
concomitant medications and their interaction with warfarin produce additional difficulties 
in the daily management of warfarin-treated patients. In the same way, there are growing 
concerns over inter-individual variability in drug response to antiplatelet drugs, which have 
been given so far in a universal dose estimated as effective in clinical trials (Steinhubl et al., 
2002; Yusuf et al., 2001). Specifically, there is an increasing awareness of the need for 
individualized dosing of the high-profile antiplatelet clopidogrel (Bonello et al., 2008), to 
which this review dedicates special discussion. 
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Abbreviations: VKORC1 vitamin K epoxide reductase; CYP2C9, CYP3A4-5 and  
CYP2C19 cytochrome P450 enzymes; COX1 cyclooxygenase-1; P2Y12 platelet plasma membrane 
receptor; INR International Normalized Ratio. 
Table 1. Antithrombotic drugs including generic, FDA approved and currently tested 
anticoagulants and antiplatelet agents 
While the phenomenon of individual drug response variability has been well-recognized, 
its causes are not well-defined and are likely to be multifactorial, in which patient’s age, 
sex, weight, nutrition, infections, concomitant medications and genetics play an important 
role (Sadee & Dai, 2005). Pharmacogenetic point of view, essentially referred to as 
"personalized medicine", suggests that in parallel to the development of new drugs 
improvement of known drugs efficacy and safety should be pursued and can be achieved 
by taking into account an individual’s genetic make up (Aspinall & Hamermesh, 2007). 
Pharmacogenetics suggests that knowing more about genes implicated in drug 
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Pharmacogenetics suggests that knowing more about genes implicated in drug 
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mechanisms, drug pharmacokinetics (drug metabolic enzymes and transporters) and 
pharmacodynamics (target enzymes or receptors), and genetic variations with meaningful 
biological and population impacts, could potentially lead to more intelligent clinical 
decisions on therapeutic doses and risks of adverse events for individual patients. 
Pharmacogenetic approaches, using only a limited number of genetic variations, are 
currently emerging across broad classes of antithrombotic drugs. For warfarin in 
particular, it has been recently demonstrated that incorporation of a pharmacogenetic 
rationale into the clinical decision making may hold promise for better optimization of 
drug benefit-to-risk outcomes (Klein et al., 2009). In the near future, pharmacogenetics 
together with advanced diagnostic technologies such as molecular imaging may enable to 
shift from the study of single genes to more comprehensive paradigms focusing on 
functions and interactions of multiple genes and gene products, among themselves and 
with an environment. The information gained from such analyses, in combination with 
clinical data will improve individual risk assessments, eventually guiding clinical 
management and decision-making to improved use of antithrombotic drugs for 
prevention and treatment of CVD.  
This review provides an update on the most significant pharmacogenetic studies on the 
commonly used oral anticoagulants and antiplatelet drugs, principally including warfarin, 
clopidogrel and aspirin. It summarizes knowledge on the known genetic polymorphisms, 
their therapeutic effects and utility in pharmacogenetic approaches in various world 
populations, with special emphasis on current gaps of knowledge and challenges for future 
research. There is an ongoing debate over the utility of pharmacogenetic diagnostics in the 
routine clinical practice (Woodcock, 2010). This review tackles on these unresolved issues in 
the context of antithrombotic drug, specifically whether implementation of pharmacogenetic 
testing indeed improves therapy benefits, damage reduction and clinical outcomes. In a 
broader sense, this review relates to the place of genetics among traditional approaches to 
personalized clinical care, which rely on knowledge of patient’s behavior, diet, social 
circumstances and environment, and if in the future physicians could use genetics to 
"personalize" treatment.  
3. Pharmacogenomics 
The conceptual basis of pharmacogenetics was laid more that 50 years ago (Motulsky, 1965). 
Since then, the science behind pharmacogenetics has contributed a great deal to basic 
understanding of molecular mechanisms responsible for variation in drug response and to 
translation of that understanding to the drug development process (Weinshilboum & Wang, 
2006). Clinically relevant pharmacogenetic examples, mainly involving drug metabolism, 
have been recognized. With the completion of the Human Genome Project and 
advancement of genotyping technologies, both genomic science and its application to drug 
response have undergone major advances (Feero et al., 2010). The field of pharmacogenetics 
has evolved into "pharmacogenomics", involving a shift from candidate gene approach to 
whole genome studies that now can be performed with more precision in a lot more 
samples. Former analyses of genetic variations using lower density chromosomal markers, 
such as tandem nucleotide repeats (VNTRs and STRs), are now mostly focus on more 
ubiquitous and informative variations - single-nucleotide polymorphisms (SNPs). More 
efficient and accurate platforms are now adapted for ever smaller DNA samples to detect 
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SNPs, gene copy variations (CNV) and insertion/deletion (INDEL) mutations, and also for 
analyses of gene expression (RNA/protein microarrays) and DNA chemical modifications 
(epigenomics). The HapMap project, launched in 2002, now includes a remarkable number 
of common human genetic variations. Most notably, new methods have dramatically 
increased the rates and lowered costs of DNA sequencing (Collins, 2010; Venter, 2010), 
facilitating the discovery of new genetic variations. More advanced bioinformatic and 
statistical tools have enabled genome-wide association studies (GWAS) that transformed the 
search for genetic factors in complex traits (Manolio, 2010), although applicability of GWAS 
to drug response has been hampered by the complexity and multifactorial nature of this 
phenotype. 
It is not uncommon that drugs have a narrow therapeutic index. Warfarin and clopidogrel, 
the most widely prescribed antithrombotic drugs, have narrow therapeutic indexes that  are 
influenced by genetic variations, a hallmark of drugs for which pharmacogenetic/genomic 
approaches can potentially provide substantial clinical benefits (Wang et al., 2011). 
Pharmacogenetic studies of these drugs illustrate the rapid evolution of our understanding 
regarding the relationships between genetic variations and drug efficacy and safety. For 
both these drugs, the classical candidate gene approach provided identification of important 
genetic markers of inter-individual variability in drug response. Additional data supporting 
pharmacogenetic testing for both these drugs are rapidly accumulating, among them a 
recent GWAS confirming the principal genetic determinants of warfarin response (Takeuchi 
et al., 2009) and most recent studies supporting the significance of the only known genetic 
factor in clopidogrel response (Mega et al., 2010b; Pare et al., 2010). Despite only partial 
resolution of clopidogrel pharmacogenetics, the American Food and Drug Association 
(FDA) acted quickly on these data by re-labeling warfarin and adding a warning on the 
clopidogrel label to include relevant genetic testing prior to drug use. In addition, the FDA 
approved several diagnostic kits for genetic testing of warfarin dosing markers, specifically 
those associated with warfarin sensitivity and related risk of bleedings. It is not surprising 
that dosing markers of warfarin and clopidogrel include variants of cytochrome P450 (CYP) 
enzymes that are responsible for drug metabolism or pro-drug activation. Distinct CYP 
polymorphisms related to reduced enzyme activity have been demonstrated as significant 
determinants of warfarin and clopidogrel responses and toxicity effects (Higashi et al., 2002; 
Mega et al., 2009b). As CYPs are responsible for metabolism of many other types of drugs 
(Sadee & Dai, 2005), we can presume that inclusion of genetic data on CYP polymorphisms 
in drug package labels is only starting to emerge. While these developments represent 
relative success of pharmacogenetics in the antithrombotic drug therapy, they also raised 
some pressing questions regarding clinical utility of pharmacogenetic testing, especially in 
the general population of patients (Woodcock, 2010). One problem is that the 
pharmacogenetic puzzle for clopidogrel is far from being complete (Fuster & Sweeny, 2010), 
and even more so for prasugrel, the third generation antiplatelet drug acting by the same 
mechanism, in addition evaluation of relative effects of genetic and non-genetic factors is 
still limited (Zhang et al., 2008). From an evolutionary point of view, pharmacogenetically 
meaningful inherited variations have most probably evolved and persisted in the human 
population due to ancient natural stressors such as nutrition and parasites, understanding of 
which may provide yet unknown and unexpected insights into the etiopathology and 
mechanisms of human diseases and evolutionary adaptations.  
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mechanisms, drug pharmacokinetics (drug metabolic enzymes and transporters) and 
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and even more so for prasugrel, the third generation antiplatelet drug acting by the same 
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population due to ancient natural stressors such as nutrition and parasites, understanding of 
which may provide yet unknown and unexpected insights into the etiopathology and 
mechanisms of human diseases and evolutionary adaptations.  
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On the way towards personalize medicine, pharmacogenetics ultimately aims to replace 
"one drug fits all" or "trial and error" methods in choosing an optimal drug at the most 
advantageous dose for each patient. Even if pharmacogenetics is still unable to achieve 
accurate predictions of therapeutic dose at an individual level, it can assist in identifying 
patients who are likely to benefit from a drug from those who are prone to adverse reactions 
that could lead to toxicity and death ("outliers"). Perhaps the most promising advances in 
implementation of pharmacogenetics have been made so far in the field of oncology, using a 
patient's genetic profile to predict the need and the choice of chemotherapy (Huang et al., 
2003; Kroese et al., 2007). Adverse drug reactions are a major problem with current 
antithrombotic drugs and are the major cause of hospitalizations in the US today (Lloyd-
Jones et al., 2009). Reducing the number of failed drug attempts and number 
hospitalizations due to adverse events, are all reasons why the implementation of 
pharmacogenetics could be beneficial and cost effective, and overall could potentially lead 
to decreased costs of health care (Ginsburg et al., 2005). 
4. Warfarin pharmacogenetics 
The most complete pharmacogenomic picture is presently available on the anticoagulant 
warfarin. Warfarin (coumadin), originally patented as rat poison, was introduced into the 
clinical practice in the 40s as an anticoagulant inhibiting the vitamin K cycle and thereby 
the action of vitamin K-dependent factors of the coagulation cascade, specifically factors 
II, VII, IX, and X (Figure 1). Warfarin and other coumarin derivatives are indicated in a 
wide range of clinical conditions, including prevention and treatment of venous 
thrombosis (VTE) and arterial thromboembolism in patients with AF and mechanical 
heart valves. Maintenance on warfarin most often persists for years or lifetime. Warfarin 
is still the most commonly prescribed oral anticoagulant in the North America and much 
of Europe (phenprocoumon and acenocoumarol) (Daly & King, 2003). Every year, two 
million patients start warfarin therapy in the US alone (Melnikova, 2009). One problem 
with warfarin is a narrow therapeutic index resulting in serious risks of adverse reactions 
at both ends of the dosing scale: low-responders to warfarin are at increased risk for 
embolic events and high-responders can develop intracranial hemorrhages or 
gastrointestinal bleeds. The other problem is an extensive variability in warfarin dose 
response, reflected in more than 20-fold inter-individual differences in warfarin dosing. 
All patients receiving warfarin are closely monitored using INR, a universal laboratory 
test for anticoagulation efficiency (prothrombin time). Frequent INR monitoring is 
especially crucial in naive patients at the beginning of warfarin administration. For most 
clinical indications, the therapeutic range for target INR is between 2.0 and 3.5, while 
INRs below or above this range are indicative of under-anticoagulation (risk of 
thrombosis) or over-anticoagulation (risk of bleeding), respectively. Although therapeutic 
control, i.e. achieving and maintaining target INR within the therapeutic range, is 
considered an important predictor of adverse events, it is still insufficient even in clinical 
trials settings, in which the average time spent in the therapeutic INR is only 50-70% 
(Ansell et al., 2008). Thus, it is not surprising that warfarin still ranks among the five top 
most “hazardous” drugs that are most often responsible for emergency room visits 
(Budnitz et al., 2007; Wysowski et al., 2007), making it a leading candidate for genetic 
testing before starting any patient on warfarin therapy.  
 




Abbreviations: VKORC1 vitamin K epoxide reductase; GCCX -glutamyl carboxylase;  
CYP2C9 cytochrome P450 enzyme; OH-Warfarin inactive hydroxylated warfarin metabolites;  
LMWH low molecular weigh heparins; arrows indicate activation and blocked lines inhibition.  
Fig. 1. Targets of anticoagulants and direct thrombin inhibitors (DTIs)  
Warfarin pharmacokinetics is predominantly determined by the hepatic CYP2C9 enzyme 
responsible for its metabolism. Warfarin is a racemic mixture of S and R enantiomers, S-
warfarin is the main CYP2C9 substrate, has a shorter half-life and is 3-5 times more potent 
anticoagulant. Other drugs interfering with CYP2C9 activity and warfarin clearance 
(Holbrook et al., 2005), as well as age and weight (Dobrzanski et al., 1983; Wynne et al., 
1995), can have significant effects on the efficacy of warfarin therapy, and also nutritional 
factors affecting the vitamin K cycle (Greenblatt & von Moltke, 2005). A number of genetic 
variants of CYP2C9 have been identified in various world populations 
(http://www.cypalleles.ki.se/), the two most important due to occurrence and functional 
implications are Arg144Cys (*2) and Ile359Leu (*3). CYP2C9*2 and *3 have been related to 
approximately 30% and 80% respective reductions in enzymatic activity in vitro (Rettie et al., 
1994; Takahashi et al., 1998) and to reduced S-warfarin clearance in vivo, comparing wild 
type allele homozygotes *1/*1 to mutation carriers *1/*2 or *1/*3 (40-45% reduced 
clearance) or homozygotes *2/*2 and *3/*3 (70-85%) (Kaminsky & Zhang, 1997). Following 
key study (Aithal et al., 1999) suggested that a patient’s CYP2C9 genetic composition is 
indicative of his warfarin dose requirement, in showing that hypofunctional *2 and *3 alleles 
were more common among patients with significantly lower steady-state doses, and that *2, 
*3 carriers and homozygotes had greater INR instability and more bleeding complications at 
warfarin induction. Gene-dose relationship between hypofunctional *2 and *3 alleles and 
reduced warfarin requirements was subsequently reproduced and refined in numerous 
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(http://www.cypalleles.ki.se/), the two most important due to occurrence and functional 
implications are Arg144Cys (*2) and Ile359Leu (*3). CYP2C9*2 and *3 have been related to 
approximately 30% and 80% respective reductions in enzymatic activity in vitro (Rettie et al., 
1994; Takahashi et al., 1998) and to reduced S-warfarin clearance in vivo, comparing wild 
type allele homozygotes *1/*1 to mutation carriers *1/*2 or *1/*3 (40-45% reduced 
clearance) or homozygotes *2/*2 and *3/*3 (70-85%) (Kaminsky & Zhang, 1997). Following 
key study (Aithal et al., 1999) suggested that a patient’s CYP2C9 genetic composition is 
indicative of his warfarin dose requirement, in showing that hypofunctional *2 and *3 alleles 
were more common among patients with significantly lower steady-state doses, and that *2, 
*3 carriers and homozygotes had greater INR instability and more bleeding complications at 
warfarin induction. Gene-dose relationship between hypofunctional *2 and *3 alleles and 
reduced warfarin requirements was subsequently reproduced and refined in numerous 
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studies. A retrospective study representing an unselected patients population (Higashi et al., 
2002) investigated whether patients with CYP2C9*2,*3 genotypes also demonstrate 
increased time to therapeutic INR, time taken to achieve stable dosing, incidence of supra-
therapeutic INR and risk of serious or life-threatening bleeding events. The investigators 
found that carriers of *2,*3 required more time to achieve stable dosing (hazard ratio 
HR=0.65 [95% confidence interval CI: 0.45-0.94] with a median difference of 95 days 
(p=0.004), had higher risk of supra-therapeutic INR (HR=1.4 [1.03–1.90]) and moreover were 
more prone to bleedings at warfarin initiation (HR=3.94 [1.29–12.06]) and over the entire 
study (HR=2.39 [1.18–4.86]). While deciphering the relationship between patient’s CYP2C9 
genotype and warfarin therapeutic dose, this study suggested an optimistic perspective that 
the use of genotype-guided dosing can reduce the time to reach stable therapeutic dose, risk 
of above-range INR’s and incidence of bleeding events. A recent meta-analysis (Lindh et al., 
2009) summarizing data for almost 8,000 patients from 39 studies estimated that compared 
to patients with the wild type *1/*1 genotype, the steady-state warfarin maintenance dose 
was reduced by 20% [17-22%] and 34% [29-38%] for *1/*2 and *1/*3 carriers, and by 36% 
[30-42%], 57% [49-64%] and 78% [72-84%] for *2/*2, *2/*3 and *3/*3 homozygotes and 
compound heterozygotes, respectively. It is worth mentioning that CYP2C9*2,*3 have been 
similarly associated with reduced S-acenocoumarol clearance, lower steady state 
acenocoumarol dose requirements and higher risk for supra-therapeutic INRs, but not of 
bleeding complications (Stehle et al., 2008; Teichert et al., 2009).Thus, significant 
contribution of common hypofunctional CYP2C9 variants to warfarin sensitivity has been 
well-established, although accurate estimates of their contribution varies between studies 
and is dependent on inclusion of other factors.  
Despite these advances, robust estimates of bleeding risks for specific CYP2C9 genotypes are 
still ambiguous, due to the rarity of severe bleeding events and the need of large cohort 
studies. In order to circumvent this limitation, most studies use grouping of CYP2C9 
genotypes. For instance, a 365 patients study (Sanderson et al., 2005) reported relative bleeding 
risk RR=2.26 [1.36-3.75] for carriers of *2 or *3 variants, while a 446 patients study (Limdi et al., 
2008) a reported hazard ratio HR=3.0 [1.1-8.0] for major bleeding that was highest during 
induction (5.3-fold) but remained increased (2.2-fold) after stabilization. A large prospective 
Swedish Warfarin Genetics (WARG) cohort of 1496 patients (Wadelius et al., 2009) reported 
that 1 of 8 (12.5%) patients homozygous for *3 experienced a serious bleeding event, compared 
to 4 of 1482 (0.27%) with other CYP2C9 genotypes (p=0.066). Judging from these and other 
observations, it was clear that CYP2C9 polymorphisms can not explain the entire inter-
individual variability in warfarin dose response. In addition, CYP2C9*2,*3 allele frequencies in 
various world populations were not entirely matching to previous epidemiological findings of 
ethnic differences in warfarin dose requirements, suggesting that individuals of Asian origin 
are relatively low dose requirers and individuals of African origin are high dose requirers 
compared to Caucasians (Absher et al., 2002; Dang et al., 2005). Conversely, CYP2C9*2 and *3 
were found prevalent in Caucasians (12% and 8% respectively), but were hardly present in 
African or Asian populations (Moyer et al., 2009; Stehle et al., 2008).  
Recent studied suggested implication of yet another cytochrome P450 in warfarin dose, 
CYP4F2, showing that coding and exceptionally common Val433Met polymorphism (up to 
30% allele frequency in white populations) is associated with 4-12% increase in warfarin 
dose requirements (Borgiani et al., 2009; Caldwell et al., 2008). Contribution of this factor 
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was further supported in recent GWAS showing that when CYP2C9 and VKORC1 effects 
were removed through multiple regression adjustments, an additional signal for CYP4F2 
was observed (Takeuchi et al., 2009). Although the effect of this CYP4F2 polymorphism is 
probably small (about 1.1% variability explained), the suggested molecular explanation of 
this effect is interesting. CYP4F2 was shown to catalyze vitamin K oxidation, while the 
presence of 433Met variation reduced its catalytic ability, potentially leading to 
accumulation of the VKORC1 substrate - vitamin K epoxide and larger warfarin doses 
required for inhibition of this pathway (McDonald et al., 2009). CYP4F2 Val433Met was also 
associated with acenocoumarol dose requirements with similar modest effect (1.2-1.3%) 
(Perez-Andreu et al., 2009; Teichert et al., 2009). 
A major step forward has been taken with discovery of an enzyme responsible for warfarin 
pharmacodynamics and direct warfarin target, the vitamin K epoxide reductase (VKOR). 
When VKOR is blocked by warfarin, vitamin K epoxide cannot be reduced to replenish the 
active form of vitamin K, which is necessary for activation of coagulation factors by  
-carboxylation (Figure 1). Therefore, lack of active vitamin K eventually results in less 
activated coagulation factors and decreased coagulation activity. After more than 50 years of 
search for the warfarin target, the gene encoding the VKOR catalytic subunit (VKORC1) was 
identified in parallel by two independent groups (Li et al., 2004; Rost et al., 2004), the latter 
also provided first evidence of rare VKORC1 mutations in patients with exceptionally high 
warfarin dose requirements (i.e. warfarin resistance). Shortly after, several studies reported 
that VKORC1 polymorphisms affect warfarin dose response (Bodin et al., 2005; D'Andrea et 
al., 2005; Sconce et al., 2005) and studies considering both CYP2C9 and VKORC1 
polymorphisms suggested that they provide relatively good explanation of low dose 
requirements conditional on enzymes insufficiencies and a total of about 50% variability 
explained (Bodin et al., 2005; Sconce et al., 2005). A landmark study (Rieder et al., 2005) 
revealed a series of VKORC1 polymorphisms (10 SNPs including previously reported) that 
construct high-linkage disequilibrium haplotype structure with distinct frequencies among 
human populations. Specifically, haplotypes H1 and H2 containing promoter -1639G>A 
(also 3673G>A), and intragenic 1173C>T (also 6486C>T), 6853G>C and 7566C>T variations 
were associated with reduced VKORC1 transcription and lower warfarin doses, consistent 
with the notion that lower target enzyme production leads to lower requirement of its 
specific inhibitor. Since then, numerous studies have supported the notion that H1 and H2 
haplotype variants (also VKORC1*2 (Geisen et al., 2005) are associated with warfarin 
sensitivity. Studies examining VKORC1 haplotype frequencies in various world populations 
confirmed that VKORC1 alleles/haplotypes are important genetic factors in determining 
individual as well as populational warfarin dose response variability, particularly the 
occurrence of warfarin sensitivity (Mushiroda et al., 2006; Takahashi et al., 2006; Veenstra et 
al., 2005). A paramount analysis of VKORC1 alleles/haplotypes in 8,750 patients from 11 
countries partaking in the International Warfarin Pharmacogenetics Consortium (IWPC) , 
the largest cohort representing three racial groups (Asians, whites and blacks) (Limdi et al., 
2010), showed that the -1639G>A marker is sufficient to explain the variance across all three 
racial groups. In fact, the -1639G>A marker has been incorporated into all warfarin genetic 
testing kits approved by the FDA. However this study acknowledged that the contribution 
of VKORC1 to dose requirements is higher in whites than in non-whites. The most 
compelling evidence for VKORC1 contribution to warfarin sensitivity were provided by the 
IWPC study of over 5,000 patients (Klein et al., 2009), showing that patients with -1639 GG, 
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studies. A retrospective study representing an unselected patients population (Higashi et al., 
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was further supported in recent GWAS showing that when CYP2C9 and VKORC1 effects 
were removed through multiple regression adjustments, an additional signal for CYP4F2 
was observed (Takeuchi et al., 2009). Although the effect of this CYP4F2 polymorphism is 
probably small (about 1.1% variability explained), the suggested molecular explanation of 
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accumulation of the VKORC1 substrate - vitamin K epoxide and larger warfarin doses 
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-carboxylation (Figure 1). Therefore, lack of active vitamin K eventually results in less 
activated coagulation factors and decreased coagulation activity. After more than 50 years of 
search for the warfarin target, the gene encoding the VKOR catalytic subunit (VKORC1) was 
identified in parallel by two independent groups (Li et al., 2004; Rost et al., 2004), the latter 
also provided first evidence of rare VKORC1 mutations in patients with exceptionally high 
warfarin dose requirements (i.e. warfarin resistance). Shortly after, several studies reported 
that VKORC1 polymorphisms affect warfarin dose response (Bodin et al., 2005; D'Andrea et 
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explained (Bodin et al., 2005; Sconce et al., 2005). A landmark study (Rieder et al., 2005) 
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human populations. Specifically, haplotypes H1 and H2 containing promoter -1639G>A 
(also 3673G>A), and intragenic 1173C>T (also 6486C>T), 6853G>C and 7566C>T variations 
were associated with reduced VKORC1 transcription and lower warfarin doses, consistent 
with the notion that lower target enzyme production leads to lower requirement of its 
specific inhibitor. Since then, numerous studies have supported the notion that H1 and H2 
haplotype variants (also VKORC1*2 (Geisen et al., 2005) are associated with warfarin 
sensitivity. Studies examining VKORC1 haplotype frequencies in various world populations 
confirmed that VKORC1 alleles/haplotypes are important genetic factors in determining 
individual as well as populational warfarin dose response variability, particularly the 
occurrence of warfarin sensitivity (Mushiroda et al., 2006; Takahashi et al., 2006; Veenstra et 
al., 2005). A paramount analysis of VKORC1 alleles/haplotypes in 8,750 patients from 11 
countries partaking in the International Warfarin Pharmacogenetics Consortium (IWPC) , 
the largest cohort representing three racial groups (Asians, whites and blacks) (Limdi et al., 
2010), showed that the -1639G>A marker is sufficient to explain the variance across all three 
racial groups. In fact, the -1639G>A marker has been incorporated into all warfarin genetic 
testing kits approved by the FDA. However this study acknowledged that the contribution 
of VKORC1 to dose requirements is higher in whites than in non-whites. The most 
compelling evidence for VKORC1 contribution to warfarin sensitivity were provided by the 
IWPC study of over 5,000 patients (Klein et al., 2009), showing that patients with -1639 GG, 
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GA, and AA genotypes had mean warfarin weekly doses of 42.6mg [41.5-43.7], 30.7mg [29.9-
31.5] and 20.3mg [19.8-20.8], respectively, corresponding to approximately 25% dose 
reduction per A allele. Moreover, the -1639A allele was associated with other clinical 
outcomes indicative of increased warfarin sensitivity, specifically with higher INR values 
and shorter time spent within the therapeutic range, but not with bleeding complications 
(Limdi et al, 2008; Schwarz et al, 2008; Wadelius et al, 2009), as previously mentioned, 
evaluation of bleeding risks may require larger studies. VKORC1 alleles/haplotypes were 
shown to have similar effects on increased sensitivity to acenocoumarol (Stehle et al., 2008).  
Thus, added genetic data on CYP2C9 and VKORC1 provided sufficiently good resolution of 
warfarin sensitivity but not of warfarin resistance, showing by default that patients of 
African origin (African-Americans), in which warfarin resistance is common, are essentially 
lacking markers of warfarin sensitivity. In addition, use of correlation analyses and more 
complex models accounting for other genetic and non genetic factors in African-American 
patients, did not reach the values achieved in Caucasian and Asian patients (Momary et al., 
2007; Schelleman et al., 2007). Rare VKORC1 mutations identified in singular families with 
multiple coagulation factor deficiency (Rost et al., 2004) and rare patients with severe 
warfarin resistance (Harrington et al., 2005) also could not explain the relatively common 
occurrence of warfarin resistance in patients of African origin. Other gene variants, such as 
polymorphisms in the microsomal epoxide hydrolase (EPHX1) and calumenin (CALU), 
were shown to have only marginal contribution to higher warfarin doses (Loebstein et al., 
2005; Wadelius et al., 2007). This gap of knowledge was resolved by two studies reporting a 
common warfarin resistance marker, the VKORC1 Asp36Tyr mutation, with significant 
contribution to high warfarin doses (>70 mg/week) and dominant effect over warfarin 
sensitivity markers in the same individual (Loebstein et al., 2007; Scott et al., 2008). Initially 
described in the Jewish Ashkenazi (4% allele frequency), Asp36Tyr was further found 
surprisingly prevalent in individuals from Ethiopia (15%) (Aklillu et al., 2008). Most recent 
study specifically focusing on high-dose coumarins requirers reported that Asp36Tyr is the 
most common VKORC1 mutation also among European warfarin resistant patients and 
appears to affect phenprocoumon therapeutic in the same way (Watzka et al., 2011). 
5. Implementation of warfarin pharmacogenetics 
Prior to the genetic era, warfarin dose prediction at the initiation of therapy used a clinical 
algorithm, including variables such as age, weight or height, race, concomitant medication 
and dietary vitamin K consumption, all together accounting for 20-30% of warfarin dose 
variability (Gage et al., 2008). Taken together, CYP2C9 and VKORC1 genotypes could 
explain additional 20-30% of warfarin dose variability (Wu, 2007) and by other estimates 
even 30-40% (Manolopoulos et al., 2010), again showing an overriding effect of genetic 
factors. These observations raised the possibility that genetic testing of patients prior to 
therapy initiation might provide information that could enhance the clinical algorithm. 
Several prospective studies examined potential clinical utility of the pharmacogenetic 
algorithm including genetic and clinical data. The first prospective randomized study 
comparing between the pharmacogenetically-guided and standard dosing algorithms for 
206 patients initiating warfarin therapy (Anderson et al., 2007b) failed to show significant 
differences between groups for the primary endpoint, i.e. the number of out-of-range INR 
standardized by the number of INRs obtained (30.7%±22.9 in pharmacogenetic-guided 
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versus 33.1%±22.9 in standard dosing group). However, the investigators succeeded to show 
that the pharmacogenetic algorithm slightly, but significantly, decreased the number of dose 
adjustments from 3.6 to 3.0 per patient (mean decrease of 0.62 adjustments [0.04–1.19], 
p=0.035). While it was clear that a patient’s genetics influences warfarin dosing, it was still 
unclear how this data could be utilized in the clinic. Several groups suggested other 
pharmacogenetic algorithms, using genetic and clinical factors (Gage et al., 2008; Limdi et 
al., 2008; Takahashi et al., 2006). The IWPC pharmacogenetic algorithm was constructed on 
the basis of analysis of 4000 patients of various ethnicities, accounting for patients’ genetic 
(VKORC1 and CYP2C9) and clinical data (age, weight and early INR values) (Klein et al., 
2009). The predictive value of this pharmacogenetic algorithm was then validated in a 
cohort of 1000 patients, calculating the percentage of patients whose predicted dose was 
within 20% of the actual stable therapeutic dose. The investigators found that the 
pharmacogenetically-guided dosing was more accurate compared to the traditional 
approach. The greatest predictive value of the pharmacogenetic algorithm was seen in 
patients receiving weekly doses of 21mg or less, and 49mg or more to achieve the target 
INR, 49.4% in pharmacogenetically-guided versus 33.3% in traditional among patients 
requiring  21mg and 24.8% versus 7.2% among patients requiring  49mg (p<0.001 for both 
comparisons). Thus, the conclusion was that the addition of genotype information enhanced 
outcomes, especially for patients who required unusually high or low warfarin doses 
(outliers). CYP4F2 was not included in this algorithm but has been included in several 
algorithms developed later (Sagreiya et al., 2010; Zambon et al., 2011). Probably the most 
direct evidence for benefits of the pharmacogenetically-guided approach were provided in 
the latest study comparing nearly 900 patients for whom genetic information on CYP2C9 
and VKORC1 was made available to prescribing physicians with matched 2,690 patients 
control group who started warfarin therapy without genetic information (Epstein et al., 
2010). Six months after warfarin initiation, the genotyped cohort had 31% fewer 
hospitalizations overall (HR=0.69 [0.58-0.82], p< 0.001) and 28% fewer hospitalizations for 
bleeding or thromboembolism (HR=0.72 [0.53-0.97], p=0.029) 
In February 2010, the FDA revised warfarin label providing genotype-specific ranges of 
doses and recommending, but not requiring, that genotypes be taken into consideration 
when the drug is prescribed. The wide availability of CYP2C9 and VKORC1 genotyping and 
the release of both Web-based and personal decision-support tools have facilitated clinical 
use of this information. Nevertheless, clinical adoption of genotype-guided administration 
of warfarin has been slow (Ansell et al., 2008). Several prospective clinical trials are 
currently ongoing to fill the need for prospective assessment of the value of genetic 
information in warfarin therapy (Ginsburg & Voora, 2010). Alternative anticoagulant 
therapies are also being developed that might replace warfarin, perhaps in patients with 
genotypes associated with extreme warfarin dose response (Kanagasabapathy et al., 2010). 
6. Antiplatelet therapies 
Platelets play a central role in cardiovascular arterial thrombosis caused by endothelial 
damage due to a ruptured atherosclerotic plaque, they adhere to the damaged sub-
endothelial matrix and aggregate with each other to form a prothrombotic surface that 
promotes clot formation and subsequently vascular occlusion. Treatment of cardiovascular 
arterial disease has been using drugs targeting key pathways of platelet activation, 
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GA, and AA genotypes had mean warfarin weekly doses of 42.6mg [41.5-43.7], 30.7mg [29.9-
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variability (Gage et al., 2008). Taken together, CYP2C9 and VKORC1 genotypes could 
explain additional 20-30% of warfarin dose variability (Wu, 2007) and by other estimates 
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factors. These observations raised the possibility that genetic testing of patients prior to 
therapy initiation might provide information that could enhance the clinical algorithm. 
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comparing between the pharmacogenetically-guided and standard dosing algorithms for 
206 patients initiating warfarin therapy (Anderson et al., 2007b) failed to show significant 
differences between groups for the primary endpoint, i.e. the number of out-of-range INR 
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versus 33.1%±22.9 in standard dosing group). However, the investigators succeeded to show 
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p=0.035). While it was clear that a patient’s genetics influences warfarin dosing, it was still 
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2009). The predictive value of this pharmacogenetic algorithm was then validated in a 
cohort of 1000 patients, calculating the percentage of patients whose predicted dose was 
within 20% of the actual stable therapeutic dose. The investigators found that the 
pharmacogenetically-guided dosing was more accurate compared to the traditional 
approach. The greatest predictive value of the pharmacogenetic algorithm was seen in 
patients receiving weekly doses of 21mg or less, and 49mg or more to achieve the target 
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doses and recommending, but not requiring, that genotypes be taken into consideration 
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the release of both Web-based and personal decision-support tools have facilitated clinical 
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information in warfarin therapy (Ginsburg & Voora, 2010). Alternative anticoagulant 
therapies are also being developed that might replace warfarin, perhaps in patients with 
genotypes associated with extreme warfarin dose response (Kanagasabapathy et al., 2010). 
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Platelets play a central role in cardiovascular arterial thrombosis caused by endothelial 
damage due to a ruptured atherosclerotic plaque, they adhere to the damaged sub-
endothelial matrix and aggregate with each other to form a prothrombotic surface that 
promotes clot formation and subsequently vascular occlusion. Treatment of cardiovascular 
arterial disease has been using drugs targeting key pathways of platelet activation, 
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including thromboxane A2 synthesis and ADP-mediated and integrin IIb 3 signaling 
pathways. The most common antiplatelet agents include aspirin, clopidogrel and integrin 
IIb 3 antagonists (Figure 2). Numerous clinical trials have accumulated substantial evidence 
for efficacy of aspirin and clopidogrel, or both, in the primary and secondary prevention of 
MI, stroke and cardiovascular death (Wang et al., 2006). However, these trials have also 
demonstrated subsets of patients in which failure of antiplatelet therapy increased risks of 
vascular event and death. It has been estimated that 10-15% of the population is resistant to 
aspirin and close to 30% to clopidogrel, while resistance to both aspirin and clopidogrel 
occurs in 9% (Dupont et al., 2009). A lot of focus has been drawn to defining antiplatelet 
drug resistance and understanding how it develops. The term ‘resistance’ has been coined 
for lack of ability to attain the expected pharmacologic effect in the laboratory in vitro tests of 
platelet function (Barragan et al., 2003; Mehta et al., 1978; Muller et al., 2003). However, lack 
of agreement on a standardized definition for antiplatelet resistance contributed to the 
disparity in its incidence among different studies. Multiple assays for platelet function have 
been developed, among them the test considered the gold standard for aspirin response - 
light transmittance aggregometry (LTA), the point-of-care platelet function analyzer PFA-
100 device and the newly introduced ‘VeryfyNow’ assays for aspirin and clopidogrel. One 
problem is the extent to which these laboratory methods correlate with one another, recent 
study using six different platelet function test has demonstrated that their results are weakly 
comparable regarding aspirin response (Lordkipanidze et al., 2007). The other problem is 
that the phenomenon of resistance is not well understood and, apart from genetic factors, is 
highly dependent on drug-drug interactions, diet and clinical conditions associated with 
high platelet turnover, such as inflammation, chronic infection and other disorders 
(Musallam et al., 2011). Therefore, a more subtle term, i.e. “non-responsiveness”, have been 
suggested (Hennekens et al., 2004) until the reasons for antiplatelet treatment failure are 
better recognized.  
7. Aspirin 
For over 50 years, aspirin has been the foundation of antiplatelet therapy. Aspirin 
(acetylsaliylic acid) irreversibly acetylates the platelet cyclooxygenase-1 (COX1) at serine 
529, which reduces the production of thromboxane A2, a potent platelet activator (Figure 2). 
Oral aspirin is rapidly absorbed from the stomach and small intestine, reaching peak plasma 
levels in 1-4 hours, its plasma half-life is only 15–20 minutes, but the platelet inhibitory 
effect lasts for platelets lifespan because of the irreversible inactivation of COX1 (Patrono et 
al., 2008). In high-risk patients, aspirin reduces vascular death by approximately 15% and 
non-fatal vascular events by 30% (Patrono et al., 2008). Aspirin may also be of benefit in the 
primary prevention of cardiovascular events, but the effect is more modest (Patrono et al., 
2008). Consensus guidelines on the role of laboratory testing for aspirin response remain 
lacking, as evaluation of platelet function for aspirin is highly test specific. The very low cost 
of the drug is a major advantage.  
Potential contribution of genetic factors to aspirin resistance has been investigated in 
numerous studies, but has not been entirely resolved. Early studies suggested that 
polymorphisms in the COX1 gene could be responsible for partial resistance to low dose 
aspirin (Eikelboom et al., 2002; M.K. Halushka & P.V.Halushka, 2002). Further study of 144 
CVD patients on aspirin using LTA for platelet activity studies (Maree et al., 2005) 
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confirmed that polymorphisms in COX1 significantly affect arachidonic acid (AA)-induced 
platelet aggregation and serum thromboxane A2 levels (p=0.004). However, more recent 
systematic review has not supported the association between COX1 polymorphisms and 
aspirin resistance (Goodman et al., 2008). Candidate polymorphisms in platelet glycoprotein 
receptors (GPIa/IIa, GP Ib  and GPIIIa) have been also considered as potential contributors 
to variability in aspirin response. An original study of 100 patients on low dose aspirin 
using PFA-100 method for measuring platelet-induced hemostasis in vitro (Macchi et al., 
2003) reported that patients with poor platelet response to aspirin therapy had significantly 
more often GPIIIa A1/A1 genotype (86.2%) than good responsers (59.4%; p = 0.01). No 
relation was found between aspirin resistance and other GP genotypes. Association between 
homozygosity for the GPIIIa A1 allele and resistance to aspirin inhibition was furhter 
supported by several studies (Dropinski et al., 2007; Feher et al., 2009; Papp et al., 2005), but 
refuted by others (Lev et al., 2007). Another interesting study re-assessing the effects of 
various polymorphisms in COX1 or platelet glycoprotein receptors on variable response to 
aspirin, used both PFA-100 and LTA platelet activity assays (Lepantalo et al., 2006). This 
study emphasized the effect that the two methods may have on association findings, in 
addition, the authors suggested that the poor response to aspirin was also associated with 
female gender (p=0.019). Several studies using female platelets have shown increased 
platelet reactivity at baseline and a less effective inhibition of platelet aggregation by aspirin 
(Zuern et al., 2009). The mechanisms underlying these differences are still to be elucidated, 
but influences of female sex hormones may play an important role. As a consequence, 
inhibition of platelet aggregation in women treated with aspirin may be insufficient, and 
female patients might benefit from higher maintenance dosages or the use of alternative 
antiplatelet medications. 
Thus, the potential causes, incidence and clinical impact of aspirin resistance are still 
obscure. Measured variability in response to aspirin is most probably multifactorial, with 
genetics playing what appears to be a small, undefined role. Others suggest that the actual 
incidence of true clinical aspirin resistance is very low, and that aspirin failure has little to 
do with ex vivo-determined responsiveness (Cuisset et al., 2009). Alternate pathways for 
platelets activation that are not inhibited by aspirin, such as erythrocyte induced platelet 
activation (Santos et al., 1991), may be responsible for aspirin resistance. Based on these 
notions and the mixed results shown in the above studies, there is currently no defined role 
for pharmacogenetic testing to dose aspirin.  
8. Clopidogrel high-risk pharmacokinetics 
Thienopyridines, such as clopidogrel and prasugrel, irreversibly bind to the purinoceptor 
P2Y12 receptor resulting in inhibition of platelets activation in response to adenosine 
diphosphate (ADP) and inhibition of platelet aggregation (Figure 2). Clopidogrel is given 
orally in a daily universal dose, it has substantial benefits in patients after PCI and stent 
implantation (Anderson et al., 2007a). Dual antiplatelet therapy (aspirin plus clopidogrel) is 
the standard of care for patients with acute coronary syndrome managed medically after 
coronary stenting or by PCI (Anderson et al., 2007a). However, major adverse 
cardiovascular events including stent thrombosis can occur despite antiplatelet therapy, 
recent meta-analysis showed that persistent platelet reactivity on clopidogrel treatment 
confers a five-fold increased risk of major adverse cardiovascular events (Sofi et al.,2010). All 
 
Clinical Applications of Pharmacogenetics 
 
132 
including thromboxane A2 synthesis and ADP-mediated and integrin IIb 3 signaling 
pathways. The most common antiplatelet agents include aspirin, clopidogrel and integrin 
IIb 3 antagonists (Figure 2). Numerous clinical trials have accumulated substantial evidence 
for efficacy of aspirin and clopidogrel, or both, in the primary and secondary prevention of 
MI, stroke and cardiovascular death (Wang et al., 2006). However, these trials have also 
demonstrated subsets of patients in which failure of antiplatelet therapy increased risks of 
vascular event and death. It has been estimated that 10-15% of the population is resistant to 
aspirin and close to 30% to clopidogrel, while resistance to both aspirin and clopidogrel 
occurs in 9% (Dupont et al., 2009). A lot of focus has been drawn to defining antiplatelet 
drug resistance and understanding how it develops. The term ‘resistance’ has been coined 
for lack of ability to attain the expected pharmacologic effect in the laboratory in vitro tests of 
platelet function (Barragan et al., 2003; Mehta et al., 1978; Muller et al., 2003). However, lack 
of agreement on a standardized definition for antiplatelet resistance contributed to the 
disparity in its incidence among different studies. Multiple assays for platelet function have 
been developed, among them the test considered the gold standard for aspirin response - 
light transmittance aggregometry (LTA), the point-of-care platelet function analyzer PFA-
100 device and the newly introduced ‘VeryfyNow’ assays for aspirin and clopidogrel. One 
problem is the extent to which these laboratory methods correlate with one another, recent 
study using six different platelet function test has demonstrated that their results are weakly 
comparable regarding aspirin response (Lordkipanidze et al., 2007). The other problem is 
that the phenomenon of resistance is not well understood and, apart from genetic factors, is 
highly dependent on drug-drug interactions, diet and clinical conditions associated with 
high platelet turnover, such as inflammation, chronic infection and other disorders 
(Musallam et al., 2011). Therefore, a more subtle term, i.e. “non-responsiveness”, have been 
suggested (Hennekens et al., 2004) until the reasons for antiplatelet treatment failure are 
better recognized.  
7. Aspirin 
For over 50 years, aspirin has been the foundation of antiplatelet therapy. Aspirin 
(acetylsaliylic acid) irreversibly acetylates the platelet cyclooxygenase-1 (COX1) at serine 
529, which reduces the production of thromboxane A2, a potent platelet activator (Figure 2). 
Oral aspirin is rapidly absorbed from the stomach and small intestine, reaching peak plasma 
levels in 1-4 hours, its plasma half-life is only 15–20 minutes, but the platelet inhibitory 
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CVD patients on aspirin using LTA for platelet activity studies (Maree et al., 2005) 
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confirmed that polymorphisms in COX1 significantly affect arachidonic acid (AA)-induced 
platelet aggregation and serum thromboxane A2 levels (p=0.004). However, more recent 
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8. Clopidogrel high-risk pharmacokinetics 
Thienopyridines, such as clopidogrel and prasugrel, irreversibly bind to the purinoceptor 
P2Y12 receptor resulting in inhibition of platelets activation in response to adenosine 
diphosphate (ADP) and inhibition of platelet aggregation (Figure 2). Clopidogrel is given 
orally in a daily universal dose, it has substantial benefits in patients after PCI and stent 
implantation (Anderson et al., 2007a). Dual antiplatelet therapy (aspirin plus clopidogrel) is 
the standard of care for patients with acute coronary syndrome managed medically after 
coronary stenting or by PCI (Anderson et al., 2007a). However, major adverse 
cardiovascular events including stent thrombosis can occur despite antiplatelet therapy, 
recent meta-analysis showed that persistent platelet reactivity on clopidogrel treatment 
confers a five-fold increased risk of major adverse cardiovascular events (Sofi et al.,2010). All 
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thienopyridines are pro-drugs requiring activation by the hepatic cytochrome P450 enzyme 
system. Clopidogrel is metabolized to its active metabolite through a two-step process 
mediated by various CYPs, among which CYP2C9 and CYP2C19 play a major role (Brandt 
et al., 2007), the activation of prasugrel, in contrast, is mediated by esterases and by CYP3As 
with lesser contribution of CYP2C9 and CYP2C19 (Jakubowski et al., 2007). Inter-patient 
response variability to clopidogrel became evident from platelet function assays in vitro 
(Barragan et al., 2003; Muller et al., 2003) and from associations of poor clopidogrel response 
in vitro (clopidogrel resistance or none-responsiveness) to poor clinical response evidenced 
by major adverse events (Snoep et al., 2007).  
 
Abbreviations: CYP2C19 cytochrome P450 enzyme; ADP adenosine diphosphate; P2Y12 and P2Y1 
purinoceptor receptors; coupled Gi and Gq proteins; Gi protein  and  subunits; AC adenyl cyclase; 
PI3K phosphatidylinositol 3-kinase; PLC phospholipase C; AA arachidonic acid; PGG2 and PGH2 
endoperoxides; TXA2 TXB2 thromboxanes; COX1 cyclooxygenase 1; surface GPVI glycoprotein VI and 
integrin 2b 1; VWF von Willebrand factor; arrows indicate activation and blocked lines inhibition.  
Fig. 2. Targets of several antiplatelet agents, clopidogrel, aspirin and integrin 2b 3 inhibitors 
Multiple factor have been implicated in high-on clopidogrel platelet reactivity, including 
drug compliance, drug-drug interactions, age, diabetes, body-mass index, left ventricle 
ejection function and inflammation (Giusti et al., 2010). Several studies have demonstrated 
that common and functional polymorphisms in CYPs responsible for clopidogrel 
pharmacokinetics can affect clopidogrel responsiveness. In a key study (Brandt et al., 2007), 
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the investigators hypothesized that polymorphisms inducing loss-of-function of CYP2C19, 
CYP2C9, and CYP3A5 could contribute to decreased formation of the active clopidogrel 
metabolite and thereby affect inhibition of platelet activation. They examined the effect of 
loading doses of clopidogrel and prasugrel on platelet function in vitro, showing significant 
association between the CYP2C19*2 allele encoding a truncated protein product with little 
enzymatic activity and poor response to clopidogrel, but not to prasugrel. CYP2C9*2 and *3 
showed similar tendencies. Carriers of CYP2C19*2 were more frequency poor responders 
compared to patients without the allele (72% versus 41% respectively, p=0.030). A similar 
trend was observed among CYP2C9*2,*3 homozygotes compared to patients with the wild 
type genotype (75% versus 41.4%, p=0.024). Overall, the presence of either CYP2C19*2 or 
CYP2C9 (*2/*2 or *3) was strongly associated with poor clopidogrel response (p<0.001). No 
association was found between CYP3A5 polymorphisms and clopidogrel response. In 
addition, the presence of these or any other CYP polymorphisms had no effect on response 
to prasugrel. The effect CYP3A5 polymorphisms on clopidogrel response is still elusive, a 
follow up study of 348 patients treated with clopidogrel after stent placement (Suh et al., 
2006) suggested that the CYP3A5*3 ‘non-expressor’ allele contributed to significantly 
increased risk of atherothrombotic events, however these findings could not be reproduced 
by others (Simon et al., 2009). Since CYP3A5 and A4 have an overlapping substrate 
specificity (Lamba et al., 2002), variability in CYP3A4 activity was also associated with 
clopidogrel response (Lau et al., 2004). As a result, other drugs that are metabolized by 
CYP3A4, e.g. certain statins commonly used in patients with athrosclerosis, could interfere 
with clopidogrel activation.  
The concept of high-risk pharmacokinetics in response to clopidogrel and specifically the 
role of CYP2C19*2 became increasingly recognized owing to several recent studies. Sub-
group analysis of the EXCELSIOR study examined whether the loss-of-function CYP2C19*2 
allele is associated with increased platelet reactivity despite clopidogrel treatment in 
patients undergoing elective PCI with stent placement (Trenk et al., 2008). CYP2C19*2 was 
significantly associated with residual platelet aggregation (RPA>14%) before hospital 
discharge. Patients with RPA>14% had significantly increased risk of death or MI (HR=3.0 
[1.4–6.8], p=0.004) 1-year post-procedure. The authors concluded that patients carrying at 
least one CYP2C19*2 allele are more prone to high-on clopidogrel platelet reactivity, 
although this study was not adequately powered to determine the effect of variant alleles on 
clinical outcomes. A consecutive study (Shuldiner et al., 2009) clarified the association 
between CYP2C19*2 and clinical outcomes, by doing GWAS and CYP2C19*2 genotyping in 
conjunction with platelet function assays in 429 healthy Amish volunteers on clopidogrel 
from the Amish Pharmacogenomics of Antiplatelet Intervention (PAPI) study, and then re-
examining PAPI findings in relation to cardiovascular outcomes in an independent cohort of 
227 clopidogrel-treated patients after PCI. The investigators established that CYP2C19*2 was 
associated with reduced clopidogrel response in PAPI study accounting for 12% of the 
variability in ADP-induced platelet aggregation (p=4.3x10-11). The relation between 
CYP2C19*2 genotype and platelet aggregation was replicated in the patients cohort (p=0.02). 
Moreover, patients with the CYP2C19*2 variant were more likely (20.9% versus 10.0%) to 
have cardiovascular ischemic events or death during the 1-year follow-up period (HR=2.42 
[1.18-4.99], p=0.02) (Shuldiner et al., 2009). In patients no longer taking clopidogrel after 1-
year, no increase was observed between carriers and non-carriers of CYP2C19*2 (Mega et al., 
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trend was observed among CYP2C9*2,*3 homozygotes compared to patients with the wild 
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CYP2C9 (*2/*2 or *3) was strongly associated with poor clopidogrel response (p<0.001). No 
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addition, the presence of these or any other CYP polymorphisms had no effect on response 
to prasugrel. The effect CYP3A5 polymorphisms on clopidogrel response is still elusive, a 
follow up study of 348 patients treated with clopidogrel after stent placement (Suh et al., 
2006) suggested that the CYP3A5*3 ‘non-expressor’ allele contributed to significantly 
increased risk of atherothrombotic events, however these findings could not be reproduced 
by others (Simon et al., 2009). Since CYP3A5 and A4 have an overlapping substrate 
specificity (Lamba et al., 2002), variability in CYP3A4 activity was also associated with 
clopidogrel response (Lau et al., 2004). As a result, other drugs that are metabolized by 
CYP3A4, e.g. certain statins commonly used in patients with athrosclerosis, could interfere 
with clopidogrel activation.  
The concept of high-risk pharmacokinetics in response to clopidogrel and specifically the 
role of CYP2C19*2 became increasingly recognized owing to several recent studies. Sub-
group analysis of the EXCELSIOR study examined whether the loss-of-function CYP2C19*2 
allele is associated with increased platelet reactivity despite clopidogrel treatment in 
patients undergoing elective PCI with stent placement (Trenk et al., 2008). CYP2C19*2 was 
significantly associated with residual platelet aggregation (RPA>14%) before hospital 
discharge. Patients with RPA>14% had significantly increased risk of death or MI (HR=3.0 
[1.4–6.8], p=0.004) 1-year post-procedure. The authors concluded that patients carrying at 
least one CYP2C19*2 allele are more prone to high-on clopidogrel platelet reactivity, 
although this study was not adequately powered to determine the effect of variant alleles on 
clinical outcomes. A consecutive study (Shuldiner et al., 2009) clarified the association 
between CYP2C19*2 and clinical outcomes, by doing GWAS and CYP2C19*2 genotyping in 
conjunction with platelet function assays in 429 healthy Amish volunteers on clopidogrel 
from the Amish Pharmacogenomics of Antiplatelet Intervention (PAPI) study, and then re-
examining PAPI findings in relation to cardiovascular outcomes in an independent cohort of 
227 clopidogrel-treated patients after PCI. The investigators established that CYP2C19*2 was 
associated with reduced clopidogrel response in PAPI study accounting for 12% of the 
variability in ADP-induced platelet aggregation (p=4.3x10-11). The relation between 
CYP2C19*2 genotype and platelet aggregation was replicated in the patients cohort (p=0.02). 
Moreover, patients with the CYP2C19*2 variant were more likely (20.9% versus 10.0%) to 
have cardiovascular ischemic events or death during the 1-year follow-up period (HR=2.42 
[1.18-4.99], p=0.02) (Shuldiner et al., 2009). In patients no longer taking clopidogrel after 1-
year, no increase was observed between carriers and non-carriers of CYP2C19*2 (Mega et al., 
 
Clinical Applications of Pharmacogenetics 
 
136 
2009a). Apart from the CYP2C19*2 contribution (12%), age, body mass, and lipid levels 
accounted for additional 10% of clopidogrel response. Essential confirmation of CYP2C19*2 
as an important determinant of clopidogrel response was provided by a sub-analysis of the 
randomized TRITON-TIMI 38 trial of clopidogrel and prasugrel outcomes using similar 
two-phase approach (Mega et al., 2009a). This study tested associations between CYP2C19 
reduced-function alleles (five alleles were tested) and measurements of active drug 
metabolite in plasma and platelet aggregation in response to clopidogrel in healthy 
individuals (n=162), and then re-evaluated these associations in a separate cohort of patients 
with acute coronary syndrome (n=1477) considering cardiovascular outcomes. In healthy 
individuals, carriers of at least one CYP2C19 reduced-function allele (approximately 30% of 
the population) had 32.4% reduction in plasma exposure to the active drug metabolite and 
reduction in maximal platelet aggregation in response to clopidogrel, as compared to non-
carriers (both p<0.001). Among TRITON–TIMI 38 patients, carriers of the CYP2C19 reduced-
function allele had 53% increase in the risk of death from cardiovascular causes, MI or 
stroke compared to non-carriers (12.1% versus 8.0%, HR=1.53 for carriers [1.07-2.19], p=0.01) 
and increase in the risk of stent thrombosis (2.6% versus 0.8%, HR=3.09 [1.19-8.00], p=0.02). 
These findings imply that in patients receiving clopidogrel reduced-function CYP2C19 
alleles can lead to reduced exposure to the active metabolite, less platelet inhibition and 
reduced protection from ischemic events, including stent thrombosis. Interestingly, no 
associations were found with any of these CYP variants among patients randomized to 
prasugrel therapy in the TRITON trial (Mega et al., 2009b). One drawback raised in a 
parallel study of the French FAST-MI registry including 2,208 patients (Simon et al., 2009), 
suggested that only carriers of two loss-of-function alleles CYP2C19*2, *3, *4, or *5 (i.e. 
homozygotes or compound heterozygotes) have increased risk of death, nonfatal MI or 
stroke during 1-year period (21.5% versus 13.3%, HR=1.98 [1.10–3.58]). This risk was 
increased even further in PCI (HR=3.58 [1.71–7.51]). This question has been resolved in the a 
meta-analysis including 9,685 patients with acute coronary syndrome or PCI (Mega et al., 
2010b), showing that carriers of even one reduced-function CYP2C19 allele may have 
significantly increased risks of major adverse cardiovascular events, particularly stent 
thrombosis.  
Platelet response to clopidogrel is not fully explained by the CYP2C19 loss-of-function 
alleles. Other pharmacokinetic sources of inter-patient variability have been suggested, 
specifically  the effect of the 3435C>T polymorphism in the p-glycoprotein ABCB1 on 
clopidogrel absorption and metabolism (Hoffmeyer et al., 2000; Owen et al., 2005; Taubert et 
al., 2006). However, this issue remains controversial in the recent sub-analysis of TRITON–
TIMI 38 and PLATO trials considering ABCB1 genotypes and clinical outcomes of patients 
on clopidogrel (Mega et al., 2010a; Wallentin et al., 2010a). Most recently, a novel 
determinant of clopidogrel efficacy was proposed (Bouman et al., 2011), namely the estrase 
PON1, a key enzyme in the rate limiting step of clopidogrel bioactivation and that a coding 
Q192R PON1 polymorphism can affect plasma concentrations of active metabolite, 
clopidogrel inhibition and risk of stent thrombosis,. Large randomized replication studies 
are needed to confirm these interesting and new observations. In addition, few contrasting 
data are available on pharmacodynamic factors, particularly polymorphisms in genes 
encoding platelet glycoproteins involved in thienopyridines intestinal absorption and 
platelet receptors that serve as thienopyridines targets. Effects of polymorphisms in 
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glycoprotein GPIIIa, and platelet receptors P2Y12 and P2Y1 related to aspirin and 
clopidogrel response were evaluated in a preliminary study (Lev et al., 2007), finding no 
definitive associations between various polymorphisms and clopidogrel response assessed 
by platelet aggregation studies. Another study (Shuldiner et al., 2009) relating to clinical 
outcomes also did not find an association between the P2Y12 polymorphism and the risk of 
death, non-fatal MI, or stroke in patients treated with clopidogrel. 
9. Implementation of clopidogrel pharmacogenetics 
Early in 2010, the FDA added a boxed warning to prescribing information for clopidogrel, 
stating that persons with the low-rate metabolizing CYP2C19 variant might require dose 
adjustment or the use of another drug. After this FDA action, the American Heart 
Association and the American College of Cardiology issued a joint endorsement of CYP2C19 
genotyping for patients at moderate or high risk for cardiovascular events who are treated 
with clopidogrel (Holmes et al., 2010), this genetic test is now widely available in the US. 
Despite that, there are studies that challenge the clinical impact of polymorphisms on the 
effectiveness of clopidogrel. Most recently, the CHARISMA genomic sub-study reported at 
the TCT 2009 meeting http://www.theheart.org/article/1008623.do that while patients 
homozygous for the loss-of-function CYP2C19 allele appeared to have an increased risk of 
ischemia when compared with patients with the wild-type allele, they also had fewer 
bleeding events. Conflicting results of many different studies exemplify many unanswered 
questions regarding clinical significance of pharmacogenetics in antiplatelet drugs. Being 
able to predict the specific response of an individual patient based on his or her genetic code 
has yet to be defined, especially for clopidogrel. Despite the lack of clear guidance regarding 
how clinicians could utilize the pharmacogenetic information on clopidogrel, some clinical 
laboratories, especially in the US, now offer genetic screening for markers associated with 
response to antithrombotics including clopidogrel.  
10. New generation antithrombotic drugs 
Novel orally active antiplatelet agents are now available. Prasugrel, the third-generation 
thienopyridine, has been associated with greater active metabolite generation, superior 
inhibition of platelet aggregation and less response variability than clopidogrel (Gurbel & 
Tantry, 2008). In the TRITON-TIMI 38 trial of patients with acute coronary syndrome 
undergoing PCI, the prevalence of cardiovascular death, non-fatal MI or stroke was lower 
with prasugrel than with clopidogrel, although rates of bleeding were higher in the 
prasugrel group (Wiviott et al., 2007). A novel selective inhibitor of P2Y12-receptor, 
ticagrelor has been also evaluated against clopidogrel in patients with acute coronary 
syndrome in the PLATO trial (Wallentin et al., 2009). Ticagrelor was associated with 
significant reduction in cardiovascular death, MI and stroke, without any difference in the 
overall incidence of major bleeding, but with increase in major bleeding related to 
noncoronary-artery bypass graft.  
In October 2010, the FDA approved the oral anticoagulant dabigatran (Pradaxa; Boehringer 
Ingelheim), a direct thrombin inhibitor (DTI), for stroke prevention in patients with AF 
(SPAF). The clinical community is excited at the prospect of having an alternative for 
warfarin therapy, the current gold standard therapy for stroke prevention, a challenge that 
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overall incidence of major bleeding, but with increase in major bleeding related to 
noncoronary-artery bypass graft.  
In October 2010, the FDA approved the oral anticoagulant dabigatran (Pradaxa; Boehringer 
Ingelheim), a direct thrombin inhibitor (DTI), for stroke prevention in patients with AF 
(SPAF). The clinical community is excited at the prospect of having an alternative for 
warfarin therapy, the current gold standard therapy for stroke prevention, a challenge that 
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has taken more than 50 years. SPAF is not the only indication for dabigatran and other new 
DTIs, ongoing trials are evaluating DTIs for the treatment of acute coronary syndromes and 
VTE after major orthopaedic surgery (Hughes, 2010). Initially, dabigatran will probably 
substitute warfarin in patients who have problems with INR management, investigators of 
the Phase III RE-LY trial comparing between dabigatran and warfarin effects in 18,113 
patients suggest that the rates of adverse events were similar for dabigatran and warfarin in 
patients with good INR control, whereas dabigatran was always superior to warfarin in 
patients with poor INR control (Wallentin et al., 2010b). Thus, successful entry of dabigatran 
may benefit from identification of warfarin dose outliers by genetic testing for CYP2C9 and 
VKORC1 markers and in the same way, the next generation DTIs, rivaroxaban and apixaban 
that are currently tested in the Phase III ROCKET-AF and ARISTOTLE trials, respectively 
(http://clinicaltrials.gov/).  
11. Conclusions 
Pharmacogenetics is one of the major components of personalized therapy. However, even 
though the conceptual basis for pharmacogenetics has existed for over half century and 
recent scientific and technological advancements in the field, and the FDA awareness of the 
necessity to integrate genomic data into regulatory review, the translation of 
pharmacogenetics into the clinic has been slow. The cardiovascular field and particularly the 
antithrombotic drug therapy have provided some excellent examples of clinical utility of 
pharmacogenetic approaches. The impact of VKORC1 and CYP2C9 variants on warfarin 
response, established the value of genetic variability to predict the appropriate warfarin 
dose for improving and easing the transition to a therapeutic INR level. In fact, the labeling 
for warfarin now includes recommendations for genetic testing. Nevertheless, the clinical 
application of this information has yet to become universal, in part due to ethical and 
confidentiality issues regarding genetic information, logistic issues with obtaining timely 
genotyping, and resolution of appropriate genetically-guided dosing algorithms for 
warfarin in various populations. Specifically to this last point, the validity of the existing 
genetically-guided dosing algorithms in ethnically heterogonous populations, such as in the 
US, has been seriously compromised by ethnic stratification of certain genetic warfarin 
dosing markers and inability to predict with equivalent degree of confidence in individual 
dose response. In addition, as warfarin pharmacogenetics is extensively affected by 
environmental interactions, differences in lifestyle, nutrition and traditional medical 
routines may have significant impact on how warfarin genetic testing is translated to clinical 
decision making in various population. Once again, large-scale prospective studies are 
needed to confirm the usefulness and pharmacoeconomic benefits of personalized 
genetically-guided treatment for warfarin on a population basis.  
Similar to the evolution of personalized medicine for the anticoagulant warfarin, the 
antiplatelet drug clopidogrel has also demonstrated strong potential for improving therapy 
by pharmacogenetic approach. For now, however, clopidogrel pharmacogenetics is even 
farther from obtaining widespread application than warfarin. There is a much smaller 
percentage of variability explained by the current paradigm and fewer prospective studies 
confirming the worthiness of genetic information for improving clinical outcomes. Likewise, 
any potential economic savings of this strategy have not been demonstrated. Most 
importantly, it is unclear how the genetic information on CYP2C19 can be utilized for 
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adjustment of the treatment regime, for example by increasing the dosing of clopidogrel or 
by substituting clopidogrel for the recently approved prasugrel or for the potentially soon to 
be available ticagrelor. The appropriate use of these strategies is difficult to assess in the 
absence of genetic information on clopidogrel alternatives, and incomplete understanding 
about other potential predictors, i.e. genetic, epigenetic and environmental modulators of 
response to antiplatelet agents. This problem is moreover accentuated by lack of reliable and 
validated assays for measuring platelet function with sensitivity, consistency, 
standardization and correlation with clinical outcomes, in order to tailor with confidence 
personalized antiplatelet therapy.  
There has been significant discussion in the scientific press (Collins, 2010; Varmus, 2010; 
Venter, 2010; Woodcock, 2010) about the slow pace of the application of genomics to 
clinical practice. All parties point to the need for increasingly large and complex studies to 
test pharmacogenomic paradigms in the clinical setting; economic disincentives for 
pharmaceutical industry to accept the implications of individualized drug response; and 
the slow pace of the incorporation of pharmacogenomics into the drug evaluation process. 
In line with this critique, the FDA has recently released several regulatory guidelines 
(Guidance for Industry: Pharmacogenomic Data Submission 2005 and Companion 
Guidance 2007) on integration of genomic data in the evaluation process of new drug 
applications. Finally, there is a need for concerted effort directed at the education of 
healthcare professionals as well as patients to understand, accept and utilize genomic 
information 
As time progresses, technology will continue to decrease the cost of whole-genome scans 
and other genetic tools, allowing more efficient and secure transfer of genetic information. 
Challenges that are associated with replication of study findings and evaluation of the 
clinical significance of genetic variants, underscore the importance of functional 
experiments to test their biological implications and to extend our understanding of drug 
mechanisms. These advances, along with development of logistical platforms for 
universal application of genetic information will allow realization of personalized 
medicine across all therapeutic areas, antithrombotic drug therapy. Finally, additional 
scientific, regulatory, and psychological factors must be addressed before 
pharmacogenomic tests will become a routine part of medicine. The FDA-mandated 
incorporation of pharmacogenomic information in drug labeling will remain an important 
step in the acceptance of pharmacogenomics in clinical practice. Perhaps equally 
important will be the willingness of physicians to reexamine suboptimal pharmacologic 
management programs.  
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Antiplatelet therapy with clopidogrel (Plavix ) is now considered a cornerstone of 
cardiovascular medicine. Clopidogrel resistance is an emerging clinical entity with potentially 
severe consequences such as recurrent myocardial infarction (MI), stroke, or death. Since its 
initial description, multiple investigators have confirmed the phenomenon of clopidogrel 
resistance (Dziewierz et al., 2005; Gurbel & Tantry, 2007; Mega et al., 2009; Mobley et al., 2004; 
Müller et al., 2003). The prevalence of clopidogrel non-responsiveness has been reported at  
5–44% in other populations (Gurbel & Tantry, 2007). Although the occurrence of clopidogrel 
resistance is multi-factorial, it has been associated with a CYP2C19- and PON1-mediated1 
patient’s metabolic inability to generate sufficient active metabolite to arrest platelet reactivity. 
Rapid and accurate detection of clopidogrel resistance in Hispanic Puerto Rican patients 
remain unsolved as new bedside genetic tests are developed.  
In a recent GWAS analysis, it was estimated that up to 83% of individual variance in response 
to clopidogrel might be attributable to genetic effects (Shuldiner et al., 2009), but the gene 
variants investigated thus far explain only a minor proportion of such response variability 
(Holmes et al., 2010; Hulot et al., 2010). The high heritability of clopidogrel response but 
relatively weak prediction by existing proposed genetic markers argues for the involvement of 
some as yet undiscovered genetic factors. The CYP2C19*2 allele was reported to account for 
only 12% of the variability in ADP-stimulated platelet response to clopidogrel (Shuldiner et al., 
2009). The PON1 Q192R polymorphism explained 72.5% of clopidogrel response variability in 
individuals of European ancestry (Bouman et al., 2011). However, a previous GWAS in a 
cohort of related healthy subjects of Amish descent provided no evidence for an association of 
the PON1 gene region with the platelet response to clopidogrel (Shuldiner et al., 2009). 
Due to its remarkable heterogeneity and trichotomous ancestral genetic admixture, the 
Puerto Rican population may significantly differ from other earlier pharmacogenetically 
                                                 
1 CYP2C19 stands for Cytochrome P450 isoform 2C19 (family 2, subfamily C, polypeptide 19) gene; 
PON1 stands for Paraoxonase 1 gene.  
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characterized populations with respect to the frequency, distribution and combination of 
allelic variants in genes associated with drug response and diseases (González-Burchard et 
al., 2005; Suarez-Kurtz et al., 2006). We have published a physiogenomic analysis to infer 
structure and ancestry in the Puerto Rican population. The Puerto Rican sample was found 
to be broadly heterogeneous, with three main clusters reflecting the historical admixture 
from Taino Amerindians, West-Africans, and Iberian European ancestors (Ruaño et al., 
2009). Our results matched previously published estimations of Puerto Rican admixture that 
were ascertained using more traditional ancestral genetic markers (Bertoni et al., 2003; 
Bonilla et al., 2004a, 2004b; Choudhry et al., 2006; Hammer et al., 2006; Hanis et al., 1991; 
Martinez-Cruzado et al., 2001, 2005). The study provided a set of 384 physiologically 
informative SNPs from 222 cardio-metabolic and neuro-endocrine genes that can be used to 
facilitate the translation of genome diversity into personalized medicine and control for 
admixture in Puerto Ricans. The observed large variance in admixture proportions 
suggested that this population is ideal for admixture matching studies. 
Admixture is of great relevance to the clinical application of pharmacogenetics and 
personalized medicine, but unfortunately these studies have been scarce. As 
physiogenomic-guided multi-gene models are developed to predict drug response, the 
range of possible allelic combinations in the Puerto Rican population is certain to exceed 
that in populations without admixture. In addition, the allele frequencies for both the 
CYP2C19 and PON1 candidate genes in this population have not been fully characterized. 
Accordingly, we investigated whether a correlation between overall genetic similarity and 
CYP2C19 and PON1 genotypes could be established in the study population. This chapter 
also provides valuable evidence on the importance of controlling for admixture in 
pharmacogenetic studies of admixed populations like Puerto Ricans. Indeed, we will discuss 
how known or cryptic population stratification can have a strong confounding effect on 
further clinical association analysis. Finally, the necessity to utilize results of our admixture 
analysis to parameterize population structure appropriately and account for it as a covariate 
in the corresponding association studies will also be considered. 
2. Methods 
2.1 Specimens  
100 human genomic DNA samples (40-60 ng/ L) were extracted and purified from existing 
dried blood spots on Guthrie cards supplied by the Puerto Rico Newborn Screening 
Program (PRNSP), where >95% of Puerto Rican newborns are screened for common 
hereditary diseases. Accordingly, sample analysis in this survey (protocol #A4070107) was 
exempt from IRB review under FDA and OHRP guidelines based on category 4, 
45CFR46.118. A controlled stratified-by-region random sampling protocol was followed, 
taking into consideration the percentage of birth at each region across the Island of Puerto 
Rican based on the 2004 national register of total births. Two samples were discarded from 
final analysis due to poor quality. 
2.2 Array 
The extracted genomic DNA samples were genotyped on a physiogenomic (PG) array 
detecting 384 SNPs from 222 cardio-metabolic and neuro-endocrine genes spanning their 
entire genome (Ruaño et al., 2005a; Ruaño & Windemuth, 2006). Since the PG-array was 
constructed such that it covers all common variations in the general population for 
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pharmacologically relevant cardio-metabolic pathways, virtually any set of candidate 
genes within these pathways can be tested from the resulting dataset without any further 
assay. Consequently, genotypes associated with the clinically relevant CYP2C19*2 
(rs4244285; splicing defect G681A SNP) and nonsynonymous PON1 (rs662; p.Q192R) 
polymorphisms were loaded from the derived database. Instead, array translation was 
used to impute genotyping related to CYP2C19*3 (rs4986893; stop codon G636A SNP) 
with high accuracy, given its strong linkage disequilibrium with SNP rs3758581. Wild-
types were assigned as a result of the absence of such SNPs. The PG array has been tested 
on nearly 5,000 patients and has been successfully applied in cardiovascular and 
neuropsychiatric pharmacogenetic research, resulting in ten publications (de Leon et al., 
2008; Liu et al., 2009; Ruaño et al., 2005b, 2007a, 2007b, 2008, 2009, 2010; Seip et al., 2008; 
Windemuth et al., 2008). Careful manual analysis was performed on the alignments 
underlying the genotype calls using GenCall 6.1.3.24 and 50 SNPs with even a slight 
degree of uncertainty about calling accuracy were not included in the analysis, leaving 
332 SNPs from 196 genes. Genotyping was accomplished using Illumina® BeadArrayTM 
technology (Oliphant et al., 2002).  
2.3 Clustering and statistical analysis  
Analysis of the results using the STRUCTURE v2.2 software package was used to cluster 
those subjects with similar genetic profiles (Falush et al., 2007; Pritchard et al., 2000). 
Hierarchical clustering algorithm was blind as to ethno-geographic ancestry. A detailed 
explanation of the analytics underlying the clustering of the samples and the hierarchical 
stratification by allelic dissimilarities to infer population structure, as well as a full list of the 
genes and SNPs in the PG array, is provided elsewhere in our physiogenomic analysis study 
(Ruaño et al., 2009). Allele frequencies, f, linkage disequilibrium (LD), and haplotype 
structure were individually determined for all loci. Wright’s F-statistic was calculated for 
each locus from the observed total heterozygosity HT=Nhz/N and the subpopulation 
heterozygosity HS=2f(1-f), assumed under Hardy-Weinberg equilibrium (HWE), as FST=(HT-
HS)/HT. A t-test was performed to see whether the average Fst across all loci is different from 
zero. Departure from HWE were estimated under the null hypothesis of the predictable 
segregation ratio of specific matching genotypes (p>0.05) by use of 2 goodness-of-fit test 
with one degree of freedom. In addition, 2 test was also used to compare observed allele 
frequencies within each sector in the corresponding dendrogram with expected frequencies 
given the overall allelic ratios, at 5% of significance. 
3. Results 
Results are presented in Table 1, and graphically in Figure 1 by hierarchical dendrograms to 
illustrate the population structure as represented by allelic dissimilarity (i.e., genetic 
distance). There appear to be three main sectors, from left to right: PR126–PR341; PR321–
PR69 and PR97–PR175. There are also two smaller sectors between the three main sectors. 
One pair of samples (PR26 and PR92) shows an unusually low allelic dissimilarity, 
suggesting relatedness. However, due to anonymousness of collected samples, we were 
unable to further investigate this issue. Those individuals who shared many polymorphisms 
were grouped together in one “sector” while those with whom they had much more genetic 
dissimilarities lie on the other side of the “phylogenetic tree’ map; thus greater distances 
denoting lesser degrees of common ancestry.  
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Gene SNP Ch Location Na Allelesb MAF (%) 
Genotypes 
Fst 
WT HET MUT 
CYP2C19 rs4244285 (CYP2C19*2) 10 96541616 98 GA 14.8 52 17 2 0.042 
CYP2C19 rs3758581 (CYP2C19*3) 10 96602623 95 GA 3.5 66 5 0 0.017 
PON1 rs662 7 94937446 96 AG (T/C) 45.1 22 34 15 0.174 
Table 1. Genes, allele and genotype frequency distributions of clopidogrel-associated 
polymorphisms in the representative sample of Puerto Ricans analyzed by PG-array. Ch 
column display the chromosome on which the SNP can be found. Location column contains 
the chromosome location for each SNP given by the NCBI Entrez SNP database, build 36.3 
reference assembly. MAF stands for minor allele frequency. aTotal number of samples 
analyzed by PG-array ranged between 95 to 98. However, only 71 samples were used for 
STRUCTURE clustering analysis due to incomplete combinatorial genotyping data. Only 
those samples having a strong association with one of the three clusters were finally 
included in the superimposition analysis. bAncestral allele in bold. First allele is the 
reference one. 
To determine if there are relationships between genetic clusters defined by STRUCTURE 
analysis and clopidogrel-related genotypes, we superimposed the individual genotypes for 
CYP2C19 and PON1 on the dendrogram. Figures 1, panel A and B, show less than 98 cases 
(i.e., some lanes in the genetic distance map do not have identified ancestry) due to incomplete 
combinatorial genotyping data during the initial PG array analysis or because the individual 
residing in the site did not meet a categorical criterion of proximity (> 0.20), which precluded 
definitive assignment to any of the three STRUCTURE clusters (ancestry). Furthermore, only 
those samples having a strong association with one of the three clusters were included in the 
superimposition analysis, yielding 71 total subjects. Notice that only 52 out of these 71 
analyzed cases were actually located within any of the three identified sectors in the genetic 
distance dendrograms seen in Figures 1. The other 19 cases, although located outside the 
sectors, were also included in the analysis because they all had a significant contribution from 
one of three ancestries (i.e., Taino Amerindians, Iberian Caucasians or West-Africans), as 
denoted by their ancestral coefficients. To this purpose, each of these 19 individual was 
allocated to the sector that best matched with his/her greater ancestral coefficient. The 
distribution of samples by sectors in the corresponding genetic distance dendrograms was 
then as follows: 20 samples in sector 1; 27 in sector 2 and 24 in sector 3.  
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previously published physiogenomic population analysis [21]). Green boxes are depicting 
those individuals having a single CYP2C19*2 polymorphism (G/A); Blue-colored boxes 
represent double carriers for CYP2C19*2 (A/A); whereas, purple-colored rectangles indicate 
single carriers of CYP2C19*3 (A/G). Double-colored rectangle (subject PR224) highlights the 
one having the *2/*3 genotype. The CYP2C19*3 G A polymorphism is in high linkage 
disequilibrium with rs3758581, which has been associated with a significant decrease in 
clopidogrel activation per allele and, therefore, resistance phenotype (non-responder) to 
standard dose. Panel B: Individual PON1 Q192R genotypes overlaid on the genetic distance 
dendrogram for the samples from the Puerto Rican population. Yellow color represents 
single carriers; purple color denotes double carriers of this polymorphism (G allele). p-
values were calculated by a 2 test comparing observed allele frequencies with expected 
frequencies given the overall allelic ratios. 
By previous STRUCTURE clustering analyses, the dendrogram sectors 1, 2 and 3 in Figure 1 
correspond to Taino Amerindian, Iberian Caucasian, and West-African heritage, respectively 
(Ruaño et al., 2009). Indeed, sector 1 bears a concentration of samples assigned to cluster 2 
(Amerindians) in the STRUCTURE plot. Sector 2, in the middle, is disproportionately rich in 
samples corresponding to cluster 3 (Europeans). Sector 3, to the right, is clearly enriched with 
cluster 1 samples (Africans). For the 71 cases with complete genotypes, the CYP2C19*2 allele 
frequency was 14.8%, whereas the *3 allele frequency was 3.5%. Although slightly higher, 
these findings are consistent with early reports in 22 Latin Americans (Mexicans and Puerto 
Ricans) from the 1,000 Genomes Phase I selection, where the CYP2C19*2 and *3 minor allele 
frequencies were 13.6% and 1.7%, respectively. Regarding to CYP2C19*2 polymorphism, we 
identified 52 homozygous for the wild-type allele G, 17 heterozygous and 2 double carriers of 
the variant allele A. However, the analysis for CYP2C19*3 revealed 66 wild-types, 5 single 
carriers of the variant allele, but none double carrier of this polymorphism in the study 
population. Sectors 1 and 3 in Figure 1, panel A, show CYP2C19*2 allele frequencies of 10% (4 
out of 40) and 4.16% (2 out of 48), respectively, as compared to 27.8% (15 out of 54) in sector 2. 
Statistical analyses to compare each sector to the overall allelic ratios, revealed that sector 2 (in 
the middle of the genetic distance dendrogram, Figure 1-panel A), showed a frequency of 
CYP2C19*2 that was 4-fold higher than the rest of the population (p=0.0016). Likewise, carrier 
prevalence in sector 2 (48.15%) was significantly greater than that observed in the other two 
sectors (i.e., 20 and 8.3%, respectively). 
Sector 2 is associated with Iberian European heritage (Ruaño et al., 2009). According to the 
HapMap project dataset (International HapMap Consortium, 2005), the minor allele 
frequency for CYP2C19*2 is 14.3% in 223 Caucasians who are Utah residents with Northern 
and Western European ancestry from the CEPH collection (HapMap-CEU; data release#28, 
Phase II + III). Similarly, the CYP2C19*2 allele frequency was 13% for 261 Europeans in the 
1,000 Genomes Phase I selection (Amigo et al., 2008). The present study reports a relatively 
inflated minor allele frequency of 27.8% for the CYP2C19*2 variant in sector 2 (primarily 
Caucasian), consistent with the possible interpretation that Puerto Ricans in this sector 
reflect an increased admixture with Asians (i.e., Taino Amerindians). The link between 
Amerindians and Asians originates with the “Bering Strait” theory (Jennings, 1979). 
According to previous reports, there seems to be a very high frequency for the CYP2C19*2 
variant in East Asian populations, ranging from 27-32.5% (Amigo et al., 2008).  
Likewise, the observed minor allele frequency of 4.16% in sector 3 is lower than expected for 
a population of purely African ethno-geographic origin, no surprise given the heterogeneity 
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of the Puerto Rican population. The reported CYP2C19*3 allele frequencies of 5% for sector 
1, 3.7% for sector 2 and 2.1% for sector 3 compare to the expected HapMap values of 5.6%, 
1.7% and 0.3%, respectively. The higher than expected frequencies observed in sector 2 and 
3 seem to be a direct consequence of significant admixture with Asian ancestry in 
individuals assigned to these clusters. Interestingly, the NCBI webpage reports a CYP2C19*3 
minor allele frequency of 2.1% in 24 individuals of self-described African-American heritage 
(AFR1, SNP500Cancer project, this database is an integral component of the NCI Cancer 
Genome Anatomy Project, available at http://cgap.nci.nih.gov), which is a population with 
certain genetic admixture (Packer et al., 2006). This value matched the observed allele 
frequency in sector 3, a cluster of majorly African ancestry. 
With respect to the PON1 gene (Table 1), the overall allele frequency was 45.1% (34 
heterozygous and 15 homozygous for the variant allele), which is stratified by clusters as 
42.5%, 38.9% and 54.2% in sectors 1, 2 and 3, respectively (Figure 1-Panel B). The observed 
prevalence for this variant is consistent with early reports in both 22 Latin America 
inhabitants (Mexicans and Puerto Ricans; 1,000 Genomes Phase I selection) and 58 Mexican 
descendants who reside in Los Angeles, California (HapMap-MEX; HapMap project dataset, 
release#28, Phase II + III), where the PON1 minor allele frequencies were estimated to be 
47.7% and 50%, respectively. The minor allele frequency in the general population ranges 
from 42.2 to 47.9%. However, when comparing observed allele frequencies in each of the 
three sectors (i.e., 1=Amerindian; 2=Caucasian; 3=West African) with the HapMap and 1,000 
Genomes Phase I project values, the results are showing a significantly higher than expected 
prevalence of this PON1 polymorphism. In sector 1, there was a minor allele frequency of 
42.5% as compared with the HapMap report of about 36% for the Han Chinese of Beijing 
(International HapMap Consortium, 2005) and the 36.2% in East Asians from 1,000 Genomes 
Phase I selection (Amigo et al., 2008).  
Furthermore, the allele frequency in sector 2 was 38.9% (13 heterozygous and 4 double 
carriers), considerably higher than the reported 29% for Caucasian residents of Utah, 
documented in the HapMap database (International HapMap Consortium, 2005), and the 
28.4% presented by the 1,000 Genomes Phase I selection for Europeans (Amigo et al., 2008). 
Additionally, in sector 3 the allele frequency was 54.2% (12 heterozygous and 7 double 
carriers), which is by far a higher prevalence versus the HapMap allele frequency of 27.9% 
for the Nigerian YRI population or the 23.4% in Africans of the 1,000 Genomes Phase I 
selection (Amigo et al., 2008; International HapMap Consortium, 2005). Statistical analyses 
to compare each sector to the overall allelic ratios, revealed that sector 3 (right-most portion 
of the genetic distance dendrogram, Figure 1-panel B), showed a frequency of PON1 Q192R 
that was only marginally different than the rest of the population (p=0.047). 
Greater admixture and heterogeneity in the Puerto Rican population as compared to the 
African-American population or certainly the Yoruba population allow for the presence of 
the twenty-six PON1 variant allele observed in the twenty-four individuals in sector 3 
(Figure 1-Panel B) to have come from partial Amerindian ancestry, as no individual in that 
sector was of purely West-African descent (Ruaño et al., 2009). The observed trends may 
also be an artifact of chance given the relatively small sample size. No statistically significant 
deviations from HWE were found with respect to the distribution frequencies of either 
PON1 or CYP2C19 polymorphisms. Since no departures from HWE were observed and 
considering that our study cohort is island-wide, chosen by a controlled, stratified-by-
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previously published physiogenomic population analysis [21]). Green boxes are depicting 
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single carriers of CYP2C19*3 (A/G). Double-colored rectangle (subject PR224) highlights the 
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disequilibrium with rs3758581, which has been associated with a significant decrease in 
clopidogrel activation per allele and, therefore, resistance phenotype (non-responder) to 
standard dose. Panel B: Individual PON1 Q192R genotypes overlaid on the genetic distance 
dendrogram for the samples from the Puerto Rican population. Yellow color represents 
single carriers; purple color denotes double carriers of this polymorphism (G allele). p-
values were calculated by a 2 test comparing observed allele frequencies with expected 
frequencies given the overall allelic ratios. 
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CYP2C19*2 that was 4-fold higher than the rest of the population (p=0.0016). Likewise, carrier 
prevalence in sector 2 (48.15%) was significantly greater than that observed in the other two 
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According to previous reports, there seems to be a very high frequency for the CYP2C19*2 
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of the Puerto Rican population. The reported CYP2C19*3 allele frequencies of 5% for sector 
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Additionally, in sector 3 the allele frequency was 54.2% (12 heterozygous and 7 double 
carriers), which is by far a higher prevalence versus the HapMap allele frequency of 27.9% 
for the Nigerian YRI population or the 23.4% in Africans of the 1,000 Genomes Phase I 
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to compare each sector to the overall allelic ratios, revealed that sector 3 (right-most portion 
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that was only marginally different than the rest of the population (p=0.047). 
Greater admixture and heterogeneity in the Puerto Rican population as compared to the 
African-American population or certainly the Yoruba population allow for the presence of 
the twenty-six PON1 variant allele observed in the twenty-four individuals in sector 3 
(Figure 1-Panel B) to have come from partial Amerindian ancestry, as no individual in that 
sector was of purely West-African descent (Ruaño et al., 2009). The observed trends may 
also be an artifact of chance given the relatively small sample size. No statistically significant 
deviations from HWE were found with respect to the distribution frequencies of either 
PON1 or CYP2C19 polymorphisms. Since no departures from HWE were observed and 
considering that our study cohort is island-wide, chosen by a controlled, stratified-by-
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region, representative sampling from the Puerto Rican population, we can expect the 
observed frequencies of the PON1 and CYP2C19 polymorphisms to be representative for the 
rest of this population. 
4. Discussion 
In this work, we examined two clinically relevant CYP2C19 gene polymorphisms (i.e., 
CYP2C19*2 and CYP2C19*3) and the emerging PON1 variant in a representative sample of 
the Puerto Rican population. Our findings suggest a significant burden of loss-of-function 
CYP2C19 and PON1 carriers within the Puerto Rican population. Based on observed 
prevalence of functional CYP2C19 and PON1 polymorphisms in Puerto Ricans, and the 
postulated role of the enzymes encoded by these genes in the clopidogrel activation 
(Bouman et al., 2011; Mega et al., 2009; Shuldiner et al., 2009), we hypothesized that about 
30-40% of Puerto Ricans may be non-responders to clopidogrel and such resistant patients 
may be at particular risk for short-term thrombo-ischemic complications including 
periprocedural infarction and early stent thrombosis. 
Because thromboembolism is a major risk of cardiovascular disease, genotyping for 
clopidogrel’s response-associated gene CYP2C19, and PON1 to a lesser extent, have been 
advanced as desirable in Caucasians to improve patient’s clinical outcomes (Bouman et al., 
2011; Holmes et al., 2010; Hulot et al., 2010; Mega et al., 2009; Shuldiner et al., 2009). 
However, heterogeneity and admixture may preclude their full application in other 
populations such as Puerto Ricans. Accordingly, there is an urgent need for ascertaining 
admixture adjustments that may prove clinically useful in Puerto Ricans and other Hispanic 
groups. Indeed, the richer genetic variation in Puerto Ricans is likely to contribute 
substantially to a wider variation in response to clopidogrel treatment, a component that 
will be missed by traditional studies in homogeneous populations. This addressable 
oversight is of great concern, since it will tend to exacerbate the healthcare disparity already 
experienced by Hispanics in USA. 
The population of the Americas carries a genomic legacy resulting from the continents’ 
native inhabitants, European colonization and African slavery. In those parts of the 
Americas where admixture took hold, the populations manifest the combined 
anthropological heritage in their genomes, lifestyle, diet, and even socioeconomic status. 
Admixture is of great relevance to the clinical application of the pharmacogenetic-guided 
personalized medicine paradigm, but unfortunately these studies have been scarce in Puerto 
Ricans. We have performed pivotal physiogenomic studies on the Puerto Rican population 
by using an array of 384 SNPs in 222 cardio-metabolic and neuro-endocrine genes coding for 
relevant pharmaceutical targets. According to our findings, the Puerto Rican population 
represents different admixtures of 3 major ethno-geographic groups (i.e., Taino-
Amerindians, Iberian-Europeans and West-Africans). Notably, each subject in the study 
population was a ‘genetic mosaic’, with contributions from each of these three clusters, but 
in widely different proportions.  
Consequently, admixture in the Puerto Rican population exists in the form of a continuous 
gradient with varying levels of mixture that results in a rich repertoire of combinatorial 
genotypes for key pharmacological pathways such as the one associated with CYP2C9 and 
PON1 activity in humans. This phenomenon may explain discrepancies between observed 
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and expected genotype and allele frequencies across the three sectors in the genetic distance 
dendrograms (Figure 1-panel A and B), particularly with respect to other homogeneous 
(parental) populations previously characterized through the HapMap, SNP500Cancer and 
1,000 Genomes projects. Moreover, the diversity observed in the genetic structure within 
African populations from varying regions of this continent (Tishkoff et al., 2009) may also 
contribute to explain the higher than expected prevalence of PON1 variant allele at sector 3 
(Figure 1-panel B) in our study population, which is an Afro-Caribbean population, as 
compared to continental Africans like Yoruba from Nigeria (HapMap-YRI). Overall, our 
findings further substantiate the argument for including admixture as a critical covariant in 
predicting clopidogrel response within heterogeneous populations, but also render the 
Puerto Rican population a good resource to develop DNA-guided systems for clinical 
management of thromboembolic disorders, an urgent medical need not only in Hispanics 
but also in the population at large.  
Recently, we provided valuable evidence on the importance of controlling for admixture 
when conducting pharmacogenetic studies of warfarin (Coumadin ) in the Puerto Rican 
population and stressed the argument for incorporating admixture-matching in order to 
probe variations in warfarin response across different stratum within the population 
(Villagra et al., 2010). In this study we postulated that interindividual variations in 
ancestral contributions of Puerto Ricans may help explain the observed poor performance 
and low predictability of DNA-guided warfarin dosing algorithms derived in other 
populations. Admixture introduces distinct levels of population sub-structure or stratum, 
with marked variations in individual ancestry among the members of a particular 
population or ethnic group, depending on the dynamics of the process. Accordingly, any 
extrapolations of clinically relevant pharmacogenetic data from non-admixed to admixed 
groups will be plagued with uncertainty as exemplified by Suarez-Kurtz (Suarez-Kurtz, 
2005). Consequently, the predictive power of previously published DNA-guided 
algorithms for admixed populations like Puerto Ricans is expected to be inaccurate, if not 
inadequate. 
A previous study by Perini and co-workers (Perini et al., 2008) stated that self-reported race, 
using labels defined by skin color as a proxy for ethnicity, was not a reliable indicator of 
effective anticoagulation therapy in admixed Brazilians. What proved useful, instead, was a 
precise knowledge of individual ancestral proportions so as to place the patient on a 
continuum between “black” and “white”. The utility of this model was verified later on a 
separate cohort in the same population (Vargens et al., 2008). To control for possible 
marginal effects of ancestry on drug response, investigators of the GALA and SAGE projects 
included genetic ancestry as an independent variable in the regression model used to test 
association between IL6R SNPs and bronchodilator effect. Interestingly, the mean 
bronchodilator response for the pharmacogenetic interaction increased with increasing 
amounts of Native American ancestry; whereas, the drug response among asthmatic 
patients for the same pharmacogenetic interaction decreased with increasing amounts of 
European ancestry (Corvol et al., 2009). Differences observed among Mexican, Puerto Ricans 
and African-Americans were thus explained by the different proportions of Native 
American and European ancestries in these three ethnically diverse populations. Recently, 
Bryc and co-workers found evidence of a significant sex bias in admixture proportions of 
Hispanics that is consistent with disproportionate contribution of European male and 
Amerindian or African female ancestry to present populations (Bryc et al., 2010). These 
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region, representative sampling from the Puerto Rican population, we can expect the 
observed frequencies of the PON1 and CYP2C19 polymorphisms to be representative for the 
rest of this population. 
4. Discussion 
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CYP2C19*2 and CYP2C19*3) and the emerging PON1 variant in a representative sample of 
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prevalence of functional CYP2C19 and PON1 polymorphisms in Puerto Ricans, and the 
postulated role of the enzymes encoded by these genes in the clopidogrel activation 
(Bouman et al., 2011; Mega et al., 2009; Shuldiner et al., 2009), we hypothesized that about 
30-40% of Puerto Ricans may be non-responders to clopidogrel and such resistant patients 
may be at particular risk for short-term thrombo-ischemic complications including 
periprocedural infarction and early stent thrombosis. 
Because thromboembolism is a major risk of cardiovascular disease, genotyping for 
clopidogrel’s response-associated gene CYP2C19, and PON1 to a lesser extent, have been 
advanced as desirable in Caucasians to improve patient’s clinical outcomes (Bouman et al., 
2011; Holmes et al., 2010; Hulot et al., 2010; Mega et al., 2009; Shuldiner et al., 2009). 
However, heterogeneity and admixture may preclude their full application in other 
populations such as Puerto Ricans. Accordingly, there is an urgent need for ascertaining 
admixture adjustments that may prove clinically useful in Puerto Ricans and other Hispanic 
groups. Indeed, the richer genetic variation in Puerto Ricans is likely to contribute 
substantially to a wider variation in response to clopidogrel treatment, a component that 
will be missed by traditional studies in homogeneous populations. This addressable 
oversight is of great concern, since it will tend to exacerbate the healthcare disparity already 
experienced by Hispanics in USA. 
The population of the Americas carries a genomic legacy resulting from the continents’ 
native inhabitants, European colonization and African slavery. In those parts of the 
Americas where admixture took hold, the populations manifest the combined 
anthropological heritage in their genomes, lifestyle, diet, and even socioeconomic status. 
Admixture is of great relevance to the clinical application of the pharmacogenetic-guided 
personalized medicine paradigm, but unfortunately these studies have been scarce in Puerto 
Ricans. We have performed pivotal physiogenomic studies on the Puerto Rican population 
by using an array of 384 SNPs in 222 cardio-metabolic and neuro-endocrine genes coding for 
relevant pharmaceutical targets. According to our findings, the Puerto Rican population 
represents different admixtures of 3 major ethno-geographic groups (i.e., Taino-
Amerindians, Iberian-Europeans and West-Africans). Notably, each subject in the study 
population was a ‘genetic mosaic’, with contributions from each of these three clusters, but 
in widely different proportions.  
Consequently, admixture in the Puerto Rican population exists in the form of a continuous 
gradient with varying levels of mixture that results in a rich repertoire of combinatorial 
genotypes for key pharmacological pathways such as the one associated with CYP2C9 and 
PON1 activity in humans. This phenomenon may explain discrepancies between observed 
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(Figure 1-panel B) in our study population, which is an Afro-Caribbean population, as 
compared to continental Africans like Yoruba from Nigeria (HapMap-YRI). Overall, our 
findings further substantiate the argument for including admixture as a critical covariant in 
predicting clopidogrel response within heterogeneous populations, but also render the 
Puerto Rican population a good resource to develop DNA-guided systems for clinical 
management of thromboembolic disorders, an urgent medical need not only in Hispanics 
but also in the population at large.  
Recently, we provided valuable evidence on the importance of controlling for admixture 
when conducting pharmacogenetic studies of warfarin (Coumadin ) in the Puerto Rican 
population and stressed the argument for incorporating admixture-matching in order to 
probe variations in warfarin response across different stratum within the population 
(Villagra et al., 2010). In this study we postulated that interindividual variations in 
ancestral contributions of Puerto Ricans may help explain the observed poor performance 
and low predictability of DNA-guided warfarin dosing algorithms derived in other 
populations. Admixture introduces distinct levels of population sub-structure or stratum, 
with marked variations in individual ancestry among the members of a particular 
population or ethnic group, depending on the dynamics of the process. Accordingly, any 
extrapolations of clinically relevant pharmacogenetic data from non-admixed to admixed 
groups will be plagued with uncertainty as exemplified by Suarez-Kurtz (Suarez-Kurtz, 
2005). Consequently, the predictive power of previously published DNA-guided 
algorithms for admixed populations like Puerto Ricans is expected to be inaccurate, if not 
inadequate. 
A previous study by Perini and co-workers (Perini et al., 2008) stated that self-reported race, 
using labels defined by skin color as a proxy for ethnicity, was not a reliable indicator of 
effective anticoagulation therapy in admixed Brazilians. What proved useful, instead, was a 
precise knowledge of individual ancestral proportions so as to place the patient on a 
continuum between “black” and “white”. The utility of this model was verified later on a 
separate cohort in the same population (Vargens et al., 2008). To control for possible 
marginal effects of ancestry on drug response, investigators of the GALA and SAGE projects 
included genetic ancestry as an independent variable in the regression model used to test 
association between IL6R SNPs and bronchodilator effect. Interestingly, the mean 
bronchodilator response for the pharmacogenetic interaction increased with increasing 
amounts of Native American ancestry; whereas, the drug response among asthmatic 
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Bryc and co-workers found evidence of a significant sex bias in admixture proportions of 
Hispanics that is consistent with disproportionate contribution of European male and 
Amerindian or African female ancestry to present populations (Bryc et al., 2010). These 
 
Clinical Applications of Pharmacogenetics 
 
160 
authors also suggested that future genome-wide association studies in Hispanics will 
require correction for local genomic ancestry at a sub-continental scale. 
Population stratification by admixture is a well-known confounder in pharmacogenetic 
association studies of candidate gene to complex traits, including drug response (e.g., 
clopidogrel). In this context, it might be difficult to find a matching control for an individual 
with diverse ethnic origins; therefore, we will be forced to rely on multivariate adjustment 
models. That is, rather than allocate the subject to a single stratum in the analysis, we 
recommend to construct a covariate for each stratum, giving the corresponding ancestral 
proportion derived from our admixture-driven clustering analysis, and then include these 
covariates as adjustment factors in a multiple regression model for clopidogrel association 
studies in Puerto Ricans. In doing so, we will be able to parameterize admixture-derived 
population structure appropriately and account for it as a covariate in the corresponding 
association studies in order to minimize the effect of population stratification.  
We call these covariates “admixture indexes”, which we believe are indispensable to assure 
that pharmacogenetic research can be pursued in Hispanic populations. From a key 
methodological perspective, the wider genetic variation found in our population for these 
markers broaden the reach and enhance the statistical sensitivity of tests for the effects of 
that variation on clopidogrel response. At the same time, the admixture index could become 
indispensable for the globalization of patho- and pharmacogenetic research beyond the 
Americas, to Africa, Asia and Europe, the continents whose populations contributed to the 
admixture in the first place. 
In the context of admixture matching, if a resistant allele is more common in one of the 
ancestral populations, then non-responders to clopidogrel will share a greater level of 
ancestry from that population around the locus as compared with responders. In future 
studies, we expect to generate a detailed admixture map in the Puerto Rican population at 
very high resolution using all 1.2 million SNPs from a total genome (TG) array. Admixture 
studies at this resolution afford delineation of candidate genes for pharmacogenetic traits 
related not only to clopidogrel, but also to other drugs commonly used to treat 
cardiovascular conditions of high prevalence in Hispanics. 
A major advance in healthcare would be a transition from the current empirical approaches 
in drug therapy to a genetically predictive framework for determining the individual 
patient’s response to medicines. Accordingly, an understanding of how human genetic 
diversity and admixture in Hispanics is structured is not only of anthropological 
importance, but also of medical relevance. In addition, it is important to recognize that some 
minority groups in the U.S. (e.g., Hispanics) might be underrepresented in typical clinical 
pharmacogenetic trials with respect to the real impact of these groups on the current U.S. 
population. Because of the heterogeneity and extensive admixture of the Puerto Rican 
population, extrapolation on a global scale of data derived from well-defined ethnic groups 
(i.e., Caucasians) is clearly not applicable to the majority of Puerto Ricans. 
5. Conclusion 
In conclusion, we have established clinical correlations between overall genetic similarities 
and both CYP2C19 and PON1 genotypes in a representative sample of the Puerto Rican 
population. To this purpose, the major CYP2C19 and PON1 polymorphisms were 
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interrogated in 98 genomic DNA specimens using the physiogenomic (PG)-array that also 
inferred population structure and admixture pattern. Individual CYP2C19 and PON1 
genotypes were visually overlaid atop three major sectors of a genetic distance dendrogram 
that was constructed by clustering subjects with similar genetic profiles. Results suggest that 
the observed inter-individual variations in ancestral contributions will have significant 
implications for the way each Puerto Rican responds to antiplatelet therapy with 
clopidogrel. Our findings also provided valuable evidence on the importance of 
parameterizes the population structure in order to account for admixture as a covariate in 
pharmacogenetic association studies for clopidogrel in Hispanic Puerto Ricans. 
Rather than ignoring admixture, pharmacogeneticists should consider it as starting point for 
better understanding the underlying basis of the observed wider variability in drug 
responses among patients of mixed populations. Such understanding provides the 
opportunity to develop strategies for leapfrogging the healthcare standards in these 
populations. 
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authors also suggested that future genome-wide association studies in Hispanics will 
require correction for local genomic ancestry at a sub-continental scale. 
Population stratification by admixture is a well-known confounder in pharmacogenetic 
association studies of candidate gene to complex traits, including drug response (e.g., 
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studies in Puerto Ricans. In doing so, we will be able to parameterize admixture-derived 
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association studies in order to minimize the effect of population stratification.  
We call these covariates “admixture indexes”, which we believe are indispensable to assure 
that pharmacogenetic research can be pursued in Hispanic populations. From a key 
methodological perspective, the wider genetic variation found in our population for these 
markers broaden the reach and enhance the statistical sensitivity of tests for the effects of 
that variation on clopidogrel response. At the same time, the admixture index could become 
indispensable for the globalization of patho- and pharmacogenetic research beyond the 
Americas, to Africa, Asia and Europe, the continents whose populations contributed to the 
admixture in the first place. 
In the context of admixture matching, if a resistant allele is more common in one of the 
ancestral populations, then non-responders to clopidogrel will share a greater level of 
ancestry from that population around the locus as compared with responders. In future 
studies, we expect to generate a detailed admixture map in the Puerto Rican population at 
very high resolution using all 1.2 million SNPs from a total genome (TG) array. Admixture 
studies at this resolution afford delineation of candidate genes for pharmacogenetic traits 
related not only to clopidogrel, but also to other drugs commonly used to treat 
cardiovascular conditions of high prevalence in Hispanics. 
A major advance in healthcare would be a transition from the current empirical approaches 
in drug therapy to a genetically predictive framework for determining the individual 
patient’s response to medicines. Accordingly, an understanding of how human genetic 
diversity and admixture in Hispanics is structured is not only of anthropological 
importance, but also of medical relevance. In addition, it is important to recognize that some 
minority groups in the U.S. (e.g., Hispanics) might be underrepresented in typical clinical 
pharmacogenetic trials with respect to the real impact of these groups on the current U.S. 
population. Because of the heterogeneity and extensive admixture of the Puerto Rican 
population, extrapolation on a global scale of data derived from well-defined ethnic groups 
(i.e., Caucasians) is clearly not applicable to the majority of Puerto Ricans. 
5. Conclusion 
In conclusion, we have established clinical correlations between overall genetic similarities 
and both CYP2C19 and PON1 genotypes in a representative sample of the Puerto Rican 
population. To this purpose, the major CYP2C19 and PON1 polymorphisms were 
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interrogated in 98 genomic DNA specimens using the physiogenomic (PG)-array that also 
inferred population structure and admixture pattern. Individual CYP2C19 and PON1 
genotypes were visually overlaid atop three major sectors of a genetic distance dendrogram 
that was constructed by clustering subjects with similar genetic profiles. Results suggest that 
the observed inter-individual variations in ancestral contributions will have significant 
implications for the way each Puerto Rican responds to antiplatelet therapy with 
clopidogrel. Our findings also provided valuable evidence on the importance of 
parameterizes the population structure in order to account for admixture as a covariate in 
pharmacogenetic association studies for clopidogrel in Hispanic Puerto Ricans. 
Rather than ignoring admixture, pharmacogeneticists should consider it as starting point for 
better understanding the underlying basis of the observed wider variability in drug 
responses among patients of mixed populations. Such understanding provides the 
opportunity to develop strategies for leapfrogging the healthcare standards in these 
populations. 
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1. Introduction  
According to the World Health Organization (WHO), by 2020 depression is expected to rise to 
the number two contributor to global burden of disease (WHO, 2005). However according to 
recent reports, depression comprises the most costly brain disorder in Europe, accounting 
for 33% of the total cost that corresponds to about 1% of the European gross domestic 
product (GDP) (Sobocki et al., 2006). Despite the fact that our knowledge regarding the 
pathophysiology and the neurobiological substrate of depression has grown exponentially 
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to the first course of therapy and among responders less than half either reach remission or 
become free of symptoms (Rosenzweig-Lipson et al., 2007). Thus, the need for more effective 
pharmacotherapies to combat depression is an ever-growing concern due to the enormous 
societal and financial ramifications of these disorders.  
The present chapter focuses on current advances in the field of pharmacogenetics of major 
depression under the prism of sex differences. In order to treat depression, a personalized 
approach including better-targeted therapies may be needed. Understanding sex differences 
in response to antidepressant medications is a major step towards this direction. 
2. Sex differences in major depression  
Major depression occurs more frequently in women than in men. Despite the fact that the 
aetiology behind this sex difference is still elusive, scientists agree that it possibly reflects 
a complex genetic, hormonal, biochemical and social interplay. Prior to puberty, no 
significant differences are detected regarding the precipitation of depressive 
symptomatology between the male and the female sex (Kuehner, 2003), whereas during 
the reproductive period women appear to experience major depression at roughly twice 
the rate of men (Marcus et al., 2005; Grigoriadis & Robinson, 2007; Pitychoutis & 
Papadopoulou-Daifoti, 2010). Of note, an increasing amount of data suggests that 
associations between stressful interpersonal events and depression are stronger in women 
than in men (Oldehinkel & Bouma, 2011).  
Interestingly, in depression, a sex-specific symptom pattern may occur. According to some 
reports men seem to lose more weight while women tend to report more appetite and 
weight increase, accompanied by hypochondriasis and somatic concerns (Young et al., 1990; 
Kornstein et al., 2000b). More recently, Marcus et al. (2005) analyzed data from the STAR*D 
(Sequenced Treatment Alternatives to Relieve Depression) multicenter trial; in this sample 
women reported an earlier onset of the first major depressive episode, as well as a trend 
towards a greater length of the current episode. In the same study, alcohol and drug 
dependence were more common in men. Importantly, even though women reported greater 
likelihood of having attempted a suicide in the past, men were characterized by greater 
psychomotor agitation and suicidal ideation (Marcus et al., 2005).   
Even though these statistics have been partly attributed to the fact that women are more 
likely to seek psychiatric assistance in view of a negative affective status and to be over-
diagnosed with major depression compared to men (Grigoriadis & Robinson, 2007), 
nowadays there is enough evidence for sex-differentiated biological pathways in affective 
disorders. Notably, a variety of serotonergic sexual dimorphisms have been hypothesized to 
confer increased vulnerability of females to depression. In this context, whole brain 5-HT 
synthesis and 5-HT2 receptor binding have been reported to be lower in several regions of 
the female brain (for review see Rubinow et al., 1998). 
3. Sex differences in antidepressant response: Insights from the clinic and 
from animal models of depression 
Converging albeit inconclusive evidence support the existence of a sex-differentiated 
responsiveness to antidepressant drugs (Dalla et al., 2011; Sloan & Kornstein, 2003; Marcus et 
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al., 2005). Indeed, earlier studies reported that women presented a slower response to 
tricyclic antidepressants (TCAs) (Prange et al., 1969), while also being less likely to achieve 
remission (Glassman et al., 1977). In an intriguing study conducted in a sample of 235 male 
and 400 female depressed outpatients, women were more likely to show a favourable 
response to the SSRI sertraline than to the TCA imipramine, while the opposite association 
seemed to hold true for men (Kornstein et al., 2000a). This sex-differentiated interplay was 
also accompanied by a sex-based adverse effect profile; while depressed men treated with 
imipramine reported sexual dysfunction, urinary frequency and dyspepsia at a higher 
percentage, depressed women treated with sertraline complained more frequently about 
nausea and dizziness (Kornstein et al., 2000a). The STAR*D is the largest study of major 
depression ever conducted in the US and the largest to address sex differences in 
prospective treatment using a representative sample of 2,876 treatment-seeking depressed 
patients (Rush et al., 2004; Young et al., 2009). Using data from this study, Young et al. (2009)  
reported that women that received the SSRI citalopram for 12-14 weeks presented 33% 
greater likelihood of remission as compared to male depressed patients (Young et al., 2009). 
Importantly, this sex difference was attributed to sex-specific biological differences in the 
serotonergic system (Young et al., 2009). However, it should be noted that other studies have 
not detected sex-related effects of antidepressants in humans. For instance, Quitkin et al. 
(2002) found no significant difference in response to the SSRI fluoxetine in a sample of 840 
outpatients. In another study, Thiels et al. (2005) did not report a significant difference in 
response to 6-month treatment with the SSRI sertraline. Therefore, the clinical significance of 
these findings still remains controversial (Quitkin et al., 2002; Hildebrandt et al., 2003; Thiels 
et al., 2005).  
Sex differences in response to antidepressant pharmacotherapy have been largely attributed 
to the sex-differentiated pharmacokinetic disposition of psychotropic agents. Studies in 
humans and in laboratory animals have shown that females are characterized by increased 
levels of hepatic cytochrome P450 (CYP) 3A. Thus, it has been suggested that over-
expression of CYP3A, may modulate the effectiveness of drugs in women (Paine et al., 2005; 
Waxman & Holloway, 2009). Moreover, the estrogen-altering oral contraceptives and 
hormonal replacement therapies may ultimately influence the pharmacokinetic disposition 
of antidepressants (Yonkers et al., 1992; Hildebrandt et al., 2003). Despite the fact that 
available pharmacokinetic evidence indicates that women should perhaps receive lower 
doses of antidepressants as compared to men, current guidelines do not suggest that men 
and women should be dosed in a sex-based manner (Kokras et al., 2011).  
The clinical finding of a sex-differentiated antidepressant response has also been validated 
in preclinical research (Dalla et al., 2010; 2011). For instance, in a most recent study we 
reported that male rats may benefit to a greater extent when treated chronically with the 
TCA clomipramine (Pitychoutis et al. 2011). We further revealed that individual differences 
in response to novelty may predict differential responsiveness to clomipramine treatment 
and are associated with qualitative and quantitative sex-related behavioral and 
neurochemical alterations (Pitychoutis et al. 2011). Further, clomipramine treatment may 
induce sex-differentiated effects on cellular immunoreactivity in the chronic mild stress 
(CMS) model of depression, with female rats presenting a relatively immunosuppressed 
phenotype as compared to males (Pitychoutis et al., 2009; Pitychoutis et al., 2010b). 
Moreover, 2 weeks of clomipramine treatment in the Flinders Sensitive Line (FSL) rats, a 
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putative genetic model of depression, induced sex-related effects on behavioral despair, as 
assessed in the forced swim test (FST), that were accompanied by sexually dimorphic 
serotonergic alterations in several limbic brain regions (Kokras et al., 2009).  
4. Sex differences in the pharmacogenetics of antidepressants 
Pharmacogenetics investigates how genes influence responsiveness to drugs, both in terms 
of efficacy and adverse effects. The ultimate goal of this scientific field is to provide “tailor-
made” pharmacotherapies based on the genetic constitution of the individual. Importantly, 
genetic prediction of antidepressant response has the potential to facilitate an informed 
choice of agent and a patient-tailored dose in order for response rates to be significantly 
improved and adverse effects to be alleviated.  
Recent pharmacogenetic research on the impact of sex on antidepressant treatment has 
focused mostly on SSRIs, because these drugs represent the first-choice of pharmacological 
intervention for the treatment of major depression worldwide. Given that not all patients 
respond sufficiently to the initial treatment with an SSRI, non-response has been associated 
with individual differences in pharmacodynamic processes and in this context has been 
partly attributed to the polymorphic nature of certain genes related to the metabolism of 
monoamines, to the serotonergic and other neurobiological systems (Steimer et al., 2001). 
Multiple genes influencing central monoaminergic neurotransmission have served as targets 
of vast pharmacogenetic screening. Among these are the rate-limiting enzyme of 5-HT 
biosynthesis, tryptophan hydroxylase 1 & 2 (TPH1 & TPH2), inactivation enzymes 
monoamine oxidases A & B (MAO-A; MAO-B) and catechol-O-methyl-transferase (COMT), 
as well as 5-HT’s protein-targets, such as the 5-HT1A receptor (Drago et al., 2009). In humans, 
there are two distinct TPH genes located on chromosomes 11 and 12, coding for two 
different homologous enzymes, with TPH2 being the predominant isoform in the CNS 
(Walther & Bader, 2003).  
Therefore, sedulous research on whether/which DNA polymorphisms are somehow 
involved in SSRI responsiveness and if these vary between the two sexes, is of great 
importance for improving the clinical care of depressed patients. 
4.1 Genes related to the metabolism of monoamines 
Three monoamine-related genes have been associated to date with a sex-dependent 
antidepressant response (Table 1). The MAO-A gene is located on the X chromosome in 
humans, is expressed on the outer mitochondrial membrane where it catabolizes the 
intraneuronal deamination of dopamine (DA), norepinephrine (NA), and 5-HT. A prominent 
variable number tandem repeat (VNTR) polymorphism consists of a 30 base pair repeated 
sequence present in 2, 3, 3.5, 4, or 5 repeats (R) at 1.2 kb upstream of the MAO-A gene and 
affects its enzymatic activity. Specifically, the 3.5R and 4R alleles transcribe 2–10 times more 
efficiently as compared to 2, 3, or 5R alleles (Muller et al., 2002; Drago et al., 2009). This 
polymorphism has been associated with the response rates of depressed women to the SSRI 
fluoxetine in a Chinese patient cohort. According to this study, women carriers of the shorter 
3R-allele (low-transcribers of the MAO-A gene) responded better to 4-week fluoxetine 
treatment as compared to the longer 4R-allele carriers (high-transcribers of the MAO-A gene) 
(Yu et al., 2005). Notably, no such association was observed among the male population 
included in this study. Similar findings were observed in a cohort of Caucasian depressed 
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patients, who were treated with various antidepressant drugs (Domschke et al., 2008b). Again, 
the longer MAO-A alleles were associated with a greater risk of slower and less efficient 
response in a sex-specific context (i.e. in female patients only). Noteworthy, other studies have 
failed to detect any effect of this variant on pharmacoresponse in major depression (Cusin et 
al., 2002; Muller et al., 2002; Peters et al., 2004). A second MAO-A polymorphism (T941G) has 
been reported to affect treatment response to mirtazapine in a sex-specific manner. 
Mirtazapine-treated depressed women homozygous for the T-allele showed a faster and better 
response compared to patients carrying the TG or GG genotype, while in men no association 
was observed (Tadic et al., 2007a). Another study provided evidence regarding the implication 
of the functional A644G SNP within intron 13 of the MAO-B gene, in the outcome of treatment 
with paroxetine only in women with major depression (Tadic et al., 2007b). The 
aforementioned associations may not be unrelated to the fact that the genes encoding MAO-A 
and MAO-B are located on the short arm of the X chromosome (Yu et al., 2005). 
 
 
GENE GENETIC VARIATION DRUG RESULT REFERENCE 
MAO-A 30 bp VNTR (promoter) fluoxetine 
Women with the "shorter" 
3R/3R genotype responded 
better to fluoxetine treatment 
as compared to those with the 
"longer" 4R allele 
Yu et al., 2005 







In women, the "longer" alleles 
were associated with slower 
and less efficient response to 
antidepressant treatment 








Women homozygous for 
the T-allele presented faster 
and 
better response to 
antidepressant treatment as 
compared to TG/GG-patients 
Tadi  et al., 
2007a 
MAO-B A644G (intron 13) 
mirtazapine or 
paroxetine 
Women homozygous for the A-
allele showed a clinically 
meaningful faster and more 
pronounced response to 
treatment with paroxetine  
Tadi  et al., 
2007b 
COMT G472A (Val158Met) fluoxetine 
In men, the Val/Val genotype 
was associated with poorer 
response to antidepressant 
treatment  
Tsai et al., 2009 
Table 1. Sex differences in genetic variants implicated in the metabolism of monoamines. 
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Depressive symptomatology can be alleviated by SSRI treatment, partly due to the 
enhancement of the serotonergic tone that in turn enhances dopamine outflow in the reward 
system of the brain (Naranjo et al., 2001). Given that the COMT enzyme degrades DA, it 
represents a promising candidate for pharmacogenetics screening. A functional SNP 
(G472A) that causes a substitution of Valine to Methionine in codon 158 (Val158Met) of the 
COMT gene results in a three- to four-fold decrement of the enzymatic activity of the 
membrane-bound isoform (Lachman et al., 1996). Notably, a recent study by Tsai and 
colleagues (2009) conducted in Chinese depressed patients treated with fluoxetine revealed 
a sex-dependent association of the COMTVal/Val genotype with poorer antidepressant 
response, but only in male patients (Tsai et al., 2009). 
4.2 Genes specific to serotonergic neurotransmission 
A battery of pharmacogenetic studies have focused on genetic variations of the 5-HT 
transporter (SLC6A4; 5-HTT) gene that is located on chromosome 17 in humans (Table 2; 
Drago et al., 2009). Perhaps the most interesting is the functional polymorphism on the 
promoter of the 5-HTT gene, known as 5-HTT gene-linked polymorphic region (5-HTTLPR) 
that consists of 16 imperfect 22 base pair repeats. The polymorphic nature of this site regards 
the relative presence/absence of two of the repeats. Thus, their absence produces a shorter 
allele (S), whereas their presence produces a 44 base-pair longer allele (L). According to this 
“bi-allelic scheme”, carriers of the L-allele are characterized by an enhanced expression rate of 
the 5-HTT, with the opposite holding true for the carriers of the S-allele. Most importantly, it 
has been hypothesized that L-allele carriers may benefit to a greater extent from 
antidepressant treatment. This notion has been attributed to a generalized responsiveness of 
the serotonergic system owing to the enhanced expression/activity of 5-HTT (Serretti et al., 
2007). Notably, the 5-HT1A receptor transcription rate is modulated by a variation (C1019G) 
in the upstream regulatory region of this gene. Indeed, the C-allele appears to be associated 
with the down-regulation of 5-HT1A receptor that may explain the better response rates to 
chronic antidepressant treatment (Parsey et al., 2006; Drago et al., 2009).  
A recent study by Smits et al. (2008) screened the 5-HTTLPR polymorphism of the 5-HTT 
gene for associations with non-responsiveness to SSRI treatment (Smits et al., 2008). 
According to these results, the response of male patients of a Caucasian cohort to SSRI 
treatment was independent of the studied polymorphisms in the 5-HTT locus, whereas in 
women the 5-HTLPR S-allele was associated with a less favorable response to treatment. 
These findings replicated in part an earlier study showing that paroxetine efficacy in 
patients with panic disorder was lower in women with the SS genotype compared to 
women carrying the L-allele (Perna et al., 2005). Another  study lent further support and 
extended the aforementioned associations; in depressed patients 4-week treatment with 
either SSRIs or non-SSRI drugs, the S-allele was associated with lower antidepressant 
efficacy in depressed women but not in men, with this result being significant for both types 
of medication (Gressier et al., 2009). Importantly, in a follow-up study the same group 
reported that depressed women with the SS genotype responded poorly to antidepressant 
treatment as compared to women with LL/LS genotype, whereas no significant difference 
was detected in men (Gressier et al. 2011). Moreover, in the same study, the S-allele was 
associated with elevated concentrations of thyroid stimulating hormone (TSH) levels in 
depressed women, thus underlining the important interaction among sex, thyroid function 
and the serotonergic system (Gressier et al. 2011) 
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A study by Yu et al. (2006) further supported the impact of sex in the prediction of the 
effectiveness of SSRI treatment (Yu et al., 2006). These authors reported that the C/C 
genotype of the C1019G polymorphism of the 5-HT1A receptor gene may be considered a 
sex-specific factor for the prediction of a beneficial outcome with fluoxetine treatment, only 
in female patients of a Chinese cohort. 
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4.3 Genes related to other neurobiological systems 
Genetic variants associated with other neurobiological systems have also been implicated in 
patients’ response to antidepressant agents (Table 3). For instance, the angiotensin I 
converting enzyme (ACE) gene is expressed in the brain where it degrades several 
neuropeptides, such as substance P (Skidgel & Erdos, 1987). The latter, has been strongly 
implicated in the neurobiology of major depression, while antagonists for this neuropeptide 
have been reported to significantly improve depressive symptoms (Kramer et al., 1998; Nutt, 
1998). Research on an insertion/deletion (I/D) polymorphism, represented by the 
presence/absence of a 287 base pair region within the ACE gene has indicated that the D-
allele was associated with faster onset of antidepressant therapy (i.e. SSRIs, TCAs etc), but 
only in female depressed patients (Baghai et al., 2004).  
Preclinical research in animal models implicates the endocannabinoid system both in the 
pathogenesis of major depression and anxiety, as well as in the mediation of antidepressant 
response (Martin et al., 2002). In a study conducted in a Caucasian cohort of depressed 
patients receiving various antidepressant medications, the G-allele of a synonymous 
polymorphism (G1359A) of the cannabinoid receptor CB1 (CNR1) gene was shown to confer 
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a greater risk for resistance to antidepressant treatment, especially in depressed women with 
high comorbid anxiety (Domschke et al., 2008a).  
Galanin (GAL) is a 30-aminoacid estrogen-inducible neuropeptide that derives from 
preprogalanin (PPGAL) (Evans & Shine, 1991). GAL is highly expressed in brain regions 
involved in the regulation of anxiety and depression (Kuteeva et al., 2008). In a recent study 
Unschuld et al. (2010) reported a female-specific association of symptom severity in 
premenopausal depressed women with the rare allele of the PPGAL SNP rs948854. In 
particular, premenopausal depressed women carriers of the G-allele of rs948854, presented 
more severe vegetative but not cognitive depressive symptomatology at discharge and 
worse response to antidepressant medication (Unschuld et al. 2010). According to the 
authors, these results may be related to the existence of several estrogen-response elements 
(ERE) in the promoter region of the PPGAL gene that have been held responsible for the 
estrogenic regulation of GAL expression (Unschuld et al. 2010; Kaplan et al., 1988; Howard et 
al., 1997). 
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Table 3. Sex differences in genetic variants that are associated with other neurobiological 
systems. 
4.4 Pharmacokinetics genes 
Sex differences in antidepressant response have largely been attributed to sex-differentiated 
pharmacokinetic disposition of psychotropic agents. This notion is supported by the fact 
that hormonal fluctuations during the menstrual cycle may affect the pharmacokinetics of 
psychotropic medications (Hildebrandt et al., 2003). Importantly, cytochrome P450 (CYP)-
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3A4, CYP2D6, CYP2C19 and CYP1A2 are important for the metabolism of antidepressant 
drugs (Staddon et al., 2002). Genetic polymorphisms in these CYP genes may account for 
inter-individual pharmacokinetic disposition of psychotropic medications. However, it is 
still not known whether these actually have the same effect in both sexes (Kokras et al., 
2011). Although sex differences in the pharmacokinetics of antidepressants have been 
shown to affect response, the clinical relevance of this sex-differentiated response remains to 
be elucidated (Meibohm et al., 2002; Kokras et al., 2011). 
Notably, sex differences in human CYP-catalyzed drug metabolism are well-documented; 
for instance CYP3A4, the predominant CYP catalyst of oxidative metabolism in human liver, 
is expressed at a higher protein and mRNA levels in women versus men (Waxman & 
Holloway, 2009). Moreover, sex-differentiated genetic markers of CYP3A4 activity and 
expression have recently been reported in human liver microsomes (Schirmer et al., 2007). 
Of note, it is still not clear if sex influences CYP2C19 and CYP2D6 activity in a clinically 
meaningful way in humans (Scandlyn et al., 2008; Borobia et al., 2009). A recent study 
reported that both the CYP2D6 genotype and sex influenced the disposition of mirtazapine 
in a Spanish cohort of healthy volunteers; however, a sex x genotype interaction was not 
detected (Borobia et al., 2009). In support of the aforementioned findings, CYP2C19 and 
CYP2D6 polymorphisms were also shown to affect the disposition of citalopram similarly in 
men and women (Fudio et al. 2010).  
5. Epimyth and future challenges  
The studies reported herein tentatively indicate that variants in genes pertaining to a 
multitude of central processes may affect antidepressant response in a sex-dependent 
fashion. Among these are genes modulating the brain’s monoaminergic systems (e.g. 5-HTT, 
5-HT1A receptor and MAO-A) or even genes related to other fundamental neuromodulatory 
processes (e.g. ACE and GAL). These differences may stem from the complex crosstalk 
between sex hormones and genes modulating the monoaminergic systems by modifying 
gene expression or even epigenetic processes (Petronis, 2001; Damberg, 2005).  
It is widely accepted that there is a substantial inter-individual variation in response to 
antidepressant drugs. Research on the pharmacogenetics of antidepressants aims to identify 
genetic variants implicated in antidepressant response, in order to both serve as predictor of 
the outcome and to decipher their complex mechanism of action. However, as noted in 
recent reviews on this subject-matter, despite the initial enthusiasm, the lack of consistent 
findings regarding genes regulating pharmacokinetic and pharmacodynamic processes has 
been frustrating (Keers & Aitchison, 2011). Notably, it is believed that the few phar-
macogenetic associations that have been replicated explain only a small fraction of 
individual differences in response to antidepressant pharmacotherapies (Uher et al., 2010). 
Still, when novel genetic targets were screened the results appeared to be modest and point 
to the notion that the genetic control of responsiveness to antidepressants is determined by 
multiple genetic loci (Keers & Aitchison, 2011). 
To this direction, genome-wide association studies (GWAS) have revealed novel genetic 
variants and regulatory intergenic sequences that may be very important to the mechanism 
of action of antidepressant drugs. In the Genome-Based Therapeutic Drugs for Depression 
(GENDEP) project, previously unexpected genes related to neurogenetic and immune 
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3A4, CYP2D6, CYP2C19 and CYP1A2 are important for the metabolism of antidepressant 
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inter-individual pharmacokinetic disposition of psychotropic medications. However, it is 
still not known whether these actually have the same effect in both sexes (Kokras et al., 
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shown to affect response, the clinical relevance of this sex-differentiated response remains to 
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for instance CYP3A4, the predominant CYP catalyst of oxidative metabolism in human liver, 
is expressed at a higher protein and mRNA levels in women versus men (Waxman & 
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gene expression or even epigenetic processes (Petronis, 2001; Damberg, 2005).  
It is widely accepted that there is a substantial inter-individual variation in response to 
antidepressant drugs. Research on the pharmacogenetics of antidepressants aims to identify 
genetic variants implicated in antidepressant response, in order to both serve as predictor of 
the outcome and to decipher their complex mechanism of action. However, as noted in 
recent reviews on this subject-matter, despite the initial enthusiasm, the lack of consistent 
findings regarding genes regulating pharmacokinetic and pharmacodynamic processes has 
been frustrating (Keers & Aitchison, 2011). Notably, it is believed that the few phar-
macogenetic associations that have been replicated explain only a small fraction of 
individual differences in response to antidepressant pharmacotherapies (Uher et al., 2010). 
Still, when novel genetic targets were screened the results appeared to be modest and point 
to the notion that the genetic control of responsiveness to antidepressants is determined by 
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variants and regulatory intergenic sequences that may be very important to the mechanism 
of action of antidepressant drugs. In the Genome-Based Therapeutic Drugs for Depression 
(GENDEP) project, previously unexpected genes related to neurogenetic and immune 
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processes implicated in the pathophysiology of depression, appeared to serve as potent 
predictors of antidepressant response in patients treated for 12 weeks with escitalopram 
(SSRI; N=394) or nortriptyline (TCA; N=312) (Uher et al., 2010). Pharmacogenomic analyses 
revealed a significant association between the uronyl 2-sulphotransferase (UST) gene and 
response to nortriptyline. On the other hand, response to escitalopram was predicted by a 
marker in the gene encoding interleukin-11 (IL-11), with this being further supported by a 
less robust association in the IL-6 gene (Uher et al., 2010). In another GWAS study, Garriock 
et al. (2010) used the STAR*D sample in order to determine which DNA variations 
influenced response to citalopram treatment and also implicated novel genes in the 
mechanism of action of SSRIs (Garriock et al., 2010). Despite the significance of these studies 
in the field, the role of sex was not determined.  
Overall, despite the promising advances in this field, pharmacogenetics-driven, 
personalized antidepressant pharmacotherapies are still far from being introduced into the 
clinical practice (Drago et al., 2009). Although it is still early for firm conclusions, the 
currently available evidence seems to suggest that an intriguing genetic x sex interplay may 
be associated with the differential responsiveness that the two sexes exhibit upon 
antidepressant treatment. Therefore, a profound analysis of the role of sex in the 
pharmacogenetics of depression is considered imperative in order for the clinical 
significance of this interaction to be determined.  
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processes implicated in the pathophysiology of depression, appeared to serve as potent 
predictors of antidepressant response in patients treated for 12 weeks with escitalopram 
(SSRI; N=394) or nortriptyline (TCA; N=312) (Uher et al., 2010). Pharmacogenomic analyses 
revealed a significant association between the uronyl 2-sulphotransferase (UST) gene and 
response to nortriptyline. On the other hand, response to escitalopram was predicted by a 
marker in the gene encoding interleukin-11 (IL-11), with this being further supported by a 
less robust association in the IL-6 gene (Uher et al., 2010). In another GWAS study, Garriock 
et al. (2010) used the STAR*D sample in order to determine which DNA variations 
influenced response to citalopram treatment and also implicated novel genes in the 
mechanism of action of SSRIs (Garriock et al., 2010). Despite the significance of these studies 
in the field, the role of sex was not determined.  
Overall, despite the promising advances in this field, pharmacogenetics-driven, 
personalized antidepressant pharmacotherapies are still far from being introduced into the 
clinical practice (Drago et al., 2009). Although it is still early for firm conclusions, the 
currently available evidence seems to suggest that an intriguing genetic x sex interplay may 
be associated with the differential responsiveness that the two sexes exhibit upon 
antidepressant treatment. Therefore, a profound analysis of the role of sex in the 
pharmacogenetics of depression is considered imperative in order for the clinical 
significance of this interaction to be determined.  
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1. Introduction  
Pharmacogenetics uses genetic information to help adjusting treatment for individual 
patients. It improves efficacy of therapy and enables avoiding side effects basing on 
genetic knowledge. Different asthmatic patients with similar disease severity, who are 
treated with the same medication, may respond to the therapy differently. After excluding 
non-genetic causes of such variability (like patient’s compliance, environmental and 
psychological factors), the most possible reason for the variability appears to be a 
different genetic structure. Changes in gene structure resulting in inter-individual 
dissimilarities, occur mostly as single nucleotide polymorphism (SNP). Different 
strategies play a role in searching and identifying SNPs, that influence pathogenesis of 
asthma and its response to treatment, (Kazani et al., 2010). One of the strategies involved 
is candidate gene studying, that focuses on finding genes responsible for therapy 
effectiveness as well as asthma development and its clinical severity (Moffatt & Cookson, 
1997). Pharmacogenetics of asthma concentrates on genes coding: drug binding receptors, 
enzymes (important both in drug metabolism and metabolic cycles, eg. arachidonic acid 
cascade), chemokines, cytokines or growth factors relevant to asthma pathogenesis and 
pathophysiology. Genes need to be studied for known SNPs and new variants as well. 
When an SNP is found a thorough check for possible correlation between this 
polymorphism and disease phenotype or treatment response is needed. An expanded 
strategy for searching candidate genes involves screening of genes encoding proteins 
(enzymes) active in metabolic cycles important for drug response or key disease 
pathologies. In asthmatic patients this last method is often used to examine the 
leukotriene pathway in order to elucidate different patient reactions to leukotriene 
modifiers. Other options are genome-wide association studies that analyze genetic 
markers across the entire genome that may be connected with the phenotype. The 
identification of such a marker generated investigation of surrounding genes for SNPs 
related to the phenotype (Kazani et al., 2010). This procedure needs numerous and 
phenotypically well characterised populations and enables examination of the most 
frequent SNPs. There are some fields of medicine where pharmacogenetics is already in 
clinical use but in asthma treatment further investigation is still needed. This chapter 
reviews recent knowledge of pharmacogenetics of drugs commonly used in asthma 
treatment. We focus on bronchodilators, iCS (inhaled corticosteroids) and leukotriene 
modifiers.  
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2. Pharmacogenetics of antiasthmatic medications 
2.1 Pharmacogenetics of 2-agonists 
2-adrenoreceptor ( 2-ADR) agonists are fundamental relief medications and among the 
most important chronic treatments in asthma. These drugs exert their action by activation 
of 2-adrenoreceptors located among others on smooth muscle cells. This results in 
smooth muscle relaxation, airway dilatation and improved airflow. Depending on the 
duration of their action 2-agonistss are divided into two groups: short acting (SABA) and 
long acting 2-agonists (LABA). SABA are used exclusively as rescue medicines. They 
quickly reduce asthma symptoms: wheezing, shortness of breath and coughing. While 
LABA when used on a daily basis in combination with iCS help to improve asthma 
control. The side effects are common for both groups and these are: tachycardia, muscle 
tremble, mild hypokalaemia.  
The 2-adrenoreceptor is a member of the 7-transmembrane domain G-protein coupled 
receptor family. It consists of seven transmembrane spanning domains, 3 extracellular and 3 
intracellular (Fig. 1) (Dixon et al., 1986). Stimulation of 2-adrenoreceptor is G-protein 
dependent and results in activation of the second messenger, the adenylate cyclase. This in 
turn leads to an increase of cAMP level and smooth muscle relaxation. Another mechanism 
resulting from 2-adrenoreceptor stimulation is potassium channels opening by cAMP or 
directly by G-protein (Kowalski & Woszczek, 2002).  
 
Fig. 1. Most common clinically relevant polymorphisms of the 2-adrenoreceptor (Ligget, 1997- 
changed). Black - nucleic acid deviations from wild type not resulting in nucleotide changes. 
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2.1.1 Polymorphisms of the 2-adrenergic receptor 
Examination of the intronless 2-adrenoreceptor gene, which is located on chromosome 
5q31.32 (Kobilka et al., 1987), revealed over 80 SPNs (Weiss et al., 2006). Two of these 
polymorphisms: Arg Gly16 (46A G) and Gln Glu27 (79C G) are the most frequent 
ones (see Figure 1.) (Green et al.,1994, 1995; Lee et al., 2004). Their occurrence results in 
receptor function change, different ligand binding and impaired signal transmission. The 
occurrence of the Gly16 gene variant is higher than that of the wild-type Arg16 and ranges 
between 67% in British asthmatics and 72% in British and American healthy subjects 
(Liggett, 1997; Tan et al., 1997; Lipworth et al., 1999). It has been estimated that the 
homozygous genotype Arg16 appears in 16% Caucasians and 25% Afro-Americans. Studies 
of Xie (Xie, et al., 2001) and co-workers revealed further differences between 2-
adrenoreceptor polymorphisms and ethnic groups. In a study, that examined 415 healthy 
subjects, Glu27 allele were the most frequent in Caucasian-Americans (34.8%). Other groups 
had much lower occurrence of this allele: Afro-Americans (20.7%) and Chinese (7.2%). 
Individuals with homozygous Glu27 genotype were mostly Caucasian-Americans (15.4%). 
This genotype occured only in  4.9% African-Americans and was not observed in Chinese 
subjects (Xie, et al., 2001). Both Gly16 and Glu27 polymorphisms are involved in higher 
agonist promoted receptor down-regulation, moreover, Glu27 is related with a stronger 
desensitization of the receptor (Green et al., 1994, 1995). Another defined polymorphism: 
Thr Ile164 is associated with diminished affinity of 2-agonist to the receptor, decreased 
adenylate cyclase binding and 50% shorter lasting salmeterol (one of the long acting beta2 
agonists) effect (Green et al., 2001).  
2.1.1.1 Correlation between 2-adrenoreceptor gene polymorphism and short acting  
-agonists action 
Short acting -agonists are drugs commonly used in asthma treatment, especially in 
asthma exacerbations or as regular rescue medications. However, they are not 
recommended as regular antiasthmatic drugs. Several studies demonstrated higher FEV1 
increase (forced expiratory volume in the first second, a spirometric parameter used to 
determine the level of airways narrowing) increase after SABA (salbutamol) 
administration in homozygous Arg16 individuals as compared to heterozygous and 
homozygous Gly16 patients with polynosis (Martinez et al., 1997; Woszczek et al., 2005). 
Different results were obtained during asthma exacerbation. Patients who were 
homozygous Arg16 had impaired SABA response compared to homozygous Gly16 
individuals (Carroll et al., 2009). Systematic administration of SABA to Arg16 asthmatics 
caused deterioration of lung function (as evaluated with PEF - peak expiratory flow, 
another parameter used to monitor airway narrowing), that did not stop even with 
treatment discontinuation. In contrast patients homozygous for Gly16 demonstrated 
improved lung function (evaluated by PEF measurement as well) (Israel, 2000, 2004). 
Based on these studies it has been postulated that Arg16 homozygotes may be at higher 
risk during long-term SABA therapy. According to the 2010 updated GINA guidelines  
(Global Initiative for Asthma [GINA], 2010) regular long-term SABA treatment is not 
recommended for any individual. But due to relatively low differences in PEF-worsening 
between the two groups more research is needed to fully elucidate this problem.   
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2. Pharmacogenetics of antiasthmatic medications 
2.1 Pharmacogenetics of 2-agonists 
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smooth muscle relaxation, airway dilatation and improved airflow. Depending on the 
duration of their action 2-agonistss are divided into two groups: short acting (SABA) and 
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dependent and results in activation of the second messenger, the adenylate cyclase. This in 
turn leads to an increase of cAMP level and smooth muscle relaxation. Another mechanism 
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directly by G-protein (Kowalski & Woszczek, 2002).  
 
Fig. 1. Most common clinically relevant polymorphisms of the 2-adrenoreceptor (Ligget, 1997- 
changed). Black - nucleic acid deviations from wild type not resulting in nucleotide changes. 
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2.1.1 Polymorphisms of the 2-adrenergic receptor 
Examination of the intronless 2-adrenoreceptor gene, which is located on chromosome 
5q31.32 (Kobilka et al., 1987), revealed over 80 SPNs (Weiss et al., 2006). Two of these 
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2.1.1.1 Correlation between 2-adrenoreceptor gene polymorphism and short acting  
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Different results were obtained during asthma exacerbation. Patients who were 
homozygous Arg16 had impaired SABA response compared to homozygous Gly16 
individuals (Carroll et al., 2009). Systematic administration of SABA to Arg16 asthmatics 
caused deterioration of lung function (as evaluated with PEF - peak expiratory flow, 
another parameter used to monitor airway narrowing), that did not stop even with 
treatment discontinuation. In contrast patients homozygous for Gly16 demonstrated 
improved lung function (evaluated by PEF measurement as well) (Israel, 2000, 2004). 
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(Global Initiative for Asthma [GINA], 2010) regular long-term SABA treatment is not 
recommended for any individual. But due to relatively low differences in PEF-worsening 
between the two groups more research is needed to fully elucidate this problem.   
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2.1.1.2 Correlation between 2-adrenoreceptor gene polymorphisms and long acting  
-agonists action 
Long acting 2-agonists as opposed to SABA are drugs commonly used in long-term asthma 
therapy. There are several population studies suggesting increased risk of therapy with long 
acting 2-agonists in patients with the Arg16 homozygous genotype. However, no genotype 
is currently considered a direct contraindication for LABA treatment. Some patients treated 
with salmeterol, experienced rare but severe asthma exacerbations (Nelson et al., 2006). 
Further investigation suggested a dependence between Arg16 genotype and faster decline of 
lung parameters (FEV1) after LABA application (Nelson et al., 2006; Wechsler et al., 2006; 
Lee et al., 2004; Palmer et al., 2006). A good example is a study of Wechsler and co-workers 
comparing salmeterol response in individuals with asthma homozygous for arginine 
(Arg16) with glycine homozygous (Gly16) group of patients. Patients were divided in two 
groups . The first group was treated with salmeterol without iCS and the second continued 
iCS therapy while randomized for salmeterol. In both groups Arg16 patients didn’t draw 
benefit from salmeterol therapy comparing to Gly16 patients, which resulted in lower 
morning PEF, increased symptom scores and albuterol rescue use especially in trial without 
iCS. Present asthma treatment guidelines allow use of LABA only together with iCS since it 
has been demonstrated that iCS ameliorate the LABA effect. It is possible that in the future 
patients with Arg16Arg genotype will constitute a group requiring different treatment 
guidelines, but up to date therapeutic indications are uniform irrespective of the patient’s 
genotype.     
2.1.1.3 Correlation between 2-adrenoreceptor gene polymorphisms and asthma 
exacerbations 
It has been proven that exacerbations of asthma during short acting -agonist therapy is 
related to 2-adrenoreceptor gene polymorphisms (Taylor et al., 2000). Recent studies 
reveal, that children and adolescent asthmatics with the Arg16 genotype suffer from asthma 
exacerbations more frequently than the Gly16 subpopulation (OR 2.05, 95% CI 1.19 to 3.53, 
p=0.010). This genotype-exacerbation correlation significantly increases after salmeterol 
treatment (OR 3.40, 95% CI 1.19 to 9.40, p=0.022) (Palmer et al., 2006). Other studies confirm 
the conclusion that risk of asthma exacerbation in the Arg16 group rises with higher doses 
and more frequent use of 2-agonists. Individuals with the Arg16 genotype receiving short- 
or long-acting 2-agonists on everyday basis had significantly higher risk of asthma 
exacerbation (OR 1.64, 95% CI 1.22 to 2.20, p=0.001) than patients with the Arg16 genotype 
taking 2-agonist less than once daily (Basu et al., 2009). According to the LARGE study 
patients with the Gly16 genotype have diminished bronchial  hyperresponsiveness to 
matacholine after adding inhaled corticosteroids (at an average dose 480µg of 
beclomethasone daily) to salmeterol treatment (Wechsler et al., 2009). Arg16 genotype Afro-
Americans have a lower chance for lung function improvement after co-administration of 
LABA and inhaled corticosteroids what may be related to more frequent prevalence of 
Arg16 polymorphism in this population (25%). This can also explain ethnic differences in 
asthma manifestation – more frequent severe asthma occurrence in Afro-Americans. 
According to Liggett (Liggett, SB., 2000) 2-adrenoreceptors in Gly16 subjects are down 
regulated at baseline by exposure to endogenous cathecholamines what explains why 
reaction to exogenous 2-agonists is more evident in Arg16Arg individuals. At the same 
time however, Arg16 patients seem to have higher risk of asthma exacerbation especially 
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during 2-agonist therapy. Despite these differences present guidelines [GINA, BTS (British 
Thoracic Society)] do not recommend checking the patients’ genotype before starting 
therapy. In our opinion LABA-treatment failure should be a recommendation for 2-
adrenoreceptor genotype verification. This may increase both treatment effectiveness and 
safety. More research in this field is needed, however.         
2.2 Pharmacogenetics of leukotriene modifiers 
Leukotrienes are a family of polyunsaturated eicosatetraenoic acids that are derived from 
arachidonic acid in an enzymatic pathway called arachidonic acid cascade (see Figure 2.). In 
this pathway 5-lipoxygenase plays probably the most important role (Dixon et al., 1990). 5-
lipoxygenase (5-LOX) catalyzes the conversion of arachidonic acid to leukotriene-A4 (LTA4) 
(Silverman & Drazen, 1999). All leukotrienes include cysteine and are called cysteinyl 
leukotrienes (with the exception of LTB4). Cysteinyl leukotrienes bind to CysLT1 receptor 
causing among others airway smooth muscle contraction, eosinophilic influx and mucus 
hypersecretion. Another important enzyme in the leukotriene pathway is LTC4 synthase, 
which is responsible for LTA4 to LTC4 conversion. Leukotrienes have been shown to be 
potent pro-inflammatory mediators in asthma pathology (Chanarin & Johnston, 1994). They 
are produced and released by several types of inflammatory cells including eosinophils, 
neutrophils and mast cells.  
 
 
Fig. 2. The lipoxygenase pathway of leukotriene synthesis 
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during 2-agonist therapy. Despite these differences present guidelines [GINA, BTS (British 
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therapy. In our opinion LABA-treatment failure should be a recommendation for 2-
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Fig. 2. The lipoxygenase pathway of leukotriene synthesis 
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Leukotriene modifiers are an important group of drugs in asthma treatment as well as in 
other diseases including allergic rhinitis. Based on their mode of action they can be divided 
into two groups: first – cysteine leukotrienes receptor antagonists (montelukast, zafirlukast, 
pranlukast and tomelukast), second - 5-lipoxygenase inhibitors (zileuton). These drugs show 
strong anti-inflammatory activity, ameliorate asthma clinical course and improve disease 
control with minimal or no side effects. Currently, they are listed in GINA 2010 (GINA, 
2010) guidelines for asthma treatment as number two anti-inflammatory treatment (number 
one are still inhaled steroids), even though not all asthmatic patients benefit substantially 
from anti-leukotriene therapy. Based on the knowledge on leukotriene synthesis pathway, 
studies of genotype dependent therapeutic reactions have used strategies of candidate gene 
screening and examination of SNPs in genes encoding different proteins (enzymes) of the 
arachidonic acid cascade. To date, most investigations of the genetic factors which may 
affect therapy with anti-leukotriene drugs have focused on the 5-LOX enzyme and the LTC4 
synthase. Possible genetic alterations of cysteine leukotriene receptors have also been 
investigated. The following paragraphs discuss the most important pharmacogenetic studies 
presenting major polymorphisms relevant in asthma and allergy as well as their impact on 
drug action. 
2.2.1 Polymorphisms of the 5-lipoxygenase gene 
The 5-LOX gene (ALOX5) is located on chromosome 10q11.12, contains 14 exons and its 
activity is associated with a number of repetitions of Sp1/Erg1 binding motifs in the 
promoter region (Hoshiko et al., 1990; Funk et al., 1989; Silverman et al., 1998). The promoter 
region containing five tandem motifs binding Sp1/Erg1 transcription factors (GGGCGG) is 
known as wild-type allele (Silverman et al., 1998). Polymorphisms of this region result from 
additions or deletions of binding motifs and are called non-wild-type alleles (In et al., 1997; 
Silverman et al., 1998). A polymorphism with one additional Sp1/Erg1 binding motif has 
been found in 35% of both asthmatic and non-asthmatic population (Fenech, A & Hall, IP., 
2002). Further, 3% of the subjects without any copy of a wild-type allele are expected to have 
lower ALOX-5 gene transcription, which leads to reduced enzyme production and finally to 
lower LTA4 levels (Drazen et al., 1999; Kalayci et al., 2003). In consequence, the low level of 
cysteinyl leukotriene does not intensify allergic inflammation in asthma, but patients who 
do not have a wild-type allele, experience only 1% FEV1 improvement after 5-LOX inhibitor 
treatment comparing to wild-type patients (FEV1 improves up to 15-20%) and are 
considered non-responders for this type of therapy (Drazen et al., 1999). The same concerns 
to montelukast treatment (antagonist of cysteine leukotriene receptors): wild-type 
homozygous and heterozygous patients present benefit greatly from treatment (measured 
as FEV1 improvement (Telleria et al., 2008)), while non-wild-type are considered relative-
non-responders. Other studies demonstrated however, that subjects with non-wild-type 
allele(s) treated with montelukast had reduced (73%) risk of asthma exacerbation (Lima et 
al., 2006). Because the role of leukotriene modifiers in asthma control increased significantly 
in the past five years, further studies are necessary to define responders and non-responders 
phenotypes. Defining standards of responding to leukotriene modifier therapy is extremely 
important at least in two subpopulations: in non-wild-type individuals, who in previous 
tudies have not experienced treatment benefit and in patient with steroid resistance or at 
least with partially impaired response to iCS.  
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2.2.2 Polymorphisms of the leukotriene C4 synthase gene (LTC4S) 
LTC4 synthase (LTC4S) belongs to S-glutathione synthases family and is responsible for 
leukotriene A4 and glutathione bonding. This reaction results in leukotriene C4 synthesis. 
LTC4 is a potent contractor of bronchial smooth muscles. The gene for LTC4 synthase is 
located on chromosome 5q35. In the promoter region of this gene several polymorphism 
have been described. One of the most important is substitution of nucleotide A by C in 
position 444 (-444A C). The -444A C SNP results in increased LTC4S gene transcription 
and therefore higher LTC4 level in eosinophils (Sampson et al., 2000; Sanak et al., 2000). This 
variant occurs more often in patients suffering from aspirin induced asthma (in patients 
with aspirin idiosyncrasy in general) (Sanak et al., 1997). Presence of the C nucleotide is also 
related to better response to cysteine leukotriene receptor 1 (LTRA1) blockers. During 
montelukast therapy 80% reduction of asthma exacerbation risk was observed in 
heterozygous individuals with C allele when compared to AA homozygous (Lima et al., 
2006). Similar results were reported from a study in Japan, where patients with moderate, 
well controlled asthma, treated with inhaled corticosteroids, received pranlukast as an add-
on treatment. Again, individuals with the C allele had more pronounced FEV1 
improvement than AA homozygous patients (FEV1 improvement in C allele group 5.3% vs. 
in AA group 2.4%). Heterozygous population also showed higher values of bronchial 
dilatation after salbutamol usage (Asano et al., 2002).  
2.2.3 Polymorphisms of the cysteine leukotriene receptors 1 and 2 genes (CYSTLTR1, 
CYSTLTR2)  
The human CYSLT1 and CYSLT2 receptors have been characterized as G-protein coupled 
receptors (Lynch et al., 1999; Heise et al., 2000). The gene coding for the CYSLT1 receptor is 
located on chromosome X and the CYSTLT2 receptor gene maps to chromosome 13q14 
(Lynch et al., 1999; Heise et al., 2000). Polymorphisms of these genes are studied in relation 
to the probability of asthma development. Previous data suggest however, that 
polymorphisms of CYSTLTR1 and CYSTLTR2 genes play a minor role in the determination 
of asthma severity and clinical symptoms’ expression (alike other genes encoding proteins 
related to leukotriene pathway) (Tantisira & Drazen, 2009). As for now there are no 
unequivocal results concerning polymorphisms of the CYSLT receptor genes in relation to 
anti-leukotriene treatment effects.  
Although zileuton does not directly act through the CYSLT1 receptor, the possible 
correlation between this medication and CYSLT1R polymorphisms was also investigated. 
These studies, including genotype analysis of over five hundred patients treated with 
zileuton did not show any significant correlation between CYSLT1R gene polymorphisms 
and clinical response to therapy (Tantisira et al., 2009).  
2.2.4 Polymorphisms of the ABCC1 gene 
The ABCC1 gene (ATP-binding cassette, subfamily C, member 1) encodes MRP1 (Multiple 
Drug Resistance Protein 1) that takes a part in transmembrane LTC4 transport. This gene is 
located on chromosome 16p13.12 and demonstrates significant heterogeneity (Saito et al., 
2002; van der Deen et al., 2005). One of the polymorphisms of this gene, that was thought to 
be correlated to drug response,  namely rs119774, described by Lima et al. was related to a 
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LTC4 is a potent contractor of bronchial smooth muscles. The gene for LTC4 synthase is 
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significant FEV1 improvement in subjects receiving montelukast for 6 months (Lima et al., 
2006). Heterozygous patients had a 24% FEV1 rise as compared to only a 2% improvement 
in homozygous individuals (Lima et al., 2006). Since there are no further studies of this 
correlation available data are insufficient to have any treatment implications. Again, further 
studies would help to elucidate whether the two phenotypes differ enough to justify 
different treatment regimens.      
2.2.5 Polymorphism of LTA4 hydrolase gene 
Hydrolase LTA4 is an enzyme that converts LTA4 to LTB4. The gene encoding this protein 
is located on chromosome 12q22. One of the known polymorphisms for this gene 
(rs2660845) involves a nucleotide change A->G at intron. Patients, whose genotypes contain 
at least one G allele (heterozygous), when treated with montelukast, have 4-5 higher risk of 
asthma exacerbation when compared to AA homozygous subjects (Lima et al., 2006). The 
pathogenetic mechanism of this phenomenon remains unclear. It has been hypothesized 
that this SNP causes a decreased enzyme activity that results in diminished LTB4 synthesis, 
therefore stimulating the LTC4-synthase pathway and leading to cysteine leukotriene 
synthesis (Lima et al., 2006) (Fig. 2).  
There are big individual differences in response to leukotriene modifiers. All 
polymorphisms listed in paragraph 2.2 contribute to these differences. It remains extremely 
important to determine which patient subpopulation benefit most from the treatment.  
2.2.6 Polymorphisms of the SLCO2B1 gene 
The gene SLCO2B1 (solute carrier organic anion transporter family - 2B1) encodes the 
protein 2B1, that plays an important role in the active transport of organic anions through 
the intestinal wall. Protein 2B1 is thought to be a key transporter of montelukast through the 
intestinal wall. A recently described, common, SLCO2B1 polymorphism, namely rs12422149 
935G A (Arg312Gln), appears to relate to changes in montelukast pharmacokinetics. 
Specifically, individuals with this SNP have a significantly lower serum drug concentration 
(Mougey et al., 2009). So far, there are no data on other possible SLCO2B1 gene 
polymorphisms that could affect montelukast transport or serum level. 
 
Gene  Chromosomal location 
Polymorphisms with potential pharmacogenetic 
consequences during leukotriene modifier therapy  
ALOX5 10q11.12 Promoter Sp1/Egr1binding motif  (G+C rich sequence, i.e. –GGGCGG-) different than 5 sequence repeats, -212 to -88 bp 
LTC4S 5q35 Promoter -444A C 
CYSLTR1 Xq13.2-q21.1 927C T 
ABCC1 16p13.12  rs119774,  G A intron 
LTA4H 12q22 rs2660845, A G intron  
SLCO2B1 11q13 rs12422149 935G A 
Table 1. Genes polymorphisms with potential pharmacogenetic consequences for 
leukotriene modifier therapy  
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Leukotriene modifiers are widely used in asthma treatment and they are orally 
administered which improves patients compliance and therefore efficacy. However, genes 
linked to their metabolism, drug-receptor interactions etc. have not intensively investigated. 
In our opinion, cytochrome P450, that metabolises both groups of leukotriene modifiers 
(especially CYP1A2 and CYP3A4), is a promising target. Studies investigating genetic 
variants of cytochrome P450 enzymes in relation to leukotriene modifiers response are 
necessary to establish possible dosing variations.   
2.3 Pharmacogenetics of inhaled corticosteroids (iCS) 
Corticosteroids are the most important and the most effective medication in asthma therapy. 
They are powerful anti-inflammatory agents in asthma management, mostly being “anti-
eosinophilic”. Although many asthmatics derive therapeutic benefit from inhaled 
corticosteroids, many fail to respond or at least need to be treated with much higher doses. 
Despite iCS being considered a safe treatment, side effects of increased dosage may be 
clinically significant and include: adrenal suppression, osteoporosis, skin changes, cataract, 
and growth retardation in children. There at least two different mechanisms of CS 
resistance, but both are still under investigation. 
Candidate gene studies were used to determine the pharmacogenetics of response to 
inhaled corticosteroids. 
2.3.1 Glucocorticoid receptor 
Corticosteroids exert their action by binding to the glucocorticoid intracellular receptor 
(GR), a nuclear receptor. The GR gene is located on the long arm of chromosome 5 (5q31-32). 
Members of the superfamily of nuclear receptors share a structural pattern containing a 
short central DNA-binding domain, a variable N-terminal domain as well as a C-terminal, 
which is the steroid hormone binding part, and a transcription regulator (Beato et al., 1996; 
Gronemeyer, 1992). There are two different GR isoforms known: one consisting of 777 
(called GR ) and the other of 742 amino acids called GR . These isoforms are created during 
alternative splicing of the GR pre-mRNA (Bamberger et al., 1996). GR  varies from the other 
isoform only in the length of C-terminal domain, which is shorter by five amino acids. This 
results in reduced glucocorticoid binding affinity of the GR  receptor. Both receptors are 
expressed in all human cells, but GR  plays a regulatory role and its concentration is much 
lower than that of GR . Although there is no evidence to support that this polymorphism is 
responsible for reduced responsiveness to GC in clinical practice, this concept has been 
widely discussed and related studies are currently carried out (Brogan et al., 1999; Gagliardo 
et al., 2000; Malmstrom et al., 1999). In the cytoplasm, the glucocorticoid receptor is linked 
with several regulatory proteins, with the heat shock protein (hsp90), p59 immunophilin 
and p23 phosphoprotein being the most important (Smith & Toft, 1993). GR and hsp90 
coupling enables ligand (CS) binding to the receptor and facilitates correct receptor 
“maturation” after synthesis (Smith & Toft, 1993). After CS binding the complex GR/hsp90 
is disunited and activated GR/CS translocates to the nucleus and binds to DNA via the 
central domain consisting of two “zinc fingers”(Mitchell & Tjian, 1989). On the DNA side 
the fragment interacting with GR is called GRE (glucocorticoid response elements). This is 
one of the two mechanisms for CS to stimulate or inhibit transcription and therefore mRNA 
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(rs2660845) involves a nucleotide change A->G at intron. Patients, whose genotypes contain 
at least one G allele (heterozygous), when treated with montelukast, have 4-5 higher risk of 
asthma exacerbation when compared to AA homozygous subjects (Lima et al., 2006). The 
pathogenetic mechanism of this phenomenon remains unclear. It has been hypothesized 
that this SNP causes a decreased enzyme activity that results in diminished LTB4 synthesis, 
therefore stimulating the LTC4-synthase pathway and leading to cysteine leukotriene 
synthesis (Lima et al., 2006) (Fig. 2).  
There are big individual differences in response to leukotriene modifiers. All 
polymorphisms listed in paragraph 2.2 contribute to these differences. It remains extremely 
important to determine which patient subpopulation benefit most from the treatment.  
2.2.6 Polymorphisms of the SLCO2B1 gene 
The gene SLCO2B1 (solute carrier organic anion transporter family - 2B1) encodes the 
protein 2B1, that plays an important role in the active transport of organic anions through 
the intestinal wall. Protein 2B1 is thought to be a key transporter of montelukast through the 
intestinal wall. A recently described, common, SLCO2B1 polymorphism, namely rs12422149 
935G A (Arg312Gln), appears to relate to changes in montelukast pharmacokinetics. 
Specifically, individuals with this SNP have a significantly lower serum drug concentration 
(Mougey et al., 2009). So far, there are no data on other possible SLCO2B1 gene 
polymorphisms that could affect montelukast transport or serum level. 
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linked to their metabolism, drug-receptor interactions etc. have not intensively investigated. 
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(especially CYP1A2 and CYP3A4), is a promising target. Studies investigating genetic 
variants of cytochrome P450 enzymes in relation to leukotriene modifiers response are 
necessary to establish possible dosing variations.   
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corticosteroids, many fail to respond or at least need to be treated with much higher doses. 
Despite iCS being considered a safe treatment, side effects of increased dosage may be 
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and growth retardation in children. There at least two different mechanisms of CS 
resistance, but both are still under investigation. 
Candidate gene studies were used to determine the pharmacogenetics of response to 
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Corticosteroids exert their action by binding to the glucocorticoid intracellular receptor 
(GR), a nuclear receptor. The GR gene is located on the long arm of chromosome 5 (5q31-32). 
Members of the superfamily of nuclear receptors share a structural pattern containing a 
short central DNA-binding domain, a variable N-terminal domain as well as a C-terminal, 
which is the steroid hormone binding part, and a transcription regulator (Beato et al., 1996; 
Gronemeyer, 1992). There are two different GR isoforms known: one consisting of 777 
(called GR ) and the other of 742 amino acids called GR . These isoforms are created during 
alternative splicing of the GR pre-mRNA (Bamberger et al., 1996). GR  varies from the other 
isoform only in the length of C-terminal domain, which is shorter by five amino acids. This 
results in reduced glucocorticoid binding affinity of the GR  receptor. Both receptors are 
expressed in all human cells, but GR  plays a regulatory role and its concentration is much 
lower than that of GR . Although there is no evidence to support that this polymorphism is 
responsible for reduced responsiveness to GC in clinical practice, this concept has been 
widely discussed and related studies are currently carried out (Brogan et al., 1999; Gagliardo 
et al., 2000; Malmstrom et al., 1999). In the cytoplasm, the glucocorticoid receptor is linked 
with several regulatory proteins, with the heat shock protein (hsp90), p59 immunophilin 
and p23 phosphoprotein being the most important (Smith & Toft, 1993). GR and hsp90 
coupling enables ligand (CS) binding to the receptor and facilitates correct receptor 
“maturation” after synthesis (Smith & Toft, 1993). After CS binding the complex GR/hsp90 
is disunited and activated GR/CS translocates to the nucleus and binds to DNA via the 
central domain consisting of two “zinc fingers”(Mitchell & Tjian, 1989). On the DNA side 
the fragment interacting with GR is called GRE (glucocorticoid response elements). This is 
one of the two mechanisms for CS to stimulate or inhibit transcription and therefore mRNA 
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synthesis. The other mechanism involves intra-cytoplasmic interaction of GR/CS with 
transcription factors, resulting in the blockage of their activity and consequently hampering 
transcription of several inflammatory agents as cytokines and chemokines, simplifying  
synthesis of anti-inflammatory agents (Barnes, 1996).  
The importance of iCS in asthma treatment made the glucocorticoid receptors gene 
polymorphisms the obvious target of pharmacogenetic studies. However, despite the 
large number of researchers involved and the considerable funds devoted by both 
academic and industrial teams, only few polymorphisms have been discovered until now: 
Val Asp641, that results in a three-fold lower binding affinity for dexamethasone, 
Val Ile729 - with four-fold decrease in dexamethasone activity and Asn Ser363 that 
results in higher activity to exogenous corticosteroids (Hurley et al., 1991; Malchof et al., 
1993; Huizenga et al., 1998). From published studies we know, that patients with GR gene 
polymorphisms Val Asp641 and Val Ile729 may be predisposed to a relatively 
decreased response to CS therapy (Koper et al., 1997; Lane et al., 1994). A three marker 
long haplotype G-A-T  (frequency 23% in general population; G allele - BclI SNP, A allele - 
intron B 33389, T allele - intron B 33388) was described in 2004 by Stevens and coworkers. 
It is associated with enhanced GC sensitivity measured as low postdexamethasone 
cortisol (frequency 41%). Subjects homozygous for G-A-T had over twofold FEV1 
improvement after CS treatment compared to heterozygous or non-G-A-T haplotypes 
(Tantisira et al., 2004). 
However, all these studies have not demonstrated a correlation between GR polymorphisms 
and corticosteroid resistance in asthma. Corticosteroid resistance does not seem to be 
dependent on a single GR gene polymorphism.  
2.3.2 Polymorphisms of the CRHR1 gene (corticotropin releasing hormone receptor 
type 1) 
In contrast to the GR gene polymorphism studies, CRHR1 investigations seem to yield 
more promising results. The CRHR1 gene is the major receptor for corticotropin that in 
turn is the key regulator of corticosteroids synthesis and catecholamine production.  
The gene for CRHR1 is located on chromosome 17q12-22, in the genomic region linked to 
asthma in a genome-wide-screen (Zandi et al., 2001). Most important data came  
from studies by Tantisira et al (Tantisira et al., 2004) that analyzed 14 genes connected 
with biological pathways of corticosteroids in three large groups of patients. Study 
participants were recruited from several other clinical trials studying the use of inhaled 
corticosteroids in asthma. The first group consisted of 470 adult individuals and was 
encoded AD (Adult Study), the second included 336 adult patients - ACRN (Asthma 
Clinical Research Network), and the third one included 311 children from CAMP 
(Childhood Asthma Management Program). This project revealed a significant correlation 
between lung function improvement after inhaled corticosteroid therapy and SNPs 
(rs1876828, rs242939 and rs242941) and haplotype occurrence within the CRHR1 gene, 
especially rs242941 (G T, intron located) polymorphism, in all populations. In the AD 
population homozygous individuals with this polymorphism had average FEV1 
improvement, higher than homozygous patients lacking this SNP. Similar results were 
obtained for the paediatric population that was studied. These data can contribute to our 
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understanding of the diverse patient reactions to iCS treatment but further investigation is 
still necessary.   
2.3.3 Polymorphisms of the TBX21 gene (T-box expressed in T cells) 
Another gene modulating inhaled corticosteroids action is TBX21 that encodes T-bet 
transcription factor (Tantisira et al., 2004). It plays an important role in balancing 
lymphocyte subpopulations, enhancing Th1 and inhibiting Th2 clone formation. TBX21 
knockout mice develop bronchial hyperresponsiveness, enhanced airway eosinophilia and 
faster airway remodelling (Finotto et al., 2002) proving that TBX21 is crucial for asthma 
protection. 
So far one clinically important SNP, His Glu33 (H33Q), was found within this gene’s 
area in mice. Cellular models suggest that the H33Q allele can activate Th1 cytokine 
production (including interferon  – INF ) that in turn decreases Th2 cytokine synthesis 
providing a stable protection against asthma and allergy development. Surprisingly 
enough, it has been demonstrated that corticosteroids are able to inhibit T-bet induction 
(Refojo et al., 2003) resulting in Th2 domination. These findings still require a direct in 
vivo confirmation. 
Studies in children (CAMP population) showed 4.5% occurrence in general population of 
homozygous Glu33 individuals. The presence of even one copy of this allele in subjects 
treated with iCS was associated with a significant decrease in airway hyperresponsiveness 
(measured as PC20) as compared to His33His homozygous subjects and individuals not iCS-
treated (Tantisira et al., 2004).  
2.3.4 Polymorphisms of the FCER2 gene (Fc fragment of IgE, low affinity II, receptor 
for (CD23)) 
The FCER2 gene encodes a protein, which is the low-affinity receptor for IgE and a key 
molecule for B-cell activation and growth. FCER2 gene polymorphism was predicted to 
bronchial hypperresponsiveness and IgE-mediated allergic diseases. Within this gene three 
SNPs have been described, all connected to higher risk of severe asthma and asthma 
exacerbations in spite of inhaled corticosteroids therapy. The polymorphism 2206T C 
occurs relatively often (allelic frequency 0.26 in Caucasians and 0.44 in black population) 
and was carefully analyzed for potential association to inhaled corticosteroids therapy 
response (Tantisira et al., 2007). The presence of the C allele increases three- to four-fold the 
risk of severe asthma exacerbations. This effect was confirmed both in Afro-American and 
Caucasian individuals being under iCS therapy.     
2.3.5 Polymorphism of AC9 gene (cyclase adenylate 9) 
Although adenylate cyclase is activated via the 2-adrenoreceptor it may also influence 
inhaled corticosteroids reaction. Individuals carrying the polymorphism Ile Met 772 
demonstrate increased bronchial dilatation after SABA when treated with corticosteroids 
compared to wild-type individuals (isoleucine in 772 position) (Tantisira et al., 2005). This 
substitution results in a loss of function. Met772 has lower basic as well as beta2-mediated 
adenylyl cyclase activities compared to Ile772.  
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understanding of the diverse patient reactions to iCS treatment but further investigation is 
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transcription factor (Tantisira et al., 2004). It plays an important role in balancing 
lymphocyte subpopulations, enhancing Th1 and inhibiting Th2 clone formation. TBX21 
knockout mice develop bronchial hyperresponsiveness, enhanced airway eosinophilia and 
faster airway remodelling (Finotto et al., 2002) proving that TBX21 is crucial for asthma 
protection. 
So far one clinically important SNP, His Glu33 (H33Q), was found within this gene’s 
area in mice. Cellular models suggest that the H33Q allele can activate Th1 cytokine 
production (including interferon  – INF ) that in turn decreases Th2 cytokine synthesis 
providing a stable protection against asthma and allergy development. Surprisingly 
enough, it has been demonstrated that corticosteroids are able to inhibit T-bet induction 
(Refojo et al., 2003) resulting in Th2 domination. These findings still require a direct in 
vivo confirmation. 
Studies in children (CAMP population) showed 4.5% occurrence in general population of 
homozygous Glu33 individuals. The presence of even one copy of this allele in subjects 
treated with iCS was associated with a significant decrease in airway hyperresponsiveness 
(measured as PC20) as compared to His33His homozygous subjects and individuals not iCS-
treated (Tantisira et al., 2004).  
2.3.4 Polymorphisms of the FCER2 gene (Fc fragment of IgE, low affinity II, receptor 
for (CD23)) 
The FCER2 gene encodes a protein, which is the low-affinity receptor for IgE and a key 
molecule for B-cell activation and growth. FCER2 gene polymorphism was predicted to 
bronchial hypperresponsiveness and IgE-mediated allergic diseases. Within this gene three 
SNPs have been described, all connected to higher risk of severe asthma and asthma 
exacerbations in spite of inhaled corticosteroids therapy. The polymorphism 2206T C 
occurs relatively often (allelic frequency 0.26 in Caucasians and 0.44 in black population) 
and was carefully analyzed for potential association to inhaled corticosteroids therapy 
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substitution results in a loss of function. Met772 has lower basic as well as beta2-mediated 
adenylyl cyclase activities compared to Ile772.  
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Gene  Chromosomal location 
Polymorphism with potential pharmacogenetic 
consequences during iCS therapy  
CRHR1 17q12-22 rs242941 (G T, intron) 
TBX21 17q21.32 His Glu33 (H33Q) 
FCER2 19p13.3 2206T C 
AC9 16p13.3-13.2 Ile Met 772 
Table 2. List of gene polymorphism examples that could have pharmacogenetic 
consequences during corticosteroids therapy  
2.4 Pharmacogenetics of anticholinergic treatment  
2.4.1 Polymorphisms of the muscarinic receptor 
Anticholinergics are used mainly in chronic obstructive pulmonary disease (COPD) but 
sometimes also in asthma as second line bronchodilators. Anticholinergics are antagonists of 
muscarinic receptors: M1, M2 and M3. SNPs have been found in coding regions of M2 and 
M3 receptors (Fenech, 2001). The expression of M2 and M3 receptors is dependent on 
transcription regulation in the gene promoter region and polymorphisms have been 
demonstrated in both promoter regions (Fenech, 2004; Donfack, 2003). Furthermore 
different expression of M2 receptor may be related to various number of dinucleotide CA 
repetitions in gene promoter region. None of these changes has been investigated in relation 
to bronchodilation in asthma or COPD yet.  
3. Conclusions 
Genome analysis, candidate gene studies and SNP investigation represent a new approach 
to pharmacological treatment in all chronic diseases. Genetically defined differences 
combined with clinical phenotyping lead to treatment personalization. At this point 
“personalization” means selecting different treatment regimens for different groups of 
patients. The more knowledge on pharmacogenetics and general genetics we have, the 
smaller these groups are likely to be.  
iCS remain the mainstream therapy in asthma. Despite intensive research in this field there 
is only one biological treatment available for asthma and allergy (anti-IgE monoclonal 
antibody). Several other have been suggested and underwent pre-clinical or clinical tests, 
but to prove either their effectiveness and safety.   
All the studies presented in this chapter have aimed at the identification and 
characterization of subgroups of asthmatic patients that will derive optimal therapy benefit 
while minimizing or eliminating drug side effects. The ultimate goal in the 
pharmacogenetics of antiasthmatic medication is to enable the optimization of individual 
therapies from the very start, maximizing efficacy without exposing patients to side effects. 
That would also significantly improve patient’s treatment compliance. The amount of clear 
data from pharmacogenetics of antiasthmatic drugs is still limited due, among others, to the 
vast number of genotype variants in different populations. 
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Combined research of the past decade seem to suggests that either asthma has several 
phenotypes distinct in terms of inflammatory mechanisms (eosinophilic versus neutrophilic, 
IL-17 dependent vs non-dependent etc.) or “asthma” is rather a group of respiratory 
diseases with similar symptomatology than a uniform disease. Computerized multivariate 
analysis has to be employed in the process of defining clinically relevant disease phenotypes 
of asthma before effective pharmacogenetic research can be undertaken.  
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different expression of M2 receptor may be related to various number of dinucleotide CA 
repetitions in gene promoter region. None of these changes has been investigated in relation 
to bronchodilation in asthma or COPD yet.  
3. Conclusions 
Genome analysis, candidate gene studies and SNP investigation represent a new approach 
to pharmacological treatment in all chronic diseases. Genetically defined differences 
combined with clinical phenotyping lead to treatment personalization. At this point 
“personalization” means selecting different treatment regimens for different groups of 
patients. The more knowledge on pharmacogenetics and general genetics we have, the 
smaller these groups are likely to be.  
iCS remain the mainstream therapy in asthma. Despite intensive research in this field there 
is only one biological treatment available for asthma and allergy (anti-IgE monoclonal 
antibody). Several other have been suggested and underwent pre-clinical or clinical tests, 
but to prove either their effectiveness and safety.   
All the studies presented in this chapter have aimed at the identification and 
characterization of subgroups of asthmatic patients that will derive optimal therapy benefit 
while minimizing or eliminating drug side effects. The ultimate goal in the 
pharmacogenetics of antiasthmatic medication is to enable the optimization of individual 
therapies from the very start, maximizing efficacy without exposing patients to side effects. 
That would also significantly improve patient’s treatment compliance. The amount of clear 
data from pharmacogenetics of antiasthmatic drugs is still limited due, among others, to the 
vast number of genotype variants in different populations. 
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Combined research of the past decade seem to suggests that either asthma has several 
phenotypes distinct in terms of inflammatory mechanisms (eosinophilic versus neutrophilic, 
IL-17 dependent vs non-dependent etc.) or “asthma” is rather a group of respiratory 
diseases with similar symptomatology than a uniform disease. Computerized multivariate 
analysis has to be employed in the process of defining clinically relevant disease phenotypes 
of asthma before effective pharmacogenetic research can be undertaken.  
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1. Introduction  
The prescription of drugs is an instrumental practice of modern therapeutics. According to 
the definition of the World Health Organization, the adequate prescription involves the 
selection of the correct drug, dose and duration of administration. In this sense, it is known 
that drugs that are prescribed for certain indications cannot produce the desired therapeutic 
effect in approximately 30 to 60% of the cases (Wang et al., 2011). 
The pharmacological effects of most drugs depend on the result of a series of 
pharmacokinetic processes, which determine the amount of drug that reaches the 
biophase (target tissues), as well as on pharmacodynamics, involving the interaction 
between the drug and its site of action. These processes occur at variable levels in 
different individuals, and one of the major determinants of this variability is genetics. The 
structure, function and expression of most enzymes involved in drug transport and 
metabolism as well as the specific drug receptors may be affected by the presence of 
genetic variants, which may in turn modify the intended therapeutic effect or the 
appearance of adverse effects. In cases in which polymorphisms or mutations affect the 
structure or expression of these proteins, with corresponding implications in their 
function, genomic analyses can be applied to predict the patient’s response prior to 
treatment. This concept represents the central aim of pharmacogenomics (Weinshilboum 
& Wang, 2006). 
Importantly, pharmacogenomic analyses do not explain all of the variability in drug 
responses. The new paradigm of individualized therapy must combine genetic 
information and non-genetic factors, such as sex, age, diet, environmental factors, drug 
interactions, demographics and clinical observations to determine the best treatment for a 
patient, both in the selection of drugs and in the dosage; the aim is to optimize the 
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patient’s therapeutic experience (Belloso & Redal, 2010). As with other areas of modern 
therapeutics, pharmacogenomics is gaining a place in the treatment of gastroenterological 
diseases.  
Some gastroenterological diseases, such as gastroesophageal reflux and peptic ulcer disease, 
are among the most frequent and relevant pathologies in adult patients. In addition, 
inflammatory bowel disease, hepatitis C and postoperative or cancer-associated nausea and 
vomiting are conditions in which pharmacological therapy does not show a universal 
response. Interestingly, genetic factors may partially explain this variability of therapeutic 
efficacy for most drugs that are used in the treatment of these important gastroenterologic 
disorders. 
In this chapter, we evaluate the major polymorphisms that are associated with the 
effectiveness or toxicity of drugs that are commonly used in gastroenterology. 
2. Genes and polymorphisms 
The magnitude of the expression of transporters, metabolizing enzymes and receptors 
depend primarily on genetic factors. Among these factors, different types of inherited 
genetic variants may be found, such as deletions, insertions and the multiplication or 
repetition of sequences, which may involve large portions of DNA. However, the most 
frequent variants and the most common targets of pharmacogenetic tests are the single 
nucleotide polymorphisms (SNPs). SNPs are modifications of a single base in the nucleotide 
sequence.  
Studies of the human genome sequence have established that there are more than 15 
million SNPs, of which only a small minority appear to have any impact on the kinetics or 
dynamics of drugs. Different approaches of pharmacogenomic study can range from 
purely genetic to the identification of those SNPs that confer clinical impacts; conversely, 
they can include the identification of specific sequences of nucleotides to recognize 
individuals with particular behaviors in relation to metabolism or drug responses (The 
International HapMap Consortium: A haplotype map of the human genome, 2005; Redon et al., 
2006). 
The genes that encode metabolic proteins, transporters or receptors may have different 
polymorphisms, and some of these polymorphisms will confer a particular impact on the 
magnitude of the expression of the gene products (Leucuta & Viase, 2006). 
A polymorphism is considered when an allelic variant appears in more than 1% of the 
general population. These variants may be associated with a deficient expression or, in a 
minority of the cases, the overexpression of the enzyme, transporter or receptor. 
For most drugs, the genotypic study of its metabolizing enzymes does not exhaust the 
potential sources of genetic variability. By accounting for the overall potential 
polymorphisms of transporters and receptors that are involved in the pharmacology of 
drugs, it may be possible to characterize multiple SNPs from multiple genes, which would 
refine our understanding of the impact of pharmacogenomics in the selection of therapeutic 
agents. 
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3. Peptic ulcer disease by Helicobacter pylori infection and gastro 
esophageal reflux disease 
3.1 Clinical characteristics 
Helicobacter pylori (HP) infection is associated with chronic gastritis, peptic ulcer disease, 
gastric mucosal associated lymphoid tissue (MALT) lymphoma and gastric cancer. The 
eradication of bacterial infection provides an effective means of curing or preventing these 
HP-associated diseases.  
Gastroesophageal reflux disease (GERD) is noted by its prevalence, variety of clinical 
presentations and under-recognized morbidity. In general, GERD is considered for patients 
who demonstrate symptoms that are suggestive of reflux or complications thereof and with 
or without esophageal inflammation. 
The most common symptoms of GERD are heartburn (or pyrosis), regurgitation and 
dysphagia. In addition, a variety of extraesophageal manifestations have been described 
including bronchospasm, laryngitis, and chronic cough. 
A possible role for HP in the pathogenesis of GERD has also been suggested. However, the 
link between GERD and HP is complex and remains poorly defined. 
3.2 Pharmacological treatment 
The current treatment strategies for the cure of HP infection are based on a triple therapy that 
includes a proton pump inhibitor (PPI) and two antibiotics, which are usually amoxicillin 
and/or clarithromycin or metronidazole. These regimens are effective in 70-90% of patients. 
Treatment failures have been attributed to bacterial resistance to the antibiotics.  
PPIs also constitute the standard treatment for GERD; in fact, the introduction of PPIs for 
the management of acid-peptic disorders constitutes one of the great success stories in 
gastroenterology because of their efficacy and safety. Nevertheless, the treatment response 
is not uniform, and in fact, the average response to treatment may actually hamper the 
identification of two different populations of patients, which include those who respond 
almost completely and those who have a consistently suboptimal response. 
3.3 Pharmacogenomic considerations 
Among the mechanisms of drug metabolism in the body, the most important is cytochrome 
P450. The complex enzymes that are involved in the metabolism of drugs include CYP2C19, 
CYP2D6, CYP2C9 and CYP3A4/5/7. 
The CYP2C19 isoenzyme metabolizes all of the PPIs that are currently available, some 
antidepressant drugs, the antifungal voriconazole, thalidomide and the antiplatelet 
clopidogrel.  
The gene that encodes CYP2C19 has been mapped to chromosome 10 (10q24.1-q24.3). At 
least 21 variants of CYP2C19, from *1 to *20, have been identified. CYP2C19*1 is the wild-
type allele. The variant allele CYP2C19*2, which contains 681G>A on exon 5 that causes a 
splicing defect, which is the major genetic defect that is responsible for the polymorphism of 
S-mephenytoin metabolism in humans. CYP2C19*3 carries the 636G>A SNP, which results 
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in a premature stop codon in exon 4. Both CYP2C19*2 and *3 are null alleles, which result in 
the absence of enzymatic activity (de Morais et al., 1994). The majority of the PMs of 
CYP2C19 are due to these two variant alleles (Desta et al., 2002). 
It has been described that approximately 3-5% of the Caucasian population has a total 
absence of enzymatic activity that is primarily associated with the gene variant CYP2C19*2, 
and it is associated to a lesser extent with CYP2C19*3. The frequency of these 
polymorphisms is highly variable among different populations (Goldstein et al., 1997). 
Likewise, the CYP2C19 * 17 variant (I331V) was identified more recently, and it is found in 
ultra-rapid metabolizers (UMs) (Sim, 2006). The alleles *2 and *3, which are associated with 
poor metabolizers (PMs), have been found in approximately 85% of the Caucasian 
population and nearly 100% of the Asian population. If the alleles *4 and *6 are included, the 
prevalence of the PM phenotype in Caucasians is 92%. 
The biotransformation of PPI occurs primarily through CYP2C19, and the study of 
polymorphisms for these drugs has a specific application. CYP2C19 is responsible for the 
initial hydroxylation of omeprazole and lanzoprazole and, to a lesser extent, the 
demethylation of pantoprazole and rabeprazole, which are the steps that produce 
metabolites without antacid activity (figure 1). The ability of these drugs to reduce gastric 
acidity depends largely on the concentration that is reached in the plasma after absorption. 
Therefore, those who rapidly metabolize the drugs ,rapid metabolizers (RMs) have 
significantly lower gastric pH values than those who are “extensive metabolizers”, 
“intermediate metabolizers” (IMs) or PMs. The PMs have inherited variations in both of the 
alleles and therefore cannot express the functional enzyme. The differences in the area 
under the curve (AUC), which is a variable that quantifies the exposure of the subject to the 
current drug, can be up to 13-fold higher for the PM in the case of omeprazole. 
In addition, it has been observed that these pharmacokinetic and pharmacodynamic 
differences result in diverse clinical outcomes by using proton- pump inhibitor therapies, 
which are primarily used in the treatment of gastroesophagic reflux disease (GERD) and the 
eradication of HP (Furuta, 2005).  
 
Fig. 1. Metabolism of omeprazole, lanzoprazole and rabeprazole 
3.4 Pharmacogenomic influences in the treatment of GERD with PPIs  
In recent years, it has been established that one of the causes of GERD that is refractory to 
PPI therapy, which occurs in approximately 10% of patients, is related to differences in the 
 
Pharmacogenomics in Gastroenterology 
 
205 
efficiency of the metabolism of the drug. Endoscopic cure rates are much lower in RMs than 
in IMs, and higher cure rates are observed in the PMs, which display a poorer outcome in 
relation to the severity of the injury (less than 17% for RM C or D lesions, Los Angeles 
classification). It was established that the genotype is also crucial for the nocturnal acid 
bouts, which are episodes in which the pH falls below 4 for more than an hour and are 
considered to be an influential factor in the treatment outcome. These intrusions are much 
more frequent in RMs than in the other two types of metabolizing patterns. This result 
suggests that patients who are refractory to standard doses of PPI should be offered an 
increased dose or frequency on the premise that they are RMs (Kawamura et al., 2007; Egan 
et al., 2003). 
The safety profile of PPIs also seems to be influenced by pharmacogenetics, which is 
illustrated in the case of GERD treatments that require long treatment periods. There is 
some evidence that IMs and, to a larger extent, PMs, have a higher risk of hyperplasia of 
enterochromaffin-like cells, which is related to the development of carcinoid tumors, than 
their RM counterparts (Rosemary & Adithan, 2007). Likewise, the first two groups have 
higher rates of megaloblastic anemia by vitamin B12 deficiency, which arises from the 
neutralization of the gastric pH for extended periods; these groups also suffer from atrophic 
gastritis, which is especially likely if it coexists with HP infection (Kang, 2008).  
3.5 Pharmacogenomic influences on the eradication of Helicobacter pylori  
To eradicate and as a part of the therapeutic strategy for managing patients with various 
conditions, such as peptic ulcer disease or MALT, PPIs are a central part of the scheme 
that also require the addition of antibiotics. The suppression of gastric acidity is also 
crucial for the bioavailability and stabilization of the plasma concentration of antibiotics, 
which can force HP to its growth phase, which is where it is most responsive to treatment, 
increase the intragastric concentrations of antibiotics and provide some intrinsic actions 
against HP. 
Response rates in the eradication of HP are also influenced by the genotype of the patient 
(figure 2), such that the PMs are able to achieve 100% eradication with the standard dose of 
PPIs and with the addition of 500 mg of amoxicillin and omeprazole four times a day for 
two weeks. In this scheme, the eradication rate for IMs is 60%, and that for RMs is only 30% 
(Kang, 2008). In addition, adequate results have been reported with dual schemes that 
utilize 10 mg of rabeprazole twice per day, which has a greater ability to suppress gastric 
acidity than omeprazole that is combined with amoxicillin, and has reached 90% eradication 
in both PMs and IMs (Furuta, 2005). Therefore, in a large number of cases, the use of a 
second antibiotic may be avoided. Moreover, in the cases of eradication failure, an attempt 
can be made by doubling the dose of rabeprazole with amoxicillin before a third antibiotic is 
added; the intention of this treatment is to achieve effectiveness in the case of RMs. This 
differential approach that permits the individualization of PPI treatment according to the 
CYP2C19 genotype constitutes a real breakthrough, and it facilitates the avoidance of the 
addition of clarithromycin or metronidazole, which are not exempt from adherence 
problems, cost, resistance and adverse effects. 
The addition of clarithromycin to the regimen of PPIs and amoxicillin has a pharmacokinetic 
basis: clarithromycin inhibits another cytochrome, CYP3A4, which is an alternative pathway 
for the metabolism of PPIs. Therefore, PPI concentrations are extremely high when PMs are 
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Fig. 1. Metabolism of omeprazole, lanzoprazole and rabeprazole 
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in IMs, and higher cure rates are observed in the PMs, which display a poorer outcome in 
relation to the severity of the injury (less than 17% for RM C or D lesions, Los Angeles 
classification). It was established that the genotype is also crucial for the nocturnal acid 
bouts, which are episodes in which the pH falls below 4 for more than an hour and are 
considered to be an influential factor in the treatment outcome. These intrusions are much 
more frequent in RMs than in the other two types of metabolizing patterns. This result 
suggests that patients who are refractory to standard doses of PPI should be offered an 
increased dose or frequency on the premise that they are RMs (Kawamura et al., 2007; Egan 
et al., 2003). 
The safety profile of PPIs also seems to be influenced by pharmacogenetics, which is 
illustrated in the case of GERD treatments that require long treatment periods. There is 
some evidence that IMs and, to a larger extent, PMs, have a higher risk of hyperplasia of 
enterochromaffin-like cells, which is related to the development of carcinoid tumors, than 
their RM counterparts (Rosemary & Adithan, 2007). Likewise, the first two groups have 
higher rates of megaloblastic anemia by vitamin B12 deficiency, which arises from the 
neutralization of the gastric pH for extended periods; these groups also suffer from atrophic 
gastritis, which is especially likely if it coexists with HP infection (Kang, 2008).  
3.5 Pharmacogenomic influences on the eradication of Helicobacter pylori  
To eradicate and as a part of the therapeutic strategy for managing patients with various 
conditions, such as peptic ulcer disease or MALT, PPIs are a central part of the scheme 
that also require the addition of antibiotics. The suppression of gastric acidity is also 
crucial for the bioavailability and stabilization of the plasma concentration of antibiotics, 
which can force HP to its growth phase, which is where it is most responsive to treatment, 
increase the intragastric concentrations of antibiotics and provide some intrinsic actions 
against HP. 
Response rates in the eradication of HP are also influenced by the genotype of the patient 
(figure 2), such that the PMs are able to achieve 100% eradication with the standard dose of 
PPIs and with the addition of 500 mg of amoxicillin and omeprazole four times a day for 
two weeks. In this scheme, the eradication rate for IMs is 60%, and that for RMs is only 30% 
(Kang, 2008). In addition, adequate results have been reported with dual schemes that 
utilize 10 mg of rabeprazole twice per day, which has a greater ability to suppress gastric 
acidity than omeprazole that is combined with amoxicillin, and has reached 90% eradication 
in both PMs and IMs (Furuta, 2005). Therefore, in a large number of cases, the use of a 
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exposed concomitantly to these drugs and clarithromycin, although the rise of the plasma 
concentration has been observed with all of the genotypes (Furuta, 1999).  
This technique may represent one mechanism to increase the effectiveness of the triple 
scheme regardless of the CYP2C19 genotype. Nevertheless, the RMs cure rates are lower 
than the IMs and PMs cure rates, which is probably because the RMs receive insufficient 
doses of PPIs in accordance with the enzyme expression. It is believed that in the case of the 
triple scheme, prior knowledge of CYP2C19 genotype may help to optimize the dose of PPI 
to minimize the possibility of therapeutic failures. It is recommended that the dose and the 
dosing interval, up to four times daily, should be increased to ensure a gastric pH that is 
close to 7 for the majority of the day (Chaudhry & Kochhar, 2008). 
Finally, in patients for whom therapy has been individualized but fails to eradicate the 
disease, a consideration should be made regarding the possibility of an infection by a HP 













Fig. 2. Omeprazole metabolism by CYP2C19. (Furuta et al, 1998) 
The percent of HP eradication is dependent upon the metabolizer phenotype. 
4. Inflammatory Bowel Disease 
4.1 Clinical characteristics 
Inflammatory bowel disease (IBD) is a chronic, disabling disease that generally presents 
with flares and remissions. Ulcerative colitis (UC) and Crohn's disease constitute the most 
frequent forms of presentation.There are remarkable differences between both conditions 
regarding the clinical presentation, extension and extra-intestinal manifestations of the 
disease. The precise etiology of IBD is unknown, but both ambient and genetic factors may 
play a significant role. 
4.2 Pharmacological treatment 
The clinical course of this condition has changed substantially since immune modulator 
therapies and monoclonal antibodies were introduced to the therapeutic armamentarium; as 
a result, the extent of the remission periods has increased. However, a curative 
pharmacological approach is not yet available.  
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In addition, considerable variability exists regarding the efficacy and toxicity of the 
treatment. Multiple factors may influence the response to treatment, which include disease 
severity and complications; environmental factors, such as smoking; and genetic factors. It is 
estimated that between 20% and 95% of the variability in the toxicity and the treatment 
response may be explained by polymorphisms. The overall response rate to the treatment is 
more difficult to estimate than toxicity because there are multiple confounding factors, such 
as the concomitant use of other drugs, which may influence outcomes. The polymorphism 
of the enzyme thiopurine methyl transferase (TPMT) (figure 3) and its influence on 
treatment with Azathioprine (AZA) and 6-mercaptopurine (6-MP) is the best example of 
how genotyping can help to optimize therapy in inflammatory bowel disease (Hindorf et al., 
2002), (table 1). 
 
Fig. 3. Allelic variant of the TMPT locus. The boxes depict exons in the TMPT gene. The grey 
boxes are the untranslated region and blue boxes represent exons in the open reading frame. 
The green boxes are exons that contain mutations resulting in amino acid changes. 
 
Genotype Phenotype / Activity AZA dose 
TMPT*1/*1 High Standard doses 
TMPT*1/*2 
TMPT*1/*3 (A,B or C) Intermediate Half dose 
TMPT*2/*3 (A,B or C) 




Table 1. Relationship between genotype and phenotype in TPMT and doses of AZA in 
patients with IBD 
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AZA is a thiopurine derivative with immunosuppressive properties that has been 
available on the market for almost 40 years. It is widely used in the treatment of 
rheumatic diseases of children and adults, transplantation and inflammatory bowel 
disease, and it is used in different treatment combinations. However, approximately 40% 
of IBD patients do not respond to AZA treatment, and 10-25% must discontinue treatment 
because of adverse reactions, being either major (leukopenia, pancreatitis and hepatitis) or 
minor (rash, nausea, flu-like syndrome and diarrhea) Adverse reactions, which include 
liver, gastrointestinal and bone marrow toxicity are present in approximately 15-28% of 
patients.  
Hematologic toxicity occurs in approximately 2-9% of patients, and it can, in extreme cases, 
lead to death (Pierik et al., 2006).  
AZA is a pro-drug that is administered orally in doses of approximately 2.5 mg/kg per day. 
Fifteen to sixty percent of the drug is absorbed in the intestine, and after it enters the body, it 
is converted to 6-MP by a non-enzymatic reaction. 6-MP is also a pro-drug that undergoes a 
series of enzymatic reactions to form thioguanide nucleotides (6-TGNs), which are active 
metabolites that antagonize the metabolism of purines; inhibit the synthesis of DNA, RNA 
and proteins; and may also interfere with cellular metabolism and prevent mitosis. 6-TGNs 
are responsible for the immunosuppressive activity and the myelosuppressive action of 
AZA. 
The inactivation of AZA and 6-MP depend primarily on two metabolic pathways; one 
pathway utilizes xanthine oxidase, producing 6-thiouric acid, and the other utilizes TPMT, 
which converts the original drug to 6-methylmercaptopurine. Both of the metabolites are 
inactive.  
In myelopoietic precursors, no xanthine oxidase activity is observed; therefore, TPMT 
expression and function are vital for the inactivation of thiopuric derivatives.  
However, the accumulation of active metabolites also depends on the activity of these 
enzymes. In this regard, the toxicity of both AZA and 6-MP are strongly related to the TMPT 
activity. The decreased activity or deficiency of TMPT causes 6-MP to be preferentially 
metabolized to 6-TGNs, which are responsible for much of the toxicity of 6-MP. 
Following the introduction of the pharmacogenetic test for TPMT, there have been major 
changes in the prescription patterns of AZA in the last decade. The choice to use or not use 
AZA in accordance with the TPMT genotype offers the possibility of a safer and more 
effective treatment. 
Several studies have shown that 80-90% of patients who have at least one of the 
aforementioned variants will have to discontinue AZA treatment due to adverse effects, 
which primarily include neutropenia (Evans & McLeod, 2003). 
4.3 Pharmagenomic considerations 
Supporting evidence currently exists for the pre-treatment genetic testing of TPMT in the 
reduction of neutropenic episodes in patients receiving azathioprine, although the evidence 
regarding its contribution in increasing drug efficacy is not as strong (Lakatos, 2010). A 
recent survey in the UK showed that 67% of gastroenterologists used TPMT testing before 
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prescribing AZA (Payne et al., 2007). In 2004, the US Food and Drug Administration (FDA) 
approved TPMT testing in the US and made the recommendation to include this 
information in the drug prescription brochure; however, no formal recommendation was 
made for mandatory testing. 
A socio-economic study of IBD has demonstrated that TPMT genotyping is a cost-effective 
method that can identify patients with active low/absent enzyme to avoid treatment with 
AZA and its subsequent severe hematologic complications (van den Akker, 2006) 
It is now recommended that patients with IBD who have low or intermediate enzyme 
activity should receive a starting dose of 50% of the usually prescribed does, and treatment 
with AZA should be avoided in patients with null enzymatic activity to prevent toxicity 
(Pierik et al., 2006; Lakatos, 2010) 
5. Gilbert Meulengracht syndrome and irinotecan 
5.1 Clinical characteristics 
Gilbert syndrome is characterized by the presence of unconjugated hyperbilirubinemia, 
which is usually moderate, transient or intermittent; has a non-obstructive origin without 
liver inflammation or fibrosis; and is not associated with changes in histology. 
The occurrence of this syndrome is primarily related to the genetic variability in a family of 
enzymes (UDP-glucuronyltranferase (UGTs)) that are part of a detoxification system against 
endogenous toxins and xenobiotic chemicals. These membrane enzymes catalyze the 
glucuronidation of different substances by making them more polar to facilitate their 
excretion through bile or urine.  
This is a route of detoxification that is used for substances that are taken with meals, tobacco 
smoke, or drugs; however, this route is primarily involved in the maintenance of the 
homeostasis of endogenous substances, such as bilirubin, steroids, thyroid hormones and 
bile acids (Strassbourg, 2008).  
5.2 Pharmacogenomic considerations 
Different polymorphisms are associated with the variable activity of these enzymes, 
which affects their ability to detoxify substances. Subsequently, the glucuronidated 
products are recognized by transport systems for organic anions, and they are secreted in 
urine or bile.  
From a pharmacogenetic standpoint, the primary current use of the identification of alleles 
of UGT1A1 is focused on the ability to adequately predict the occurrence of severe 
hematologic toxicity (grade 3 or 4) in cytostatic treatment combinations, which include high 
doses of irinotecan. 
The UGT1A1 enzyme is the only enzyme that is relevant in the metabolism of bilirubin. 
At least 113 variants have been identified, but very few are common in the general 
population. One hundred ninety-five SNPs have been identified in the UGT1A1 gene. 
Among these, there are 11 SNPs in exons 1-5. The UGT1A1*6 (211 G>A) in exon 1 is the 
most common SNPs that is found in the East Asian population (15.7%), but it is not 
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common in the Caucasian population (0.7%) (Bernabeu et al., 2010). It has been suggested 
that the allele *6 contributes to the high incidence of neonatal hyperbilirubinemia in Asian 
children (Akaba et al., 1999). Exon 1 is unique for each member of the UGT1A1 subfamily, 
whereas exons 2 to 5 are common to all of the members of the subfamily. The variants in 
the 3´UTR of UGT1A1 in exon 5, therefore, may have distinct effects on all of the members 
of the UGT1A1 subfamily.  
Polymorphism in the promoter region of the UGT1A1 gene is caused by variability in the 
number of TA repeats in the TATA-box that is located upstream of UGT1A1. The presence 
of seven TA repeats (UGT1A1*28) is associated with reduced UGT1A1 expression 
compared to the wild type allele (UGT1A1*1), which contains six TA repeats. 
Homozygous individuals who carry the A (TA)7 TAA allele show significantly higher 
plasma levels of unconjugated bilirubin caused by a 30% reduction in the transcription of 
UGT1A1 (Lyer et al., 2002). There are interethnic differences in the frequency of the 
UGT1A1*28 allele, which has an approximate incidence of 6-12% in the Caucasian 
population, 0-3% in the Asian population and 16-19% in the African population (Shu-Feng 
Zhou et al., 2008). 
However, there are other polymorphisms, such as UGT1A1*36, which contains 5 TA; 
UGT1A1*37, which contains 8 TA; and other polymorphisms that are not linked to the 
TATA-box region, such as the variant UGT1A1*7 (1456T>G, mutation in exon 1); 
UGT1A1*27 (686C>A), which is very rare in all of the ethnic groups that were examined; 
and the variant UGT1A1*62, which is found exclusively in Asians and is not present in 
either Caucasians or Africans.  
Because haplotypes with UGT1A1 variants may coexist in the same person, the scenario is 
actually more complex. This may help to explain why there is hyperbilirubinemia in 5-9% 
of Caucasians, while 10-16% are homozygous for the UGT1A1*28 variant (Strassburg, 
2010).  
Irinotecan is a derivative of camptothecin. Camptothecins interact specifically with the 
enzyme topoisomerase I, which relieves DNA torsional strain by inducing reversible single-
strand breaks. Irinotecan and its active metabolite SN-38 bind to the topoisomerase I-DNA 
complex and prevent the relegation of these single-strand breaks. Current research suggests 
that the cytotoxicity of irinotecan is related to double-strand DNA damage that is produced 
during DNA synthesis, when replication enzymes interact with the ternary complex that is 
formed by topoisomerase I, DNA, and either irinotecan or SN-38. Mammalian cells cannot 
efficiently repair these double-strand breaks. The irinotecan metabolite SN-38 is conjugated 
by UGT1A1. The presence of seven TA repeats, rather than the wild type number of six, in 
the UGT1A1 promoter reduces enzyme expression and consequently the expression of SN-
38; this also confers a higher chance of developing diarrhea and/or leukopenia during 
irinotecan therapy when compared to patients with a wild type genotype. Gilbert´s 
syndrome is also associated with the TA7/TA7 genotype, and these patients may have an 
increased risk of irinotecan-induced toxicity (Côté et al., 2007).  
In the same way, the recognition of patients with UGT1A1 deficiency may contribute to the 
prediction of the development of severe hyperbilirubinemia in patients with HIV infection 
who are treated with atazanavir, which is an enzyme blocker, and increased plasma 
concentrations of the integrase inhibitor raltegravir. 
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Irinotecam is primarily converted to its active metabolite SN-38 by liver carboxylesterases. 
UGT 1A1 inactivates SN-38 into the more polar SN-38 glucuronide, which is further 
eliminated in bile and urine (figure 4).  
 
 
Fig. 4. Metabolic pathway of irinotecan 
6. Hepatitis C infection 
6.1 Clinical characteristics 
The hepatitis C virus (HCV) infection affects over 170 million people worldwide; it causes 
chronic hepatitis, which may, in turn, lead to cirrhosis and hepatocellular carcinoma (HCC). 
There are six different genotypes whose prevalence varies geographically. Genotype I is 
responsible for most of the infections in North America, South America and Europe. Direct 
contact with blood (as in uncontrolled transfusions) or the use of parenteral drugs constitute 
the most common method of transmission, while unprotected sex is a secondary risk factor. 
A patient´s immune response will determine whether HCV is eventually eliminated or 
remains, which can produce a persistent infection; this latter outcome occurs in the majority 
of cases. The course of HCV infection is variable, although in most patients, it will progress 
toward cirrhosis.  
The hepatitis C virus is a flavivirus. The HCV genome is a positive-sense RNA molecule of 
approximately 9500 nucleotides and encodes a polyprotein precursor of approximately 3000 
amino acids. 
The observation of nucleotide and amino acid mutations that are specifically segregated in 
groups or subgroups in almost all of the regions of the HCV genome has permitted the 
classification of HCV genotypes and subtypes whose sequences differ from each other by 
30% and 20%, respectively. Currently, we accept the existence of at least 6 genotypes that are 
divided, in turn, into more than 84 subtypes. These genotypes were identified by a number 
(1 through 6), and the subtypes were identified by a lowercase letter in the order of their 
discovery (e.g., 1a, 1b, 2a, 3a, etc.). 
After they bind to the cell surface, HCV particles enter the cell by receptor-mediated 
endocytosis. The cytosolic recognition of specific motifs in viral products induces the 
production of interferons and proinflammatory cytokines, which leads to the recruitment of 
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Irinotecam is primarily converted to its active metabolite SN-38 by liver carboxylesterases. 
UGT 1A1 inactivates SN-38 into the more polar SN-38 glucuronide, which is further 
eliminated in bile and urine (figure 4).  
 
 
Fig. 4. Metabolic pathway of irinotecan 
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6.1 Clinical characteristics 
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a signaling complex that activates transcription factors. The subsequent expression of 
interferon alpha regulatory factor 3 (IRF-3) target genes, and likely lambda (type III) 
interferons induces innate immune programs and drives the maturation of adaptive 
immunity for infection control. The coordinated activities of CD4+ T cells and cytotoxic 
CD8+ T cells, which are primed in the context of HLA class II and I alleles, respectively, on 
antigen presenting cells, are critically important for the control of acute HCV infection. 
Mutations in viral epitopes that are targeted by cytotoxic CD8+ T cells can permit the virus 
to escape immunomediated clearance. The up-regulation of inhibitory receptors on 
exhausted (functionally impaired) T cells is another mechanism of T-cell dysfunction during 
chronic infection. 
The host immune response determines whether the HCV persists or is eradicated 
spontaneously.  
One of the most influential factors appears to be related to certain polymorphisms of a site 
that is in close proximity to the IL28B gene (Thomas et al., 2009; Grebely et al., 2010).  
The risk of chronic infection that follows an acute episode of hepatitis C is high. In most 
studies, 80% to hundred percent of patients remain HCV RNA-positive, and 60 to 80 percent 
have persistently elevated liver enzymes (Chu et al., 1999; Farci et al., 1991). The mechanism 
that is responsible for the high prevalence of chronic infection is unclear. This mechanism 
may be related to the genetic diversity of the virus and its tendency toward rapid mutation, 
which allows HCV to constantly escape immune recognition. Most patients with chronic 
infection are asymptomatic or have only mild, nonspecific symptoms. The most frequent 
complaint is fatigue; other less common manifestations include nausea, anorexia, myalgia, 
arthralgia, weakness, and weight loss.  
Cirrhosis occurs in up to 50 percent of chronically infected patients (Tong et al., 1995; 
Takahashi et al., 1993; Yano  et al., 1996). Complications of hepatitis C are mostly confined to 
patients who have developed cirrhosis. The development of cirrhosis is silent in the majority 
of patients in whom it occurs. The progression to fibrosis and later to cirrhosis depends on 
many factors, such as the duration of infection, advanced age, male sex, co-infection with 
other viruses (HIV or HBV), or alcohol intake. HCC in patients with hepatitis C occurs 
almost exclusively in those with cirrhosis, which suggests that this is the major risk factor. 
The deaths that are associated with chronic hepatitis C are more likely to be related to end-
stage liver disease rather than hepatocellular carcinoma (HCC). However, HCV accounts for 
approximately one-third of HCC cases in the United States. Estimations of the risk of 
developing HCC after the development of cirrhosis have varied from 0 to 3 percent per year 
in various reports. The risk appears to be greater with genotype 1b when compared with 
genotype 2a/c (Fattovich et al., 1997; Hu & Tong , 1999; Planas et al., 2004; Bruno  et al., 
2007).  
Once the complications of cirrhosis have occurred, liver transplantation is the only effective 
therapy. Recurrent HCV infection of the graft occurs in almost all patients, although the 
long-term survival following transplantation for HCV is similar to the survival that is 
related to other causes of hepatic failure (60 to 80 percent). Several factors may be important 
determinants of disease progression in individual patients; these factors include age, ethnic 
background, gender, HCV-specific cellular immune response, viral diversity, alcohol use, 
daily use of marijuana, viral coinfection, environmental factors and geography.  
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6.2 Pharmacological treatment  
The decision to treat a patient with chronic HCV infection is based upon several factors, 
which include the natural history of the disease, the stage of fibrosis, and the efficacy and 
adverse effects that are related to the therapy. For patients with clinically significant hepatic 
fibrosis, there is widespread agreement that antiviral therapy is indicated because of the 
high risk of cirrhosis. 
Currently, the standard treatment for HCV infection is ribavirin in combination with  
peg-interferon (INF), but unfortunately, approximately 50% of patients with genotype I 
do not respond to the treatment (Liapiakis & Jacobson , 2010). In contrast, 70-80%  
of patients with genotypes II or III have sustained virological response (SVR) that is 
defined as undetectable HCV RNA 6 months after the treatment. Although the treatment 
response rate depends on several factors, such as patient age, sex, viral genotype, viral 
load at the start of treatment and the liver fibrosis rate, genetic factors that may be related 
with the rate of response to treatment and disease progression have been recently 
identified (table 2). 
Ribavirin is a nucleoside analogue. The mechanism by which ribavirin contributes to its 
clinical antiviral efficacy is not fully understood. Ribavirin has direct antiviral activity in 
tissue culture against many RNA viruses. Ribavirin increases the mutational frequency in 
the genomes of several RNA viruses, and ribavirin triphosphate inhibits HCV polymerase in 
a biochemical reaction. Ribavirin is generally well tolerated. The major adverse effects 
include hemolysis, nonspecific fatigue, depression, insomnia, vertigo, anorexia, nausea, 
nasal congestion, and pruritus. As a result of hemolysis, ribavirin treatment may be 
associated with a mild reversible increase in serum bilirubin and uric acid.  
Peg-INF is derived from the recombinant human interferon Alpha2a. Alpha interferons 




 Non I HCV Genotype 
 Low viral load 
 Caucasian descent 
 IL28B Genotype 
 Absence of fibrosis 
 Weight < 85kg 
 Age< 40 years 
 Female gender 
Before treatment initiation  
 Absence of insulin resistance 
 Absence of liver steatosis 
 Use of statins 
During treatment  
 Rapid virological response (at week 4 
of treatment) 
 Adherence to treatment  
 Standard dose of ribavirin. 
Table 2. Predictors of adequate responses to treatment with ribavirin and INF in HCV  
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They induce interferon-stimulated genes (ISGs) that help to establish an antiviral status 
milieu within cells, although the response is not virus-specific. Alpha interferons act by 
binding to cell surface receptors, which activates a response cascade that culminates in the 
expression of multiple ISGs, some of which block viral protein synthesis. Peg-INF binds the 
human type I INF receptor, which leads to receptor dimerization. Receptor dimerization 
activates multiple intracellular signal transduction pathways that are initially mediated by 
the JAK/STAT signal cascade. A combination therapy with ribavirin and interferon may be 
associated with an increased risk of side effects (such as nausea, rash, and dyspnea) when 
compared to the treatment with interferon alone (table 2). However, a meta-analysis and the 
large studies that were discussed above have suggested that the incidence of serious side 
effects of these treatments are not significantly different (Schalm et al., 1997; Mc Hutchison 
et al., 1998). 
6.3 Pharmacogenomic considerations 
As aforementioned, the efficacy of INF treatment is determined by a number of factors. 
Among these factors, genetic variance has been established as an important predictor of 
treatment response and viral clearance. 
Four independent genetic studies (Genome Wide Association Study (GWAS)) have 
identified a polymorphism in the IL28B gene on chromosome 19 that encodes IFN-  that has 
a strong association with the response rate to combination therapy with peg-INF and 
ribavirin (Ge et al., 2009; Suppiah et al., 2009; Tanakah et al., 2009; Rauch et al., 2010).  
Using a GWAS, several investigators from the US and the UK identified a SNP on 
chromosome 19, rs12979860. The rs12979860 SNP is 3 kb upstream of the aforementioned IL-
28B gene (Brian, 2011). Ge et al. identified rs1297960 as the variant that is most strongly 
associated with SVR in European–American, African-American and Hispanic populations. 
Their study showed an association of the CC genotype with a greater rate of SVR than the 
TT genotype. The frequency of the CC genotype was 39%, 16% and 35% in European-
American, African- American and Hispanic populations, respectively. 
Suppah et al. and Rauch et al. -in a European cohort- and Tanaka et al. -in Japanese patients- 
found the strongest association with rs8099917 (located 8 kb upstream of IL28B), which is in 
linkage disequilibrium with rs12979860. The TT genotype of rs8099917 was significantly 
associated with the presence of a sustained virological response (SVR) following treatment 
with peg-IFN and ribavirin in patients who were chronically infected with genotype 1, while 
the minor allele G is associated with the absence of the response and the increased risk of 
progression to chronic states. 
A higher prevalence of the T allele in the HIV-negative control population was also found, 
which suggests that this allele may be associated with the possibility of the clearance of the 
hepatitis C virus (Thomas et al., 2009; Aparicio et al., 2010). 
These findings may impact the prognosis and treatment of HCV infection. Furthermore, the 
ability to identify patients with a risk allele, particularly in homozygosity, in which the 
response to treatment would be very poor, would make them candidates for alternative 
therapies.  
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7. Postoperative and cancer-associated nausea and vomiting 
7.1 Clinical characteristics 
Postoperative nausea and vomiting is a frequent experience for patients who are subjected 
to surgery with general anesthesia. Twenty to forty percent of surgical patients may display 
this disorder, and in certain high-risk groups, the incidence is even higher (Candiotti et al., 
2005). In addition, nausea and vomiting is one of the most distressful side effects of cytotoxic 
drugs that are administered to patients with oncologic conditions. There are multiple factors 
related to the individual risk of developing nausea and vomiting, such as female sex, young 
age, alcohol consumption, preexisting nausea, and the emetogenic potential of the 
chemotherapeutic agents that are used (Perwitasari et al., 2011).  
7.2 Pharmacological treatment 
Among the most commonly used drugs, the receptor antagonists of serotonin type 3 (5HT3), 
such as ondansetron, granisetron and tropisentron, are widely used as antiemetics to 
primarily prevent nausea and vomiting that are associated with chemotherapy and 
postoperative conditions. These drugs provide a substantial contribution toward the 
prevention and the treatment of nausea and vomiting in these scenarios. However, 20-30% 
of patients do not respond to treatment with 5HT3 antagonists.  
7.3 Pharmacogenomic considerations 
One reason that may explain these interindividual differences in the response to treatment is 
the variation in the hepatic biotransformation of the drug, which, in turn, could be 
genetically determined by polymorphic variants of the gene that encodes CYP2D6. All of the 
5HT3 antagonists are metabolized by the CYP450 complex, and they are primarily 
metabolized by the CYP2D6 isoenzyme.  
The CYP2D6 gene is mapped to chromosome 22q13.1 and encompasses nine exons with an 
open reading frame of 1383 base pairs that encode 461 amino acids (Eichelbaum et al., 1987). 
More than 63 different CYP2D6 variants have been identified by the human cytochrome 
P450 allele nomenclature. Relative to the wild type CYP2D6 allele, different variants of the 
CYP2D6 gene may result in the complete absence of enzyme activity, reduced activity, 
normal activity or even increased activity. Null alleles of CYP2D6 do not encode a functional 
protein, and there is no detectable residual enzymatic activity. These null alleles are 
responsible for the PM phenotype when they are present in homozygosity or compound 
heterozygosity. The mechanisms by which there variants are leading to a total loss of 
function include the following: a) single-base changes or small insertions/deletions that 
interrupt the reading frame or interfere with the correct splicing, which leads to a 
prematurely terminated protein or stop codon (e.g., CYP2D6*3, *4, *6, *8, *11, *15, *19, *20, 
*38, *40, *42, and *44) (Kagimoto et al., 1990); b) nonfunctional full-length coded alleles (e.g., 
CYP2D6*5, *12, *14 and *18) (Evert. et al., 1997); and c) the deletion of the entire CYP2D6 
gene as a result of large sequence deletions (e.g., CYP2D6*5, *13, and *16) (Gaedigk et al., 
1991). However, extremely high CYP2D6 activity results from the gene duplication of 
functional alleles *1 and *2 that are fused in a head-to-tail orientation as a result of unequal 
crossover events and other mechanisms. This was noted by a molecular characterization of 
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the CYP2D6 locus in patients with extremely rapid metabolism (Bertilsson et al., 1993). 
Approximately 5-10% of the Caucasian population has no activity of the enzyme (PMs) and 
approximately 2% are UMs. These patients have two active gene copies resulting in the 
production of enzymes with increased activity which will rapidly decrease the plasma 
concentration of the substrate drug with subsequent treatment failure (Lewis et al., 2010; Ho 
et al., 2006; Vermiere et al., 2010). 
Therefore, antiemetic treatment may be optimized through CYP2D6 genotyping prior to 
chemotherapy or surgical treatment by identifying the patients that will behave as PMs or 
UMs for these drugs; this analysis can specifically identify which patients would require a 
dose adjustment (Perwitasari et al., 2011). 
Because the CYP2D6 polymorphism explains only a proportion of the therapeutic failures in 
these patients, it has been postulated that changes in both the dopamine receptor and 
serotonin receptor may also be related to the antiemetic treatment response (Perwitasari, 
2011). Interestingly, it has also been postulated that CYP2D6 polymorphisms may be related 
to the predisposition to the development of dyskinesias with the use of metoclopramide, but 
the confirmation of these findings has not yet been provided (van der Padt et al., 2006). In 
summary, genetic variants may help in the individualization of drug dosing and the 
prediction of treatment outcome with the use of 5HT3 antagonists, although its routine use 
in therapeutics will require further confirmation by larger studies.  
8. Resume 
In table 3 major gastroenterological diseases are described as well as the drugs available for 
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Table 3. Gastroenterological diseases, drug and associated metabolic enzyme 
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In table 4, the genes involved in the pharmacogenomic studies for gastroenterological 
diseases are summarized, as well as their effects in the enzymatic activities and phenotypic 
consequences. 
 
GENE POLIMORPHISM EFFECT CONSEQUENCES 
CYP2C19 
SNPs-Alleles: 
*2, *3, *4, *6 
Decrease 
activity Poor metabolizers 
SNPs-Allele: *17 Increase activity 
Ultrarapid 
Metabolizers 
TMPT SNPs-Alleles: *2, *3ª, *3B, *3C 
Decrease 
activity Toxicity 
UGT1A1 STRs -Short Tandem Repeats-:113 Alleles 
Different 
activity levels 
Predict the occurrence of 
severe hematologic toxicity 
with irinotecan 






Impact on the prognosis and 
treatment of Hepatitis C 
with interferon 
CYP2D6 SNPs: more than 50 alleles 
Different 
activity levels 
Poor to Ultrarapid 
Metabolizers 
Table 4. The most important genes, variants and their effects on the enzymatic activities 
involved in pharmacological treatment of gastroenterological diseases. 
9. Conclusions 
In some of the most important areas of gastroenterological therapy, the relevance of 
pharmacogenomic analysis has been already demonstrated or is in the process of 
confirmation for both the identification of the proper dosage for a particular patient and the 
prevention of significant toxicity. 
The major polymorphisms (*2 and *3) of CYP2C19 associated with the phenotype of poor 
metabolizers in certain drugs, can identify patients who will achieve higher plasma 
concentrations of the main proton-pump inhibitors with the use of standard doses. Because 
this particular therapeutic group has a wide therapeutic range, the presence of higher 
concentrations is associated with higher treatment success rates for the treatment of 
Helicobacter pylori in either peptic ulcer disease or gastroesophagic reflux disease. The 
knowledge of these associations is particularly useful in populations with a higher 
prevalence of these polymorphisms. The analysis of variants in the promoter region of the 
UGT1A1 enzyme coding gene facilitates the identification of patients with Gilbert 
Meulengracht syndrome, although its pharmacogenetic relevance is currently limited to the 
cytostatic irinotecan. The experience that has been gained with the use of pharmacogenomic 
studies in the context of inflammatory bowel disease is currently limited to the analysis of 
variants of the TMPT coding gene. These variants are associated with the risk of the 
hematologic adverse effects of azathioprine, and its analysis has resulted in favourable 
pharmacoeconomic evaluations.  
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the CYP2D6 locus in patients with extremely rapid metabolism (Bertilsson et al., 1993). 
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UMs for these drugs; this analysis can specifically identify which patients would require a 
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summary, genetic variants may help in the individualization of drug dosing and the 
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In table 4, the genes involved in the pharmacogenomic studies for gastroenterological 
diseases are summarized, as well as their effects in the enzymatic activities and phenotypic 
consequences. 
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*2, *3, *4, *6 
Decrease 
activity Poor metabolizers 
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Ultrarapid 
Metabolizers 
TMPT SNPs-Alleles: *2, *3ª, *3B, *3C 
Decrease 
activity Toxicity 
UGT1A1 STRs -Short Tandem Repeats-:113 Alleles 
Different 
activity levels 
Predict the occurrence of 
severe hematologic toxicity 
with irinotecan 






Impact on the prognosis and 
treatment of Hepatitis C 
with interferon 
CYP2D6 SNPs: more than 50 alleles 
Different 
activity levels 
Poor to Ultrarapid 
Metabolizers 
Table 4. The most important genes, variants and their effects on the enzymatic activities 
involved in pharmacological treatment of gastroenterological diseases. 
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variants of the TMPT coding gene. These variants are associated with the risk of the 
hematologic adverse effects of azathioprine, and its analysis has resulted in favourable 
pharmacoeconomic evaluations.  
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Other polymorphisms, such as the ones in the intracellular glucocorticoid receptor, the 
MDR1 gene that encodes P-glycoprotein and the TNF receptor, warrant further evaluation. 
However, to date there is no incontrovertible evidence regarding their clinical usefulness. 
The identification of polymorphisms in IL28 likely represents a potential new paradigm in 
the treatment of Hepatitis C infection. Genetic testing for antiemetic drugs will likely show 
great potential are expected to be developed in the near future, although their final 
usefulness will only be established after the acquisition of more clinical data. 
Currently, pharmacogenomics only constitutes a tool that can be utilized for personalized 
medicine, and it provides a concrete potential to predict therapeutic responses beyond the 
population level. Because it has been recently developed, it also benefits from the interest 
that is generated by its novelty. In the next few years, it will become more clear which 
aspects of this method can offer specific advantages regarding the efficacy and safety of the 
patients when compared to the aspects that are only of an academic interest.  
However, given the fact that the therapeutic experience with the use of drugs in 
gastroenterology is far from satisfactory, any firm step in the direction of individualizing 
drug treatment will facilitate better patient care. 
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Malaria is globally the most lethal parasitic disease. With an annual number of new cases 
reaching hundreds of millions and a mortality of circa 800.000 (WHO, 2010), this disease 
represents a worldwide major public health concern.  
Malaria generally occurs in tropical and subtropical areas, with most of the lethality focused 
in the African continent, particularly among children under five. The disease further 
commands a major economic impact in the Developing World estimated as a Gross Internal 
Product reduction of more than US$ 6 billion for the year 2010 alone (Sachs and Malaney, 
2002)(WHO, 2010). Such burden has significantly slowed down the social development of 
these regions in the last decades. 
Malaria is caused by an intracellular Protozoan belonging to the genus Plasmodium. P. 
falciparum, P. vivax, P. ovale, P. malariae and P. knowlesi are the five different species able to 
infect humans (Levine, 1988)(Cox-Singh et al., 2008). P. falciparum is responsible for the most 
severe forms of the disease, and hence the near totality of the mortality. 
The parasites are transmitted through an arthropod vector, the dynamics of the disease 
being the result of a complex interplay between the human host, the parasite and its 
mosquito vector.  
2. Plasmodium falciparum – A brief reference to its life-cycle 
As a referential example, the 48-hour life cycle of P. falciparum, the major malaria pathogen – 
and the principal target of complex chemotherapeutic measures – is herein presented.  
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infect humans (Levine, 1988)(Cox-Singh et al., 2008). P. falciparum is responsible for the most 
severe forms of the disease, and hence the near totality of the mortality. 
The parasites are transmitted through an arthropod vector, the dynamics of the disease 
being the result of a complex interplay between the human host, the parasite and its 
mosquito vector.  
2. Plasmodium falciparum – A brief reference to its life-cycle 
As a referential example, the 48-hour life cycle of P. falciparum, the major malaria pathogen – 
and the principal target of complex chemotherapeutic measures – is herein presented.  
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We assume as an arbitrary starting point the moment when a female Anopheles mosquito 
infected with P.falciparum penetrates the human skin to obtain a blood meal. If the 
mosquito saliva is infected with parasite sporozoites, these will be injected into the 
bloodstream of the host. These forms travel in the bloodstream to the liver where they 
invade hepatocytes. In this intracellular environment it rapidly divides asexually, 
generating the next life cycle stage form, the merozoites. These, following the rupture of 
the hepatocyte, are released in the bloodstream. Here, they invade erythrocytes. Once 
inside the erythrocyte, the merozoite develops towards the mature trophozoite stage. 
After these, the parasite undergoes a series of asexual divisions to produce a large 
segmented schizont filled with mono-nucleated merozoites. The erythrocyte then ruptures 
releasing the merozoites, a clinically important event associated to the characteristic 
malaria peaks of fever and chills. These merozoites swiftly reinvade new red blood cells, 
reinitiating the intra-eryrthocytic cycle. In parallel, a small proportion of merozoites take a 
new development route towards becoming sexual forms: the male and female 
gametocytes. These can reinvade the mosquito vector during its blood meal. Inside the 
mosquito, zygotes will form after meiotic events. Further development will lead to the 
formation of oocysts. These, after repeated mitotic divisions, produce a large number of 
sporozoites, which actively migrate to the salivary glands of the mosquito, ready to be 
injected into the bloodstream of a human. The cycle is hence restarted.  
3. Malaria chemotherapy 
Chemotherapy has been the mainstay for the clinical control of malaria for hundreds of 
years. Starting with the introduction of artemisinin rich teas in China 1500 years ago (Hsu, 
2009) and the use of barks containing quinine in South America in the XVII Century (Peters, 
1970), the XX Century saw the development of several synthetic and semi-synthetic 
compounds. Quinine prevailed as the major antimalarial drug used worldwide for near 300 
years, until the advent of the Second World War. The extension of this conflict drove the 
search for alternative synthetic variants. Derived from these efforts, chloroquine (CQ), a 
highly effective 4-aminoquinoline, emerged in the immediate post-War as the global 
mainstay for the treatment and control of malaria (Coatney et al., 1963). By the end of the 
1950s the next major malaria challenge emerged: P. falciparum have been able to develop 
resistance to this drug (Young and Moore, 1961). From two main foci in South East Asia and 
South America, resistance parasites invaded most of the other malaria-affected regions. In 
the late 1970s reached Africa. By the end of the Century the burden of malaria topped in a 
calculated multi-million death toll and an uncontrolled situation in large regions, 
particularly in the African Continent (Marsh, 1998).  
The severity of the situation demanded a change in concept. This came from South East Asia. 
In the late 1980s, Thailand - a region known to be a major cradle for the development of drug 
resistance – was fighting with a steep decrease of efficacy of their main national control 
programme drug, mefloquine (Nosten et al., 1991). A strategy of combining this long half-life 
drug with the fast acting/short half-life antimalarials of the artemisinin class (re-discovered in 
China during the 1970s) saved the former during the next decade (Nosten et al., 2000). 
The success of artemisinin combination therapy (ACT) in the Thai national malaria 
programme drove the rapid adoption, and progressive worldwide implementation of this 
strategy for the treatment of uncomplicated malaria. 
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This relatively new antimalaria strategy is based on the powerful pharmacodynamic action 
of the artemisinin derivatives (ARTs). These, typically artesunate or artemether, are known 
to have a Parasite Reduction Ratio of 1:10.000 (i.e., a reduction towards 0.01% of the initial 
parasitaemia in 48 hours of treatment), orders of magnitude above the typically found with 
long lasting quinoline drugs (White, 1997). This effect is short-lived, due to the characteristic 
very short half live of the ARTs, typically 20 minutes to 2-3 hours (Gautam et al., 2009). 
Upon this first impact, the long-standing partner is expected to handle more efficiently the 
remaining parasite population. The association of drugs with different expected 
mechanisms of action and associated modes of parasite resistance has been deemed as a 
strong deterrent for the development of the latter (Eastman and Fido, 2009). 
The two global main ACTs in use are artemether-lumefantrine and artesunate-amodiaquine. 
(WHO, 2010). The latter represents the main drive for this review. 
4. Amodiaquine  
Amodiaquine (AQ) emerged in the shadow of CQ success, in the late 1940s (Burckhalter et 
al., 1948). Similar to CQ, AQ has a core 4-aminoquinoline structure. Contrarily to CQ it also 
represents a Mannich base. 
AQ was never used to the same extent as CQ due to the large prevalence of the latter in the 
global malaria control programmes until the end of the XX Century. Also, its use was 
severely curtailed in the beginning of the 1990s, upon its removal from the WHO list of 
recommended antimalarials for the treatment of uncomplicated malaria (WHO, 1990). This 
decision followed the emergence of a number of clinical reports on rare (ca. 1:2000) but life-
threatening secondary events associated to its use in prophylaxis regimens among 
Caucasian travellers (Larrey et al., 1986)(Rouveix et al., 1989)(Neftel et al., 1986)(Hatton et al., 
1986). These included in most cases acute agranulocytosis, but also severe liver damage. 
During the 1990s, research - mainly based on in vitro approaches and the use of animal 
models - have pointed for the causing agent to be a toxic short lived quinone-imine (QI) 
metabolite of AQ (Jewell et al., 1995)(Tingle et al., 1995)(Naisbitt et al., 1997). The mode of 
action of this putative metabolite is still under discussion, but it is generally accepted that it 
operates by binding covalently to cell structures or/and as an hapten associated to a specific 
anti-AQ IgG antibody driven immunological response (Clarke et al., 1990). 
The described prophylaxis effects were never formally confirmed in circumstances of the 
regular treatment of uncomplicated malaria. This lack of confirmatory data has raised some 
criticisms concerning a possible over-cautious decision at WHO (Olliaro et al., 1996). In fact, 
the actual usefulness of this decision in a time when the efficacy of CQ was collapsing 
worldwide is still open to discussion. Nevertheless, AQ as a monotherapy kept being used 
in many African and South American regions for decades, both in the public and in the 
private sector. 
Interestingly, the fact that AQ has not been as intensively used as CQ possibly slowed down 
the development of parasite resistance against this drug. AQ was recovered for global use in 
the XXI Century as combination therapy partner, due its low price and capacity to handle CQ 
resistance parasites. Two combinations are available, artesunate-AQ (an ACT), and AQ-
sulfadoxine-pyrimethamine, although the latter has been recently considered to be withdrawn 
from the WHO list of recommended drugs for the treatment of uncomplicated malaria (WHO, 
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2010). Artesunate-AQ (AS-AQ) is particularly prevalent in the African continent, the epicentre 
of malaria mortality and morbidity. The combination represents the first or second line 
antimalarial treatment for uncomplicated malaria in more then twenty sub-Saharan countries 
(www.who.int/entity/malaria/am_drug_policies_by_region_afro/en/). 
AS-AQ is administrated orally in one daily dose, for three days. The present guideline is: 
4mg/Kg/day artesunate + 10mg/Kg/day AQ (WHO, 2010). Contrarily to other 
antimalarials (e.g. lumefantrine, CQ, piperaquine), the age of the patient does not seem to 
affect the plasma concentrations of AQ. The present dosing has shown to be effective in 
areas where resistance to AQ monotherapy was not widespread (<20% of the infections). In 
the event of rising resistance, changes in the formulation might be necessary, namely 
increasing the dosing in AQ. Such changes in the dosing have been applied in the past, e.g. 
with CQ (Peters, 1970) and mefloquine (Carrara et al., 2009).  
Presently, AS-AQ is available as a fixed formulation in three tablet options: 25 mg AS/67.5 
mg AQ, 50 mg AS/135 mg AQ or 100 mg AS/270 mg AQ (Coarsucam®/Winthrop®,Sanofi-
Aventis, Paris; DNDi, Geneva). 
Both AQ and desethylamodiaquine (DEAQ, AQ main active metabolite) show significant 
inter-individual variation on their pharmacokinetic parameters. AQ has a relatively short 
half-life of 4-12 hours (Giao and de Vries., 2000), being readily biotransformed in the liver 
towards DEAQ. DEAQ is a fully active antimalarial that, albeit less potent then AQ 
(Gerstner et al., 2003)(Echeverry et al., 2007) is the main responsible for the long 
pharmacodynamic effect of AQ therapy (Winstanley et al., 1990). DEAQ has a longer half-
life of 3-20 days (Hombhanje et al., 2005)(Hietala et al., 2007). Although AQ has been even 
considered as a pro-drug due to its short half-life, circumstances of extreme AQ exposure 
have been documented where this drug was detected in the urine of patients, months after 
its administration (Winstanley et al., 1987). 
AQ has been associated with both mild and severe adverse events. Mild events include 
mainly gastro-intestinal effects, particularly vomiting (Brasseur et al., 1999)(Adjuik et al., 
2002)(Cairns et al., 2010)(Nankabirwa et al., 2010) and self-reported abdominal pain (Parikh 
et al., 2007)(Bojang et al., 2010), both frequently observed in amodiaquine efficacy clinical 
trials. Most importantly, several studies have noted situations of (clinically asymptomatic) 
neutropenia upon AQ therapies in subsets of the treated population (Staedke et al., 
2001)(Adjuik et al., 2002). Although this relatively common drop in neutrophil count is not 
an exclusive effect of this drug (Nankabirwa et al., 2010), it is possibly linked with the rare 
severe adverse events observed in AQ prophylaxis. Accordingly, in this (now abandoned) 
higher dose regimens of typically 400 mg/week, the most documented serious adverse 
event was agranulocytosis (~1:2000 prevalence), followed by hepatic toxicity 
(~1:16000)(Phillips-Howard and West, 1990)(Hatton et al., 1986). 
The few data available suggest that the AQ adverse events are drug dose dependent (Hatton 
et al., 1986)(Cairns et a., 2010). Although drug associated severe and lethal reactions have not 
been generally observed in AQ regimens for the treatment of uncomplicated malaria 
(Olliaro et al., 1996)(Olliaro and Mussano, 2003), mild events are relatively frequent, being a 
threat for full regimen compliance (e.g. Gerstl et al., 2010), leading to incomplete cure and 
potential selection of resistant parasites. This effect can be decreased through genetic 
evidence-based adjustment of the dose, at a personalized level.  
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In addition, the knowledge of the frequencies of rare genetic variants associated with 
documented AQ-driven adverse events in certain ethnic groups and regions under AQ 
exposure can be useful as a pharmacovigilance tool. As an example, and taking in account 
the surpassing of a specific (evidence-based) threshold of allele frequency, the use of 
alternative first line ACTs (e.g aminoalcohol quinoline based, as artemether-lumefantrine) 
for those regions could be decided. Such type of measures - although not totally preventing - 
have the potential of decreasing the occurrence of serious events. 
It should be noted that such a population pharmacogenetics approach can be of great 
importance: the effect of fatal adverse events in the public opinion can be very significant, 
especially after the 1990s temporary withdrawal of AQ from the WHO list of recommended 
antimalarials. Such dramatic events - in particular involving the typical children under five - 
could lead to a further mistrust of the public about a drug that is pivotal in a large number 
of national malaria control programmes. 
5. The main players of AQ disposition 
As previously mentioned, upon oral absorption AQ is readily metabolized towards the 
pharmacologically active DEAQ. This biotransformation occurs mostly in the liver and is 
almost exclusively performed by the cytochrome P450 (CYP) 2C8 (Li et al., 2002). The high 
specificity of CYP2C8 for this reaction has even led to the proposal of AQ as a specific probe 
drug for this P450 isoform (Walsky et al., 2004). Besides this main step, other putative AQ 
metabolites have been proposed and at least partially confirmed (figure 1). These include 2-
hydroxy-DEAQ (Churchill et al., 1985), N-Bis-DEAQ (Mount et al., 1986) and M2, the latter 
initially detected in the microsome-based seminal studies of Li et al (2002), and recently 
confirmed through in vitro electrochemical approaches (Johansson et al., 2009). A fraction of 
DEAQ itself is believed to also be transformed in 2-hydroxy-DEAQ through P450 action. 
Several of these post-CYP2C8 action steps are catalyzed by members of the CYP1 sub-family 
(Li et al., 2002)(Gil and Gil-Berglund, 2007)(Johansson et al., 2009). 
Most importantly, both AQ and DEAQ are able to generate the highly reactive quinone-
imine (QI) metabolite responsible for the described serious side affects of AQ therapies. 
DEAQ is considered less prone to create QIs (Tingle et al., 1995), reinforcing the action of 
CYP2C8 over AQ as a protective event. The generation of these compounds has been 
previously proposed to occur spontaneously, but recent investigations have pointed to a 
fundamental role of CYP1A1 and CYP1B1 as well as the family of myeloperoxidases in the 
process. In this processes, the M2 metabolite initially identified by Li et al. has been 
proposed to be a central player in the generation of the toxic QIs (Johansson et al., 2009). 
Taking in account the fact that these species are most likely short-lived, it is expected that 
the enzymes involved in its generation will be present in the location of its toxic action. 
Suggestively, CYP1A1 and CYP1B1 are essentially extra-hepatic P450 isoforms, with 
confirmed expression in several blood cell types (e.g. leukocyes)(Furukawa et al., 2004), the 
most frequent location for these fatal toxicities (neutropenia). 
Scarce information is available concerning other ADME phases in AQ metabolism. The 
analysis of QI adducts in animal models have pointed for the presence of glutathione 
conjugates, although no specific isoform has ever been determined (Masubuchi et al., 2007). 
The potential production of phase II metabolites further points to the likely involvement of 
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phase III (transport) systems. The most common phase III glutathione conjugate 
transporters are the members of the ATP binding cassette (ABC) superfamily of proteins, 
and more specifically of the ABCC (also referred as MRP) type of transporters.  
A summarized proposal of the complex metabolism of AQ is presented in figure 1. 
 
 
Abbreviations - 1A1: CYP1A1; 1B1: CYP1B1; DEAQ:desethylAQ; QI: quinoneimine;  
N-bis DEAQ: bis-desethylAQ; C8: compound 8; C9: compound 9; C10: compound 10;  
QI-GS: quinoneimine-glutathione conjugates; GST: glutathione S-transferase;  
MRPs: multidrug resistance proteins.  
Fig. 1. The metabolism of AQ. Although the main biotransformation in this process is the 
synthesis of DEAQ, a constellation of minor – but most likely non-negligible – metabolites 
have been proposed to result in parallel (Churchill et al., 1985)(Mount et al., 1986)(Li et al., 
2002). Most importantly, events leading to the formation of the toxic QIs, involving both AQ 
and DEAQ are included among them. The presented scheme represents a summary of the 
available data from in vitro studies with microsomes, animal models, the few available 
human in vivo data, as well as the most recent information utilizing electrochemical 
approaches to simulate drug oxidation in vitro (Harrison et al., 1992)(Jewell et al., 
1995)(Tingle et al., 1995)(Naisbitt et al., 1997)(Li et al., 2002)(Johansson et al., 2009). 
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The previously identified M2 metabolite (Li et al., 2002) seems to be a central component in 
the generation of the QIs from both AQ and DEAQ, with CYP1A1 and CYP1B1 being the 
main enzymes involved in the process (Johansson et al., 2009). The QIs have been proposed 
to result from the action of myeloperoxidases, an event that is herein tentatively proposed to 
involve the M2 metabolite, although a direct action of these enzymes in both AQ and DEAQ 
cannot be disregarded. 
In vitro electrochemical approaches have generated a number of putative compounds, the 
most relevant being indicated here (C8, C9 and C10). This complex of compounds, due to its 
expected hydroxylated structures has been proposed to most likely represent the previously 
reported 2-hydroxy-DEAQ (Churchill et al., 1985). 
6. The pharmacogenetics of AQ metabolism 
As described, based on current knowledge, three main drug metabolizing enzymes are 
involved in the biotransformation of AQ: CYP2C8 (the main one), CYP1A1 and CYP1B1. All 
of them harbour significant genetic polymorphisms, some with marked effects in the 
catalytic activities of the respectively coded proteins. 
6.1 CYP2C8  
The CYP2C8 comprises nine exons. 14 alleles have been annotated in the gene coding for 
this 490 amino acid enzyme (http://www.cypalleles.ki.se/cyp2c8.htm), most of them rare. 
Apart from the most prevalent alleles, 2C8*1 (wild type), 2C8*2, 2C8*3, and 2C8*4, the 
majority of the remaining ones (2C8*5 - 2C8*12, see figure 2) have been identified only in the 
Japanese population (Soyama et al., 2001)(Nakajima et al., 2003). Few works have evaluated 
the presence of these minor alleles in other regions (Cavaco et al., 2006)(Suarez-Kurtz  
et al., 2010), although the output of large consortium projects (e.g. HapMap, 
www.sanger.ac.uk/resources/downloads/human/hapmap3.html) supports the view of 
these alleles being specific among the Japanese. On the other hand, 2C8*2, 2C8*3 and 2C8*4 
are rare in this population. (Nakajima et al., 2003)(table 1). 
African settings represent the major context where AQ therapy is practiced, both in 
combination with artesunate or sulfadoxine-pyrimethamine. The first CYP2C8 
pharmacogenetic study in endemic African populations was performed in East African 
populations, in the islands of Zanzibar (Cavaco et al., 2005)(table 1). In this population all the 
most studied mutant alleles, namely 2C8*2, 2C8*3 and 2C8*4, were detected.  Further studies 
in other regions of the continent have confirmed 2C8*2 as the main allele among the native 
populations (see table 1). Interestingly, outside Zanzibar, 2C8*3 (when found) has been 
documented at lower frequencies, while 2C8*4 has not been detected at all. These results 
point to the populations of Zanzibar as somewhat particular, perhaps due to the 
historical/migration influences from the Arabian Peninsula (Low and Smith, 1976).  
The data from native African populations was consistent with previous reports in African-
American, where the 2C8*2 allele represents the main mutant allele in Black populations 
(table 1), with the non-active 2C8*3 mostly present among Caucasians (Cavaco et al., 2006). 
A number of in vitro studies have been performed to characterize the phenotypic effect of 
the CYP2C8 polymorphisms. 
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Region (n*) 2C8*2 2C8*3 2C8*4 Reference 
     
Zanzibar (Unguja and Pemba)(n= 165) 13.9% 2.1% 0.6% Cavaco et al., 2005 
Ghana (Accra)(n= 204) 17.9% 0% 0% Kudzi et al., 2009 
Ghana (n= 92) 17.9% n/ta n/ta Adjei et al., 2008 
Ghana (Tamale) (n= 200) 16.8% 0.0% 0.0% Rower et al., 2005 
Burkina Faso (Bobo-Dioulasso) (n=275) 11.5% 0.4% n/t Parikh et al., 2007 
     
Southern India (n=245) 0.8% 2.9% n/t Arun Kumar et al., 2011 
Malaysiab (n= 57) 0.8% 1.2% 0% Muthiah et al., 2005 
South East Asia (n= 20) c 0.0% 5.0% 0% Solus et al, 2004 
     
Papua-New Guinea (Madang) (n = 305) 0% 0% 0% Hombhanje et al., 2005 
     
Brazil (scattered regions)(n= 1034)d 6.4% 8.6% 3.4% Suarez-Kurtz et al., 2010 
*number of subjects analysed; n/t (non tested) 
a Any 2C8*3 or 2C8*4 alleles present confounded in the 2C8*1 group. 
b Indian ethnic group 
c Derived from a commercial repository – no specific origin disclosed. 
d Ethnically mixed populations, originated from several scattered regions of the country. The sample is 
claimed by the authors to be representative of the present day Brazilian population; when considering self-
reporting ethnic origin, the 2C8*3 frequency increased among “White” subjects, while the *2 among “Black” 
individuals. 
(note: this compilation is intended to be a representative sample of the published information and not an 
exhaustive collection of the available data) 
Abbreviation – CYP2C8: 2C8 
Table 1. CYP2C8 main allele frequencies in populations from malaria endemic regions 
(Africa, Asia, Oceania and South America).  
The CYP2C8*2 allele is characterized by the presence of an I269F SNP. Quantitative 
HPLC/UV analysis of the DEAQ resulting from in vitro incubations of recombinant 
CYP2C8*2 enzyme with AQ pointed to a significant decrease of approximately 30% in the 
Vmax, (maximum substrate transformation rate) as compared with the wild-type (2C8*1) 
reference (0.16 ± 0.06 µmol/min/µmol P450 vs 0.23 ± 0.09 µmol/min/µmol P450).  
In parallel, the mutant allele was associated with a three-fold increase in its Km (substrate 
concentration at which the reaction reaches half of the Vmax value) (2.55 ± 1.06 µM vs  
0.81 ± 0.23 µM) (Parikh et al., 2007). This decreased performance was reflected in a 
significantly lower intrinsic clearance (Vmax/Km) of AQ (2C8*2: 0.05 l/min/µmol P450 vs 
2C8*1: 0.30 l/min/µmol P450). As for the CYP2C8*3, the presence of the two linked 
mutations characterizing this protein (R139K and R399K) had a marked effect on its catalytic 
capacities, with no AQ metabolism detected at any of the tested substrate concentrations 
(Parikh et al., 2007). It was concluded that the 2C8*3 protein has very low AQ metabolism 
activity. These results obtained with AQ are supported by data from previous studies using 
the CYP2C8 probe drug paclitaxel (Dai et al., 2001).  
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As for 2C8*4, in vitro experiments by Singh et al. have reported this protein as having a 10 
fold decrease in paclitaxel 6-alpha hydroxylase activity. The associated SNP (I264M, see 
figure 2) was proposed to affect heme insertion and the correct folding of the protein (Singh 
et al., 2008). It is expectable that this also represents a low activity allele as for the 
biotransformation of amodiaquine. 
More recently, Gao and collaborators performed tests based on the heterologous expression 
of 2C8*2, 2C8*3 and 2C8*4 in Saccharomyces cerevisae. Microsomes prepared from the 
transfected yeast cells were incubated with different concentrations of AQ. The experiments 
showed a decrease in the overall activity of the mutant alleles towards ~ 45-75% of the wild 
type values (Gao et al., 2010). The reasons behind the observed large differences in the 
capacities of these alleles between the microsome based systems and the in vitro based ones 
(i.e. reconstituted protein) are not fully clear. 
Some of the remaining minor alleles have been studied in some detail in Japan. The 2C8*5 
allele carries a 475delA mutation causing a frameshift effect leading to a premature 
translation termination at residue 177, and hence no functional protein (Soyama et al., 2002). 
Using microsomes obtained from CYP2C8 transfected COS-1 cells, the 2C8*6, 2C8*9 and 
2C8*10 proteins were shown not to significantly differ from the wild type (2C8*1) on 
paclitaxel 6-alpha hydroxylase activity. As for 2C8*8, this allele showed more than ten fold 
decrease in catalytic activity, associated with a less stable protein. As expected, 2C8*7 – 
involving the introduction of a translational stop codon - had no detectable enzyme activity 
(Hichiya et al., 2005). Finally, Hanioka and collaborators have recently used the same yeast 
system for testing the 2C8*13 and 2C8*14 alleles. While 2C8*13 did not show significant 
differences in Vmax and Km for paclitaxel 6-alpha hydroxylation as compared with 2C8*1, 
2C8*14 showed a 3 fold higher Km, albeit with no changes in the Vmax. 
A summary of relevant CYP2C8 SNPs and the associated phenotype characteristics is 
presented in figure 2. 
In vivo, there is limited information on the impact of CYP2C8 polymorphisms in AQ 
therapy, both in terms of efficacy and risk of adverse events. 
Parikh and collaborators have performed a retrospective analysis of an AQ monotherapy 
efficacy trial searching for in vivo phenotype/2C8 genotype associations (Parikh et al., 2007). 
The study involved 275 uncomplicated malaria patients from the region of Bobo-Dioulasso, 
southwest Burkina Faso. No associations were found between the clinical success of AQ 
therapy and the presence of minor CYP2C8 alleles (2C8*2 and 2C8*3). This is probably due 
to the fact that DEAQ, the main AQ metabolite, also represents a fully active antimalarial 
entity, i.e. enhanced AQ metabolism does not lead to an inactive metabolite that would 
decrease the clinical (pharmacodynamic) success of the therapy. More importantly, Parikh et 
al found a positive correlation between harbouring a 2C8*2 allele and events of mild side 
effects, mainly abdominal pain (self reported): 52% of occurrences among the 2C8*2 carriers 
versus 30% for the 2C8*1/*1 subjects. This is until now the only reported association between 
the patient CYP2C8 status and effects of AQ therapy. Another trial, performed in Ghana did 
not report such an association (Adjei et al., 2008). It also did not find clear associations 
between the pharmacokinetic parameters of AQ and the presence of less active alleles, 
although a trend for decreased DEAQ plasma concentrations among the 2C8*2 carriers was 
noted. It must be noted however, that the smaller size of this study (n=92) might have 
prevented the detection of such associations.  
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Region (n*) 2C8*2 2C8*3 2C8*4 Reference 
     
Zanzibar (Unguja and Pemba)(n= 165) 13.9% 2.1% 0.6% Cavaco et al., 2005 
Ghana (Accra)(n= 204) 17.9% 0% 0% Kudzi et al., 2009 
Ghana (n= 92) 17.9% n/ta n/ta Adjei et al., 2008 
Ghana (Tamale) (n= 200) 16.8% 0.0% 0.0% Rower et al., 2005 
Burkina Faso (Bobo-Dioulasso) (n=275) 11.5% 0.4% n/t Parikh et al., 2007 
     
Southern India (n=245) 0.8% 2.9% n/t Arun Kumar et al., 2011 
Malaysiab (n= 57) 0.8% 1.2% 0% Muthiah et al., 2005 
South East Asia (n= 20) c 0.0% 5.0% 0% Solus et al, 2004 
     
Papua-New Guinea (Madang) (n = 305) 0% 0% 0% Hombhanje et al., 2005 
     
Brazil (scattered regions)(n= 1034)d 6.4% 8.6% 3.4% Suarez-Kurtz et al., 2010 
*number of subjects analysed; n/t (non tested) 
a Any 2C8*3 or 2C8*4 alleles present confounded in the 2C8*1 group. 
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exhaustive collection of the available data) 
Abbreviation – CYP2C8: 2C8 
Table 1. CYP2C8 main allele frequencies in populations from malaria endemic regions 
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In parallel, the mutant allele was associated with a three-fold increase in its Km (substrate 
concentration at which the reaction reaches half of the Vmax value) (2.55 ± 1.06 µM vs  
0.81 ± 0.23 µM) (Parikh et al., 2007). This decreased performance was reflected in a 
significantly lower intrinsic clearance (Vmax/Km) of AQ (2C8*2: 0.05 l/min/µmol P450 vs 
2C8*1: 0.30 l/min/µmol P450). As for the CYP2C8*3, the presence of the two linked 
mutations characterizing this protein (R139K and R399K) had a marked effect on its catalytic 
capacities, with no AQ metabolism detected at any of the tested substrate concentrations 
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fold decrease in paclitaxel 6-alpha hydroxylase activity. The associated SNP (I264M, see 
figure 2) was proposed to affect heme insertion and the correct folding of the protein (Singh 
et al., 2008). It is expectable that this also represents a low activity allele as for the 
biotransformation of amodiaquine. 
More recently, Gao and collaborators performed tests based on the heterologous expression 
of 2C8*2, 2C8*3 and 2C8*4 in Saccharomyces cerevisae. Microsomes prepared from the 
transfected yeast cells were incubated with different concentrations of AQ. The experiments 
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the patient CYP2C8 status and effects of AQ therapy. Another trial, performed in Ghana did 
not report such an association (Adjei et al., 2008). It also did not find clear associations 
between the pharmacokinetic parameters of AQ and the presence of less active alleles, 
although a trend for decreased DEAQ plasma concentrations among the 2C8*2 carriers was 
noted. It must be noted however, that the smaller size of this study (n=92) might have 
prevented the detection of such associations.  
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These are the only two published studies exploring the impact of the CYP2C8 
polymorphism in AQ based therapies, while near 100 million treatments performed in the 
last five years (WHO, 2010). It is evident that there is an urgent need of further research in 
this area, in order to guarantee the longest “useful life” for this drug, presently a cornerstone 
in the global control of malaria. 
6.2 CYP1A1  
CYP1A1 represents a 512 amino acid cytochrome P450 enzyme mainly expressed in extra-
hepatic tissues, including the lungs (Willey et al., 1997), intestine (Paine et al., 1999)(Paine et 
al., 2006), placenta (Hakkola et al., 1996) and, importantly, lymphocytes (Dey et al., 2001, van 
Duursen et al., 2005). It is usually present at low constitutive baseline levels. The gene is 
readily inducible through the AHR (Aryl Hidrocarbon Receptor) regulatory pathway, 
typically by exposure to PAHs (polycyclic aromatic hydrocarbons, e.g. components of 
tobacco smoke). Upon induction, CYP1A1 can also be found in the liver, where it usually is 
at very low (pre-induction) baseline levels. CYP1A1 is able to metabolize a number of 
clinically relevant drugs, including the calcium blocker flunarizine, the anticancer drug 
toremifene and the cardiovascular disease drug fluvastatin. Significant inter-individual 
variability in the elimination of these drugs has been described. This variability is probably 
of minor clinical concern, due to the non-hepatic patterns of expression of the gene. In the 
context of this review, the importance of CYP1A1 is mainly focused in its probable 
involvement in the generation of short lived but toxic AQ metabolites (Johansson et al., 
2009). 
The CYP1A1 gene (15q24.1) is organized in 7 exons. It harbours significant polymorphisms, 
comprising eleven established alleles (figure 2), as well as a number of SNPs with haplotype 
associations still to be assigned (http://www.cypalleles.ki.se/cyp1a1.htm). A significant 
portion of the non-synonymous polymorphisms is concentrated at exon 7 (figure 2)(table 2).  
The CYP1A1*2 allele has been documented in vitro to represent a more drug responsive gene 
upon exposure to the prototype inducer 2,3,7,8-tetrachlorodibenzo-para-dioxin 
(TCDD)(studies with the 1A1*2A and 1A1*2B haplotypes)(Spurr et al., 1987)(Landi et al., 
1994). Also, at least in the case of 1A1*2B and 1A1*2C, this allele was shown to code for more 
active enzymes (Cosma et al., 1993). The increased transcriptional response is related to the 
presence of a T3801C transition in the gene’s 3’ UTR, while the referred enhanced enzymatic 
activity (reflected specifically in an increased Vmax) is linked with a non-synonymous I462V 
SNP at exon 7 (Cosma et al., 1993). This enhanced activity of the proteins harbouring 462V 
(1A1*2B and 1A1*2C) was also confirmed in terms of estrone and 17 ß-estradiol 2-
hydroxylation, as a 5-10 fold increase in comparison to the wild type (Kisselev et al., 2005).    
The T461N SNP (defining 1A1*4) was shown not to alter significantly the behaviour of its 
coded enzyme (Kisselev et al., 2005). As for the 3’ UTR T3204C transition defining the 1A1*3 
allele (proposed to be specific of African populations) it does not seem to influence the levels 
of CYP1A1 expression (Smart and Daly, 2000). 1A1*7 represents a frameshift mutation 
leading to the generation of a stop codon and hence precluding the production of an active 
enzyme. Finally, alleles 1A1*8 (T448N), 1A1*9 (R464C) and 1A1*10 (R477W) carry non-
synonymous SNPs located close to the protein heme binding protein, and are hence 
expected to affect the activity of the enzyme (Saito et al., 2003). 
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Region (n*) 1A1*2 1A1*7 1A1*3 1A1*4 Reference 
      
Namibiaa (n= 134) 14.9%b n/t n/t n/t Fujihara et al., 2009 
Southwest Libya (El Awaynat 
and Tahala)c (n=129) 6.5%
d n/t 0% 18.1% Martinez-Labarga et al., 2007 
Midwest and Southeast Nigeria 
(n= 250) 24.2%
e n/t 13% 0% Okobia et al., 2005 
South Africaf (n= 96) 0% g n/t n/t n/t Dandara et al., 2002 
Zimbabwe  (n= 148) 0% g n/t n/t n/t Dandara et al., 2002 
Tanzania (n= 114) 1.3% g n/t n/t n/t Dandara et al., 2002 
Mali (n=116) 24.0% g n/t n/t n/t Garte et al., 1998 
      
East India (Chennai) (n=150) 33% g n/t n/t n/t Suneetha et al., 2011 
Southwest India (Kerala)  
(n = 146) 20.9% n/t n/t n/t Sreeja et al., 2005 
Northern India (Delhi) (n= 309) 71.4%h n/t n/t 0% Kumar et al., 2010 
Northern Thailand 
(Lampang)(n= 287) 84.9%
h,i n/t n/t n/t Pisani et al., 2006 
China (Peking)(n= 284)j 28.2%h n/t n/t 0% Zhang et al., 2010 
* number of subjects analyzed; n/t: not tested 
a Bantu (Ocambo) ethnicity 
b T3798C tested, defining the presence of 1A1*2A or 1A1*2B. As the I462V was not determined (1A1*2C 
contribution not included) it is not possible to distinguish between these two forms. 
c Although these are regions not directly affected by malaria, the nomadic characteristics of the Tuareg 
populations under study puts them in risk when travelling to sub-Saharan areas (e.g. Northern Mali, 
Mauritania) 
d 1A1*2A= 4.5%, 1A1*2B= 0.2%, 1A1*2C=1.8% 
e 1A1*2A= 24%, 1A1*2C= 0.2%. Data on 1A1*2B not available. 
f Venda ethnicity 
g Only T3798C tested, so the data should be considered as the result of the 1A1*2A + 1A1*2B composite. 
h T3798C and I462V tested but no information on the composite of the two giving rise to *2B 
i 286 subjects analysed for 1A1*2A 
j Only the I462V analysed so 1A1*2A not included and 1A1*2B contribution not available 
(note: this compilation is intended to be a representative sample of the published information and not an 
exhaustive collection of the available data). 
Abbreviation - CYP1A1: 1A1 
Table 2. CYP1A1 allele frequencies of population from malaria affected regions of Africa and 
Asia. 
6.3 CYP1B1 
Similarly to CYP1A1, the expression of the CYP1B1 isoform is also predominantly extra-
hepatic, including peripheral blood cells (Hanaoka et al., 2002)(Furukawa et al., 2004), and it 
is inducible by exposure to several xenobiotics, namely PAHs (Nebert et al., 2004). 
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Null alleles are rare in the general population. Most were identified among patients with 
glaucoma, for which these alleles are an established risk factor (Stoilov et al., 1998), and are 
not a major concern in the context of this review. The main polymorphic positions in this 
gene are summarized in figure 2. 
The functional consequence of the major CYP1B1 alleles has been studied in vitro upon 
heterologous expression in E. coli and the quantification of the enzyme’s capacity of 
catalyzing the 4- and 2- hydroxylation of estradiol. The introduction of the R48G, A119S and 
N453S SNPs did not significantly change the Vmax and Km of the resulting proteins, as 
compared with the wild type (1B1*1) (Li et al., 2000). The L432V SNP was on the other hand 
associated increased of circa 3 fold in the Km. Later works using Saccaromyces cervisae 
heterologous expression systems supported the view of L432V carrier proteins as less active 
(>Km values <Vmax values). Interestingly, in these works this effect was only observed in the 
context of a SNP haplotype including other polymorphic positions (R48G + A119S + 
L432V)(Aklillu et al., 2002). Finally, several minor allele of this SNP (present in the 1B1*3, 
1B1*5, 1B1*6 and 1B1*7 alleles) have been proposed as associated with a transcriptionaly less 
active gene (Helmig et al., 2009, 2010). 
Presently there is still scarce information available concerning the CYP1B1 allele frequencies 
in populations living in malaria regions (table 3). 
 
Region (n*) 1B1*2 1B1*3 1B1*4 1B1*5 1B1*6 1B1*7 Reference 
        
Ethiopia (Adis Ababa) 
(n=150) 36.7% 39.0% 2.0% 0.7% 6.3% 7.0% 
Aklillu et al., 
2002 
        
North India (Lucknow) 
(n=200) 33.0% 21.3% 18.3% n/t n/t n/t Shah et al., 2008 
South Central Chin 
(Chengdu) (N= 400a) n/t 57.5%
b n/t n/t n/t n/t Wang et al., 2011 
Northeast China (Nanjing) 
(N= 227) n/t 15.1%
c n/t n/t n/t n/t Liang et al., 2005 
* number of subjects analyzed; n/t: not tested. 
a Only women were included in the study. 
b Only the L432V SNP was analysed, meaning that the declared frequency for 1B1*3, also is likely to 
include also the 1B1*5, 1B1*6 and 1B1*7 alleles. 
c Only women included in the study. The sole analysis of the A119S does not distinguish between the 
1B1*2, 1B1*6 and 1B1*7. 
(note: this compilation is intended to be a representative sample of the published information and not an 
exhaustive collection of the available data). 
Abbreviation – CYP1B1: 1B1 
Table 3. CYP1B1 allele frequencies of population from malaria affected regions in Africa and 
Asia. 
 




a Haplotype not determined yet (reference SNP: rs11572102, NCBI 
(http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=11572102);  
b Discovered by Soyama et al., 2001 and phenotypically characterized by reduced catalytic activity 
(Soyama et al., 2002)(Jiang et al., 2011). 
c The colour code was herein applied according to the data of Aklillu et al. (2002). It is to note that initial 
studies by Li et al (2000) noticed a significant decrease in the activity of the protein. 
Fig. 2. Genetic diversity of CYP2C8, CYP1A1 and CYP1B1, the main polymorphic genes 
involved in AQ phase I metabolism. Although the gene structures are represented, the 
locations of established polymorphisms are presented using the amino acid nomenclature as 
this is more relevant for the present review. For the sake of clarity, only the most studied 
alleles, with established haplotype structures are presented. Alleles shown in red color 
indicate protein products reported to be less active than the reference wild type (*1). Alleles 
in green do not have a significant differences as compared with *1, whereas alleles flagged 
in blue have higher activity than the wild type. For alleles in black there is currently no 
experimental information available. In the case of the CYP1B1 the use of the colors is restricted 
to alleles (and not SNPs) due to the availability of haplotype data (Akillilu et al., 2002). 
7. The CYP2C8, CYP1A1, CYP1B1 trio - Potential implications 
In terms of therapeutic efficacy, since DEAQ is a powerful and clinically valuable 
antimalarial, variations in the CYP2C8 enzymatic capacity are not expected to have 
significant pharmacodynamic consequences. As mentioned, this expectation is in line with 
observations by Parikh et al in Burkina-Faso, where the presence of CYP2C8*2 did not 
influence the treatment outcome of AQ monotherapy. On the other hand, pharmacogenetics 
might be of particular importance in the identification of individuals in higher risk of 
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observations by Parikh et al in Burkina-Faso, where the presence of CYP2C8*2 did not 
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developing AQ-related adverse events. This is supported by the observation in the same 
study that the presence of CYP2C8*2 (still an allele associated with significant catalytic 
capacity, as compared with the much less functional 2C8*3 and 2C8*4) can influence the 
individual risk for mild adverse events, even in heterozygous form could. 
Recently in vitro evidence was published supporting the involvement of CYP1A1 and 
CYP1B1 in the generation of toxic QIs from AQ (and DEAQ) (Johansson et al., 2009). This 
confirmation of preliminarily reports (Li et al., 2002, I. Cavaco, Universidade do Algarve, 
unpublished) has opened a new perspective towards individualization of AQ therapy to 
minimize adverse events. In fact, contrarily to the previous view of a spontaneous formation 
of QIs (Tingle et al., 1995), the involvement of these polymorphic P450s reinforces a broader 
genetic basis for the phenomenon, which was until now almost exclusively focused on 
CYP2C8 (Cavaco et al., 2005). The now recognized more extensive genetic background of AQ 
adverse drug events underlines the importance of individualized medicine and the 
possibility to identify appropriate molecular markers for predicting response to 
treatment/risk of adverse reactions. 
With this new data, the hypothetical characterization of the sub-group of subjects in higher 
risk is starting to emerge. The first assumption is that such individuals carry a deficient 
CYP2C8 gene (2C8*2, ideally the very low active 2C8*3 or 2C8*4), allowing an extended half-
life for AQ (Parikh et al., 2007). This will probably represent the group with T1/2 values >12 
hours (Giao and de Vries, 2001), as well as the observed outliers showing very long 
exposure to the drug (Winstanley et al., 1987). With this increased pool of circulating AQ (as 
previously referred, a compound more prone than DEAQ for the formation of the QI 
reactive species (Tingle et al., 1995)), the drug will have higher chances to be extra-
hepatically catalysed by CYP1A1 and CYP1B1 - both present in leucocytes, where AQ tends 
to accumulate (Naisbitt et al., 1997). The rate of QI formation is expected to be further 
enhanced if particularly efficient versions of CYP1A1 and CYP1B1 are present, namely the 
CYP1A1*2, and CYP1B1*1 (wild type) enzymes. The resulting enhanced generation of QIs in 
the blood, coupled with the referred low CYP2C8 activity could be the basis of the 
previously documented AQ induced severe agranulocytosis. 
Interestingly, the involvement of CYP1A1 and CYP1B1 has another implication: In adult 
patients whom are smokers, both genes are likely to be induced by the polycyclic aromatic 
hydrocarbons (PAHs), which is present in tobacco smoke, through the activation of the aryl 
hydrocarbon receptor (AhR) based pathway (Nebert et al., 2004). This will also lead to the 
expression of these genes in the liver, another location for fatal AQ induced toxicity. Adult 
patients are characteristic of areas of low transmission, where the low exposure during the 
earlier periods of life does not allow the development of natural immunity to the diseases as 
an adult (premunition, frequent in the African continent (Struik and Riley, 2004)). Such 
malaria settings are the norm in South America regions, where populations carry a 
significant Caucasian genetic background and hence, an expected high frequency of the 
CYP2C8*3 allele. This has been confirmed in a pilot screening study conducted in 
populations of Northern Colombia where the frequency of this allele was ca. 7% (I. Cavaco, 
Universidade do Algarve, unpublished). In such areas it would be worthwhile to conduct 
trials in order to understand the influence that tobacco habits might have in the incidence of 
mild and serious adverse events associated to AQ treatments. Its connection with the 
CYP2C8/CYP1A1/CYP1B1 polymorphic set would be of interest, e.g. identifying patients 
that should be advised to decrease their smoking rate in time periods relevant for treatment. 
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Currently the epicentre of AQ use is in the Africa where the 2C8*3 and 2C8*4 alleles seem 
to be rare in the native populations. However, this observation is based on a very limited 
number of small studies, surely not representative of the overall population of the 
continent, the genetically most diverse on the planet (Lambert and Tishkoff, 2009). In 
addition, even though these alleles are considered “rare”, one has to take into account the 
dimensions of the malaria control challenge. A frequency of 1% for the 2C8*3 allele in a 
universe of at least 20 million AS-AQ treatments performed per year (WHO, 2010 - just 
the public sector, and not counting with the SP-AQ combination), would translate to 
~2,000 homozygotes for 2C8*3 patients per year. Secondly, AQ resistance, although still 
not globally prevalent, is slowly increasing (Holmgren et al., 2006). Its potential expansion 
might lead to the need for increased drug dosage, as previously decided in the cases of 
CQ (Peters, 1970)(Ursing et al., 2009, 2011) and mefloquine (Carrara et al., 2009). By 
approaching the top of the AQ therapeutic window, the risks of toxicity will increase to a 
point when serious side effects might be “under the reach” of the less compromised 2C8*2 
allele. 
8. The CYP2C8, CYP1A1, CYP1B1 trio  - Potential applications 
Pharmacogenetic markers in AQ therapies are expected to serve mostly as surveillance tools 
of adverse events of the drug. The identification of individuals with a genetic predisposition 
to AQ side effects (e.g. a 2C8*2/*2 carrier) would prompt the direct diversion of this patient 
towards different doses or the available second line treatment (e.g. artemether-lumefantrine 
or artesunate-mefloquine).  
An alternative therapeutic strategy could be the use of a more personalized (i.e. more 
optimized) AQ dosing, with values below the conventional 10 mg/Kg, or through a 
different regimen schedule. As the incidence of side effects is dose dependent (Cairns et al., 
2010), individualized treatment would be expected to reduce those events. The success of 
such strategies could boost the patient’s (and specially their guardians) trust on the 
treatment, leading to increased compliance to the full dosing regimen. This effect has been 
witnessed with the anti-HIV drug abacavir, where the application of pharmacogenetic 
testing has increased the use of this drug (Ingelman-Sundberg, 2008)(Chaponda and 
Pirmohamed, 2011). Unfortunately, clinical studies to support future guidelines concerning 
the ideal dose for certain pharmacogenetic configurations are clearly missing. Initiatives to 
address this issue, such as the WANECAM Consortium in East Africa, are presently under 
way (see: www.edctp.org/annualreport2010/EDCTP_Annual_Report_2010_English.pdf). 
The application of pharmacogenetics can contribute to an extended useful life of AQ, 
through its better use. Chemotherapy represents a central strategy for the long desired 
global elimination of the disease (malERA Consultative Group on Drugs, 2011), an event 
fundamental for the social-economical development of the Developing World. AQ is one of 
its central tools in these efforts (Bhattarai et al., 2007) – its safer and consequently longer use 
can be pivotal in this process.  
But, although promising, are these pharmacogenetic applications possible in the present 
context of the Developing World health systems? In short, no. The prices of 
pharmacogenetic testing are still very high, totally eclipsing the costs of the therapy itself. 
A complete AS-AQ treatment in Africa will cost below US$5, already taking in 
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consideration a price of US$ 0.5-1 for the Coarsucam®/Winthorp® fixed combination 
supplied by Sanofi-Aventis (Shillcutt et al., 2008). As previously calculated (Ferreira et al., 
2008), the analysis of the CYP2C8*3 allele alone will demand a minimum of US$50, taking 
in account the local costs of human resources and reagents. An upgrade towards the 
determination of the CYP2C8*2 allele, plus CYP1B1*2 and CYP1A1*2, would increase the 
financial burden per patients to values well above US$ 100 per patient, the equivalent of 
more than one hundred treatments. Besides, the maintenance of a system with the 
required quality standards for molecular diagnostic analysis would be in the order of 
many tens of thousands of US$/year. All this has to be put further in the context of 
populations with an available national health expenditure of less then 
US$25/year/citizen. The pharmacogenetic testing for AQ therapy alone would consume 
the funds of four years of health care. 
So, what is the translational value of pharmacogenetics in such scenario? In fact there are at 
least two venues of development. 
The first is what will be called here as “population pharmacogenetics”. As explained, the 
application of individual dose adjusted AQ therapies based on pharmacogenetics is 
essentially not viable. Alternatively, the study of the allele frequencies of pivotal markers 
in representative samples of specific populations/regions can be of considerable interest 
for national and regional health programmes, particularly in countries with a rich ethnic 
diversity, as it is frequent in the African continent. This would define the populations 
where therapeutics based in AQ would be safe, and the ones where an alternative 
antimalarial (like artemether-lumefantrine) would be the better choice. In a way, it would 
be the equivalent of rationally deciding not to introduce AQ in Europe, due to the high 
prevalence of the CYP2C8*3 allele (Cavaco et al., 2006). Several malaria endemic countries 
have more than one first line recommended treatment (e.g. Burkina Faso, Mali, Colombia, 
Peru (http://www.who.int/malaria/publications/treatment-policies/en/index.html), 
having as such a start up capacity for implementing region-specific policies. Such a 
programme could be centralized taking advantage of pre-existing molecular technology 
facilities used e.g. for molecular parasitology. In this context it is worth mentioning that 
new techniques are surfacing for the extraction of DNA from Rapid Diagnostic Tests  
(P. Ferreira, Karolinska Institutet, pers. commun)(Alam et al., 2011). These can be further 
coupled with novel inexpensive amplification-free genotyping approaches (Aw et al., 
2011), allowing the ready molecular characterization of the patient in field settings.  
Such an application of pharmacogenetics would aid evidence-based decisions for optimized 
antimalarial use, at a population level. This would allow the use of safer ACT alternatives 
for the benefit of specific populations. 
The second venue has to do with the target country. Malaria is a significant public health 
concern in three of the “BRIC” emerging economies: Brazil, India and China. These large 
countries are rapidly developing economic capacity compatible with a first large scale 
application of personalised anti-infection therapies. In this context, it should be noted that 
the populations of Brazil and India (incidentally, the ones with larger malaria burden) have 
been shown to harbour non-negligible CYP2C8*3 frequencies (Arun Kumar et al., 
2011)(Suarez-Kurtz et al., 2010)(table 1). In these countries the resources for personalized 
medicine as previously described are potentially available. 
 




Although tens of millions of AQ doses are prescribed per year, the knowledge of the 
pharmacogenetics of this drug is still limited. In particular, stronger in vivo 
phenotype/genotype associations are needed for the definition of genetic markers of AQ 
overexposure risk.  
This must be obtained through several venues. A basic need is the performance of clinical 
trials designed for the detection of adverse events, mild or eventually serious. These are 
needed to be relatively large (>500 subjects), due to the non-precise nature of the former (e.g. 
self reported abdominal pain in children under five), and the rarity of the latter. Such studies 
must include a long follow up for the detection of possible late onset events, as well as the 
reaction of the subject upon repetitive treatments. Also, the inclusion of full sequencing 
approaches in such reference studies would be fundamental, especially in cases of particularly 
relevant phenotypes. As previously mentioned, studies of this type are presently undergoing. 
Such trials will allow the establishment of better phenotype/genotype associations that can be 
further explored in the context of health structures integrated in national malaria programmes. 
In this second step, technologies like the DNA extraction from Rapid Diagnostic Test devices, 
coupled with novel simple genotyping methods with applications in the field can be used in 
order to further establish polymorphisms in CYP2C8, CYP1A1, CYP1B1 or other relevant 
genes (e.g. myeloperoxidases) as risk markers of AQ over-exposure. 
With true personalized medicine being presently out of reach in most malaria affected 
countries, population pharmacogenetics of such markers will supply information for the use 
of the best available chemotherapy option, at a public health level. An example of such 
application would be the use of an alternative second line treatment (e.g. artemether-
lumefantrine) as first liner for certain regions and/or populations of a country. Such a 
strategy would optimize the use of the available antimalarial arsenal in the national control 
programmes. A more personalized analysis could be potentially applied in the much less 
frequent (< 10%) situations of AS-AQ use as second liner.  
A population-based approach, as described, can offer true benefits for the optimization of 
national malaria treatment, in particular when integrated in malaria elimination efforts, where 
the maintenance of the useful life of well established and effective therapies is key. Once the 
incidence of malaria decreases, as for example witnessed in the Zanzibari islands (Bhattarai et 
al., 2007), countries will be able to start supporting more personalized application of 
pharmacogenetics. In conclusion, upon the solid establishment of pharmacogenetics markers, 
the success of their application at a population level can lay the basis for a future more 
personalized pharmacogenetics, once the countries would be able to finance it. By the same 
token, the Developing World would not be left behind in this area of translational medicine. 
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1. Introduction 
Approximately 50 years ago, pharmacogenetics emerged as a new field of medicine that 
may explain human drug action. Anesthesia, in particular, played a key role in these early 
investigations. An understanding of how an individual’s genetic footprint influences drug 
metabolism and effectiveness may allow tailored prescriptions, improving outcomes and 
safety; and such concepts, which form the backbone of personalized medicine, have raised a 
lot of hope. The ultimate goal of pharmacogenetics research is to offer ‘tailored personalized 
medicine’ with a view to improving the efficacy of medication as well as patient safety by 
helping predict risks of adverse outcomes.  
In this Chapter, we first present a selection of historical landmarks related to anesthesia as a 
catalyst for the development of pharmacogenetics, we then cite practical examples of 
relevant candidates genes and common polymorphisms that are known to alter the response 
to medication prescribed in the perioperative and peripartum period as well as clinical 
outcomes in the parturient. To conclude, we hope to present current views and potential 
exciting perspectives that may arise from the application of pharmacogenetics to the daily 
practice of obstetric anesthesia and pain medicine.  
2. The history of pharmacogenetics related to anesthesia 
Medical genetics began with the 20th century rediscovery of Gregor Mendel’s original 19th 
century work on plant genetics 1. In 1949, the landmark paper in Science by Linus Pauling 
and colleagues linked sickle cell anemia to a derangement in a specific protein 2, and was the 
first proof that a genetic change alters the structure and function of a protein and results in a 
human disease. This set the stage for the birth of pharmacogenetics, a field first described by 
Arno Motulsky in 1957 3, named by Friedrich Vogel in 1959 4, and established by Werner 
Kalow in 1962 5. These scientists defined pharmacogenetics as the study of the variability in 
drug response due to genetic variability. In the early 1950s, prolonged apnea after 
succinylcholine was one of the drug responses that provided a starting point from which the 
new field of pharmacogenetics would launch. In 1956, The Lancet published a paper that was 
the first to suggest a genetic basis for prolonged apnea after succinylcholine 6. Werner 
Kalow reported soon after the occurrence of prolonged postoperative muscle relaxation 
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following the administration of succinylcholine for endotracheal intubation, and described 
how an inherited variation of drug metabolism involving the enzyme butyrylcholinesterase 
affects the response to succinylcholine 7. Malignant hyperthermia after succinylcholine or 
inhaled volatile anaesthetics is another example of an adverse reaction important to the 
history of pharmacogenetics. To date, 30 causative mutations have been identified on the 
ryanodine receptor gene (RYR1) that are associated with malignant hyperthermia 8,9. 
Guidelines proposed by the European Malignant Hyperthermia Group were the first to 
describe comprehensive genetic screening for a pharmacogenetic test in the field of 
anesthesia 10.  
3. The pharmacogenetics research network 
Since the first reports ten years ago describing initial findings from the Human Genome 
Project 11,12, and its completion in 2003 13, promises that these discoveries would translate 
into tangible clinical tests that may change drug prescriptions have been somewhat 
unfulfilled. Working towards this translation, the pharmacogenetics research network has 
established a pharmacogenomics knowledge base (PharmGKB) with the goal to collect, 
encode, and disseminate knowledge about the impact of human genetic variations on drug 
response, curate primary genotype and phenotype data, annotate gene variants and gene-
drug-disease relationships via literature review, and summarize important pharmacogenetic 
genes and drug pathways (http://www.pharmgkb.org) (Figure 1).  
 
 
Fig. 1. Pharmacogenomics (PGx) information flow 
Adapted from the NIH Pharmacogenomics Research Network – Pharmacogenomics 
Knowledge Base (http://www.pharmgkb.org) 
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4. The relevance for obstetric anesthesia and analgesia 
Numerous clinical trials and reviews have surfaced in recent years describing genetic 
associations with clinical outcomes in the field of anesthesia, peri-operative outcomes and 
pain medicine 14-28. An overview of all the drugs utilized in the peri-operative and 
peripartum period is beyond the scope of this review. For this Chapter, we selected several 
clinical examples for which gentoype/phenotype effects have been evaluated and present 
their relevance for clinical practice.  
4.1 The 2-adrenergic receptor genotype  
Several single nucleotide polymorphisms (SNPs) that have been described in the gene 
encoding the human 2-adrenergic receptor ( 2AR) affect the function of the receptor in vitro. 
Substitution of glycine for arginine at position 16 (Arg16Gly) has been associated with 
enhanced agonist-induced desensitization, while substitution of glutamic acid for glutamine 
at position 27 (Gln27Glu) has been associated with resistance to desensitization 29. 
Significant differences in the response of individuals to 2AR therapeutic manipulation 
related to the particular genotype/haplotype of the 2AR have been demonstrated. The 
2AR is of particular interest for obstetric anesthesia, since drugs that are given to ensure 
hemodynamic stability at the time of delivery, as well as drugs to promote uterine 
quiescence (tocolysis) act via 2-agonism. 
4.1.1 Vasopressor requirement during spinal anesthesia for Cesarean delivery 
Numerous clinical trials have evaluated the response to vasopressors to prevent and or treat 
hypotension during spinal anesthesia for elective Cesarean delivery 30. For decades, 
ephedrine has been considered the safest and probably the sole acceptable strategy, based 
on classic studies in sheep that suggested deleterious effects of pure -adrenergic agonists 
on uteroplacental blood ow. Ephedrine has been widely used in a variety of regimens 
(different bolus doses, infusions and in combination with phenylephrine) although no 
consensus has ever been achieved as to which of these modes of administration provides the 
most reliable and effective response. Ephedrine is a sympathomimetic amine, the principal 
mechanism of its action relies on its direct and indirect actions on the adrenergic receptor 
system (both an - and -adrenergic agonist).  
A pharmacogenetic study in an obstetric population showed that the incidence and severity 
of maternal hypotension after spinal anesthesia for Cesarean delivery and the response to 
treatment is clearly affected by 2AR genotype/haplotype 31. Women Gly16 homozygous 
and carrying one or two Glu at position 27 (heterozygous or homozygous for the minor 
Glu27 allele) were found to require significantly less vasopressors (ephedrine) for treatment 
of hypotension during spinal anesthesia. The two haplotypes that seem to ‘protect’ women 
from requiring higher doses of ephedrine are relatively common in Caucasians, and in this 
study 20% of the women carried either one of these haplotypes. This pharmacogenetic effect 
may explain in part why the numerous studies trying to prevent or treat hypotension 
during spinal anesthesia for Cesarean section failed to define one single optimal strategy 
(fluid loading, ephedrine or phenylephrine) that would ‘fit all’.  
Since the incidence of spinal hypotension and vasopressor use is reduced in preeclampsia 
32,33, it has been further hypothesized that haplotypes of 2AR gene influence hemodynamics 
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during spinal anesthesia for Cesarean delivery in women diagnosed with severe pre-
eclampsia. In a prospective case-control study, we compared the incidence of hypotension 
and vasopressor requirements in a predominantly African-American cohort 34. Despite a 
trend towards fewer pre-eclamptic women requiring vasopressors, the total vasopressor 
dose was higher in those in whom treatment was indicated. However, no woman in the pre-
eclamptic group carried the Gly16Gly/Glu27Glu haplotype, and since this was one of the 
two haplotypes that predicted less vasopressor requirement in normotensive women 31, this 
might provide an explanation for these unexpected results. Whether these findings are 
specific to African-American women remains to be determined in larger studies in other 
ethnic groups. These findings illustrate the importance of ethnicity when assessing genetic 
associations, and similar interactions between ethnicity and genetics have been suggested 
for other SNPs presented in this review ( -OR). In the long term, if these findings are 
confirmed, clinical implications could involve using haplotype of 2AR to predict spinal 
hypotension and to guide hemodynamic management in women with compromised 
cardiovascular function and altered uteroplacental perfusion.  
4.1.2 Ephedrine-induced neonatal acidosis 
Meanwhile, the direct effects of ephedrine on the fetus have been revisited recently 35. 
Evidence that ephedrine crosses the placenta to a greater extent and undergoes less early 
metabolism and redistribution than phenylephrine (a direct -adrenergic agonist) causing 
direct fetal metabolic acidosis has made ephedrine less desirable as a first-line treatment 36. The 
proposed mechanism is that direct fetal -adrenergic stimulation increases anaerobic 
glycolysis and causes a hypermetabolic state. The hypothesis that neonatal ADRB2 genotype 
may directly influence the degree of neonatal acidemia in response to ephedrine given to the 
mother prior to delivery has just recently been explored. The most clinically relevant and 
intriguing finding of a study conducted in Asian woemen was that umbilical artery (UA) pH 
was overall higher and UA lactate was lower in neonates that were Arg16 homozygous as 
compared to neonates with the two other genotypes of ADRB2 37. Furthermore, among babies 
born to mothers receiving ephedrine, ephedrine dose was associated with neonatal acidemia 
(decreased UA pH) only in neonates carrying a Gly16 allele, but not in neonates who were 
Arg16 homozygous. Since there was no significant difference in ephedrine concentration as 
determined by maternal and umbilical cord assays among genetic groups, any difference in 
metabolic markers are unlikely to have resulted from differential transplacental transfer of 
drug or a pharmacokinetic effect. Arg16 homozygous neonates seem to be protected from the 
risk of developing acidemia when exposed to ephedrine, irrespective of the dose given to the 
mother (Figure 2). These findings provide interesting insight on fetal acidosis and metabolic 
responses in neonates born to mothers who have received -agonists (ephedrine and/or other 
-stimulants prescribed for tocolysis or bronchodilation) prior to delivery. 
4.1.3 Tocolytics for management of preterm labor and delivery 
Stimulation of the 2AR results in uterine smooth muscle relaxation, and thus the 2AR has 
long been a therapeutic target for the treatment of preterm labor. 2-agonist therapy, in 
common with virtually all tocolytics, has not been consistently successful at stopping 
preterm labor or prolonging pregnancy, in part due to the multifactorial nature of preterm 
labor, and possibly because of a wide variability in therapeutic response within the 
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population. The mechanisms involved in regulation of myometrial smooth muscle 
contraction and relaxation in preterm labor or even at term are not yet fully elucidated. 
Genetic variability of ADRB2 has been evaluated in several studies in the context preterm 
labor and delivery. Arg16 homozygosity of ADRB2 appears to confer a protective effect 
against preterm delivery while the minor allele at position 27 (Glu) increases the risk for 
preterm delivery 38-40. Furthermore, a pharmacogenetic effect, with a better response to 
2agonist therapy (hexoprenaline) for tocolysis in women Arg16 homozygous with idiopathic 
preterm labor between 24 and 34 weeks gestation has been demonstrated 41. This had a 
significant impact on neonatal outcomes, with higher birth weights and less neonatal intensive 
care unit (NICU) admissions for respiratory or other complications due to prematurity in 
babies born to mothers with that genotype. Meanwhile, a variety of genomic studies have 
examined the influence of genetic variants on the incidence of preterm labor 42, and proteomic 
studies to validate biomarkers that could identify women at risk for preterm delivery and 
serve as predictive tools are ongoing 43,44.  
 
Fig. 2. Ephedrine-induced neonatal acidosis according to p.16Arg/Gly of ADRB2 
From Landau R, Liu SK, Blouin JL, Smiley RM, Ngan Kee WD: The Effect of Maternal and Fetal 2-
Adrenoceptor and Nitric Oxide Synthase Genotype on Vasopressor Requirement and Fetal Acid-Base 
Status During Spinal Anesthesia for Cesarean Delivery. Anesth Analg 2011; 112: 1432-7 
4.1.4 Course of labor and delivery 
Recent studies have confirmed that ADRB2 haplotype is important not only in the context of 
preterm onset of labor and delivery, but also on the course of labor and delivery in the term 
parturient. In a recent observational study in North-American women enrolled between 34-40 
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weeks gestation, the progress of active labor was found to be slower in women homozygous 
for Arg16 45. In women at term, the rate of cervical dilatation and duration of labor was shown 
to be slower in women carrying the wild-allele (Gln) at position 27 46. Taken together, both 
studies confirm that uterine quiescence during pregnancy and progression of cervical 
dilatation during labor are strongly associated with ADRB2 haplotype. 
5. Analgesia and pain-related candidate genes 
Interindividual variability in pain perception and sensitivity to analgesic therapy with a 
large unpredictability in efficacy, side effects and tolerance profiles to opioids is well 
described. Genomic and pharmacogenetic research has considered numerous candidate 
genes as suitable targets for the study of pain and or analgesia 47. Among the numerous 
genes and specific polymorphisms that have been considered important in opioid response, 
the A118G polymorphism of the opioid receptor gene (OPRM1), a common variant of the 
catechol-O-methyltransferase gene (Val158Met of COMT), several genetic variants of the 
ATP-binding cassette, sub- family B gene (ABCB1) and genetic variants of the cytochrome 
P450 family of enzymes have been extensively reviewed 22,24,48. In addition, a genetic 
database of knock-out mice allowing the study of genetic variations in the context of specific 
pain phenotypes was made public 49. 
Recently an extremely rare phenotype characterized by a total absence of pain perception 
(‘congenital indifference to pain’) with no associated neuropathy has been associated with the 
mutations in the gene SCN9A, encoding the -subunit of the voltage-gated sodium channel, 
Nav1.7 50-52. Individuals with loss-of-function mutations of the NaV1.7 lack protective 
mechanisms that allow tissue damage detection and suffer severe injuries because they do not 
learn pain-avoiding behaviors. This discovery opens new directions for development of novel 
generations of drugs with blocking Nav1.7 proprieties, which should provide more selective 
and safe analgesia. Meanwhile, we are still in the era of opioid therapy, and the analgesic effect 
may be influenced by alterations in the metabolism of analgesic drugs (cytochrome P450), 
variants coding for the -opioid receptor ( OR) as well as other targets. 
5.1 Cytochrome P450 and the codeine story 
Cytochrome P450 (CYP450) is a super-family of liver enzymes that catalyze phase 1 drug 
metabolism. The D6 isozyme of the CYP2 family is particularly affected by genetic 
variability and currently has 80 identified CYP2D6 alleles (http://www.cypalleles.ki.se/), 
resulting in a variable enzymatic activity ranging from 1 to 200%. As a result, each 
individual can be classified as having an “ultra-rapid metabolism” (UM), an “extensive 
metabolism” (EM), an “intermediate metabolism” (IM) or a “poor metabolism” (PM) and 
microarray technology is available to classify individuals according to their metabolic 
phenotype. Furthermore, it is important to note that the distribution of CYP2D6 phenotypes 
varies with race, since mutated alleles differ among racial and ethnic groups. Of note, 
approximately 7 to 10% of Caucasians have no CYP2D6 activity (poor metabolism) because 
of deletions, frameshift, or splice-site mutations of the gene. On the other end of the 
spectrum, 1 to 3% of Middle Europeans and up to 29% of Ethiopians have duplications of 
the CYP2D6 gene and are classified as ultra-rapid metabolizers 53. Ultra-rapid metabolizers 
have up to 50% higher plasma concentrations compared to extensive metabolizers 54. 
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Codeine is a pro-drug and needs to be converted into morphine to elicit its analgesic effect; 
therefore ‘poor metabolizers’ do not achieve analgesia with codeine while they may 
encounter side effects such as nausea and vomiting. Codeine is converted to morphine 
through O-demethylation catalyzed by CYP2D6, and accounts for 10% of codeine clearance. 
The conversion of codeine into norcodeine by CYP3A4 and into codeine-6-glucuronide by 
glucuronidation represents approximately 80% of codeine clearance. Morphine is further 
metabolized into morphine-6-glucuronide (M6G) and morphine-3-glucuronide (M3G), and 
morphine and M6G have opioid activity. While codeine is undoubtedly not a wonder 
analgesic, it was initially prescribed because of the belief that being a weak opioid, it is safe. 
There was a recent FDA warning on codeine use in nursing mothers following the death of a 
breastfed 13-day-old neonate thought to have suffered a morphine overdose because his 
mother was taking codeine 55. Toxic blood levels of morphine or its active metabolite 
morphine-6-glucuronide (M6G) may arise in mothers and neonates that are CYP2D6 ultra-
rapid or extensive metabolizers. The infant in this case report was categorized as a CYP2D6 
extensive metabolizer (extensively metabolizing the pro-drug codeine to morphine) and had 
a blood concentration of morphine at 70ng/mL; neonates breastfed by mothers receiving 
codeine typically have concentrations of 0-2.2ng/mL. The mother was categorized as a 
CYP2D6 ultra-metabolizer and her breast milk had a morphine concentration of 87ng/mL – 
the typical range being 1.9-20.5ng/mL at doses of 60mg codeine every 6 hours. Therefore, 
the infant had two reasons for having supranormal morphine levels. In light of these 
findings, it has been suggested that codeine be avoided in breastfeeding mothers with a 
CYP2D6 extensive or ultra-rapid metabolism genotype. Reports followed that studied the 
rates of codeine and morphine clearance in breastfeeding mothers and their relation to 
CYP2D6 genotypes 56-58. Other life-threatening adverse events have been reported in 
individuals who are CYP2D6 ultra-rapid metabolizers 59,60. 
Since 2007, the FDA requires manufacturers of prescription codeine products to state in the 
“Precautions” section of the drug label the known risks of prescribing codeine to breastfeeding 
mothers 61. An FDA-approved genetic test (AmpliChip CYP450: Roche Diagnostics, Palo Alto, 
CA, USA) is commercially available to test genetic variants of CYP2D6 62. 
Overall, the level of evidence linking gene variation (CYP2D6) to phenotype (increased 
biotransformation of codeine into morphine) is strong, however there is no randomized clinical 
trial assessing the benefits of genetic testing prior to codeine therapy at large. Currently, the 
only recommendation for risk aversion is a cautionary insert to avoid codeine in breastfeeding 
mothers (or to apply genetic testing in mothers/neonates if codeine is prescribed). 
5.2 The -opioid receptor genotype 
The -opioid receptor gene (OPRM1) is probably the most well studied gene in the context 
of post-operative and labor analgesia 63. The most common polymorphism of OPRM1 is a 
single nucleotide substitution at position 118, with an adenine substitution by a guanine 
(A118G) reported to occur with an allelic frequency of 10–30% among Caucasians 64, a 
higher prevalence among Asians 65 and a lower one in African-Americans 66. Clinicians are 
well aware of the large and unpredictable inter-individual variability in response to opioids 
67. A recent meta-analysis of all pain studies evaluating the impact of A118G polymorphism 
of OPRM1 on the response to opioids did not identify a strong association between this 
polymorphism and the response to opioids 63. It is likely that the heterogeneity of the clinical 
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weeks gestation, the progress of active labor was found to be slower in women homozygous 
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approximately 7 to 10% of Caucasians have no CYP2D6 activity (poor metabolism) because 
of deletions, frameshift, or splice-site mutations of the gene. On the other end of the 
spectrum, 1 to 3% of Middle Europeans and up to 29% of Ethiopians have duplications of 
the CYP2D6 gene and are classified as ultra-rapid metabolizers 53. Ultra-rapid metabolizers 
have up to 50% higher plasma concentrations compared to extensive metabolizers 54. 
 
Pharmacogenetics and Obstetric Anesthesia and Analgesia 
 
255 
Codeine is a pro-drug and needs to be converted into morphine to elicit its analgesic effect; 
therefore ‘poor metabolizers’ do not achieve analgesia with codeine while they may 
encounter side effects such as nausea and vomiting. Codeine is converted to morphine 
through O-demethylation catalyzed by CYP2D6, and accounts for 10% of codeine clearance. 
The conversion of codeine into norcodeine by CYP3A4 and into codeine-6-glucuronide by 
glucuronidation represents approximately 80% of codeine clearance. Morphine is further 
metabolized into morphine-6-glucuronide (M6G) and morphine-3-glucuronide (M3G), and 
morphine and M6G have opioid activity. While codeine is undoubtedly not a wonder 
analgesic, it was initially prescribed because of the belief that being a weak opioid, it is safe. 
There was a recent FDA warning on codeine use in nursing mothers following the death of a 
breastfed 13-day-old neonate thought to have suffered a morphine overdose because his 
mother was taking codeine 55. Toxic blood levels of morphine or its active metabolite 
morphine-6-glucuronide (M6G) may arise in mothers and neonates that are CYP2D6 ultra-
rapid or extensive metabolizers. The infant in this case report was categorized as a CYP2D6 
extensive metabolizer (extensively metabolizing the pro-drug codeine to morphine) and had 
a blood concentration of morphine at 70ng/mL; neonates breastfed by mothers receiving 
codeine typically have concentrations of 0-2.2ng/mL. The mother was categorized as a 
CYP2D6 ultra-metabolizer and her breast milk had a morphine concentration of 87ng/mL – 
the typical range being 1.9-20.5ng/mL at doses of 60mg codeine every 6 hours. Therefore, 
the infant had two reasons for having supranormal morphine levels. In light of these 
findings, it has been suggested that codeine be avoided in breastfeeding mothers with a 
CYP2D6 extensive or ultra-rapid metabolism genotype. Reports followed that studied the 
rates of codeine and morphine clearance in breastfeeding mothers and their relation to 
CYP2D6 genotypes 56-58. Other life-threatening adverse events have been reported in 
individuals who are CYP2D6 ultra-rapid metabolizers 59,60. 
Since 2007, the FDA requires manufacturers of prescription codeine products to state in the 
“Precautions” section of the drug label the known risks of prescribing codeine to breastfeeding 
mothers 61. An FDA-approved genetic test (AmpliChip CYP450: Roche Diagnostics, Palo Alto, 
CA, USA) is commercially available to test genetic variants of CYP2D6 62. 
Overall, the level of evidence linking gene variation (CYP2D6) to phenotype (increased 
biotransformation of codeine into morphine) is strong, however there is no randomized clinical 
trial assessing the benefits of genetic testing prior to codeine therapy at large. Currently, the 
only recommendation for risk aversion is a cautionary insert to avoid codeine in breastfeeding 
mothers (or to apply genetic testing in mothers/neonates if codeine is prescribed). 
5.2 The -opioid receptor genotype 
The -opioid receptor gene (OPRM1) is probably the most well studied gene in the context 
of post-operative and labor analgesia 63. The most common polymorphism of OPRM1 is a 
single nucleotide substitution at position 118, with an adenine substitution by a guanine 
(A118G) reported to occur with an allelic frequency of 10–30% among Caucasians 64, a 
higher prevalence among Asians 65 and a lower one in African-Americans 66. Clinicians are 
well aware of the large and unpredictable inter-individual variability in response to opioids 
67. A recent meta-analysis of all pain studies evaluating the impact of A118G polymorphism 
of OPRM1 on the response to opioids did not identify a strong association between this 
polymorphism and the response to opioids 63. It is likely that the heterogeneity of the clinical 
 
Clinical Applications of Pharmacogenetics 
 
256 
situations (experimental pain, acute pain, labor pain, post-operative pain, chronic pain) and 
diversity of evaluated drugs and dosages precluded from any significant findings.  
5.2.1 Response to intrathecal and systemic morphine for post-Cesarean analgesia 
The response to an intrathecal solution containing morphine and fentanyl for post-Cesarean 
analgesia according to OPRM1 genotype was evaluated in a North-American cohort 68. 
There was no difference in the duration of spinal morphine analgesia or need for analgesic 
supplementation over 72 hours in women carrying the minor allele (G118). The time for first 
opioid rescue analgesia was on average 22 hours regardless of genotype. The incidence of 
nausea was similar between groups, however pruritus was less frequent during the first 24 
hours in women carrying the minor allele (G118).  
In two studies from Singapore in women undergoing Cesarean deliveries under spinal 
anesthesia (with morphine), women with the minor allele allele exhibited increased 
consumption of iv PCA morphine 24 hours post-delivery 69,70. Women were given upon 
arrival in the post-anesthesia care unit (PACU) a morphine iv PCA pump and no other 
analgesics were prescribed. In the first study on 588 Chinese Singaporean, 24 hours post-
operative morphine iv PCA consumption was lowest in women homozygous for the wild-
type allele (A118) 69. Distribution of morphine use over time (doses were recorded in 4 
hour time intervals) demonstrated that most of morphine use occurred in the PACU 
during the first 4 hour after spinal anesthesia. It is possible that this early iv morphine use 
reflects lack of analgesia upon arrival in the PACU. Consequently, initial differences in iv 
morphine use may be due to differences in pain perception rather than impaired spinal 
morphine analgesia in women carrying the minor allele (G118), while differences of 
morphine use at 24 hour reflect either differences in intrathecal morphine duration 
and/or efficacy or more likely differences in iv morphine efficacy. The overall incidence 
of nausea was low; nonetheless it was higher in women homozygous for the wild-type 
allele (A118). 
In the second publication, 994 women from the three main ethnic groups in Singapore were 
evaluated (n=617 Chinese, n=241 Malays and n=136 Indians) 70. The authors reported a large 
inter-individual range with 65 women not using any morphine, 129 using only one dose, 
while another 122 administered 2 doses. Total iv morphine use over the first 24 hours was 
significantly higher in women homozygote for the minor allele (G118), and incidence of 
nausea was again lower in this genotypic group. In a multiple regression analysis, the most 
important factor contributing to morphine usage was maximum pain score, followed by 
ethnicity and A118G polymorphism. After correction for genotype, ethnicity was still a 
significant contributing factor, with Indian women reporting higher pain scores and using 
higher doses of iv morphine. 
This apparent discrepancy between the North-American study reporting no effect of 
OPRM1 A118G polymorphism on intrathecal morphine analgesia and the Singaporean 
results may be explained by differences in ethnicity, study design and primary outcomes. In 
the Singaporean studies, the intrathecal solution did not include fentanyl therefore it is 
possible that onset of intrathecal analgesia occurred after women arrived in the PACU. Since 
women were given iv PCA morphine as the initial rescue analgesic (rather than ibuprofen as 
in the North-American study), such study design was more likely to evaluate the effect of 
A118G polymorphism on iv morphine analgesic rather than intrathecal analgesic response. 
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Another obvious explanation may be that OPRM1 genotype interacts differently with opioid 
analgesia in different ethnic groups. 
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5.2.2 Response to intrathecal fentanyl for labor analgesia 
Using the up-down sequential allocation model to identify differences in analgesic 
requirement according to OPRM1 genotype in a Swiss cohort of nulliparous women 
requesting neuraxial analgesia early in labor, women carrying the minor allele  (G118) 
required substantially lower doses of intrathecal fentanyl 71. The ED50 (median effective 
dose providing labor pain relief defined on a 0-10 verbal numerical pain scale as being < 1 
for at least 60 minutes) of intrathecal fentanyl given as part of a combined-spinal epidural 
(CSE) was 1.5 fold higher in A118 homozygotes versus that in women carrying at least one 
minor allele (G118). Moreover, this finding was replicated using random-dose allocation 
(doses ranging from 2.5-35µg), with a 2.1-fold difference between genetic groups. Of note, 
cervical dilatation at the time of analgesia request was significantly less in women 
homozygote for wild-type allele (A118) than in women carrying one or two minor alleles 
(G118). This is of interest because women received the CSE analgesic when they requested 
pain relief at the time they experienced painful contractions. It has previously been 
demonstrated that epidural analgesic requirements increase with progress of labor and 
cervical dilatation, therefore women carrying the variant G118 allele should have greater 
analgesic requirements due to the greater cervical dilatation at which they requested 
analgesia; our finding that these women require less fentanyl may actually underestimate 
the true effect of genotype. Since provision of optimal labor analgesia remains an ongoing 
challenge for obstetric anesthesiologists, the variability in ED50 according to genotype is 
clearly relevant from a clinical standpoint. These findings suggest genotyping may help 
improve the administration of labor analgesia with 30% of Caucasian women (and probably 
a vast majority of Asian women) potentially requiring lower doses of intrathecal fentanyl for 
effective analgesia during labor and delivery. 
In a North-American cohort, the effect of the A118G polymorphism on the duration of 
intrathecal fentanyl analgesia in early labor and found no difference between genotypes 68. 
The severity of nausea, pruritus or incidence of vomiting was also not different between 
genetic groups. While the A118G polymorphism may influence intrathecal fentanyl potency, 
there may be no pharmacokinetic effect altering duration of analgesic action. 
Overall, the level of evidence linking gene variation to morphine or fentanyl response is 
moderate, probably due to the inherent complexity of studying pain (different nociceptive 
modalities, gender differences, limitations in extrapolating data from animal models to the 
response in humans, interethnic and environmental differences) in addition to the obvious 
polygenic nature of pain and analgesic response. The design and execution of large clinical 
studies analyzing multiple haplotypes simultaneously remains to be the true challenge to 
date. Meanwhile, a genome-wide study in the context of acute post-operative pain was 
published 21, the possible impact of epigenetics-based strategies for pain therapy is proposed 
72 and researchers are actively working on gene therapies for chronic pain 73-75. It will also be 
of interest to see the new insights and developments brought by more research on the 
SCN9A gene, a gene involved in channelopathies that result in the inability to experience 
pain, and potential targeted therapies 76. 
6. The future of personalized medicine 
Perhaps the most exciting yet challenging development of personalized medicine emerged 
with the highly sophisticated technology that now allows whole genome sequencing at a 
 
Pharmacogenetics and Obstetric Anesthesia and Analgesia 
 
259 
cost that is no longer prohibitive. Therefore, extensive considerations are needed to decide 
how to best utilize whole genome sequencing data in clinical practice 77. Among these 
challenges, patients will need to receive complex and detailed genetic counseling before 
they can decide whether they wish to undergo such genetic risk assessment, and effective 
ways to convey meaningful information to patients about the many implications of their 
whole-genome sequences need to be developed. In addition, interpretation should take into 
account the limits of the sequencing method used. Databases with easily accessible and well 
validated information about the associations between genomic sequences and diseases 
needs to be created, maintained, and frequently updated to incorporate new information 
about disease risks, and changes in assessment will have to be communicated to patients.  
A fascinating report on the first integrated analysis of a complete human genome in the 
clinical context of a 40 year old male who presented with a family history of coronary artery 
disease and sudden death addressed these issues 78. Disease and risk analysis of the genome 
for this individual study was focused on variants associated with genes for known 
Mendelian disease, novel mutations, variants known to have a pharmacogenetic effect, and 
SNPs previously associated with complex disease. The subject was found to have an 
increased genetic risk for myocardial infarction, type II diabetes and certain cancers. With 
this report, the authors developed tools to integrate the subject’s clinical characteristics, his 
family history and the results from whole genome sequencing including 2.6 million SNPs 
and 752 copy number variations to assist clinical decision-making. Large-scale 
implementation of such sophisticated methodology will require multidisciplinary 
approaches that include medical and genetic professionals, ethicists and regulatory 
agencies.  
7. Conclusions 
There is no doubt that genetic variants affect drug responses to an extent that can have 
relevant implications beyond just the efficacy of a prescribed drug. For the clinician, and in 
particular for the anesthesiologist providing anesthesia and post-operative pain 
management, there are to date no guidelines or recommendations that suggest any 
pharmacogenetic testing prior to administering any anesthesia-related drug. Consequently, 
it is still too early to foresee immediate implications of pharmacogenetics in general and 
pharmacogenetic diagnostic tests specifically, but one can hope that future discoveries in the 
field of genomics will soon aid anesthesiologists and other clinicians in predicting efficacy 
or toxicity for some drugs.  
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about disease risks, and changes in assessment will have to be communicated to patients.  
A fascinating report on the first integrated analysis of a complete human genome in the 
clinical context of a 40 year old male who presented with a family history of coronary artery 
disease and sudden death addressed these issues 78. Disease and risk analysis of the genome 
for this individual study was focused on variants associated with genes for known 
Mendelian disease, novel mutations, variants known to have a pharmacogenetic effect, and 
SNPs previously associated with complex disease. The subject was found to have an 
increased genetic risk for myocardial infarction, type II diabetes and certain cancers. With 
this report, the authors developed tools to integrate the subject’s clinical characteristics, his 
family history and the results from whole genome sequencing including 2.6 million SNPs 
and 752 copy number variations to assist clinical decision-making. Large-scale 
implementation of such sophisticated methodology will require multidisciplinary 
approaches that include medical and genetic professionals, ethicists and regulatory 
agencies.  
7. Conclusions 
There is no doubt that genetic variants affect drug responses to an extent that can have 
relevant implications beyond just the efficacy of a prescribed drug. For the clinician, and in 
particular for the anesthesiologist providing anesthesia and post-operative pain 
management, there are to date no guidelines or recommendations that suggest any 
pharmacogenetic testing prior to administering any anesthesia-related drug. Consequently, 
it is still too early to foresee immediate implications of pharmacogenetics in general and 
pharmacogenetic diagnostic tests specifically, but one can hope that future discoveries in the 
field of genomics will soon aid anesthesiologists and other clinicians in predicting efficacy 
or toxicity for some drugs.  
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1. Introduction 
It has been observed that similar medication is subject to a considerable efficacy 
heterogeneity and toxicity across the human population and numerous studies, over the last 
30 years, have indicated that individual genetic make-up might well be the major 
determinants of this variability in drug action (Nebert et al., 2008). 
The intellectual foundation of the hypothesis that variation among individuals in drug 
response might be due to subtle genetic differences with little or no obvious phenotypes, 
except in response to the relevant drug, was first articulated by Arno Motulsky (Motulsky, 
1957). Although the notion that certain individuals inherited a predisposition, such as to 
alcaptonuria or other conditions, may most likely be attributed to the British physician 
Archibald Garrod (Garrod, 1975). Garrod observed that parental consanguinity was more 
common than usual among parents of children with alcaptonuria and, with particular 
foresight, he developed the concept of “Chemical Individuality in Man”. He proposed that 
drugs undergo biotransformation by specific pathways similarly to endogenous substrates 
and defects in such pathways, that occur with inborn metabolic errors, that could alter drug 
concentrations and, therefore, their effects (Meyer, 2004). It was then William Bateson 
(Meyer, 2004), a biologist ahead of his time, who interpreted Garrod’s reports as a recessive 
inheritance when he popularized Mendelian genetics in Britain. Bateson discovered genetic 
linkage and introduced the term “genetics” at some time between 1902 and 1913.  
The concept of familial clustering of unusual xenobiotic responses was reinforced during the 
1940s, when a high incidence of haemolysis was observed among individuals with glucose-
6-phosphate dehydrogenase deficiency when exposed to antimalarial drugs (Beutler et al., 
1955a, 1955b). In the 50s, Evans et al. identified N-acetylation as a major route of isoniazid 
elimination (Evans et al., 1960). Although individuals varied substantially in terms of the 
extent to which a single dose of the drug was acetylated, less variability was observed 
between monozygotic twins than dizygotic twins (Roden & George Jr, 2002). This 
observation led to further studies that defined the clinical consequences and genetic basis 
underlying the fast and slow acetylator phenotypes. Shortly thereafter, Friedrich Vogel first 
coined the term “Pharmacogenetics”, defining it as the “study of the role of genetics in drug 
response” (Nebert et al., 2008). More generally, the late 20th century witnessed developments 
in the understanding of the molecular basis of drug disposition, action and the mechanisms 
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Along with the increased understanding of the molecular, cellular and genetic determinants 
of drug action, has come the appreciation that variants in many genes might contribute to 
variability in drug action.  
Single Nucleotide Polymorphisms (SNPs) have been long recognized as the main source of 
genetic and phenotypic human variation and numerous recent studies have tried to 
demonstrate that SNPs make a major genetic contribution to the variability in drug effects 
(Evans & McLeod, 2003; Gardiner & Begg, 2006). However, the complete mapping of all 
human genes, arrived through the Human Genome Project, along with the advent of more 
powerful molecular technologies and other studies showing a poor correlation between 
SNPs in candidate genes and phenotypes, modifying this perception (Nebert & Vesell, 2004). 
Therefore, this chapter focuses on the development of Pharmacogenetics from SNPs to the 
new area of Genomics, or Pharmacogenomics, in an attempt to better understand and 
predict variations in drug response phenotypes. 
2. From pharmacogenetics to pharmacogenomics 
An SNP is a DNA sequence variation which occurs when a single nucleotide (A, T, C, or G) 
in the genome, or other shared sequences, differs between members of a biological species, 
or paired chromosomes in an individual. For example, a SNP might change the DNA 
sequence AAGGCTAA to ATGGCTAA (Fig.1).  
 
Fig. 1. Single Nucleotide Polymorphism 
For a variation to be considered a SNP, it must occur in at least 1% of the population. Single 
Nucleotide Polymorphisms, representing about 90% of all human genetic variations, occur 
every 100 to 300 bases along the 3-billion-base human genome. Consequently, it has been 
estimated that there are at least 10 million SNPs within the human population (Kruglyak & 
Nickerson, 2001). They can be in coding regions (where they may be either synonymous, or 
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non-synonymous) or, more commonly, in non-coding regions and frequently vary 
according to ethnicity (Sachidanandam et al., 2001). It is in these heritable variations among 
individuals that the principles of Pharmacogenetics are found. However, other types of 
genetic variations, such as small insertions (usually <1 kb), deletions, inversions, variable 
numbers of tandem repeats (minisatellite), short tandem repeats (microsatellite), copy 
number variations (Nakamura, 2009) and combinations of these changes, can also contribute 
to variability in drug response, even if to a less extent than do SNPs. Therefore, the selection 
of a non-synonymous SNPs, or other genetic variations in coding regions, in hypothesis 
driven pharmacogenetic association studies, is based on their functionality, where the 
genetic variant leads to, or is predicted to lead to, alterations in protein function and hence 
drug response variability. 
There are at least four examples where this approach has been correlated with significant 
changes in drug effects (Evans & McLeod, 2003; Gardiner & Begg, 2006). One of the best 
examples of SNPs relating to the outcome of therapy is the polymorphism of the gene 
thiopurine S-methyltransferase (TPMT) (Yates et al., 1997). Thiopurine S-methyltransferase 
is a cytosolic drug-metabolizing enzyme that catalyzes the S-methylation of 6-
mercaptopurine (6-MP) and azathioprine. Weinshilboum et al. demonstrated a very clear tri-
modal frequency of TPMT activity in red blood cells from 298 unrelated control adults 
(Weinshilboum & Sladek, 1980). One in 300 subjects lacked TPMT activity and 11% had 
intermediate levels. Family studies have demonstrated that the frequency distribution is due 
to inheritance (Weinshilboum & Sladek, 1980). While phenotypic studies have shown a clear 
tri-modal distribution, the genetic basis of phenotypic variation is a more complex question 
(Evans & Krynetsky, 2003). 
To date, about seventeen variant TPMT alleles have been identified, although 3 variant 
alleles account for the majority (>95%) of persons with intermediate (1 variant allele), or low 
(2 variant alleles) TPMT activity (Krynetski et al., 1995; Yates et al., 1997). Subsequent 
clinical studies demonstrated that TPMT polymorphism is able to predict 6-MP toxicity and 
consequences of therapy (Lennard et al., 1990; Relling et al., 1999).  
Another good example of SNPs influencing therapeutic efficacy is the polymorphism of 
genes belonging to the superfamily of cytochrome P450 enzymes (CYP450) (Wilkinson, 
2005). CYP2D6 polymorphism is clinically important mainly due to the greater likelihood of 
adverse reactions (ADRs) amongst individuals, because they can be associated with poor 
metabolism of certain drugs, resulting in high plasma concentrations and increased 
likelihood of ADRs. For example, patients carrying some of the CYP2D6 variants identified 
(http://www.imm.ki.se/cypalleles), have a greater risk of adverse effects from metoprolol, 
venlafaxine and tricyclic antidepressants, or have impaired ability to metabolically activate 
prodrugs like codeine and the selective oestrogen receptor modulator (SERM), tamoxifen, to 
form active drug metabolites (Bertilsson et al., 2002; Jin et al., 2005; Lessard et al., 1999; 
Mortimer et al., 1990; Sindrup & Brøsen, 1995; Stearns et al., 2003; Wuttke et al., 2002). 
CYP2C19 is important in the metabolism of proton-pump inhibitors (omeprazole, 
lansoprazole, rabeprazole and pantoprazole), fluoxetine, sertaline and nelfinavir. Although 
there are several inactive genetic variants, two (CYP2C19*2 and CYP2C19*3) account for 
more than 95% of cases of poor metabolism of these drugs (Wedlund, 2000). Marked 
differences in the plasma levels of protein-pump inhibitors occur between genotypes and 
phenotypes and are reflected in drug-induced changes in gastric pH (Furuta et al., 1999). 
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CYP2C9 is an enzyme involved in the hydroxylation of the S form of the anti-epileptic agent 
phenytoin and the anticoagulant warfarin. Many CYP2C9 variant alleles have now been 
reported (http://www.imm.ki.se/cypalleles) and decreased activity has been confirmed in 
cases with CYP2C9*3, by an expression system using COS cells and yeast and an in vivo test 
on healthy volunteers and patients with a known genetic polymorphism (Takahashi et al., 
1998b, 2000).  
Indeed, there was a 50% decrease in oral clearance capacity of (S)-warfarin in individuals 
with heterozygous polymorphism for CYP2C9*3 (CYP2C9*1/*3), dropping to less than 10% 
in homozygous individuals for CYP2C9*3 (Takahashi et al., 1998a).  
These successful pharmacogenetic studies, together with the glucuronidation of an 
anticancer drug, irinotecan, by a member of the UDP-glucuronosyltransferase (UGT) 
enzyme family (Gagné et al., 2002), showing gene-drug interactions, represented a 
predominantly monogenic, high-penetrance trait where the functional consequence of a 
major gene was recognized. However, these associations were not replicated by other 
investigators (Hu & Ziv, 2008) and might lead to false-positive findings (Serpe et al., 2009). 
Indeed, even with the very strong single-gene high-penetrance disorder TPMT, a study 
correlating thiopurine related ADRs with TPMT genotype, noted that 78% of ADRs were not 
associated with TPMT gene polymorphism and were attributable to factors other than this 
drug-metabolizing enzyme (van Aken et al., 2003).  
Although the presence of non-synonymous SNPs in a candidate gene may be suspected to 
cause variance in drug response, this cannot account for all SNPs able to cause drug 
response variance or susceptibility in drug response variance. Other functional SNPs 
implicated in variance in drug response or susceptibility variance in drug response include 
SNPs located in promoter, introns, splice sites and intragenic regions. Furthermore, it has 
been postulated that even synonymous or silent SNPs are implicated in functional 
consequence via hypothesized mechanisms (Kimchi-Sarfaty et al., 2007). 
A more comprehensive approach is the genome-wide method (GWA) using SNP arrays 
(Grant & Hakonarson, 2008). With this strategy we move from studies involving the effects 
of single genes on drug disposition and response, to studies where the effects of several 
genes up to whole genome are investigated. In other words we move from 
Pharmacogenetics to Pharmacogenomics.  
A clear advantage of this method is that it is hypothesis-free and that this may reveal 
unexpected SNPs related to drug response. Hence this method does not rely on current 
knowledge of the metabolism and mechanism of action to drug response. Recent genome-
wide association studies have presented novel associations between SNPs and drug 
response. Studies on drug response have detected significant genome-wide associations for 
interferon- , clopidogrel response and anticoagulant dose requirement (Cooper et al., 2008; 
Shuldiner et al., 2009; Takeuchi et al., 2009; Tanaka et al., 2009; Teichert et al., 2009). As to 
ADRs, significant associations have been reported for statin-induced myopathy and 
flucloxacillin induced liver injury (Daly et al., 2009; Link et al., 2008). Most of these studies 
reported novel findings and made important contributions to the field, some even with the 
potential to influence clinical practice. 
Since it has been estimated that the human genome contains more than 10 million SNPs, 
comprehensive genome-wide SNP pharmacogenomic association studies would require too 
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many SNPs. Various strategies may be adopted to overcome these challenges: one could be 
to improve high-throughput sequencing technologies capable of sequencing a full human 
genome in the most cost-effective way, another to combine the candidate gene approach 
with the genome wide SNP association studies strategy (Kooloos et al., 2009), or to apply 
genome-wide haplotype pharmacogenomic association studies (Srinivasan et al., 2009). 
Haplotypes are a combination of alleles at different markers along the same chromosome 
that are inherited as a unit. Unlike a genotype, the identity of a single polymorphic location 
on both chromosomal alleles, a haplotype is the specific combination of nucleotides present 
at all of the polymorphic locations within a single chromosomal allele. All the genetic 
variations in a population, or species, can be described as the sum of all haplotypes present 
among the individuals of that population, or species. Nucleotide differences between these 
haplotypes are responsible for heterozygous genotypes and provide information useful in 
ascertaining the identity and/or structure of a haplotype. Consequently, haplotyping 
nucleotide polymorphisms requires two steps: firstly, the identification of the 
polymorphisms and, secondly, the determination of which polymorphisms are allelic to one 
another (Fig.2).  
 
Fig. 2. Haplotypes: a set of closely linked genetic markers (SNPs) present on one 
chromosome which tend to be inherited together 
Although the primary tool used in pharmacogenetic association studies has traditionally 
been the genotyping of SNPs, recent evidence indicates that determining haplotypes may be 
more informative than genotyping single variants (Evans & McLeod, 2003). Indeed, in this 
context, a study evaluated whether the response to inhaled 2-agonist therapy for asthma 
was best predicted by individual non-synonymous SNPs, or 13 SNPs within the 2-
adrenoceptor gene (ADRB2) (Drysdale et al., 2000). It reported that these 13 SNPs were 
organized into only 12 of the possible 8,192 SNP haplotype combinations. Although 
haplotype analyses did define a patient group with a significantly superior response to 2-
agonist therapy, only 5/12 appeared with more than a 10% frequency in the multiethnic 
cohort studies. Therefore, there has been a great deal of interest in defining the haplotype 
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These successful pharmacogenetic studies, together with the glucuronidation of an 
anticancer drug, irinotecan, by a member of the UDP-glucuronosyltransferase (UGT) 
enzyme family (Gagné et al., 2002), showing gene-drug interactions, represented a 
predominantly monogenic, high-penetrance trait where the functional consequence of a 
major gene was recognized. However, these associations were not replicated by other 
investigators (Hu & Ziv, 2008) and might lead to false-positive findings (Serpe et al., 2009). 
Indeed, even with the very strong single-gene high-penetrance disorder TPMT, a study 
correlating thiopurine related ADRs with TPMT genotype, noted that 78% of ADRs were not 
associated with TPMT gene polymorphism and were attributable to factors other than this 
drug-metabolizing enzyme (van Aken et al., 2003).  
Although the presence of non-synonymous SNPs in a candidate gene may be suspected to 
cause variance in drug response, this cannot account for all SNPs able to cause drug 
response variance or susceptibility in drug response variance. Other functional SNPs 
implicated in variance in drug response or susceptibility variance in drug response include 
SNPs located in promoter, introns, splice sites and intragenic regions. Furthermore, it has 
been postulated that even synonymous or silent SNPs are implicated in functional 
consequence via hypothesized mechanisms (Kimchi-Sarfaty et al., 2007). 
A more comprehensive approach is the genome-wide method (GWA) using SNP arrays 
(Grant & Hakonarson, 2008). With this strategy we move from studies involving the effects 
of single genes on drug disposition and response, to studies where the effects of several 
genes up to whole genome are investigated. In other words we move from 
Pharmacogenetics to Pharmacogenomics.  
A clear advantage of this method is that it is hypothesis-free and that this may reveal 
unexpected SNPs related to drug response. Hence this method does not rely on current 
knowledge of the metabolism and mechanism of action to drug response. Recent genome-
wide association studies have presented novel associations between SNPs and drug 
response. Studies on drug response have detected significant genome-wide associations for 
interferon- , clopidogrel response and anticoagulant dose requirement (Cooper et al., 2008; 
Shuldiner et al., 2009; Takeuchi et al., 2009; Tanaka et al., 2009; Teichert et al., 2009). As to 
ADRs, significant associations have been reported for statin-induced myopathy and 
flucloxacillin induced liver injury (Daly et al., 2009; Link et al., 2008). Most of these studies 
reported novel findings and made important contributions to the field, some even with the 
potential to influence clinical practice. 
Since it has been estimated that the human genome contains more than 10 million SNPs, 
comprehensive genome-wide SNP pharmacogenomic association studies would require too 
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many SNPs. Various strategies may be adopted to overcome these challenges: one could be 
to improve high-throughput sequencing technologies capable of sequencing a full human 
genome in the most cost-effective way, another to combine the candidate gene approach 
with the genome wide SNP association studies strategy (Kooloos et al., 2009), or to apply 
genome-wide haplotype pharmacogenomic association studies (Srinivasan et al., 2009). 
Haplotypes are a combination of alleles at different markers along the same chromosome 
that are inherited as a unit. Unlike a genotype, the identity of a single polymorphic location 
on both chromosomal alleles, a haplotype is the specific combination of nucleotides present 
at all of the polymorphic locations within a single chromosomal allele. All the genetic 
variations in a population, or species, can be described as the sum of all haplotypes present 
among the individuals of that population, or species. Nucleotide differences between these 
haplotypes are responsible for heterozygous genotypes and provide information useful in 
ascertaining the identity and/or structure of a haplotype. Consequently, haplotyping 
nucleotide polymorphisms requires two steps: firstly, the identification of the 
polymorphisms and, secondly, the determination of which polymorphisms are allelic to one 
another (Fig.2).  
 
Fig. 2. Haplotypes: a set of closely linked genetic markers (SNPs) present on one 
chromosome which tend to be inherited together 
Although the primary tool used in pharmacogenetic association studies has traditionally 
been the genotyping of SNPs, recent evidence indicates that determining haplotypes may be 
more informative than genotyping single variants (Evans & McLeod, 2003). Indeed, in this 
context, a study evaluated whether the response to inhaled 2-agonist therapy for asthma 
was best predicted by individual non-synonymous SNPs, or 13 SNPs within the 2-
adrenoceptor gene (ADRB2) (Drysdale et al., 2000). It reported that these 13 SNPs were 
organized into only 12 of the possible 8,192 SNP haplotype combinations. Although 
haplotype analyses did define a patient group with a significantly superior response to 2-
agonist therapy, only 5/12 appeared with more than a 10% frequency in the multiethnic 
cohort studies. Therefore, there has been a great deal of interest in defining the haplotype 
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structure of the human genome (e.g. the human ‘‘HapMap’’ project). The HapMap project 
(The International HapMap Project, 2003) focuses on SNPs that are relatively common 
among human populations; assessing these SNPs at an appropriate density (i.e. number and 
position across the human genome) will provide new insights into the polymorphic nature 
of the human genome. 
As common SNPs are phylogenetically older than rare SNPs, they have arisen from 
recombination events of ancestral haplotypes (Wall & Pritchard, 2003). Therefore, focusing 
on these common SNPs will allow for the reconstruction of these ancestral haplotypes, 
tracing human evolutionary history. More importantly, the use of common SNPs to map the 
human haplotype structure will identify the haplotypes that make up the majority (perhaps 
up to 90%) of human variations and will be the most informative source for GWA 
pharmacogenomic studies. Recent evidence suggests that genotyping just 6 to 8 ‘‘haplotype 
tag’’ SNPs per 10–100 kb of genomic DNA may provide enough information to determine 
an individual’s haplotype for that region (Gabriel et al., 2002; Wall & Pritchard, 2003). This 
suggests that genotyping these haplotype tag SNPs will be the method of choice for the 
haplotyping of individual patients for common variations in genome-wide haplotype 
pharmacogenomic association studies. According to these new strategies, there is an ever 
increasing use of genome-wide association studies in the field of Pharmacogenomics, with 
several studies appearing between 2010 and 2011 (Daly, 2010). However, it has become 
apparent that there may be allelic epigenetic modifications at some genes that cause these 
alleles to exhibit different expression patterns (Fournier et al., 2002). Indeed, in the future it 
may be important to refine our concept of haplotypes and, therefore, GWA, beyond DNA 
sequence variations, to include other information, such as allelic epigenetic factors, which 
are inherited through mitosis and meiosis with the DNA itself and serve to extend the 
information content of the human genome (Jenuwein & Allis, 2001). 
3. Pharmacoepigenetics and pharmacoepigenomics 
Epigenetics is usually defined as the study of mitotically heritable changes in gene 
expression that are not attributable to nucleic acid sequence alterations. Therefore 
epigenetics refers to the regulation of various genomic functions controlled by stable, but 
potentially reversible changes in DNA methylation and chromatin structure (Henikoff & 
Matzke, 1997). Epigenomics refers to the study of epigenetics on a genome-wide basis 
(Peedicayil, 2008).  
There are two major mechanisms of epigenetic regulation, methylation of cytosines in the 
DNA sequence and modification of the histone proteins that the DNA is wrapped around. 
The coordination of both mechanisms results in dramatic changes in the remodelling of 
chromatin and altered gene transcription (Flanagan & Petronis, 2005). One of the most 
recent important observations is the increasing evidence that epigenetic factors play an 
important role in the etiopathogenesis of human diseases and the discovery that  epigenetic 
risk factors open new opportunities for diagnostic, prognostic and therapeutic approaches 
in human biology. Indeed, epigenetic factors contribute to numerous genomic functions, 
from the regulation of gene activity to genome stability and segregation of chromosomes, 
such as: genomic imprinting, X chromosome inactivation and suppression of parasitic DNA 
elements (Urnov & Wolffe, 2001). Moreover, epigenetic variation across individuals is much 
richer in comparison to DNA sequence variation and identical DNA sequences in unrelated 
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individuals exhibit significant epigenetic variation. Therefore, such epigenetic differences 
may have an impact on gene expression that translates into differential density of receptors, 
or varied numbers of molecules of an enzyme, factors that might contribute to the 
pharmacokinetic and pharmacodynamic drug variability. The main goals of 
Pharmacoepigenomics and Pharmacoepigenetics are to predict drug response and/or 
adverse reactions, based on the epigenetic individuality of an organism. 
3.1 The effect of methylation/deacetylation on drug response 
There are almost 300 genes involved in the absorption, distribution, metabolism, and 
excretion (ADME) of pharmaceutical compounds in humans. It has been demonstrated that 
DNA methylation, or histone modifications, potentially participate in the regulation of 
almost 60 human ADME genes (Kacevska et al., 2011). A correlation between the epigenetic 
state of the gene and a possible influence on drug therapy outcome has been experimentally 
established only for a few ADME genes. Nevertheless, there is credible evidence that 
epigenetic factors influence ADME gene expression, which, in turn, leads to changes in the 
metabolism and distribution of drugs. For example, about 30% of the lungs of heavy 
smokers and 70% of light smokers’ lungs have a CYP1A1 expression, with complete, or 
partial methylation of the CYP1A1 gene (Anttila et al., 2003). An increase in the methylation 
level was observed as early as 1-7 days after individuals had stopped smoking, possibly 
explaining the smoking-related increase in CYPA1A expression (Anttila et al., 2003). 
Moreover, hypomethylation at sites coinciding with the transcription activator binding sites, 
such as Arnt and Sp1, leads to overexpression of CYP1B1 in prostate cancer and correlates to 
the progression of malignancy (Tokizane et al., 2005). 
Similarly, CYP1A2, an enzyme abundant in the liver, is involved in the metabolism of many 
drugs (Zhou et al., 2010). Known SNPs account only partially for the wide interindividual 
differences observed for CYP1A2  (Jiang et al., 2006). Therefore, it has been implied that an 
epigenetic component in CYP1A2 regulation is responsible for the variability in CYP1A2 
expression and the methylation status of a CpG island in exon 2, consisting of 17 CpG 
dinucleotides, has been shown to correlate with interindividual differences in CYP1A2 
mRNA levels (Ghotbi et al., 2009). It has also been demonstrated that the methylation status 
of even a single CpG located far upstream from the transcriptional start site ( 2579 bp) 
could contribute to differential CYP1A2 expression. Such interindividual variations might 
affect the pharmacokinetic and pharmacodynamic metabolization of the drug through 
CYP1A2, potentially failing the drug treatment or leading to ADRs. Among the members of 
the CYP2 family, the CYP2A6, CYP2C9, CYP2D6, CYP2J2, CYP2R1, CYP2S1 and CYP2W1 
genes contain putative important CpG islands, suggesting a potential role for DNA 
methylation in their regulation (Ingelman-Sundberg et al., 2007). 
As to phase II drug metabolism, glutathione-S-transferase genes, it has been shown that the 
extent of promoter methylation is dependent on the haplotype of the glutathione-S-
transferase P1 (GSTP1) gene in breast cancer patients (Rønneberg et al., 2008). Moreover, 
hypermethylation of GSTP1 is a common molecular alteration in human prostate cancer 
(Woodson et al., 2008). Irinotecan is a first-line treatment for metastatic colorectal cancer. Its 
active metabolite is inactivated through glucuronidation mediated by the UGT1A1 enzyme. 
The level of UGT1A1 expression is highly variable among primary colon tumours, thereby 
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structure of the human genome (e.g. the human ‘‘HapMap’’ project). The HapMap project 
(The International HapMap Project, 2003) focuses on SNPs that are relatively common 
among human populations; assessing these SNPs at an appropriate density (i.e. number and 
position across the human genome) will provide new insights into the polymorphic nature 
of the human genome. 
As common SNPs are phylogenetically older than rare SNPs, they have arisen from 
recombination events of ancestral haplotypes (Wall & Pritchard, 2003). Therefore, focusing 
on these common SNPs will allow for the reconstruction of these ancestral haplotypes, 
tracing human evolutionary history. More importantly, the use of common SNPs to map the 
human haplotype structure will identify the haplotypes that make up the majority (perhaps 
up to 90%) of human variations and will be the most informative source for GWA 
pharmacogenomic studies. Recent evidence suggests that genotyping just 6 to 8 ‘‘haplotype 
tag’’ SNPs per 10–100 kb of genomic DNA may provide enough information to determine 
an individual’s haplotype for that region (Gabriel et al., 2002; Wall & Pritchard, 2003). This 
suggests that genotyping these haplotype tag SNPs will be the method of choice for the 
haplotyping of individual patients for common variations in genome-wide haplotype 
pharmacogenomic association studies. According to these new strategies, there is an ever 
increasing use of genome-wide association studies in the field of Pharmacogenomics, with 
several studies appearing between 2010 and 2011 (Daly, 2010). However, it has become 
apparent that there may be allelic epigenetic modifications at some genes that cause these 
alleles to exhibit different expression patterns (Fournier et al., 2002). Indeed, in the future it 
may be important to refine our concept of haplotypes and, therefore, GWA, beyond DNA 
sequence variations, to include other information, such as allelic epigenetic factors, which 
are inherited through mitosis and meiosis with the DNA itself and serve to extend the 
information content of the human genome (Jenuwein & Allis, 2001). 
3. Pharmacoepigenetics and pharmacoepigenomics 
Epigenetics is usually defined as the study of mitotically heritable changes in gene 
expression that are not attributable to nucleic acid sequence alterations. Therefore 
epigenetics refers to the regulation of various genomic functions controlled by stable, but 
potentially reversible changes in DNA methylation and chromatin structure (Henikoff & 
Matzke, 1997). Epigenomics refers to the study of epigenetics on a genome-wide basis 
(Peedicayil, 2008).  
There are two major mechanisms of epigenetic regulation, methylation of cytosines in the 
DNA sequence and modification of the histone proteins that the DNA is wrapped around. 
The coordination of both mechanisms results in dramatic changes in the remodelling of 
chromatin and altered gene transcription (Flanagan & Petronis, 2005). One of the most 
recent important observations is the increasing evidence that epigenetic factors play an 
important role in the etiopathogenesis of human diseases and the discovery that  epigenetic 
risk factors open new opportunities for diagnostic, prognostic and therapeutic approaches 
in human biology. Indeed, epigenetic factors contribute to numerous genomic functions, 
from the regulation of gene activity to genome stability and segregation of chromosomes, 
such as: genomic imprinting, X chromosome inactivation and suppression of parasitic DNA 
elements (Urnov & Wolffe, 2001). Moreover, epigenetic variation across individuals is much 
richer in comparison to DNA sequence variation and identical DNA sequences in unrelated 
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individuals exhibit significant epigenetic variation. Therefore, such epigenetic differences 
may have an impact on gene expression that translates into differential density of receptors, 
or varied numbers of molecules of an enzyme, factors that might contribute to the 
pharmacokinetic and pharmacodynamic drug variability. The main goals of 
Pharmacoepigenomics and Pharmacoepigenetics are to predict drug response and/or 
adverse reactions, based on the epigenetic individuality of an organism. 
3.1 The effect of methylation/deacetylation on drug response 
There are almost 300 genes involved in the absorption, distribution, metabolism, and 
excretion (ADME) of pharmaceutical compounds in humans. It has been demonstrated that 
DNA methylation, or histone modifications, potentially participate in the regulation of 
almost 60 human ADME genes (Kacevska et al., 2011). A correlation between the epigenetic 
state of the gene and a possible influence on drug therapy outcome has been experimentally 
established only for a few ADME genes. Nevertheless, there is credible evidence that 
epigenetic factors influence ADME gene expression, which, in turn, leads to changes in the 
metabolism and distribution of drugs. For example, about 30% of the lungs of heavy 
smokers and 70% of light smokers’ lungs have a CYP1A1 expression, with complete, or 
partial methylation of the CYP1A1 gene (Anttila et al., 2003). An increase in the methylation 
level was observed as early as 1-7 days after individuals had stopped smoking, possibly 
explaining the smoking-related increase in CYPA1A expression (Anttila et al., 2003). 
Moreover, hypomethylation at sites coinciding with the transcription activator binding sites, 
such as Arnt and Sp1, leads to overexpression of CYP1B1 in prostate cancer and correlates to 
the progression of malignancy (Tokizane et al., 2005). 
Similarly, CYP1A2, an enzyme abundant in the liver, is involved in the metabolism of many 
drugs (Zhou et al., 2010). Known SNPs account only partially for the wide interindividual 
differences observed for CYP1A2  (Jiang et al., 2006). Therefore, it has been implied that an 
epigenetic component in CYP1A2 regulation is responsible for the variability in CYP1A2 
expression and the methylation status of a CpG island in exon 2, consisting of 17 CpG 
dinucleotides, has been shown to correlate with interindividual differences in CYP1A2 
mRNA levels (Ghotbi et al., 2009). It has also been demonstrated that the methylation status 
of even a single CpG located far upstream from the transcriptional start site ( 2579 bp) 
could contribute to differential CYP1A2 expression. Such interindividual variations might 
affect the pharmacokinetic and pharmacodynamic metabolization of the drug through 
CYP1A2, potentially failing the drug treatment or leading to ADRs. Among the members of 
the CYP2 family, the CYP2A6, CYP2C9, CYP2D6, CYP2J2, CYP2R1, CYP2S1 and CYP2W1 
genes contain putative important CpG islands, suggesting a potential role for DNA 
methylation in their regulation (Ingelman-Sundberg et al., 2007). 
As to phase II drug metabolism, glutathione-S-transferase genes, it has been shown that the 
extent of promoter methylation is dependent on the haplotype of the glutathione-S-
transferase P1 (GSTP1) gene in breast cancer patients (Rønneberg et al., 2008). Moreover, 
hypermethylation of GSTP1 is a common molecular alteration in human prostate cancer 
(Woodson et al., 2008). Irinotecan is a first-line treatment for metastatic colorectal cancer. Its 
active metabolite is inactivated through glucuronidation mediated by the UGT1A1 enzyme. 
The level of UGT1A1 expression is highly variable among primary colon tumours, thereby 
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contributing to their differential sensitivity to irinotecan treatment. UGT1A1 expression in 
colon tumours correlates with the methylation of its promoter and the outcome of cancer 
chemotherapy (Gagnon et al., 2006). 
The SLC19A1 gene encodes the reduced folate carrier. This enzyme is responsible for 
cellular uptake of reduced folates and of antifolate drugs, including methotrexate, the most 
effective drug against primary central nervous system lymphoma. The level of reduced 
folate carrier differs significantly among lymphoma samples and is associated with 
methylation of the SLC19A1 promoter. It has been hypothesized that an increase in SLC19A1 
methylation can contribute to methotrexate resistance in tumour cells (Ferreri et al., 2004). 
The promoter of the ABCB1 gene that encodes the P-gp transporter is found 
hypomethylated in cancer cell lines, manifesting a multidrug-resistance phenotype 
compared to drug-sensitive cell lines (Baker & El-Osta, 2004). These differences in 
methylation are also associated with histone modifications. Such epigenetic mechanisms 
have been shown to be responsible for the increased tolerance shown by certain types of 
cancer cells to anticancer drugs, such as doxorubicin, paclitaxel and vincristine. 
Hypomethylation of ABCB1 can also be induced by exposure of drug-sensitive cells to 
chemotherapeutic drugs (Baker et al., 2005). Once established, this epigenetic mark can then 
stably perpetuate through mitotic divisions of cells, manifesting as acquired multidrug 
resistance.  
In addition to these ADME genes, epigenetic influence has also been documented for the -1 
adrenergic receptors ( 1-ARs). The three subtypes of 1-AR ( 1aAR, 1bAR, and 1dAR) 
display tissue-specific expression patterns and undergo subtype switching in response to 
many pathological stimuli. Basal expression of the 1dAR (ADRA1D) subtype is dependent 
on the binding of Sp1 in the two proximal promoter GC boxes of the gene and this binding 
was shown to be dependent on the methylation status of the promoter region (Michelotti et 
al., 2007). The expression of the chemokine receptor CXCR4, involved in leukocyte 
trafficking, seems to be epigenetically regulated, as reported in human pancreatic cancer, 
where aberrant methylation influences CXCR4 expression (Sato et al., 2005). This finding 
may pave the way for the development of anticancer drugs that target the CXCR4 receptor, 
which is overexpressed in various cancers. Moreover, the CXCR4 receptor ligand CXCL12, 
which has also been shown to be regulated by DNA methylation, has a role in tumour 
invasion and metastasis and may offer another target for anticancer drugs (Kubarek & 
Jagodzinski, 2007). The MGMT gene, which encodes the DNA repair enzyme O6-
methylguanine-DNA methyltransferase, plays a prominent role in the repair of DNA lesions 
caused by alkylating agents. The extent of methylation of the MGMT promoter has been 
shown to correlate with the responsiveness of gliomas to alkylating drugs, such as 
carmustine and temozolomide  (Paz et al., 2004). Lastly, although the oestrogen receptor is 
also regulated epigenetically, both by DNA methylation and histone modifications (Bovenzi 
& Momparler, 2001) in cancer, a non-cancer-related event (ischemia) has also been shown to 
affect the methylation and expression status of the oestrogen receptor in an animal model  
(Westberry et al., 2008), demonstrating the wide range of genes that may contribute to drug 
response variations by means of epigenetic regulation.  
As reported for the oestrogen receptor, also histone modifications play an important role in 
the control of genes encoding drug targets and proteins involved in drug ADME. However, it 
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must not be forgotten that DNA methylation and histone modification are interconnected 
events. Let’s go back then to CYP1A1, this enzyme has been shown to be also under histone 
modification control, particularly methylation of lysine 4, a H3 histone (3meK4H3) (Okino et 
al., 2006). Again, in phase I drug metabolism, an increase in CYP2A6 mRNA and protein 
levels was observed in human hepatocytes in response to dexamethasone. This was shown to 
be mediated by the hepatic nuclear factor 4  and the glucocorticoid receptor (GR). The 
binding of the hepatic nuclear factor 4  to the hepatic nuclear factor 4  response element was 
promoted by the increased acetylation of histone H4, also in response to dexamethasone 
(Onica et al., 2008). This modification relaxes the chromatin, thereby allowing the binding of 
DNA-binding proteins. As a response to cisplatin treatment of HeLa cells, specific 
phosphorylation of Ser-10 at histone H3 is mediated by the p38 mitogen-activated protein 
kinase pathway. Likewise, cisplatin induces phosphorylation of H3 at Ser-28 and acetylation 
of histone H4 (Wang & Lippard, 2004). These findings provide a link between the drug 
response and chromosomal structural alterations through histone modifications. 
3.2 The effect of drugs on methylation/deacetylation 
Several chemicals are able to affect the epigenome, either as agents used in clinical practice, 
or causing ADRs. A range of first-generation compounds that target the epigenome, 
including DNA methyltransferases (DNMTs) and histone deacetylase inhibitors, have met 
with success in the treatment of haematological disorders. The earliest of these, 5-
azacytidine and azacytidine, are chemical analogs of the nucleoside cytidine and its deoxy 
derivative, 5-aza-2 -deoxycytidine (decitabine). Through incorporation into DNA (during 
replication) and RNA (during transcription), they inhibit methyltransferases and lead to 
demethylation of the sequence (Christman, 2002). Other drugs that affect the epigenome 
have also emerged, such as zebularine, a cytidine analog that inhibits DNA methylation 
(Bradbury, 2004). Second-generation drugs that target epigenetic enzymes with more tightly 
defined modes of action are, at time of writing, still in the investigation phase. Some such 
drugs include MG98, an antisense oligonucleotide that targets the 3 -untranslated region of 
the maintenance methyltransferase DNMT1, inhibiting it (Goffin & Eisenhauer, 2002); 
RG108, a small molecule that effectively blocks DNMTs, particularly DNMT1 and inhibits 
their activity (Suzuki et al., 2010), and psammaplin, a natural product derived from the sea 
sponge Pseudoceratina purpurea that inhibits DNMTs as well as histone deacetylases 
(McCulloch et al., 2009). Increasing attention is being paid not only to research on drugs that 
modify the DNA methylation landscape, but also to developing drugs that affect histone 
modifications. Histone deacetylase inhibitors have been object of research in anticancer drug 
development, as they present a potential strategy to reverse aberrant epigenetic changes 
associated with cancer (Dannenberg & Edenberg, 2006). However, there is also an increasing 
awareness that commonly used drugs can affect epigenome and cause ADRs. Among the 
better-documented examples are valproic acid (VPA), hydralazine, and procainamide. 
Although VPA is an established antiepileptic and mood-stabilizing drug, clinically used 
since the 1960s, only recently it has been found that VPA is a direct inhibitor of histone 
deacetylase (Phiel et al., 2001). Furthermore, the resultant increase in histone acetylation 
caused by VPA was shown to be interrelated with changes in genomic DNA methylation 
(Milutinovic et al., 2007). Animal and cell culture studies have implicated the epigenetic 
mode of action of VPA in a wide range of gene expression changes associated with VPA-
induced side-effects, such as teratogenicity and cognitive disorders (Fukuchi et al., 2009; 
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contributing to their differential sensitivity to irinotecan treatment. UGT1A1 expression in 
colon tumours correlates with the methylation of its promoter and the outcome of cancer 
chemotherapy (Gagnon et al., 2006). 
The SLC19A1 gene encodes the reduced folate carrier. This enzyme is responsible for 
cellular uptake of reduced folates and of antifolate drugs, including methotrexate, the most 
effective drug against primary central nervous system lymphoma. The level of reduced 
folate carrier differs significantly among lymphoma samples and is associated with 
methylation of the SLC19A1 promoter. It has been hypothesized that an increase in SLC19A1 
methylation can contribute to methotrexate resistance in tumour cells (Ferreri et al., 2004). 
The promoter of the ABCB1 gene that encodes the P-gp transporter is found 
hypomethylated in cancer cell lines, manifesting a multidrug-resistance phenotype 
compared to drug-sensitive cell lines (Baker & El-Osta, 2004). These differences in 
methylation are also associated with histone modifications. Such epigenetic mechanisms 
have been shown to be responsible for the increased tolerance shown by certain types of 
cancer cells to anticancer drugs, such as doxorubicin, paclitaxel and vincristine. 
Hypomethylation of ABCB1 can also be induced by exposure of drug-sensitive cells to 
chemotherapeutic drugs (Baker et al., 2005). Once established, this epigenetic mark can then 
stably perpetuate through mitotic divisions of cells, manifesting as acquired multidrug 
resistance.  
In addition to these ADME genes, epigenetic influence has also been documented for the -1 
adrenergic receptors ( 1-ARs). The three subtypes of 1-AR ( 1aAR, 1bAR, and 1dAR) 
display tissue-specific expression patterns and undergo subtype switching in response to 
many pathological stimuli. Basal expression of the 1dAR (ADRA1D) subtype is dependent 
on the binding of Sp1 in the two proximal promoter GC boxes of the gene and this binding 
was shown to be dependent on the methylation status of the promoter region (Michelotti et 
al., 2007). The expression of the chemokine receptor CXCR4, involved in leukocyte 
trafficking, seems to be epigenetically regulated, as reported in human pancreatic cancer, 
where aberrant methylation influences CXCR4 expression (Sato et al., 2005). This finding 
may pave the way for the development of anticancer drugs that target the CXCR4 receptor, 
which is overexpressed in various cancers. Moreover, the CXCR4 receptor ligand CXCL12, 
which has also been shown to be regulated by DNA methylation, has a role in tumour 
invasion and metastasis and may offer another target for anticancer drugs (Kubarek & 
Jagodzinski, 2007). The MGMT gene, which encodes the DNA repair enzyme O6-
methylguanine-DNA methyltransferase, plays a prominent role in the repair of DNA lesions 
caused by alkylating agents. The extent of methylation of the MGMT promoter has been 
shown to correlate with the responsiveness of gliomas to alkylating drugs, such as 
carmustine and temozolomide  (Paz et al., 2004). Lastly, although the oestrogen receptor is 
also regulated epigenetically, both by DNA methylation and histone modifications (Bovenzi 
& Momparler, 2001) in cancer, a non-cancer-related event (ischemia) has also been shown to 
affect the methylation and expression status of the oestrogen receptor in an animal model  
(Westberry et al., 2008), demonstrating the wide range of genes that may contribute to drug 
response variations by means of epigenetic regulation.  
As reported for the oestrogen receptor, also histone modifications play an important role in 
the control of genes encoding drug targets and proteins involved in drug ADME. However, it 
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must not be forgotten that DNA methylation and histone modification are interconnected 
events. Let’s go back then to CYP1A1, this enzyme has been shown to be also under histone 
modification control, particularly methylation of lysine 4, a H3 histone (3meK4H3) (Okino et 
al., 2006). Again, in phase I drug metabolism, an increase in CYP2A6 mRNA and protein 
levels was observed in human hepatocytes in response to dexamethasone. This was shown to 
be mediated by the hepatic nuclear factor 4  and the glucocorticoid receptor (GR). The 
binding of the hepatic nuclear factor 4  to the hepatic nuclear factor 4  response element was 
promoted by the increased acetylation of histone H4, also in response to dexamethasone 
(Onica et al., 2008). This modification relaxes the chromatin, thereby allowing the binding of 
DNA-binding proteins. As a response to cisplatin treatment of HeLa cells, specific 
phosphorylation of Ser-10 at histone H3 is mediated by the p38 mitogen-activated protein 
kinase pathway. Likewise, cisplatin induces phosphorylation of H3 at Ser-28 and acetylation 
of histone H4 (Wang & Lippard, 2004). These findings provide a link between the drug 
response and chromosomal structural alterations through histone modifications. 
3.2 The effect of drugs on methylation/deacetylation 
Several chemicals are able to affect the epigenome, either as agents used in clinical practice, 
or causing ADRs. A range of first-generation compounds that target the epigenome, 
including DNA methyltransferases (DNMTs) and histone deacetylase inhibitors, have met 
with success in the treatment of haematological disorders. The earliest of these, 5-
azacytidine and azacytidine, are chemical analogs of the nucleoside cytidine and its deoxy 
derivative, 5-aza-2 -deoxycytidine (decitabine). Through incorporation into DNA (during 
replication) and RNA (during transcription), they inhibit methyltransferases and lead to 
demethylation of the sequence (Christman, 2002). Other drugs that affect the epigenome 
have also emerged, such as zebularine, a cytidine analog that inhibits DNA methylation 
(Bradbury, 2004). Second-generation drugs that target epigenetic enzymes with more tightly 
defined modes of action are, at time of writing, still in the investigation phase. Some such 
drugs include MG98, an antisense oligonucleotide that targets the 3 -untranslated region of 
the maintenance methyltransferase DNMT1, inhibiting it (Goffin & Eisenhauer, 2002); 
RG108, a small molecule that effectively blocks DNMTs, particularly DNMT1 and inhibits 
their activity (Suzuki et al., 2010), and psammaplin, a natural product derived from the sea 
sponge Pseudoceratina purpurea that inhibits DNMTs as well as histone deacetylases 
(McCulloch et al., 2009). Increasing attention is being paid not only to research on drugs that 
modify the DNA methylation landscape, but also to developing drugs that affect histone 
modifications. Histone deacetylase inhibitors have been object of research in anticancer drug 
development, as they present a potential strategy to reverse aberrant epigenetic changes 
associated with cancer (Dannenberg & Edenberg, 2006). However, there is also an increasing 
awareness that commonly used drugs can affect epigenome and cause ADRs. Among the 
better-documented examples are valproic acid (VPA), hydralazine, and procainamide. 
Although VPA is an established antiepileptic and mood-stabilizing drug, clinically used 
since the 1960s, only recently it has been found that VPA is a direct inhibitor of histone 
deacetylase (Phiel et al., 2001). Furthermore, the resultant increase in histone acetylation 
caused by VPA was shown to be interrelated with changes in genomic DNA methylation 
(Milutinovic et al., 2007). Animal and cell culture studies have implicated the epigenetic 
mode of action of VPA in a wide range of gene expression changes associated with VPA-
induced side-effects, such as teratogenicity and cognitive disorders (Fukuchi et al., 2009; 
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Nagai et al., 2008; Tung & Winn, 2010). Procainamide, an antiarrythmic sodium channel 
blocker and hydralazine, a vasodilator used to treat hypertension, did not have well-
characterized mechanisms of action when they were first introduced. Mechanistic studies 
have now shown that procainamide directly inhibits methyltransferases activity, specifically 
DNMT1 (Lee et al., 2005), whereas hydralazine mainly inhibits DNMT expression (Arce et 
al., 2006). Consequently, the extensive hypomethylation induced by these drugs alters 
appropriate protein expression in T cells and triggers a lupus-like autoimmune disease 
(Chang & Gershwin, 2010; Yung et al., 1996). 
The notion that some drug-induced epigenetic marks may have a transgenerational impact 
is even more alarming. It has been suggested that drugs, such as thalidomide, a sedative–
hypnotic and immunomodulatory agent and the synthetic oestrogen diethylstilbestrol may 
induce transgenerational epigenetic alterations that result in persistent pathological changes 
in subsequent generations (Holliday, 1998; Newbold et al., 2006). However, given the 
inadequacy of experimental tools and approaches, solid evidence for true transgenerational 
epigenetic impact has not been clearly established, although it is an attractive hypothesis to 
explain such observations.  
Other drugs, such as isotretinoin, methylphenidate, tamoxifen, methotrexate and even 
families of drugs, such as conventional neuroleptics, selective serotonin reuptake inhibitor 
antidepressant, -blockers, and chloroquine and fluoroquinolone antibiotics, have all been 
suggested to affect the epigenome (Csoka & Szyf, 2009). Such conclusions have been based 
mainly on observations of altered DNA methylation patterns, chromatin remodeling, or 
substantial changes in gene and protein expression that persist even after therapy has 
ceased. However, the exact mechanisms through which these drugs influence the 
epigenome and the consequences of the drug-induced epigenetic reprogramming have not 
been sufficiently investigated  
4. Pharmacogenomics of microRNA 
Although sequencing the whole genome and identifying genetic variations, such as SNPs, 
small insertions, deletions, inversions, variable numbers of tandem repeat (minisatellite), 
short tandem repeat (microsatellite), and copy number variations (Nakamura, 2009), are 
important for the understanding of human biology, having information on only these 
genomic aspects is limiting when attempting to explain interindividual differences in drug 
response and ADRs. Consequently, researchers have suggested that knowledge and 
understanding of functional genomics related to gene expression, such as transcriptional 
and translational processes, be included. One of the first steps to be taken towards 
understanding the difference in gene expression to identify the variability in drug response 
is investigating the role of nuclear receptors, or transcription factors, such as the 
arylhydrocarbon receptor (AhR), peroxisoma proliferator activated receptor (PPAR), 
pregnane X receptor (PXR) and constitutive androstane receptor (CAR), in the transcription 
control of genes encoding drug transporters, enzymes and drug targets (Lehmann et al., 
1998; Smirlis et al., 2001;  Synold et al., 2001; Xie et al., 2000a, 2000b). However the discovery 
of the world of small regulatory RNAs, or microRNA (miRNA), which are coded in our 
genomes and implicated in post-transcriptional control, has been more promising. Some 
researchers classify microRNA regulation as an epigenetic phenomenon (Peedicayil, 2008) 
but, even if it is closely related to epigenetic phenomena, microRNAs are not themselves 
epigenetic factors (Chuang & Jones, 2007). 
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MiRNAs are small, single stranded, 21–23 nucleotide-long, independent functional units of 
noncoding RNA (Lagos-Quintana et al., 2001; Lau et al., 2001; Lee & Ambros, 2001) which 
bind to the target transcript in the 3’-untraslated region (3’-UTR) to inhibit the translation of 
proteins and destabilize their target mRNAs (Baek et al., 2008, Selbach et al., 2008). MiRNAs 
regulate specific genes broadly involved in multiple pathways, like cell death, cell 
proliferation, stress resistance and fat metabolism (Ambros, 2003, Lim et al., 2003a, 2003b). 
Work on miRNA knock-down and miRNA transfections has recently shown that 
approximately one third of the miRNA targets are translationally repressed in a cell display 
mRNA destabilization (Baek et al., 2008, Selbach et al., 2008). Consequently, miRNAs fine-
tune protein output in the cell by translationally repressing and destabilizing the target 
mRNA (Baek et al., 2008; Mishra et al., 2007; Selbach et al., 2008). Other evidence suggests 
that a gain, or loss in miRNA function is associated to disease progression and prognosis 
(Lu et al., 2005; Mishra et al., 2007), as several studies have now established that miRNAs 
are expressed differently in human cancers than in normal healthy tissue (Calin et al., 2004; 
He et al., 2007; Lu et al., 2005). 
4.1 Effect of polymorphisms in miRNA in drug response and adverse drug reactions 
Polymorphisms in the miRNA regulatory pathway (miR-polymorphisms) are a novel class 
of functional polymorphisms present in the human genome. MiR-polymorphisms reside at, 
or near to, a miRNA binding site of a functional gene, influencing its expression by 
interfering with miRNA function (Bertino et al., 2007; Mishra et al., 2007, 2008). Several 
groups worldwide have acknowledged the role of miR-polymorphisms, suggesting a strong 
association between miR-polymorphisms and disease progression, as well as with drug 
response. Indeed, a single miR-polymorphism can potentially affect the expression of 
multiple genes involved in pathways regulating drug absorption, metabolism, disposition 
and may affect the overall clinical efficacy of a drug and/or resistance to that drug. 
An analysis of the publicly available SNP database revealed the presence of a relatively high 
level of variations in the 3’-UTRs of miRNA target genes (Saunders et al., 2007) 
demonstrating that some of these variations may interfere with the function of miRNA and 
are potential miR-polymorphisms with the capacity to affect the expression of miRNA 
targets (Barnes et al., 2007; Kertesz et al., 2007; Mishra et al., 2007). MiRNA mutation (miR-
mutations) can be defined as a mutation that interferes with miRNA function. MiR-
polymorphisms and miR-mutations can be present either in heterozygous, or homozygous 
forms in a population. These variants in the human genome may take the form of insertions, 
deletions, amplifications, or chromosomal translocations, resulting in loss, or gain of miRNA 
site/function (Mishra et al., 2007). Functional miR-polymorphisms, or mutations, may 
create, or destroy, a miRNA binding site within a target mRNA and affect gene expression 
by interfering with the function of a miRNA  (Bertino et al., 2007; Mishra et al., 2007, 2008). 
Recently, the role of miRNA in drug-resistance/sensitivity has been investigated. It was 
functionally demonstrated that a polymorphism in a miRNA binding site could lead to 
drug-resistance/drug sensitivity (Bertino et al., 2007; Mishra et al., 2007, 2008). For example, 
a C>T SNP present in the 3’-UTR of dihydrofolate reductase gene (DHFR) was originally 
identified in a case–control study of childhood leukaemia patients to occur with 14.2% allelic 
frequency in the Japanese population (Goto et al., 2001). Later it was demonstrated that the 
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Nagai et al., 2008; Tung & Winn, 2010). Procainamide, an antiarrythmic sodium channel 
blocker and hydralazine, a vasodilator used to treat hypertension, did not have well-
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in subsequent generations (Holliday, 1998; Newbold et al., 2006). However, given the 
inadequacy of experimental tools and approaches, solid evidence for true transgenerational 
epigenetic impact has not been clearly established, although it is an attractive hypothesis to 
explain such observations.  
Other drugs, such as isotretinoin, methylphenidate, tamoxifen, methotrexate and even 
families of drugs, such as conventional neuroleptics, selective serotonin reuptake inhibitor 
antidepressant, -blockers, and chloroquine and fluoroquinolone antibiotics, have all been 
suggested to affect the epigenome (Csoka & Szyf, 2009). Such conclusions have been based 
mainly on observations of altered DNA methylation patterns, chromatin remodeling, or 
substantial changes in gene and protein expression that persist even after therapy has 
ceased. However, the exact mechanisms through which these drugs influence the 
epigenome and the consequences of the drug-induced epigenetic reprogramming have not 
been sufficiently investigated  
4. Pharmacogenomics of microRNA 
Although sequencing the whole genome and identifying genetic variations, such as SNPs, 
small insertions, deletions, inversions, variable numbers of tandem repeat (minisatellite), 
short tandem repeat (microsatellite), and copy number variations (Nakamura, 2009), are 
important for the understanding of human biology, having information on only these 
genomic aspects is limiting when attempting to explain interindividual differences in drug 
response and ADRs. Consequently, researchers have suggested that knowledge and 
understanding of functional genomics related to gene expression, such as transcriptional 
and translational processes, be included. One of the first steps to be taken towards 
understanding the difference in gene expression to identify the variability in drug response 
is investigating the role of nuclear receptors, or transcription factors, such as the 
arylhydrocarbon receptor (AhR), peroxisoma proliferator activated receptor (PPAR), 
pregnane X receptor (PXR) and constitutive androstane receptor (CAR), in the transcription 
control of genes encoding drug transporters, enzymes and drug targets (Lehmann et al., 
1998; Smirlis et al., 2001;  Synold et al., 2001; Xie et al., 2000a, 2000b). However the discovery 
of the world of small regulatory RNAs, or microRNA (miRNA), which are coded in our 
genomes and implicated in post-transcriptional control, has been more promising. Some 
researchers classify microRNA regulation as an epigenetic phenomenon (Peedicayil, 2008) 
but, even if it is closely related to epigenetic phenomena, microRNAs are not themselves 
epigenetic factors (Chuang & Jones, 2007). 
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MiRNAs are small, single stranded, 21–23 nucleotide-long, independent functional units of 
noncoding RNA (Lagos-Quintana et al., 2001; Lau et al., 2001; Lee & Ambros, 2001) which 
bind to the target transcript in the 3’-untraslated region (3’-UTR) to inhibit the translation of 
proteins and destabilize their target mRNAs (Baek et al., 2008, Selbach et al., 2008). MiRNAs 
regulate specific genes broadly involved in multiple pathways, like cell death, cell 
proliferation, stress resistance and fat metabolism (Ambros, 2003, Lim et al., 2003a, 2003b). 
Work on miRNA knock-down and miRNA transfections has recently shown that 
approximately one third of the miRNA targets are translationally repressed in a cell display 
mRNA destabilization (Baek et al., 2008, Selbach et al., 2008). Consequently, miRNAs fine-
tune protein output in the cell by translationally repressing and destabilizing the target 
mRNA (Baek et al., 2008; Mishra et al., 2007; Selbach et al., 2008). Other evidence suggests 
that a gain, or loss in miRNA function is associated to disease progression and prognosis 
(Lu et al., 2005; Mishra et al., 2007), as several studies have now established that miRNAs 
are expressed differently in human cancers than in normal healthy tissue (Calin et al., 2004; 
He et al., 2007; Lu et al., 2005). 
4.1 Effect of polymorphisms in miRNA in drug response and adverse drug reactions 
Polymorphisms in the miRNA regulatory pathway (miR-polymorphisms) are a novel class 
of functional polymorphisms present in the human genome. MiR-polymorphisms reside at, 
or near to, a miRNA binding site of a functional gene, influencing its expression by 
interfering with miRNA function (Bertino et al., 2007; Mishra et al., 2007, 2008). Several 
groups worldwide have acknowledged the role of miR-polymorphisms, suggesting a strong 
association between miR-polymorphisms and disease progression, as well as with drug 
response. Indeed, a single miR-polymorphism can potentially affect the expression of 
multiple genes involved in pathways regulating drug absorption, metabolism, disposition 
and may affect the overall clinical efficacy of a drug and/or resistance to that drug. 
An analysis of the publicly available SNP database revealed the presence of a relatively high 
level of variations in the 3’-UTRs of miRNA target genes (Saunders et al., 2007) 
demonstrating that some of these variations may interfere with the function of miRNA and 
are potential miR-polymorphisms with the capacity to affect the expression of miRNA 
targets (Barnes et al., 2007; Kertesz et al., 2007; Mishra et al., 2007). MiRNA mutation (miR-
mutations) can be defined as a mutation that interferes with miRNA function. MiR-
polymorphisms and miR-mutations can be present either in heterozygous, or homozygous 
forms in a population. These variants in the human genome may take the form of insertions, 
deletions, amplifications, or chromosomal translocations, resulting in loss, or gain of miRNA 
site/function (Mishra et al., 2007). Functional miR-polymorphisms, or mutations, may 
create, or destroy, a miRNA binding site within a target mRNA and affect gene expression 
by interfering with the function of a miRNA  (Bertino et al., 2007; Mishra et al., 2007, 2008). 
Recently, the role of miRNA in drug-resistance/sensitivity has been investigated. It was 
functionally demonstrated that a polymorphism in a miRNA binding site could lead to 
drug-resistance/drug sensitivity (Bertino et al., 2007; Mishra et al., 2007, 2008). For example, 
a C>T SNP present in the 3’-UTR of dihydrofolate reductase gene (DHFR) was originally 
identified in a case–control study of childhood leukaemia patients to occur with 14.2% allelic 
frequency in the Japanese population (Goto et al., 2001). Later it was demonstrated that the 
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SNP is present near a miR-24 miRNA-binding site in human DHFR. The C>T SNP near the 
miRNA-binding site acts as a loss-of-function mutation and interferes with miR-24 function. 
The loss of miR-24 function results in high steady-state levels of DHFR mRNA and protein 
levels leading to drug resistance (Mishra et al., 2007). Interestingly, loss of miR-24 function, 
due to the SNP, led to a twofold increase in the half-life of the mRNA target. This 
observation not only explained the corresponding increase in DHFR mRNA and protein 
levels, but also suggested that the target mRNA destabilization could be a principle 
mechanism of action of a miRNA (Mishra et al., 2007). This finding may also be useful in 
predicting the clinical outcome of methotrexate treatment in clinical settings. Consequently, 
various miR-polymorphisms, located in many important genes that are drug targets, may 
affect drug response in patients and may lead to drug resistance and/or drug sensitivity 
and even unexpected toxicity. 
This new insight has introduced a novel and promising field of research: 
Pharmacogenomics of miRNA, that holds new possibilities for tailor-made medical therapy. 
MiRNA pharmacogenomics can be defined as the study of miRNAs and polymorphisms 
affecting miRNA function in order to predict drug behaviour and improve drug efficiency 
(Bertino et al., 2007; Mishra et al., 2008). There are several reasons why miRNA 
pharmacogenomics have strong clinical implications: miRNAs are attractive drug targets, 
are differentially expressed in abnormal cells in all different diseases versus normal cells 
and regulate the expression of several important proteins in the cell (Calin et al., 2002; Iorio 
et al., 2005) supporting the hypothesis that miRNA polymorphisms, located near the 
miRNA-binding site of important genes involved in the drug pharmacokinetics and 
pharmacodynmics, have the potential to affect drug behaviour. Therefore, these miR-
polymorphisms are potential predictors of drug response in the clinical setting and will 
hopefully lead to the development of more accurate methods of determining appropriate 
drug dosages based on a patient’s genetic make-up and decrease the likelihood of drug 
overdose (Bertino et al., 2007) 
4.2 MiRNA expression and drugs 
Even though each miRNA appears to regulate the expression of tens to hundreds of 
different genes at time of writing, there are only a few examples demonstrating the 
relevance of miRNA in the regulation of proteins involved in drug metabolism, transporting 
and targeting. In CYP research, miR-27b expression was found to be lower in breast cancer 
tissues than in neighbouring healthy tissue (P < 0.0005). This expression profile correlated 
inversely with CYP1B1 expression and, in vitro studies, showed the involvement of miR-27b 
in the post-transcriptional regulation of CYP1B1 (Tsuchiya et al., 2006). Human CYP2E1 
expression, an important CYP450 isoform from a pharmacologically and toxicological point 
of view, is regulated by miR-378, mainly via translational repression (Mohri et al., 2010). 
Again, CYP24 by miR-125b post-transcriptionally, which serves as a possible mechanism for 
the high CYP24 expression in tumour tissues, since CYP24 catalyzes the inactivation of 
1 ,25-dihydroxyvitamin D3 (calcitriol), which exerts antiproliferative effects (Komagata et 
al., 2009). Moreover, the transcription factor pregnane X receptor, which regulates the 
expression of a number of CYP members, including CYP3A4, was shown to be regulated by 
miR-148a (Takagi et al., 2008). The miR-148a–dependent decreases in pregnane X receptor 
protein attenuated the induction of CYP3A4 mRNA (P < 0.05) and protein levels (P < 0.010). 
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As to drug transporters, ABCG2 expression was found to be inhibited by miR-519c in a 
parental S1 colon cancer cell line. However, this inhibition was lost in the drug-resistant 
counterpart due to a shorter 3 -UTR in these cells, most likely responsible for  the resistance 
(To et al., 2008). There was a similar effect on drug resistance in the multidrug resistant cell 
lines (A2780DX5 and KB-V1.27), where miR-27a and miR-451 led to overexpression of P-
glycoprotein (P-gp) (Zhu et al., 2008). Again, some researchers reported that miR-451 
regulates P-gp expression in doxorubicin-resistant MCF-7 cells (Kovalchuk et al., 2008). 
There is other evidence on miRNA and anticancer agents, such as tamoxifen (Cittelly et al., 
2010), cisplatin (Bian et al., 2011; Imanaka et al., 2011), 5-fluorouracil (Shah et al., 2011; Valeri 
et al., 2010) and other anticancer drugs (Giovannetti et al., 2011). 
Other examples involve the role of miRNA as regulators of nuclear receptors. Peroxisome 
proliferator-activated receptor gamma (PPAR ) has gained considerable interest as a 
therapeutic target during chronic inflammatory diseases. Indeed, the pathogenesis of 
diseases such as multiple sclerosis, or Alzheimer, might be associated with impaired PPAR  
expression. Jennewein and colleagues have provided, in vitro, evidence of the PPAR  mRNA 
destabilization through miRNA 27b binding PPAR  3’-UTR, which is induced by 
inflammatory response (Jennewein et al., 2010). Hepatocyte nuclear factor (HNF) 4  is a key 
transcription factor regulating endo/xenobiotic-metabolizing enzymes and transporters and 
this nuclear factor was down-regulated, in vitro, by miR-24 and miR-34a, affecting the 
metabolism and cellular biology (Takagi et al., 2010). Glucocorticoids (GCs) exert profound 
effects on a variety of physiological processes, including adaptation to stress, metabolism, 
immunity, and neuronal development. Vreugdenhil et al. tested the hypothesis that miRNA 
might control GR activity by reducing GR protein levels in neuronal tissues and found that 
miRNA 18 and 124a not only reduced GR-mediated events, but also decreased GR protein 
levels, providing a better understanding of the etiology of stress-related diseases as well as 
the efficacy of GC therapy (Vreugdenhil et al., 2009). When considered as a whole, these 
results indicate a possibility of intervening in the drug response mechanisms by modulating 
miRNA expression but many hurdles must be overcome before finding methodologies or 
agents (anti-miRNA) capable of efficiently modulating miRNA expression (Thai et al., 2010). 
5. Complementary approaches  
Even if the process of understanding the mechanisms responsible for variable responses to 
the powerful therapeutic agents have been accelerated by these new approaches, the 
identification of a particular phenotype unequivocally from an equivocal genotype still 
remains a challenge. Nebert et al. report several reasons why no example can be cited in 
which a single genotype is always associated with a phenotype in all individuals within all 
human populations (Nebert & Vesell, 2004). Indeed, there is always a reason why a genomic 
event, or another phenomenon might override a single DNA variant site somewhere in a 
gene (Nebert & Vesell, 2004). Therefore, studies on drug response are expanding beyond 
genomics to new horizons encompassing trascriptomics, metabonomics, proteomics and 
mathematical models, to become a systems-based discipline, or system biology approach. 
Even if much still remains to be done in the field of genomics to better understand the exact 
role of the genotype in the development of the phenotype e.g. through gene-gene 
interactions resulting from particular stimuli that affect a complex circuitry of pathways, 
ending in a response by the cell, or organism, these new fields are very promising to 
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SNP is present near a miR-24 miRNA-binding site in human DHFR. The C>T SNP near the 
miRNA-binding site acts as a loss-of-function mutation and interferes with miR-24 function. 
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levels, but also suggested that the target mRNA destabilization could be a principle 
mechanism of action of a miRNA (Mishra et al., 2007). This finding may also be useful in 
predicting the clinical outcome of methotrexate treatment in clinical settings. Consequently, 
various miR-polymorphisms, located in many important genes that are drug targets, may 
affect drug response in patients and may lead to drug resistance and/or drug sensitivity 
and even unexpected toxicity. 
This new insight has introduced a novel and promising field of research: 
Pharmacogenomics of miRNA, that holds new possibilities for tailor-made medical therapy. 
MiRNA pharmacogenomics can be defined as the study of miRNAs and polymorphisms 
affecting miRNA function in order to predict drug behaviour and improve drug efficiency 
(Bertino et al., 2007; Mishra et al., 2008). There are several reasons why miRNA 
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drug dosages based on a patient’s genetic make-up and decrease the likelihood of drug 
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Even though each miRNA appears to regulate the expression of tens to hundreds of 
different genes at time of writing, there are only a few examples demonstrating the 
relevance of miRNA in the regulation of proteins involved in drug metabolism, transporting 
and targeting. In CYP research, miR-27b expression was found to be lower in breast cancer 
tissues than in neighbouring healthy tissue (P < 0.0005). This expression profile correlated 
inversely with CYP1B1 expression and, in vitro studies, showed the involvement of miR-27b 
in the post-transcriptional regulation of CYP1B1 (Tsuchiya et al., 2006). Human CYP2E1 
expression, an important CYP450 isoform from a pharmacologically and toxicological point 
of view, is regulated by miR-378, mainly via translational repression (Mohri et al., 2010). 
Again, CYP24 by miR-125b post-transcriptionally, which serves as a possible mechanism for 
the high CYP24 expression in tumour tissues, since CYP24 catalyzes the inactivation of 
1 ,25-dihydroxyvitamin D3 (calcitriol), which exerts antiproliferative effects (Komagata et 
al., 2009). Moreover, the transcription factor pregnane X receptor, which regulates the 
expression of a number of CYP members, including CYP3A4, was shown to be regulated by 
miR-148a (Takagi et al., 2008). The miR-148a–dependent decreases in pregnane X receptor 
protein attenuated the induction of CYP3A4 mRNA (P < 0.05) and protein levels (P < 0.010). 
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(To et al., 2008). There was a similar effect on drug resistance in the multidrug resistant cell 
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therapeutic target during chronic inflammatory diseases. Indeed, the pathogenesis of 
diseases such as multiple sclerosis, or Alzheimer, might be associated with impaired PPAR  
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destabilization through miRNA 27b binding PPAR  3’-UTR, which is induced by 
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this nuclear factor was down-regulated, in vitro, by miR-24 and miR-34a, affecting the 
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might control GR activity by reducing GR protein levels in neuronal tissues and found that 
miRNA 18 and 124a not only reduced GR-mediated events, but also decreased GR protein 
levels, providing a better understanding of the etiology of stress-related diseases as well as 
the efficacy of GC therapy (Vreugdenhil et al., 2009). When considered as a whole, these 
results indicate a possibility of intervening in the drug response mechanisms by modulating 
miRNA expression but many hurdles must be overcome before finding methodologies or 
agents (anti-miRNA) capable of efficiently modulating miRNA expression (Thai et al., 2010). 
5. Complementary approaches  
Even if the process of understanding the mechanisms responsible for variable responses to 
the powerful therapeutic agents have been accelerated by these new approaches, the 
identification of a particular phenotype unequivocally from an equivocal genotype still 
remains a challenge. Nebert et al. report several reasons why no example can be cited in 
which a single genotype is always associated with a phenotype in all individuals within all 
human populations (Nebert & Vesell, 2004). Indeed, there is always a reason why a genomic 
event, or another phenomenon might override a single DNA variant site somewhere in a 
gene (Nebert & Vesell, 2004). Therefore, studies on drug response are expanding beyond 
genomics to new horizons encompassing trascriptomics, metabonomics, proteomics and 
mathematical models, to become a systems-based discipline, or system biology approach. 
Even if much still remains to be done in the field of genomics to better understand the exact 
role of the genotype in the development of the phenotype e.g. through gene-gene 
interactions resulting from particular stimuli that affect a complex circuitry of pathways, 
ending in a response by the cell, or organism, these new fields are very promising to 
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understand and predict variation in drug response phenotype. Trascriptomics refers to the 
study of gene transcripts (Kiechle & Holland-Staley, 2003), generally analyzed by cDNA 
expression microarrays. Such cDNA expression studies have led to a number of exciting 
breakthroughs in basic science. For example, microarray analysis of certain tumours has 
been successful in correlating particular expression patterns with patient prognosis 
(Macgregor, 2003). Microarrays of cDNA expression have also been used effectively as 
predictors of success for hormone responsiveness, hormone non-responsiveness, clinical 
outcomes and anticancer chemotherapeutic drugs (Domchek & Weber, 2002; Liu & Karuturi, 
2004), even if other phenotypes may also be directly related to drug response. One of those 
phenotypes is the level of metabolites, not drug metabolites, but rather all small molecules 
that can be accurately assayed in the organism. These thousands of small molecules i.e. the 
metabolome, may also be altered by drug exposure and, consequently, able to predict 
variation in drug response. Metabonomics or metabolomics refers to the study of metabolite 
profiling, or metabolome i.e. the repertoire of small molecules present in cell, tissues, organs 
and biological fluids (Dettmer & Hammock, 2004; Lindon et al., 2004; Maddox et al., 2006; 
Plumb et al., 2003; Reo, 2002; Schmidt, 2004a, 2004b; van der Greef et al., 2007). The 
metabonome represents a real time integrated response to all endogenous and all exogenous 
stimuli (drugs, chemical exposures, occupation, lifestyle, nutrition, age, gender). Therefore, 
metabonomics might provide a sensitive means to follow an individual patient’s phenotype 
as a function of all these stimuli. Recently, metabonomics has achieved major new advances 
due to novel, highly sensitive techniques for the measurement of urinary metabolite profiles. 
The analytical data in these studies are derived from electrospray mass spectrometry 
coupled to gas chromatography, liquid chromatography, or mass spectrometry time-of-
flight (Plumb et al., 2002). The metabolites measured include, not only those from drugs, but 
hundreds of small-molecular weight compounds present in synthetic and degradation 
pathways. 
Animal model studies, using the metabonomic approach have been reported to perform a 
study of drug-induced hepatotoxicity. Hepatotoxicity is a common and potentially serious 
adverse reaction to drugs, such as acetaminophen (Fontana & Quallich, 2001; Watkins et al., 
2006). In this metabolomic study, male Sprague-Dawley rats were treated with 
acetaminophen and both pre and post-drug exposure urine samples were subjected to 
Nuclear Magnetic Resonance (NMR) analysis. A model was then developed that used pre-
drug metabolomic data to predict both ratios of acetaminophen glucuronide conjugate to 
parent drug and post-acetaminophen hepatotoxicity  (Clayton et al., 2006). 
Clinical studies using metabonomics are still in the teething stage. For example, one study 
focused on metabolic profiles of antipsychotic drugs and used a specialized lipidomic 
platform to measure more than 300 lipid metabolites for the evaluation of global lipid 
changes in schizophrenia after treatment with three commonly prescribed atypical 
antipsychotics: olanzapine, risperidone and aripiprazole (Kaddurah-Daouk et al., 2007). A 
major side-effect associated with the use of these drugs is weight gain. Effects of the three 
antipsychotic drugs on lipid biochemical pathways were then evaluated by comparing 
metabolic profiles at baseline with post treatment assays. Phosphotidylethanolamine 
concentrations were elevated after treatment with all three drugs. Olanzapine and 
risperidone affected a much broader range of lipid classes than did aripiprazole, with an 
increase in about 50 lipids after exposure to these drugs, but not after aripiprazole therapy. 
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Thus, metabonomics might well help the physician to provide each patient with 
personalized drug therapy and avoid toxicity, consequently minimizing the risk of ADRs. 
This new form of metabolite profiling would resemble what clinical pharmacology has done 
previously, with the difference that it would be several orders of magnitude more sensitive 
in detecting subtle toxicity, or other ADRs, long before these become clinically evident. 
Changes in an individual’s metabolite profile might warrant an aggressive regimen, for 
example, to prevent, or impede the onset of arthritis, or renal disease, long before clinical 
symptoms appear. It seems practicable that, in the distant future, metabonomics will go 
hand in hand with genomics to revolutionize and individualize drug therapy.  
Proteomics is the study of all proteins encoded by the genome (Tuma, 2004). Although a 
recent study (Rual et al., 2004) estimated an average of 2 to 3 human proteins per gene, 
others have estimated that the true number of proteins per gene might be considerably 
higher. Even though proteomics has not yet been widely applied to the study of drug 
response, it is however, both conceivable and feasible, that, in the future, proteomic 
investigators might identify certain protein profiles, similar to ways in which metabonomics 
can identify certain metabolite profiles, which might be useful in predicting ADRs long 
before they become overt.  
6. Future challenges 
The purpose of this chapter is to provide an overview of the development of 
Pharmacogenetics and the scientific advances that have contributed to the continuing 
evolution of this discipline. Therefore, the ultimate approach in this field would be the 
union of genomic, trascriptomic, metabonomic and proteomic data as well as clinical 
diagnosis and pharmacological treatment response to build a computational cellular, or 
organ model. If the model is sufficiently accurate and detailed, it will then be possible, firstly 
to predict the behaviour of a system given any disturbance within it, secondly, gene 
regulatory networks could be redesigned to create new system properties. This second 
possibility could take on an extremely important role in Pharmacogenomic research for the 
development of new drugs. 
However, to fully realize the potential of this approach and new insights, a number of issues 
and challenges must be met. First and foremost, researchers should continue training on 
systems biology. This will require developing new global technologies for genomics, 
trascriptomics, proteomics, metabolomics and phenotyping. It will also involve the 
development of software able to capture, store, analyze, graphically display, integrate, 
model and disperse the global data sets of systems biology. We must learn how to 
determine the nature of proteins and gene regulatory networks and their integrations and   
how to integrate many types of data as well as analyze and integrate global data sets across 
the dynamic transitions of development, or physiological responses. We also must deal with 
the challenge of providing access for the laboratories practicing small science to these global 
technologies and powerful computational tools. Lastly, access to biological samples from a 
large number of healthy and diseased subjects must be made available so as to begin the 
global correlative studies able to establish the foundational framework of predictive 
medicine and pave the way for moving forward into preventive medicine. There is, 
however, little doubt that the application of Systems Biology will significantly advance our 
ability to individualize drug therapy over the next few years. 
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7. Conclusions 
Although Pharmacogenetics and Pharmacogenomics hold out the promise of leading to 
individualized therapy, to date, relatively few Pharmacogenetic/Pharmacogenomic tests are 
currently used in the clinical setting and even those that are used are done so less frequently 
than indicated. Even if there has recently been an increase  in the awareness on the part of 
the Food and Drug Administration of the necessity to integrate genomic data into regulatory 
review (http://www.fda.gov/cder/genomic/), the goal of individualized prescribing still 
remains an arduous task. Therefore, Pharmacogenetics and/or Pharmacogenomics requires 
further research in various areas of science and the development of the capability to 
integrate them so as to be able to treat each patient as they deserve i.e. as the complex, 
unique and fascinating individual they really are. 
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